<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="EN" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Rev</journal-id><journal-id journal-id-type="iso-abbrev">Chem Rev</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">cr</journal-id><journal-title-group><journal-title>Chemical Reviews</journal-title></journal-title-group><issn pub-type="ppub">0009-2665</issn><issn pub-type="epub">1520-6890</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9614730</article-id><article-id pub-id-type="pmcid-ver">PMC9614730.1</article-id><article-id pub-id-type="pmcaid">9614730</article-id><article-id pub-id-type="pmcaiid">9614730</article-id><article-id pub-id-type="pmid">35608633</article-id><article-id pub-id-type="doi">10.1021/acs.chemrev.2c00021</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Synthetic Glycans to Improve Current Glycoconjugate
Vaccines and Fight Antimicrobial Resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name name-style="western"><surname>Del Bino</surname><given-names initials="L">Linda</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" id="ath2"><name name-style="western"><surname>&#216;sterlid</surname><given-names initials="KE">Kitt Emilie</given-names></name><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath3"><name name-style="western"><surname>Wu</surname><given-names initials="DY">Dung-Yeh</given-names></name><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath4"><name name-style="western"><surname>Nonne</surname><given-names initials="F">Francesca</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" id="ath5"><name name-style="western"><surname>Romano</surname><given-names initials="MR">Maria Rosaria</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3531-2138</contrib-id><name name-style="western"><surname>Cod&#233;e</surname><given-names initials="J">Jeroen</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath7"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5228-6088</contrib-id><name name-style="western"><surname>Adamo</surname><given-names initials="R">Roberto</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><aff id="aff1"><label>&#8224;</label><institution>GSK,
R&amp;D</institution>, Via Fiorentina 1, 53100 Siena, <country>Italy</country></aff><aff id="aff2"><label>&#8225;</label>Leiden
Institute of Chemistry, <institution>Leiden University</institution>, 2300 RA Leiden, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>jcodee@chem.leidenuniv.nl</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>roberto.x.adamo@gsk.com</email>.</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="ppub"><day>26</day><month>10</month><year>2022</year></pub-date><volume>122</volume><issue>20</issue><issue-id pub-id-type="pmc-issue-id">420230</issue-id><issue-title>Glycosciences</issue-title><fpage>15672</fpage><lpage>15716</lpage><history/><pub-history><event event-type="pmc-release"><date><day>28</day><month>10</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>29</day><month>10</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-05 19:25:23.857"><day>05</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cr2c00021.pdf"/><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="ab-tgr1" position="float" orientation="portrait" xlink:href="cr2c00021_0022.jpg"/></p><p>Antimicrobial resistance
(AMR) is emerging as the next potential
pandemic. Different microorganisms, including the bacteria <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Clostridioides difficile</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Neisseria gonorrhoeae</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, non-typhoidal <italic toggle="yes">Salmonella</italic>, and <italic toggle="yes">Staphylococcus aureus</italic>,
and the fungus <italic toggle="yes">Candida auris</italic>, have been identified
by the WHO and CDC as urgent or serious AMR threats. Others, such
as group A and B <italic toggle="yes">Streptococci</italic>, are classified as
concerning threats. Glycoconjugate vaccines have been demonstrated
to be an efficacious and cost-effective measure to combat infections
against <italic toggle="yes">Haemophilus influenzae</italic>, <italic toggle="yes">Neisseria
meningitis</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic>, and,
more recently, <italic toggle="yes">Salmonella typhi</italic>. Recent times have
seen enormous progress in methodologies for the assembly of complex
glycans and glycoconjugates, with developments in synthetic, chemoenzymatic,
and glycoengineering methodologies. This review analyzes the advancement
of glycoconjugate vaccines based on synthetic carbohydrates to improve
existing vaccines and identify novel candidates to combat AMR. Through
this literature survey we built an overview of structure&#8211;immunogenicity
relationships from available data and identify gaps and areas for
further research to better exploit the peculiar role of carbohydrates
as vaccine targets and create the next generation of synthetic carbohydrate-based
vaccines.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>H2020 Marie Sklodowska-Curie Actions</institution><institution-id institution-id-type="doi">10.13039/100010665</institution-id></institution-wrap></funding-source><award-id>861194</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cr2c00021</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cr2c00021</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Vaccination is one of the most impactful medical strategies protecting
human health, and it has been shown to be the most effective intervention
to control infectious diseases.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Carbohydrates,
surrounding the surface of bacteria and fungi, play important roles
in the establishment of infection, acting as virulence factors but
also hiding the microorganisms from the immune system of the host
and activating inflammatory responses. For these reasons, cell surface
polysaccharides have been targeted for the development of bacterial
vaccines. A first generation of polysaccharide-based vaccines against <italic toggle="yes">meningococcus</italic>, <italic toggle="yes">pneumococcus</italic>, and <italic toggle="yes">Haemophilus influenzae</italic> type b (Hib) was licensed between
the &#8217;70s and the early &#8217;80s and demonstrated to be efficacious
in adults. However, these vaccines failed to provide adequate protection
in infants and children under two years of age, which are the populations
at higher risk of infections.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> The introduction of
glycoconjugate vaccines, composed of a carbohydrate covalently linked
to a carrier protein, has overcome this limitation, by raising a carbohydrate
directed T-cell-dependent immune response,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> ensuring efficaciousness in children and the elderly. Today commercial
glycoconjugate vaccines are available to prevent bacteremia, pneumonia,
and meningitidis caused by <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Haemophilus influenzae</italic> type b, and <italic toggle="yes">Neisseria
meningitidis</italic> in infants. Recently, the FDA approved the PCV15
and PCV20 pneumococcal vaccines from Merck and Pfizer,<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> containing 15 or 20 different serotypes, that have shown an impact
in reducing noninvasive illnesses such as acute otitis media, nonbacteremic
pneumonia, and sinusitis.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> A conjugate
vaccine against typhoid fever caused by <italic toggle="yes">Salmonella</italic> Typhi,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> showing high protectivity and
a sustained immune response in children as young as six months of
age, has also been licensed. The glycoconjugate vaccines licensed
to date by the Food and Drug Administration (FDA) and European Medicines
Agency (EMA) are shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. All marketed vaccines are based on the chemical conjugation
of capsular polysaccharides, and because of their capacity to control
a variety of bacterial infections, more vaccines targeting unmet medical
needs are either under development at a preclinical level or in clinical
trials (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Over the last two years the world has seen the
SARS-Cov2 pandemic become a major scourge, and the preparedness for
future pandemics has become a priority for governments. The emergence
of antimicrobial resistance (AMR) can be considered a silent pandemic
that could lead to consequences far more deadly than COVID-19.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> The threat of AMR undermines progress in health
care, food production, and life expectancy and can have a major impact
on society. Reports from the Center for Disease Control (CDC)<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and the European Antimicrobial Resistance Surveillance
Network (EARS-Net)<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> have identified different
microorganisms, including the bacteria <italic toggle="yes">Acinetobacter baumannii,
Clostridioides difficile</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Neisseria gonorrhoeae</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, non-typhoidal <italic toggle="yes">Salmonella</italic>, and <italic toggle="yes">Staphylococcus
aureus</italic> and the fungus <italic toggle="yes">Candida auris</italic>, as
serious AMR threats.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Others, such as
group A and B <italic toggle="yes">Streptococci</italic>, are classified as concerning
threats. As the diseases associated with these pathogens are currently
not prevented by vaccination, the identification of novel candidates
is becoming an urgent need.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Vaccination
appears to be less vulnerable to genetic evolution and, consequently,
to resistance, as compared to antibiotic treatment, and it can also
provide protection for individuals who are not vaccinated through
herd immunity.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> Different from the currently
commercialized glycoconjugate vaccines, which are generally administered
to healthy individuals to prevent the disease, vaccines against AMR
pathogens should provide a fast and robust immune response also in
a nosocomial setting or in subjects with underlying conditions, for
example to combat the carbapenem-resistant <italic toggle="yes">K. pneumoniae</italic>, that often occurs in hospitalized older adult patients.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p><table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Glycoconjugate Vaccines
Licensed by
the FDA, EMA, and WHO</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">Pathogen</th><th style="border:none;" align="center" colspan="1" rowspan="1">Commercial trade name/manufacturer</th><th style="border:none;" align="center" colspan="1" rowspan="1">Carrier protein</th><th style="border:none;" align="center" colspan="1" rowspan="1">Saccharide
chain length</th><th style="border:none;" align="center" colspan="1" rowspan="1">Conjugation chemistry</th><th style="border:none;" align="center" colspan="1" rowspan="1">Approved by</th></tr></thead><tbody><tr><td rowspan="9" style="border:none;" align="left" colspan="1"><italic toggle="yes">Haemophilus influenzae</italic> type B</td><td style="border:none;" align="left" colspan="1" rowspan="1">ActHIB/Sanofi Pasteur (monovalent)</td><td rowspan="3" style="border:none;" align="left" colspan="1">TT</td><td rowspan="3" style="border:none;" align="left" colspan="1">Native polysaccharide</td><td rowspan="3" style="border:none;" align="left" colspan="1">Information not available</td><td rowspan="3" style="border:none;" align="left" colspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Hexyon/Sanofi Pasteur* (Hib-TT ads, DT, TT, aP, hepatitis B rDNA and inactivated
poliomyelitis
at 6 months)</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Hexaxim/Sanofi Pasteur* (Hexavalent
composition of Hib-TT ads,
DT, TT, aP, HBsAg and inactivated poliovirus indicated as boost)</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Hiberix/GSK</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native
polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Quinvaxem/Berna* (Pentavalent fully liquid formulation
containing
DT, TT, PT, HBsAg and Hib conjugate ads)*</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Active ester chemistry</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">PedvaxHIB/Merck</td><td style="border:none;" align="left" colspan="1" rowspan="1">OMPC</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Information
not available</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Vaxelis/Sanofi
Pasteur &amp; Merck* (Hexavalent fully liquid
composition of DT, TT, Bordetella pertussis antigens: PT, filamentous
haemagglutinin, pertactin, fimbriae Types 2 and 3; HBsAg; poliovirus
(inactivated): Hib-OMPC conjugate</td><td style="border:none;" align="left" colspan="1" rowspan="1">OMPC</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Information
not available</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Infanrix/GSK*
(Hexavalent composition of Pediarix-DPT, TT, acellular pertussis, rDNA HBV, inactivated IPV- and Hib-TT on AlOH)</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native
polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">QuimiHib/CIGB</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Synthetic
oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Thiol-maleimide addition</td><td style="border:none;" align="left" colspan="1" rowspan="1">WHO</td></tr><tr><td rowspan="4" style="border:none;" align="left" colspan="1"><italic toggle="yes">Neisseria meningitidis</italic> serogroup&#160;C</td><td style="border:none;" align="left" colspan="1" rowspan="1">NeisVac-C/Pfizer</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native
polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Meningitec/Nuron Biotech</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Menjugate/GSK</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Active
ester chemistry</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Menitorix/GSK
(with Hib)</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Information not available</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Neisseria meningitidis</italic> serogroup CY</td><td style="border:none;" align="left" colspan="1" rowspan="1">MenHibrix/GSK (with Hib)</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native
polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Information not available</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td rowspan="5" style="border:none;" align="left" colspan="1"><italic toggle="yes">Neisseria meningitidis</italic> serogroup
ACWY</td><td style="border:none;" align="left" colspan="1" rowspan="1">MenQuadfi/Sanofi Pasteur</td><td rowspan="2" style="border:none;" align="left" colspan="1">TT</td><td rowspan="2" style="border:none;" align="left" colspan="1">Replaced Menactra that was based on
depolymerized
polysaccharide. It could be now based on a longer PS</td><td rowspan="2" style="border:none;" align="left" colspan="1">Information not available</td><td rowspan="2" style="border:none;" align="left" colspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Fully liquid formulation</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Menveo/GSK</td><td rowspan="2" style="border:none;" align="left" colspan="1">CRM<sub>197</sub></td><td rowspan="2" style="border:none;" align="left" colspan="1">Oligosaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">Active ester chemistry</td><td rowspan="2" style="border:none;" align="left" colspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Fully liquid under approval</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Nimenrix/Pfizer</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide (microfluidized)</td><td style="border:none;" align="left" colspan="1" rowspan="1">CDAP-ADH-EDAC</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> PCV10, serogroup
(1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F,&#160;23F)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Synflorix/GSK</td><td style="border:none;" align="left" colspan="1" rowspan="1">NTHi PD, DT, TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide (microfluidized)</td><td style="border:none;" align="left" colspan="1" rowspan="1">CDAP</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> serogroup 1, 3, 4,
5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F,&#160;23F</td><td style="border:none;" align="left" colspan="1" rowspan="1">Prevnar PCV13/Pfizer</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA/EMA</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> serogroup 1, 3, 4,
5, 6A, 6B, 7F, 8, 9 V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F,&#160;33F</td><td style="border:none;" align="left" colspan="1" rowspan="1">Prevnar PCV20/Pfizer</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA (approved in June 21)</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> serogroup
1, 3, 4,
5, 6A, 6B, 7F, 9 V, 14, 18C, 19F, 19A, 22F, 23F, 33F</td><td style="border:none;" align="left" colspan="1" rowspan="1">Vaxneuvance PCV15/Merck</td><td style="border:none;" align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td style="border:none;" align="left" colspan="1" rowspan="1">Native polysaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Reductive amination</td><td style="border:none;" align="left" colspan="1" rowspan="1">FDA approved in Jul 21</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Glycoconjugate Vaccines Currently
under Clinical Development<xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">Pathogen</th><th style="border:none;" align="center" colspan="1" rowspan="1">Commercial trade
name/manufacturer</th><th style="border:none;" align="center" colspan="1" rowspan="1">Carrier protein</th><th style="border:none;" align="center" colspan="1" rowspan="1">Saccharide chain length</th><th style="border:none;" align="center" colspan="1" rowspan="1">Conjugation chemistry</th><th style="border:none;" align="center" colspan="1" rowspan="1">Clinical development phase</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic></td><td rowspan="2" style="border:none;" align="left" colspan="1">Affinivax</td><td rowspan="2" style="border:none;" align="left" colspan="1">Rhizavidin fused protein</td><td rowspan="2" style="border:none;" align="left" colspan="1">Native polysaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">MAPS technology</td><td rowspan="2" style="border:none;" align="left" colspan="1">Phase&#160;II</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Serogroup 1, 2, 3, 4, 5, 6A, 6B, 7F, 8,
9N, 9 V, 10A, 11A,
12F, 14, 15B, 177, 18C, 19A, 19F, 20B, 22F, 23F,&#160;33F</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic></td><td rowspan="2" style="border:none;" align="left" colspan="1">QuimiVio/CIGB</td><td rowspan="2" style="border:none;" align="left" colspan="1">TT</td><td rowspan="2" style="border:none;" align="left" colspan="1">Native
polysaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">Ugi reaction</td><td rowspan="2" style="border:none;" align="left" colspan="1">Phase III</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Serogroup 1, 5, 6B,
14, 18C, 19F,&#160;23F</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Extraintestinal pathogenic <italic toggle="yes">Escherichia Coli</italic> (ExPEC)</td><td rowspan="2" style="border:none;" align="left" colspan="1">J&amp;J</td><td rowspan="2" style="border:none;" align="left" colspan="1">EPA</td><td rowspan="2" style="border:none;" align="left" colspan="1">Oligosaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">Bioconjugation</td><td rowspan="2" style="border:none;" align="left" colspan="1">Phase III</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Serogroup O25B, O16, O75, O2, O1A, O15, O18A, O6A,
O4 and/or&#160;O8</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Group B <italic toggle="yes">Steptococcus</italic></td><td rowspan="2" style="border:none;" align="left" colspan="1">Pfizer</td><td rowspan="2" style="border:none;" align="left" colspan="1">CRM<sub>197</sub></td><td rowspan="2" style="border:none;" align="left" colspan="1">Native polysaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">Reductive
amination</td><td rowspan="2" style="border:none;" align="left" colspan="1">Phase II</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Serotype Ia, Ib, II, III, IV,&#160;V</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">PNAG (<italic toggle="yes">Staphylococcus aureus, Klebsiella
pneumoniae.
Escherichia Coli, Neisseria gohorrheae, Neisseria meningitidis, Streptococcus
pneumoniae</italic>)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Alopexx</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Synthetic oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Thiol-maleimide addition</td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase II</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Shigella</italic> 2a and 4&#160;V</td><td style="border:none;" align="left" colspan="1" rowspan="1">LMTB-GSK</td><td style="border:none;" align="left" colspan="1" rowspan="1">EPA</td><td style="border:none;" align="left" colspan="1" rowspan="1">Oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Bioconjugation</td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Shigella</italic>&#160;2a</td><td style="border:none;" align="left" colspan="1" rowspan="1">Pasteur Institute</td><td style="border:none;" align="left" colspan="1" rowspan="1">TT</td><td style="border:none;" align="left" colspan="1" rowspan="1">Synthetic
oligosaccharide</td><td style="border:none;" align="left" colspan="1" rowspan="1">Thiol-maleimide addition</td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">Klebsiella</italic>&#160;4&#160;V</td><td rowspan="2" style="border:none;" align="left" colspan="1">LMTB-GSK</td><td rowspan="2" style="border:none;" align="left" colspan="1">EPA</td><td rowspan="2" style="border:none;" align="left" colspan="1">Oligosaccharide</td><td rowspan="2" style="border:none;" align="left" colspan="1">Bioconjugation</td><td rowspan="2" style="border:none;" align="left" colspan="1">Phase
I</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">O-antigen based</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Abbreviations: TT, tetanus toxoid;
CRM<sub>197</sub>, cross-reactive material 197; OMPC, outer membrane
porin C; PD, protein D; DT, diphteria toxoid; MAPS, multiple antigen
presentation system; EPA, <italic toggle="yes">Pseudomonas aeruginosa</italic> exotoxin
A. *Glycoconjugate vaccines in multivalent combination with other
vaccines.</p></fn></table-wrap-foot></table-wrap><p>Historically,
vaccines were constructed using polysaccharides isolated
from pathogens and were developed primarily based on empirical evidence.
Recent times have seen enormous progress in methodologies for the
assembly of complex glycans and glycoconjugates, with developments
in synthetic, chemoenzymatic, and glycoengineering methodologies.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Synthetic carbohydrate chemistry offers a unique
tool to obtain well-defined, thoroughly characterized carbohydrate
antigens of high purity and devoid of any potential microbial contaminant.
Fully synthetic antigens reached the clinic by the synthetic <italic toggle="yes">Haemophilus influenzae</italic> type b (Hib) vaccine in Cuba,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> and more recently a vaccine to fight shigellosis
has progressed to phase II clinical trials.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> The use of synthetic glycans with modern structural glycobiology
approaches, such as glycan arrays, X-ray crystallography, surface
plasmon resonance, and saturation transfer difference NMR, can nowadays
be used for rational rather than trial-and-error-based glycoconjugate
vaccine design.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> This review aims at discussing
the advancement of glycoconjugate vaccines based on synthetic carbohydrates
to improve existing vaccines and identify novel candidates to combat
AMR. Through this literature survey we intend to build structure&#8211;immunogenicity
relationships from available data and identify gaps to be covered
to advance synthetic carbohydrate-based vaccines to fight AMR.</p><sec id="sec1.1"><label>1.1</label><title>Carbohydrates in Gram-Positive and Gram-Negative
Bacteria</title><p>The bacterial cell wall is surrounded by a dense
layer of polysaccharides and glycoproteins, named the glycocalyx,
which allows bacteria to survive in the surrounding environment, while
permitting the exchange of nutrients from the outside and waste products
from the inside. Generally, the outermost surface of both Gram-positive
and Gram-negative bacteria presents capsular polysaccharides (CPS),<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> which can have different structures within the same bacterial species
and can, therefore, be used for serotyping. Gram-negative bacteria
present an outer membrane (OM) to which lipopolysaccharides (LPS),
CPS, and proteins are attached (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). A thin layer of peptidoglycan is located between
the OM and the inner cytoplasmic cell membrane. In contrast, Gram-positive
bacteria lack an OM and are surrounded by a much thicker layer of
peptidoglycans as compared to Gram-negative bacteria.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> CPS are known virulence factors and are typically made
of highly hydrophilic, often negatively charged, long-chain polysaccharides,
anchored to the cell membrane, to the peptidoglycans, or to membrane
components.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Their hydrophilic character
protects microorganisms from desiccation during transmission from
host to host. CPS may also mediate adhesion to abiotic surfaces and
to each other, promoting the formation of biofilms, conferring protection
against specific and nonspecific host immunity. They display a vast
structural diversity, that is brought by numerous different composing
monosaccharides, varying types of glycosidic linkages, and different
substituents such as acetyl groups, phosphates, and pyruvate ketals.
Examples of the enormous structural diversity of CPS include the 80
different capsular serotypes of <italic toggle="yes">E. coli</italic>, the more
than 90 serotypes of <italic toggle="yes">S. pneumoniae</italic>, and the 70 capsular
serotypes reported for <italic toggle="yes">K. pneumoniae</italic>.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup></p><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Surface glycans commonly found on Gram-positive and Gram-negative
bacteria. Gram-positives lack an outer membrane and present a thick
peptidoglycan (PG) layer, to which lipoteichoic (LTA) and wall teichoic
acids (WTA) are connected. The Gram-negative bacterial cell wall features
two membranes and a thin PG layer. Both can be surrounded by capsular
polysaccharide (CPS). The Gram-negative outer membrane is decorated
with lipopolysaccharide (LPS) or a truncated form lacking of the O-antigen,
termed lipooligosaccharide (LOS).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="cr2c00021_0001.jpg"/></fig><p>The OM of Gram-negative bacteria is an asymmetrical lipid bilayer,
which has phospholipids on the inner side while the outside is densely
functionalized with lipopolysaccharide (LPS),<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> which is responsible for the endotoxic shock associated with septicemia.</p><p>LPS consists of three parts: lipid A, the core oligosaccharide,
and the O-specific side chains known as O-antigens (OAg) or O-polysaccharides.
Lipid A is the most conserved part, shares structural similarity between
most LPS, and consists of a glucosamine disaccharide substituted with
fatty acids, whose acyl chains enable tight packing of the OM, contributing
to its barrier function. Lipid A carries the endotoxic properties
of the LPS. The core oligosaccharide is divided into two regions:
the inner core, consisting of 2-keto-3-deoxy-octulosonic acid (Kdo)
and <sc>l</sc>-glycero-<sc>d</sc>-mannoheptose residues, that is highly
conserved, and the outer core, which displays some structural diversity
and which consists mainly of hexose sugars. The OAg domain is made
up of repeating units of one or more sugar residues and exhibits remarkable
structural diversity. Variations in its composition are often the
basis for serotype classification. The OAg is an important virulence
factor and helps the bacterium to escape the complement system and
to resist environmental stresses.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Some
bacterial species, such as <italic toggle="yes">Neisseria</italic> spp., are unable
to synthesize OAg but produce a form of LPS which is referred to as
lipooligosaccharide (LOS), that contains an inner core from which
one or more oligosaccharide branches extend.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></p><p>Differently from Gram-negative bacteria, Gram-positive bacteria
lack the OM but are surrounded by a thick layer of peptidoglycan (PG).
PG has numerous important functions, the most important being stabilization
of the cell wall, enabling it to withstand high internal osmotic pressure.
PG is made up of repeating units of the disaccharide <italic toggle="yes">N</italic>-acetylglucosamine-<italic toggle="yes">N</italic>-acetylmuramic acid, which are
cross-linked by pentapeptide side chains.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> Gram-positive bacteria expose teichoic acids (TAs), zwitterionic
glycopolymers containing phosphodiester-linked polyol repeating units.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> TAs play a crucial role in cell shape determination,
regulation of cell division, and other aspects of Gram-positive bacterial
physiology. They can be divided in two major classes: lipoteichoic
acids (LTAs), anchored in the bacterial membrane via a glycolipid,
and wall teichoic acids (WTAs), covalently attached to PG. WTAs consist
of two parts: a disaccharide unit highly conserved across bacterial
species, which is connected at the reducing end to the PG via a phosphodiester
linkage, and a main chain polymer composed of phosphodiester-linked
polyol repeating units, most commonly 1,5-<sc>d</sc>-ribitol phosphate
(RibP) or (1&#8211;3)-<italic toggle="yes">sn</italic>-1-glycerol-phosphate (GroP).<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> The structural diversity of WTA can derive from
the presence or absence of substituents attached to the backbone,
including cationic <sc>d</sc>-alanine esters and a variety of mono-
or oligosaccharides, most commonly glucose (Glc) or <italic toggle="yes">N</italic>-acetyl glucosamine (GlcNAc).<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> LTAs typically
consist of a poly-<italic toggle="yes">sn</italic>-3-glycerolphosphate chain that
can be decorated with <sc>d</sc>-alanine residues as well as different
carbohydrates.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></p><p>Numerous pathogenic
bacteria also synthesize and secrete exopolysaccharides
as part of the biofilm matrix, a slime composed of extracellular material
embedding the bacterial cells. Biofilms protect the microbial community
from environmental stresses, allowing resistance to bacteriophages,
amoebae, host immune responses, and antibiotics.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></p><p>Many extracellular polysaccharides are polyanionic,
such as alginate,
xanthan, and colanic acid. Polycationic exopolysaccharides also exist,
such as PNAG, a polymer of &#946;-(1&#8211;6)-<italic toggle="yes">N</italic>-acetylglucosamine secreted by many pathogens including <italic toggle="yes">Staphylococcus
aureus</italic> and <italic toggle="yes">Staphylococcus epidermidis</italic>.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup><italic toggle="yes">Pseudomonas aeruginosa</italic> is one
of the most studied biofilm forming pathogens, and it produces at
least three distinct exopolysaccharides which are involved in biofilm
formation: alginate, Pel, and Psl. Alginate is high molecular weight,
unbranched heteropolymer consisting of (1&#8211;4)-linked &#946;-<sc>d</sc>-mannuronates and &#945;-<sc>l</sc>-guluronates, and it is
involved in the establishment of microcolonies at the beginning of
biofilm formation. Pel is a cationic galactosamine-rich polysaccharide,
essential for biofilm formation, while Psl consists of a repeating
pentasaccharide containing <sc>d</sc>-mannose, <sc>d</sc>-glucose,
and <sc>l</sc>-rhamnose and has been shown to be involved in the adherence
to biotic and abiotic surfaces.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Carbohydrates
are also abundant on the surface of fungi. Similar to bacteria, fungal
cell walls are composed of chemically different carbohydrate polymers
forming a robust scaffold that incorporates a variety of proteins
and other surface components, conferring flexibility. The majority
of fungal cell walls is constituted by a conserved inner layer and
a more heterogeneous outer layer. The inner layer is a core of chitin
and &#946;-(1&#8211;3) glucan polymers with &#946;-(1&#8211;6)
branches (about 60%) forming intrachain hydrogen bonds.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> The outer layer of the fungal cell wall comprises
proteins and/or other polysaccharides whose composition may vary with
the fungal species. For example, the outermost glycan layer of <italic toggle="yes">Candida albicans</italic> is composed of mannans.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup></p></sec><sec id="sec1.2"><label>1.2</label><title>Technologies for Manufacturing
Glycoconjugate
Vaccines</title><p>Glycoconjugate vaccines are most commonly prepared
using polysaccharides, which are extracted from bacteria, purified,
and coupled to a carrier protein through random linkages along the
saccharide chain (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). This results in the formation of high molecular weight,
cross-linked, heterogeneous, and rather undefined structures.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref></sup> Carriers currently used in licensed
vaccines include tetanus toxoid (TT), diphtheria toxoid (DT), CRM<sub>197</sub>, the outer membrane protein complex of meningococcus B
(OMPC), Protein D from <italic toggle="yes">H. influenzae</italic>, and the recombinant
exotoxin A of <italic toggle="yes">P. aeruginosa</italic>.<sup><xref ref-type="bibr" rid="ref42">42</xref>&#8722;<xref ref-type="bibr" rid="ref45">45</xref></sup> One of the most commonly used
chemistries for conjugation involves NaIO<sub>4</sub> oxidation of
the polysaccharides, generating aldehydes from <italic toggle="yes">cis</italic>-diols, that can be used for reductive amination with amine groups
of the protein.<sup><xref ref-type="bibr" rid="ref46">46</xref>&#8722;<xref ref-type="bibr" rid="ref48">48</xref></sup> Also 1-cyano-4-dimethylaminopyridinium tetrafluoroborate
(CDAP) chemistry is often exploited to randomly activate hydroxyl
groups of polysaccharides for subsequent direct condensation with
amines of the protein or the incorporation of linker moieties, such
as dihydrazine adipate, for further reaction with carboxylic acid
residues of the protein.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup></p><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Approaches for manufacturing
of glycans for vaccine development
based on (A) bacterial fermentation, including classic polysaccharide
extraction from pathogens and Protein Glycan Coupling Technology (PGCT)
and (B) total synthesis of oligosaccharides via solution phase chemical/chemoenzymatic
approaches or solid phase automated synthesis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="cr2c00021_0002.jpg"/></fig><p>Better defined glycoconjugate vaccines can be generated by using
shorter oligosaccharides, obtained by chemical (using acidic or oxidative
conditions) or mechanical polysaccharide fragmentation, followed by
size fractionation. These fragments can be linked directly to the
protein either through the end-reducing sugar or via a spacer (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A).<sup><xref ref-type="bibr" rid="ref50">50</xref>&#8722;<xref ref-type="bibr" rid="ref52">52</xref></sup> Classic and emerging methods for conjugation of poly- or oligosaccharides
to protein carriers have been recently thoroughly reviewed.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup></p><p>Other approaches to obtain glycoconjugate
vaccines include the
so-called &#8220;protein glycan coupling technology&#8221; (PGCT)
or &#8220;bioconjugation&#8221;,<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> which
is based on the genetic engineering of the <italic toggle="yes">E. coli</italic> Wxx-Wzy biosynthetic pathway to express a glycoprotein containing
a heterologous polysaccharide. This is achieved by incorporating the
genome clusters of choice in <italic toggle="yes">E. coli</italic>, along with
the oligosaccharyl transferase PglB from <italic toggle="yes">Campylobacter jejuni</italic> and a plasmid or gene encoding for the carrier protein carrying
the N-glycosylation consensus sequence D/E-N-X-S/T, where X can be
any amino acid except proline.<sup><xref ref-type="bibr" rid="ref55">55</xref>&#8722;<xref ref-type="bibr" rid="ref57">57</xref></sup></p><p>This methodology has been
successfully applied to advance vaccines
against <italic toggle="yes">Shigella</italic> spp. (Limmatech Biologics)<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> and extra intestinal pathogenic <italic toggle="yes">E. coli</italic> (Janssen/J&amp;J).<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> The translational
machinery of <italic toggle="yes">E. coli</italic> has also been engineered to
express proteins with unnatural (i.e. not naturally found or encoded)
amino acids (uAAs) to provide specific groups for conjugation.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> The inverse demand Diels&#8211;Alder reaction
between tetrazine functionalized glycans and genetically encoded trans-cyclooctene
or bicyclononyne-modified uAAs has been used for conjugation, either
in cellular media or in lysates.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> Based
on the &#8220;XtractCF&#8221; system, which enables the production
of proteins displaying uAAs for subsequent click chemistry with carbohydrates,
Vaxcyte (former Sutrovax) is currently developing a pneumococcal 24-valent
conjugate vaccine.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup></p><p>Another emerging
approach is based on the protein capsular matrix
vaccine (PCMV; Matrivax) technology to connect the glycan and protein
components in a nonconventional manner. In this approach a biotinylated
polysaccharide and the carrier protein fused with a streptavidin domain
are crosslinked in a matrix.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> This technology
has been used by Affinivax for a prototype 24-valent pneumococcal
vaccine, which was demonstrated to provide protection against invasive
disease and carriage in mice<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> and has
been advanced to phase II clinical trials, where it was shown to be
well tolerated and immunogenic in an adult population (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref65">65</xref></sup></p><p>Regardless of the approach used, the immunological activity
of
the glycoconjugates is influenced by a variety of factors, including
the nature and length of the carbohydrate, the substitution pattern,
and the number of glycans attached to the protein (i.e. the saccharide/protein
ratio).<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p><p>This review will focus on
glycoconjugates obtained from synthetic
glycans (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B).
Because of their well-defined length and composition, synthetic glycans
offer clear advantages in the elucidation of the parameters impacting
the immunogenicity of glycoconjugate vaccines.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> In addition, synthetic glycans are typically assembled
with a linker preinstalled at the downstream end of the oligosaccharides,
allowing conjugation to the protein with preservation of the integrity
of all sugar moieties. Numerous methodologies for fast assembly of
oligosaccharides, including one-pot protocols<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> in solution phase, enzymatic approaches,<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> and solid phase automated synthesis,<sup><xref ref-type="bibr" rid="ref69">69</xref>&#8722;<xref ref-type="bibr" rid="ref71">71</xref></sup> have now become available.
Site-selective conjugation methods have also been developed to direct
this step to preselected sites on carrier proteins, which enables
investigations into the impact of the position of the glycan on the
protein carrier on the activity of the glycoconjugates.<sup><xref ref-type="bibr" rid="ref72">72</xref>,<xref ref-type="bibr" rid="ref73">73</xref></sup> We will first provide examples how synthetic chemistry can be used
to improve existing vaccines and then continue to outline the progress
that has been made to generate vaccines to combat AMR.</p></sec></sec><sec id="sec2"><label>2</label><title>Improving Existing Vaccines</title><sec id="sec2.1"><label>2.1</label><title><italic toggle="yes">Haemophilus influenzae</italic></title><p><italic toggle="yes">H. influenzae</italic> is a Gram-negative coccobacillus
part of the nasopharynx microbiota in healthy adults, children, and
infants.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> Serotype b (Hib) causes severe
diseases in humans such as epiglottitis, sepsis, pneumonia, and meningitis.
The Hib CPS is made up of poly(ribosyl ribitolphosphate) (PRP) repeating
units (RUs) and represents the most important virulence factor.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> PRP was conjugated to a diphtheria toxoid (DT)
protein in 1983, resulting in the first glycoconjugate vaccine ever
developed.<sup><xref ref-type="bibr" rid="ref76">76</xref>,<xref ref-type="bibr" rid="ref77">77</xref></sup> Currently, different Hib glycoconjugate
vaccines with different carrier proteins are available on the EU and
US market, either in single form or in combination with other vaccines
(<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref78">78</xref>,<xref ref-type="bibr" rid="ref79">79</xref></sup> Quimi-Hib (<bold>1</bold>, <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>) is based on a synthetic PRP and has been licensed
in Cuba in 2004. It is composed of a synthetic antigen with an average
of seven RP repeating units conjugated to a thiolated TT carrier protein
through a 3-(maleimido)-propylamide linker.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> This vaccine represents the first licensed glycoconjugate vaccine
based on a synthetic carbohydrate antigen. The large scale production
of the PRP fragments was achieved through a one-step polycondensation
reaction using H-phosphonate chemistry, where the spacer containing
end residue <bold>(2)</bold> and H-phosphonate derivative <bold>(3)</bold> were oligomerized in a pivaloyl chloride mediated polycondensation.</p><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Synthetic
polyribosyl-ribitol-phosphate (PRP) antigen of Quimi-Hib,
the first synthetic glycan-based vaccine for prevention of <italic toggle="yes">Haemophilus influenzae</italic> type b, is produced by a controlled
polycondensation of a H-phosphonate building block.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="cr2c00021_0003.jpg"/></fig><p>Over the years, different methods have been developed to
obtain
Hib oligosaccharides by depolymerization of natural polysaccharide<sup><xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref77">77</xref>,<xref ref-type="bibr" rid="ref80">80</xref>,<xref ref-type="bibr" rid="ref81">81</xref></sup> and by chemical synthesis.<sup><xref ref-type="bibr" rid="ref82">82</xref>&#8722;<xref ref-type="bibr" rid="ref84">84</xref></sup></p><p>Recently, Baek et al. synthesized
oligomers ranging in length from
a tetramer up to a decamer, using a [2+2] elongation strategy in an
iterative approach involving a ribosyl-ribitol acceptor, with the
ribitol C5-OH acting as the nucleophile, and a ribosyl-ribitol C-3&#8242;-H-phosphonate
aminopentyl donor, in line with the approach taken to construct the
Quimi-Hib vaccine antigen.<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> The CRM<sub>197</sub> conjugates of the obtained oligosaccharides were used to
immunize Zika-rabbits, and the sera were analyzed using a glycan array.</p><p>The tetramer and octamer revealed the highest immunogenicity although
no linear or marked length-dependent trend could be shown. This study
suggests that four repeating units would fully cover the Hib polysaccharide
epitope and represent an optimal length for vaccine design.</p><p>Similarly to other phosphodiester bridged polymers, Hib polysaccharide
suffers from intrinsic lability, especially in the presence of metal
cations. The hydrolysis of the phosphodiester linkages has been explained
with a mechanism involving the 2-OH of the ribose moiety;<sup><xref ref-type="bibr" rid="ref86">86</xref></sup> therefore, analogues with different functional
groups (<italic toggle="yes">e.g</italic>. -OCH<sub>3</sub> and -F) to replace
the 2-OH have been developed, resulting in higher stability.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> In the post-Hib vaccine era, other serotypes
and nontypeable strains (NTHi) are emerging as a significant cause
of invasive infections and meningitis.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup><italic toggle="yes">H. influenzae</italic> serotype a (Hia) represents the second
most virulent capsular serotype of <italic toggle="yes">H. influenzae</italic>,
especially in children aged six months to two years, and it can cause
meningitis, pneumonia, septic arthritis, and bacteremia.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> The Hia capsule is a polymer of glucose and
ribitol connected by phosphodiester linkages. The synthesis of oligomers
up to two repeating units was reported in 1988 and was achieved through
condensation of an <italic toggle="yes">&#945;-</italic><sc>d</sc>-glucopyranosyl
bromide derivative with 5-<italic toggle="yes">O</italic>-allyl-1,2,3-tri-<italic toggle="yes">O</italic>-benzyl-<sc>d</sc>-ribitol, followed by phosphorylation
and removal of protective groups.<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> Development
of Hia vaccines should be technically feasible, but a limited market
would likely require donor support to incentivize a manufacturer.<sup><xref ref-type="bibr" rid="ref90">90</xref></sup> An approach similar to the Hib oligomers can
be envisaged. Considering the structural and infectious similarities
between Hia and Hib serotypes, the success of Hib vaccination could
suggest a rational background for the development of a Hia glycoconjugate
vaccine protective both in adults and infants.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Indeed, a CPS-based glycoconjugate vaccine has shown promising
results, and it is at an early stage of development.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup> In silico studies have recently shown important conformational
differences between the serotype a and b polysaccharides, explaining
the lack of cross-reactivity, justifying the need for a separate conjugate
vaccine to target Hia.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup></p></sec><sec id="sec2.2"><label>2.2</label><title><italic toggle="yes">Neisseria meningitidis</italic></title><p>Efforts in
the generation of meningococcal vaccines have been directed
to the pathogen-free production of structures identical to the natural
glycans and to the design of glycomimetics with improved stability.
The serotype A CPS is composed of (1&#8211;6)-linked <italic toggle="yes">N</italic>-acetyl-&#945;-<sc>d</sc>-mannosamine-1-phosphates with acetyl esters
at C-3 or C-4 (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p><fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Meningococcal capsular polysaccharide structures and related synthetic
conjugates. On the right the structure of the repeating unit of the
natural CPS is described. Synthetic structures include copies of the
natural polysaccharide (<bold>4</bold>&#8211;<bold>6</bold>) and
analogues (<bold>7</bold> and <bold>8</bold>). In conjugate <bold>(6)</bold> the 11-mer molecule was obtained in a one-pot fashion
using the enzymatic elongation of a synthetic acceptor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr4" position="float" orientation="portrait" xlink:href="cr2c00021_0004.jpg"/></fig><p>The synthesis of a nonacetylated MenA CPS up to a trimer
has been
achieved using a 2-azido mannosamine H-phosphonate building block
using pivaloyl chloride mediated condensations followed by iodine
oxidation of the intermediate phosphites.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup> A 3-<italic toggle="yes">O</italic>-acetylated MenA tetramer was successfully
assembled using a 3-<italic toggle="yes">O</italic>-acetyl-2-azido-4-<italic toggle="yes">O</italic>-benzyl-6-<italic toggle="yes">O</italic>-<italic toggle="yes">tert</italic>-butyldimethylsilyl-2-deoxy-&#945;-<sc>d</sc>-mannopyranosyl H-phosphonate.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup> The TT conjugate obtained incorporated an <italic toggle="yes">S</italic>-acetylthioglycolic
linker for subsequent thiol-maleimide addition and inhibited the binding
of anti-MenA PS serum to the capsular PS.</p><p>Synthetic routes have
also been exploited for other serotypes.
The MenX CPS is composed of (1&#8211;6)-linked <italic toggle="yes">N</italic>-acetyl-&#945;-<sc>d</sc>-glucosamine-1-phosphates (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>), and a MenX CPS trimer was
synthesized from a 2-azide glucose building block using H-phoshonate
chemistry.<sup><xref ref-type="bibr" rid="ref95">95</xref></sup> Fragments ranging in length
from a monomer to a trimer were obtained and conjugated to CRM<sub>197</sub> using active ester chemistry. Only the trimer conjugate
induced bactericidal anti-MenX PS antibodies in mice.<sup><xref ref-type="bibr" rid="ref96">96</xref></sup> Subsequently a tetramer fragment was generated,<sup><xref ref-type="bibr" rid="ref97">97</xref></sup> and a competitive ELISA showed that the corresponding
TT conjugate was a much better competitor than the unconjugated form,
indicating the need for longer length CPS fragments to sufficiently
emulate the PS epitope. Recently, the structural epitope of the MenX
CPS was mapped using a Fab derived from a murine bactericidal monoclonal
antibody (mAb) obtained against the conjugated MenX PS.<sup><xref ref-type="bibr" rid="ref98">98</xref></sup> Surface Plasmon Resonance (SPR), isothermal
titration calorimetry (ITC), and STD-NMR showed binding for a fragment
longer than 5 RUs. In silico docking with a hexamer and the structure
of the Fab resolved by X-ray crystallography confirmed binding through
a network of salt bridges and hydrophobic interactions. Upon conjugation,
5 RUs were sufficient to elicit functional antibody levels at a level
comparable to a longer 10 RU fragment, suggesting that glycoconjugates
with relatively short structures can be used for vaccine development.</p><p>Recent progress in the construction of the challenging &#945;-sialic
acid linkage has enabled access to polysialic acid MenC structures.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup> An <italic toggle="yes">N</italic>5,<italic toggle="yes">O</italic>4-carbonyl-protected
&#945;-sialyl phosphate donor was a key intermediate for the assembly
of &#945;-(2&#8211;9)-linked oligoasialic acids up to a dodecamer.<sup><xref ref-type="bibr" rid="ref100">100</xref>,<xref ref-type="bibr" rid="ref101">101</xref></sup> Conjugates with KLH (Keyhole Limpet Hemocyanin) induced murine antibodies
recognizing MenC cells in ELISA. Recently, a synthetic MenC tetramer
and octamer were assembled and conjugated with TT, inducing in mice
bactericidal IgGs at a level comparable to a licensed vaccine.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> A fully synthetic MenC-glycan antigen linked
to a monophosphoryl lipid A (MPLA) carrier (<bold>4</bold>) has also
been generated and shown to elicit good levels of bactericidal antibodies.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup> The MenW CPS is composed of &#8594;6)-&#945;-<sc>d</sc>-Gal-(1&#8211;4)-&#945;-<sc>d</sc>-Neu5Ac-(2&#8594; repeats,
and the synthesis of MenW CPS fragments up to the length of a decamer
was accomplished using a sialylated galactosyl disaccharide thiophenyl
building block.<sup><xref ref-type="bibr" rid="ref104">104</xref></sup> Conjugated oligomers
induced an immune response in mice against themselves, with the octamer
providing the most bactericidal serum against a MenW135 strain. Differently
from ACWYX capsular polysaccharides that have been successfully advanced
as vaccine antigens, MenB CPS, composed of a &#8594;8)-&#945;-<sc>d</sc>-Neu5Ac-(2&#8594; repeating unit, exhibits high similarity
with gangliosides expressed during fetal development (GD3) and involved
in neural growth.<sup><xref ref-type="bibr" rid="ref105">105</xref></sup> Although an <italic toggle="yes">N</italic>-propionyl sialyl conjugate vaccine generated in a preclinical
model<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> antibodies not or minimally cross-reactive
with purified human glycans,<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> safety
concerns have prevented the use of MenB CPS for clinical applications.</p><p>As an alternative to the use of CPS, the use of a highly conserved
LPS portion has been considered. A model vaccine, constructed by conjugation
of a deacetylated truncated LPS form to CRM<sub>197</sub> through
the Kdo residue was able to elicit anti-LPS antibodies in both rabbits
and mice.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> However, the raised sera cross
reacted only with de-<italic toggle="yes">O</italic>-acylated LPS of MenB strains
but not with the native fully acylated LPS. Recently, the core tetrasaccharide
composed of two heptose residues and two Kdo saccharides (Hep2Kdo2),
a common motif shared by different pathogenic strains of <italic toggle="yes">N.
meningitidis</italic> but also <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">E. coli</italic>, has been synthesized.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> The related CRM<sub>197</sub> conjugate raised murine antibodies,
which recognized in vitro the inner core of the LPS. Combination of
the antibodies with an inhibitor of capsular polysaccharide transport
enabled bacterial killing of MenB strains. This shows that the LPS
is effectively masked by CPS, and its use as a vaccine target remains
challenging. Today vaccines based on the outer membrane vesicle (OMV)
and the proteins, Bexsero and Trumemba, are available against MenB,<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> as well as a bivalent MenB/MenC vaccine composed
of MenB, OMV, and MenC CPS (VamengocBC).<sup><xref ref-type="bibr" rid="ref111">111</xref></sup></p><p>Enzymes involved in the biosynthesis of natural polysaccharides
have also been explored as powerful tools to simplify and accelerate
manufacturing of meningococcal CPS oligomers. The biosynthesis of
the MenA CPS consists of three steps: (i) the epimerization of UDP-GlcNAc
to UDP-ManNAc by the epimerase CsaA; (ii) the condensation of this
UDP donor at the C-6 of an ManNAc-1P acceptor by the polymerase CsaB;
and (iii) the acetylation of the assembled polymer by the acetyl transferase
CsaC. By cloning and expressing a soluble form of these three enzymes,
the biosynthesis of the MenA CPS was replicated in vitro, providing
structures identical to the native polysaccharide, in terms of both
structure and immunological activity.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup> A synthetic disaccharide was required for priming the polymerase
reaction and allowing the enzymatic elongation of MenA CPS.</p><p>The mechanism of <italic toggle="yes">O</italic>-acetylation has been further
detailed by structural studies showing that the CsaC selectively transfers
an acetyl ester to the O3 position; however, part of the acetyl esters
migrates to the O4 position at neutral pH.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> This generates the typical acetylation pattern of MenA CPS that
is important for its immunogenicity. Similarly, the production of
MenX oligomers has been explored. The polymerase CsxA enabled elongation
of naturally derived acceptors and generation of oligomers that upon
conjugation to CRM<sub>197</sub> elicited an immunogenic response
in mice comparable to the conjugated natural PS.<sup><xref ref-type="bibr" rid="ref114">114</xref>,<xref ref-type="bibr" rid="ref115">115</xref></sup> Subsequently, an efficient chemoenzymatic approach was developed
by combining the chemical synthesis of a trisaccharide acceptor, equipped
with a linker for conjugation, and the enzymatic elongation through
a column immobi-lized truncated form of the polymerase CsxA.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup></p><p>By passing the growing oligosaccharide
together with an immobilized
truncated form of the polymerase CsxA through a column<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> with GlcNAc-UDP, a structure with an average
length of 12 RUs (<bold>6</bold>) was assembled and conjugated to
CRM<sub>197</sub>. Vaccination of mice elicited a high level of bactericidal
antibodies comparable to conjugates made from extracted material.
Compared to conventional synthetic protocols, this methodology proved
very expeditious and drastically reduced the number of purification
steps to generate the oligomers. A chemoenzymatic method has also
been developed for the synthesis of the MenC CPS. A spacer equipped
with synthetic lactosides was modified with two sialic acid residues
with a <italic toggle="yes">C. jejeuni</italic> transferase for further elongation
with the MenC sialyltransferase. A TT conjugate of the obtained oligo-(2&#8211;8)-sialyl
oligomers elicited a MenC CPS-specific immune response in mice.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup></p><p>Recently, studies on the MenW capsular
polymerase (NmSiaDW) have
identified 4-azido-4-deoxy-<italic toggle="yes">N</italic>-acetylmannosamine and
6-azid-6-deoxy-<italic toggle="yes">N</italic>-acetylmannosamine as suitable substrates
for the synthesis of MenW oligosaccharides containing 4,7-di-<italic toggle="yes">N</italic>-acetylneuraminic acid and 4,9-di-<italic toggle="yes">N</italic>-acetylneuraminic
acid.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> Through these azide intermediates
an enzymatic strategy was developed to assemble the <italic toggle="yes">N</italic>-Ac-oligosaccharides up to a length of a pentasaccharide (<bold>5</bold>). Overall, these studies suggest that chemoenzymatic approaches
can be very versatile and they can likely be expanded to other sero
groups.</p><p>The MenA polysaccharide suffers from instability in
solution because
the anomeric phosphate is relatively easily cleaved, as the neighboring <italic toggle="yes">trans</italic>-oriented acetamide can participate in its displacement.
Therefore, the development and manufacture of a MenA glycoconjugate
vaccine in liquid formulation remains a challenge.<sup><xref ref-type="bibr" rid="ref118">118</xref></sup></p><p>Typically, this issue is solved by using lyophilized
formulations,
which are reconstituted with saline before use or by storage at 2&#8211;8
&#176;C. This solution, however, implies extra costs for production
and distribution of the vaccine, particularly in areas where maintaining
the cold chain is not trivial, such as emerging and poor countries.
Therefore, stabilized analogues are desirable.</p><p>Analogues of
the MenA CPS have been designed by replacing the phosphodiesters
with a more stable C-phosphonate (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>, compound (<bold>7</bold>).<sup><xref ref-type="bibr" rid="ref119">119</xref>,<xref ref-type="bibr" rid="ref120">120</xref></sup></p><p>The critical installation of the interglycosidic phosphomonoester
linkages was accomplished using a Mitsunobu coupling of the glycosyl
C-phosphonate building block with the 6-OH moiety of the mannosamine
acceptor.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> C-phosphonate bridged oligomers
up to the trimer length (<bold>7</bold>) were conjugated to human
serum albumin (HSA), stimulating in vitro T-cell proliferation (CFSE
method) and IL-2 release (ELISA) and inducing in vivo anti-polysaccharide-specific
IgGs.<sup><xref ref-type="bibr" rid="ref120">120</xref></sup> In an alternative approach, so-called
&#8220;carba-analogues&#8221;, in which the mannosamine ring oxygen
is replaced by a methylene group, have been explored.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> These analogues are stabilized because the
lack of the ring oxygen precludes the formation of an oxocarbenium
ion-like species that would form upon cleavage of the anomeric C&#8211;O
phosphate bond and appear more suitable for large scale manufacturing
since phosphoramidite chemistry can be used for the construction of
the phosphate linkages.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> The key step
in the formation of the carbacycle analogue of mannosamine is the
Claisen rearrangement of a 6-methylene glucal. Short oligomers of
the carbaMenA analogues, containing up to three repeating units, were
initially generated using carba H-phosphonates (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>, compound (<bold>8</bold>)).<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> The carbaMenA trimer induced low levels of
antibodies, that cross-reacted with the native MenA CPS and showed
bactericidal activity. To explain the behavior of the carba analogues,
conformational modelling studies were undertaken. Molecular dynamics
simulations indicated the MenA CPS conformation to be a flexible random
coil which becomes less conformationally defined as the length increases.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> Acetylation would provide structural rigidity
to the MenA backbone. Also, the carbaMenA was predicted to present
a more random extended conformation as compared to the natural MenA.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup> A more thorough investigation was performed
by combining theoretical calculations and NMR spectroscopy experiments,
using chemically synthesized 1- or 6-phophorylated monomannosamines
and their carba analogues as chemical probes.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup></p><p>The data confirmed that in spite of a high conformational
freedom
of the key pseudoglycosidic and aglycon torsion angles in the carba
analogues, one of the favorable geometries corresponds to that of
the natural monomer.</p><p>To improve the immunogenicity of the carbaMenA
oligomers, more
recently, structures up to eight repeating units in length were assembled.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Non-<italic toggle="yes">O</italic>-acetylated 6- and 8-mers
conjugated to CRM<sub>197</sub> elicited in mice anti-MenA CPS antibodies
but still at suboptimal levels. However, the 8-mer showed the unique
capacity to recognize a bactericidal murine mAb that previously had
been shown by STD NMR and X-ray crystallography to bind to an <italic toggle="yes">O</italic>-acetylated trisaccharide epitope.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> The introduction of <italic toggle="yes">O</italic>-acetyl groups in
the carbaMenA octamer (<bold>8</bold>) through a controlled random
acetylation reaction led to an O-acetylation degree of 75%, similar
to the natural polysaccharide. Conjugation of this antigen led to
a model vaccine, that induced bactericidal antibodies to a level comparable
to the MenA vaccine benchmark.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> This
work represents an important proof-of-principle for the use of glycomimetics
as more stable alternatives for polysaccharide-based vaccines.</p><p>Novel concepts have been tested with natural CPS, and these could
be further exploited for the synthetic structures. Conjugation of
oligosaccharides from two diverse sero groups, namely MenA and C,
has been shown to induce high titers of bactericidal antibodies against
the two different sero groups after the third administration.<sup><xref ref-type="bibr" rid="ref128">128</xref></sup></p><p>The MenA CPS seems to suffer from carrier
epitope suppression as
a result of preexisting immunity to the protein carrier, in particular
CRM<sub>197</sub> and TT.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> The use of
alternative carriers, such as the pneumococcal Spr96-2021, has been
explored.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> Genetically detoxified outer
membrane vesicles (GMMA) from MenB have also been introduced as a
potent carrier for MenA and MenC polysaccharides, giving levels of
murine bactericidal antibodies superior to CRM<sub>197</sub> already
at the first dose..<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> Finally, MenC polysaccharide
conjugated to full-length hepatitis B core (HBc) antigen virus-like
particles using heterobifunctional polyethylene glycol linkers generated
10-fold higher anti-carbohydrate IgGs than the unconjugated polysaccharide
and increased IgG2a subclass production with a shift to a Th1 cellular
immune type response.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup></p></sec><sec id="sec2.3"><label>2.3</label><title><italic toggle="yes">Streptococcus pneumoniae</italic></title><p>Despite vaccines
being available in developed countries, the Institute
for Health Metrics and Evaluation (IHME) estimates that <italic toggle="yes">S.
pneumoniae</italic> accounts for 1.2 million deaths and approximately
900,000 disabled patients annually from pneumonia and meningitis.
In addition, <italic toggle="yes">S. pneumoniae</italic> is responsible for an
estimated 36% of the global burden of pneumonia and 27% of the global
burden of otitis media. A priority for pneumococcal vaccination is
to increase the global distribution in poor and emerging countries.
Some years after introduction of PCV7, a clear impact of vaccination
on community acquired pneumoniae was observed;<sup><xref ref-type="bibr" rid="ref132">132</xref></sup> however, an increase of invasive pneumoniae disease (IPD)
of non-PCV7 serotypes was observed. Although these events were far
below the magnitude of the reduction in IPD caused by the vaccine
serotypes,<sup><xref ref-type="bibr" rid="ref133">133</xref></sup> this highlights the need
for broader coverage in the countries where a vaccine is available.</p><p>Additional challenges associated with pneumococcal vaccination
have been the low immunogenicity of some glycoconjugates in the complex
multivalent formulation (<italic toggle="yes">e.g</italic>. serotype (ST) 3) and
the unexpected lack of cross protection between some structurally
similar polysaccharides (<italic toggle="yes">e.g</italic>. ST19A and 19F).</p><p>Synthetic chemistry has been a fundamental means to generate glycans
for the identification of key polysaccharide epitopes and the improvement
of pneumococcal vaccines, particularly for the most challenging serotypes.
This topic has been recently thoroughly reviewed,<sup><xref ref-type="bibr" rid="ref134">134</xref>&#8722;<xref ref-type="bibr" rid="ref137">137</xref></sup> so we will here only give an overview of the most relevant concepts
developed through synthetic carbohydrate derived glycoconjugates to
obtain vaccine candidates at the preclinical level. The seminal work
of Vliegenthart and Kamerling was pivotal to demonstrate that the
immunogenic character of long and complex polysaccharides can be related
to short defined glycan epitopes. KLH conjugates of di-, tri-, and
tetrasaccharide fragments of serotype 6A and 6B were synthesized and
shown to elicit high levels of ST6B antibodies in rabbits, that facilitated
type-specific phagocytosis (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>).<sup><xref ref-type="bibr" rid="ref138">138</xref></sup> The rabbit antisera
raised against the tri- and tetrasaccharide also reacted with the
6A PS in an ELISA assay and promoted phagocytosis of 6A pneumococci.
All rabbit antisera passively protected mice against a ST6B challenge.
In mice, however, phagocytic and protective anti-ST6B antibodies were
only induced by the tetrasaccharide conjugate, and these antibodies
did not cross-react with ST6A PS in an ELISA. Overall, these studies
have shown that the tetrasaccharide (<bold>13</bold>) was capable
of inducing ST6B-specific, fully protective antibodies in two animal
models. Likewise, through a library of ST14 derived structures, a
branched tetrasaccharide repeating unit (<bold>15</bold>) was shown
to be the functional minimal epitope in a mouse model.<sup><xref ref-type="bibr" rid="ref139">139</xref>,<xref ref-type="bibr" rid="ref140">140</xref></sup> This small epitope, that recently has been readily assembled also
by automated synthesis,<sup><xref ref-type="bibr" rid="ref141">141</xref></sup> has become a
model to obtain a fully synthetic vaccine based on gold nanoparticles
where T-cell help is provided by a synthetic peptide.<sup><xref ref-type="bibr" rid="ref142">142</xref></sup> A polysaccharide mimic composed of a sequential
synthetic tetrasaccharide unit connected through a linker has been
made and shown to be immunogenic in mice.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> A hexasaccharide conjugated to BSA induced apparently both innate
(through TLR2 activation) and humoral responses in mice, with longer
antibody persistence when aluminum hydroxide was used as adjuvant.
However, the TLR2 expression on spleen cells from immunized mice seems
not specific and caused by cytokine action rather than being the outcome
of a ligand&#8211;receptor interaction.<sup><xref ref-type="bibr" rid="ref144">144</xref></sup> A synthetic ST14 tetrasaccharide was site selectively linked via
a thiol&#8211;maleimide coupling to four different pneumococcal surface
adhesin A (PsaA) mutants, each harboring a single cysteine mutation
at a defined position.<sup><xref ref-type="bibr" rid="ref145">145</xref></sup> Antibody responses
to both the carbohydrate and PsaA protein antigens were generated
in mice. Various other pneumococcal structures have more recently
been synthesized. Synthetically made zwitterionic polysaccharides
from ST1 have been generated by different research groups.<sup><xref ref-type="bibr" rid="ref146">146</xref>&#8722;<xref ref-type="bibr" rid="ref149">149</xref></sup> This serotype has attracted attention for its property to elicit
T-cell responses without conjugation.<sup><xref ref-type="bibr" rid="ref150">150</xref></sup> An elegant strategy for insertion of a benzylthio linker in the
trisaccharide of ST1, to release a thiol group for conjugation at
the end of the assembly under Birch debenzylation conditions, enabled
the chemoselective conjugation to a carrier protein as well as a glycan
array surface, preserving potential protective epitopes.<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> The CRM<sub>197</sub> conjugate of the trisaccharide <bold>(9)</bold> induced a robust antibody response in rabbit compared
to the PCV13 commercial vaccine, that was used as a control, and it
reduced the blood bacterial load of mice in a passive immunization
approach using pooled rabbit serum.<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> The
assembly of structures up to four repeating units showed that the
longer synthetic structures adopt helical structures with approximately
eight monosaccharides completing a full turn. It was also shown that
the oligomers encompassing three RUs (nine monosaccharides) bound
monoclonal antibodies, raised against the deacetylated native CPS,
much better than shorter fragments. There, thus, seems to be a correlation
between the secondary structure and antibody binding activity. An
outstanding issue remains the introduction of <italic toggle="yes">O</italic>-acetyl
groups, that have been shown to be an important structural feature,
but the introduction of these groups, alongside the carboxylic acids,
acetamides, and free amines in the structure, represents a significant
synthetic challenge.</p><fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Pneumococcal vaccine candidates based on synthetic glycans.
Synthetic
oligosaccharides mimicking several <italic toggle="yes">Streptococcus pneumoniae</italic> serotypes (ST) have been synthesized and tested at the preclinical
level to identify key glycan epitopes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr5" position="float" orientation="portrait" xlink:href="cr2c00021_0005.jpg"/></fig><p>Conjugates of synthetic fragments of serotype 3 PS of different
lengths (up to a tetramer) have been prepared and conjugated to different
carriers, including TT, KLH, and CRM<sub>197</sub>.<sup><xref ref-type="bibr" rid="ref151">151</xref>&#8722;<xref ref-type="bibr" rid="ref153">153</xref></sup> The CRM<sub>197</sub> conjugates of the di-, tri-, and tetrasaccharides
of ST3 were shown to be protective in mice against a challenge with
ST3.<sup><xref ref-type="bibr" rid="ref151">151</xref></sup> Parameswarappa et al. showed that
a tetrasaccharide exhibited the highest recognition of human anti
PS serum on a glycan array, outperforming shorter fragments, and this
structure was selected for conjugation to CRM<sub>197</sub>, to deliver
a model vaccine (<bold>10</bold>) that induced protection against
ST3 in a mouse model.<sup><xref ref-type="bibr" rid="ref154">154</xref></sup></p><p>Oligosaccharides
deviating from the serotypes included in the PCV13
vaccine have been targeted, and this has aided in gaining relevant
structural information on key epitopes of these glycans. A synthetic
hexasaccharide repeating unit of the ST2 CPS was selected from a set
of different structures, based on glycan microarray screening.<sup><xref ref-type="bibr" rid="ref155">155</xref></sup> Vaccination with the hexasaccharide linked
to CRM<sub>197</sub> (<bold>11</bold>) stimulated a T-cell-dependent
B-cell response and induced CPS-specific opsonic antibodies in mice,
resulting in killing of encapsulated bacteria by phagocytic activity.
In addition, the neoglycoconjugate reduced the bacterial load in lung
and blood of mice, transnasally challenged with the highly virulent
ST2 strain NCTC 7466.</p><p>The combination of automated glycan assembly
(AGA) and glycan microarray-based
monoclonal antibody (mAb) binding studies has been used to identify
a protective glycan epitope from ST8.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> Out of four structures, a tetrasaccharide frameshift was shown to
be preferentially recognized by a protective anti-natural PS mAb and
this structure was conjugated to CRM<sub>197</sub>. The ST8 neoglycoconjugate <bold>(14)</bold> induced an antibacterial immune response also in coformulation
with the commercial PCV13, demonstrating the feasibility of a vaccine
with extended coverage based on mixed synthetic and naturally derived
carbohydrates.</p><p>A combination of ST2, 3, 5, 8, and 14 glycoconjugates
(sPCV5),
all obtained by chemical synthesis, has been shown to give high levels
of specific protective antibodies against the different serotypes
in rabbits.<sup><xref ref-type="bibr" rid="ref157">157</xref></sup> All STs in sPCV5 induced
immune responses comparable to the licensed control vaccines, except
ST14, which led to a lower response. Coformulation with PCV13 and
PCV10 also led to a robust protective immune response in this animal
model, highlighting the potential of a fully synthetic carbohydrate-based
multivalent vaccine as well as the combination of conjugates from
chemical synthesis and polysaccharide extraction.</p><p>Stabilization
of conjugates susceptible to degradation has been
proposed as a way to improve vaccine performance. The ST5 repeating
unit contains two rare sugars, the ketoamino sugar 2-acetamido-2,6-dideoxy-<sc>d</sc>-xylose-hexos-4-ulose (Sug<italic toggle="yes">p</italic>) and <italic toggle="yes">N</italic>-acetyl-<sc>l</sc>-pneumosamine (l-PneuNAc). The keto group of Sug<italic toggle="yes">p</italic> can cause degradation of the natural polysaccharide.<sup><xref ref-type="bibr" rid="ref158">158</xref></sup> A set of structures equipped with a linker
was synthesized, and through a glycan array, a penta- and a tetrasaccharide
both containing the immune dominant <sc>l</sc>-PneuNAc and a terminal <sc>l</sc>-FucNAc (thus lacking the vulnerable C-4-ketone) were selected
for conjugation.<sup><xref ref-type="bibr" rid="ref158">158</xref></sup> Studies in rabbit showed
that a pentasaccharide (<bold>12</bold>), presenting an additional
&#946;-Glc, induced a higher level of opsonic antibodies in comparison
to the conjugated tetrasaccharide. Notably, the identified oligosaccharide
epitope is devoid of the residues that are responsible for the product
instability.</p><p>The two structurally similar polysaccharides 19A
and 19F have also
attracted a lot of attention because of the unexpected lack of cross-reactivity
observed with PCV17, containing ST19F, with ST19A PS. Along with the
synthesis of the individual serotype fragments,<sup><xref ref-type="bibr" rid="ref159">159</xref></sup> the identification of cross-protective epitopes has been
pursued. A chimeric oligosaccharide antigen (<bold>16</bold>) containing
the repeating units of ST19A and ST19F has been assembled, and its
glycoconjugate induced good levels of antibodies in rabbits that killed
ST19A and ST19F bacteria in vitro.<sup><xref ref-type="bibr" rid="ref160">160</xref></sup> By
testing a series of synthetic short glycans, a shared ManNAc-&#946;-(1&#8211;4)-Glc
epitope, carrying a phosphate at the ManNAc-C4 has been identified,<sup><xref ref-type="bibr" rid="ref161">161</xref></sup> although the immunogenicity of this epitope
was not investigated.</p><p>Gold nanoparticles have also been used
to combine glycans from
two different serotypes onto the same carrier. Vetro et al. described
the functionalization of gold nanoparticles with the tetrasaccharide
epitope of ST14, the trisaccharide repeating unit of ST19F along with
a T-helper peptide and a <sc>d</sc>-Glc, as a hydrophilic &#8220;filler&#8221;
molecule.<sup><xref ref-type="bibr" rid="ref162">162</xref></sup> This conjugate induced specific
IgG antibodies in mice against the type 14 polysaccharide but not
against the ST19F. This could either indicate that the conjugated
ST19F fragment was suboptimal or that immune interference between
the two glycans led to suppression of the response against this serotype.</p></sec></sec><sec id="sec3"><label>3</label><title>Emerging AMR Targets</title><sec id="sec3.1"><label>3.1</label><title><italic toggle="yes">Acinetobacter baumannii</italic></title><p><italic toggle="yes">A. baumannii</italic>, a commensal Gram-negative bacterium,
is an important source of hospital acquired infections, and extremely
drug-resistant strains have emerged.<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> Intensive care patients and patients receiving mechanical ventilation
are at risk of developing lung infections, urinary tract infections,
bacteremia, endocarditis, skin infections, and meningitidis.<sup><xref ref-type="bibr" rid="ref164">164</xref></sup> The high mortality and morbidity of <italic toggle="yes">A. baumannii</italic> infections are a strong incentive for the development
of alternative treatments, such as active or passive vaccination strategies,
and whole cell vaccines, outer membrane vesicles (OMVs), as well as
protein-based vaccines are under development.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup><italic toggle="yes">A. baumannii</italic> shows an extremely diverse
CPS repertoire, with many different serotypes expressing unique structures.
Passive immunization strategies using a monoclonal antibody against
the K1 capsular polysaccharide,<sup><xref ref-type="bibr" rid="ref166">166</xref></sup> a polymer
built up from [ &#8594;3)-&#946;-<sc>d</sc>-QuiNAc4NR-(1&#8211;4)-&#945;-<sc>d</sc>-GlcNAc6OAc-(1&#8211;4)-&#945;-<sc>d</sc>-GalNAcA-(1 &#8594;]
repeats, with the quinovose residue carrying an acetyl or 3-hydroxybutyrate
residue at the C-4-amine, are under development.<sup><xref ref-type="bibr" rid="ref167">167</xref></sup></p><p>The extraordinary biodiversity of the <italic toggle="yes">A.
baumannii</italic> polysaccharides,<sup><xref ref-type="bibr" rid="ref168">168</xref></sup> of
which more than 40 different structures have been reported, poses
tremendous challenges to their syntheses. Although they serve as a
source of inspiration for the development of new synthetic methodologies,
conjugation-ready <italic toggle="yes">A. baumannii</italic> oligosaccharides with
application in initial immunology studies have not been reported.
Wu and co-workers have reported that the natural polysaccharide of
strain 54149 (a strain that was isolated from IC patients) could be
depolymerized by the tail spike protein of bacteriophage &#934;AB6TSP
to generate an octasaccharide, comprising two tetrasaccharide repeating
units of the polymer. These repeating units are built up of [&#8594;3)-&#946;-GalNAcp-(1&#8211;3)-[&#946;-Glcp-(1&#8211;6)]-&#946;-Galp-(1&#8594;]
repeating units with the characteristic pseudaminic acid residues
at the C-6 of the glucose residue.<sup><xref ref-type="bibr" rid="ref169">169</xref></sup> This
octasaccharide (<bold>17</bold>) was conjugated to CRM<sub>197</sub> by formation of the anomeric hemiaminal, reaction with dithiobis(sulfosuccinimidyl
propionate) (DTSSP), dithiothreitol (DTT) mediated reduction of the
disulfide, and addition to maleimide functionalized CRM<sub>197</sub> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Immunization
of rabbits with conjugate <bold>(18)</bold> (4 boosts in 2 weeks)
gave serum capable of recognizing <italic toggle="yes">A. baumannii</italic> 54149
CPS and <bold>(17)</bold>. Cross-reactivity of this serum with other
strains was less than the cross reactivity of sera raised using the
native polysaccharide. The pseudaminic acid residue was shown to be
a crucial binding motif for the antibodies in the sera, which showed
adequate bactericidal activity.<sup><xref ref-type="bibr" rid="ref169">169</xref></sup></p><fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Pseudaminic
acid (marked in red) containing octasaccharide conjugated
to CRM<sub>197</sub> as vaccine candidate against <italic toggle="yes">A. baumannii</italic>. Raised antibodies recognized the exopolysaccharide (EPS) and induced
bacterial killing.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr6" position="float" orientation="portrait" xlink:href="cr2c00021_0006.jpg"/></fig></sec><sec id="sec3.2"><label>3.2</label><title><italic toggle="yes">Clostridioides difficile</italic></title><p><italic toggle="yes">Clostridioides
difficile</italic>, also known as <italic toggle="yes">C. difficile</italic>, is
a Gram-positive species of spore forming
bacteria that causes severe diarrhea and inflammation of the colon
such as colitis.<sup><xref ref-type="bibr" rid="ref170">170</xref></sup><italic toggle="yes">C. difficile</italic> infection (CDI) is a global health threat with a high incidence
in both hospitals and communities. It is estimated that <italic toggle="yes">C.
difficile</italic> causes nearly half a million infections in the
US annually with associated health care costs over $5 billion.<sup><xref ref-type="bibr" rid="ref171">171</xref></sup> CDI is associated with a high risk of recurrence
(approximately 60% after three or more episodes of infection), even
in the absence of additional risk factors, such as antibiotics or
exposure to the bacterium.<sup><xref ref-type="bibr" rid="ref172">172</xref></sup></p><p>The
main risk factor for CDI is the imbalance of the microbiota, which
leads to the disruption of its barrier effect, mainly due to systemic
exposure to antibiotics. CDI affects elderly people with comorbidities,
patients undergoing surgery, long-term hospitalized patients, and
immunocompromised patients. The main virulence factors of <italic toggle="yes">C. difficile</italic> are two large exotoxins, toxins A and B (TcdA
and TcdB, respectively), which are important mediators of intestinal
damage and disease. In addition to these toxins, several surface components
have been characterized as colonization factors, and these have been
shown to be immunogenic.<sup><xref ref-type="bibr" rid="ref173">173</xref></sup></p><p>On the
cell surface of <italic toggle="yes">C. difficile</italic>, three cell-wall
polysaccharides, PSI, PSII, and PSIII, that are essential for bacterial
survival and virulence, were identified and structurally characterized.<sup><xref ref-type="bibr" rid="ref174">174</xref>,<xref ref-type="bibr" rid="ref175">175</xref></sup> PSI is expressed at low levels on the cell surface, and it is unclear
whether it is present in different <italic toggle="yes">C. difficile</italic> strains,
while PSII and PSIII appear to be conserved surface polysaccharide
antigens across the majority of <italic toggle="yes">C. difficile</italic> strains.<sup><xref ref-type="bibr" rid="ref176">176</xref></sup> PSI is a polymer of branched pentasaccharide
phosphate repeats, composed of rhamnose, glucose, and phosphate. PSII
is made up of a hexasaccharide phosphate repeat of glucose, mannose,
and <italic toggle="yes">N</italic>-acetyl-galactosamine constituents. PSIII is
a water-insoluble lipoteichoic acid-like glycan, composed of phosphate, <italic toggle="yes">N</italic>-acetyl-glucosamine, and glyceric acid with minor repetitions
of glucose and glycerol portions in the reducing regions.<sup><xref ref-type="bibr" rid="ref174">174</xref></sup> In 2013 Martin et al. synthesized the pentasaccharide
repeating unit of PSI and oligosaccharide substructures by applying
a linear synthesis strategy from monosaccharide building blocks following
the strategy schematically depicted in <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>.<sup><xref ref-type="bibr" rid="ref177">177</xref></sup> The synthetic
PSI repeating unit conjugated to CRM<sub>197</sub> was shown to be
capable of inducing immunoglobulin class switching as well as affinity
maturation in mice. A disaccharide motif was identified as the minimal
epitope, recognizing antibodies from serum and stools from CDI patients.</p><fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>(A) Chemical
structures of <italic toggle="yes">C. difficile</italic> PSI, PSII,
and PSIII. (B) Synthetic routes for PSI and related fragments have
been developed enabling identification of the disaccharide epitope
(<bold>26</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr7" position="float" orientation="portrait" xlink:href="cr2c00021_0007.jpg"/></fig><p>The synthesis of the
PSI pentasaccharide repeating unit and conjugation
to a subunit of <italic toggle="yes">C. difficile</italic> exotoxin B to yield
a potential dual vaccine were reported by Monteiro&#8217;s team.<sup><xref ref-type="bibr" rid="ref178">178</xref></sup> Sera from healthy horses were shown to contain
natural anti-PSI IgG antibodies that detected both the synthetic nonphosphorylated
PSI repeat and the native PSI polysaccharide, with a slightly higher
recognition of the native PSI polysaccharide. Adamo and co-workers
synthesized the hexasaccharide repeating unit of PSII, with and without
the phosphate group at the nonreducing end, using a convergent [4+2]
approach.<sup><xref ref-type="bibr" rid="ref179">179</xref></sup> The synthetic hexasaccharides
were conjugated to CRM<sub>197</sub> carrier protein and evaluated
in mice, showing that the hexasaccharide with the phosphate group
was able to elicit IgG antibodies that recognized PSII on the surface
of <italic toggle="yes">C. difficile</italic> cells, while the nonphosphorylated
hexasaccharide induced neither IgG nor IgM antibodies (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>).<sup><xref ref-type="bibr" rid="ref180">180</xref></sup> The synthesis of the nonphosphorylated hexasaccharide has also been
achieved by Seeberger and co-workers, who conjugated the glycan to
CRM<sub>197</sub> using squaric acid chemistry. The conjugate was
capable of inducing carbohydrate-specific antibodies in mice, which
bound to the hexasaccharide immobilized on a glycan array.<sup><xref ref-type="bibr" rid="ref181">181</xref></sup></p><fig id="fig8" position="float" orientation="portrait"><label>Figure 8</label><caption><p>(A) Synthetic fragments of PSII from <italic toggle="yes">C. difficile</italic>. (B) Recognition of PSII on ELISA by the conjugated fragments showed
the importance of the phosphate group for cross-reactivity with the
natural PS. (C) Recognition of PSII on the bacterial surface assessed
by confocal microscopy with anti-PSII (left part) and anti-(<bold>27</bold>) antibodies (right part). Adapted with permission from
ref (<xref ref-type="bibr" rid="ref180">180</xref>). Copyright
2012 American Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr8" position="float" orientation="portrait" xlink:href="cr2c00021_0008.jpg"/></fig><p>Antibodies in stool from patients were also probed. It was observed
that not all stool samples showed binding. This could be explained
by varying amounts of antibodies in the stool samples, occurrence
of CDI from a different serotype, or the need of the phosphate group
for higher affinity binding as reported above. In 2013, Seeberger&#8217;s
group reported the synthesis of phosphodiester bridged oligomers of
the PSIII repeating unit. A synthetic PSIII monomer and dimer, synthesized
using phosphoramidite chemistry, were immobilized on a glycan array
and used to detect anti-glycan antibodies in the sera of CDI patients.<sup><xref ref-type="bibr" rid="ref182">182</xref></sup> The PSIII dimer conjugated to CRM<sub>197</sub> proved to be immunogenic and capable of protecting mice from a challenge
with <italic toggle="yes">C. difficile</italic>.<sup><xref ref-type="bibr" rid="ref183">183</xref>,<xref ref-type="bibr" rid="ref184">184</xref></sup></p><p>Later,
the same team evaluated the protective efficacy of various
glycoconjugates prepared by linking the various synthetic glycans
to CRM<sub>197</sub>, demonstrating that PSI and PSIII conjugates
can reduce colonization in a murine model more effectively than an
antitoxin vaccine candidate.<sup><xref ref-type="bibr" rid="ref185">185</xref></sup> However,
no binding to <italic toggle="yes">C. difficile</italic> cells could be demonstrated
by flow cytometry, indicating that expression of the glycans was different
in the used in vitro setup, that binding was too weak, as described
above, or that cellular immune responses (as opposed to antibody mediated
effects) were responsible for the protective effect. Furthermore,
this study showed that the PSI, PSII, and PSIII glycoconjugates did
not significantly affect the murine gut microbiota, indicating that
the aroused antibodies are highly specific for <italic toggle="yes">C. difficile</italic>.</p></sec><sec id="sec3.3"><label>3.3</label><title><italic toggle="yes">Escherichia coli</italic></title><p><italic toggle="yes">E. coli</italic> is a Gram-negative bacterium of which most
strains are harmless commensal species. It is the most studied prokaryote
and the &#8220;work horse bacterium&#8221; in molecular biology,
microbiology, and biotechnology. Pathogenic <italic toggle="yes">E. coli</italic> strains, however, are causative agents of diarrhea disease, urinary
tract infections, and pyelonephritis and neonatal meningitidis,<sup><xref ref-type="bibr" rid="ref186">186</xref></sup> and pathogenic strains are emerging as the
primary cause of bacteremia and sepsis in the US<sup><xref ref-type="bibr" rid="ref187">187</xref></sup> and are associated with increasing AMR.<sup><xref ref-type="bibr" rid="ref188">188</xref></sup><italic toggle="yes">E. coli</italic> strains can be serotyped using
different antigens, including their O-antigens (based on the partial
structure of the lipopolysaccharides, of which currently &gt;180 have
been established) and K-antigens (based on the structures of the capsular
polysaccharides, of which there are currently &#8764;80 reported).<sup><xref ref-type="bibr" rid="ref189">189</xref></sup></p><p>Particularly, <italic toggle="yes">E. coli</italic> O25 ST131, producing extended-spectrum beta-lactamases (ESBLs),
has spread globally, becoming the dominant type among extraintestinal
isolates in many parts of the world.<sup><xref ref-type="bibr" rid="ref190">190</xref></sup></p><p>The development of vaccines against different strains has
taken
several approaches, including the use of attenuated pathogens and
the development of protein- and peptide-based vaccines.</p><p>Polysaccharides
have been used in the development of glycoconjugate
vaccines, that have been generated through conjugation of native polysaccharides
to carrier proteins using classic chemical conjugation or the in vivo
bioconjugation (PGCT) approach. A nine-valent bioconjugate vaccine
(ExPEC 9 V) is currently approaching phase III studies, after promising
immunogenicity data of nine out of ten conjugates tested in phase
II (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).<sup><xref ref-type="bibr" rid="ref191">191</xref></sup> The broad structural variety of the <italic toggle="yes">E. coli</italic> O- and K-antigens has been an inspiration for the
development of effective syntheses to generate well-defined fragments
of these polysaccharides. The vast majority of these synthetic efforts,
however, generated stand-alone saccharides, not suitable for the generation
of glycoconjugate vaccines. Li and co-workers reported on the assembly
of a core R3 pentasaccharide that was used to generate a conjugate
vaccine.<sup><xref ref-type="bibr" rid="ref192">192</xref></sup> The core oligosaccharides of <italic toggle="yes">E. coli</italic> lipopolysaccharides show limited variation&#8212;only
five are known, termed R1, R2, R3, R4, and K12&#8212;and therefore
represent attractive targets against which to direct the immune system. <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref> shows the structure
and synthetic strategy of the conjugation-ready R3 pentasaccharide
(<bold>32</bold>), built up from the common monosaccharides galactose,
glucose, and glucosamine.</p><fig id="fig9" position="float" orientation="portrait"><label>Figure 9</label><caption><p>Synthetic routes for conjugates of the <italic toggle="yes">E. coli</italic> O-antigen core pentasaccharide (A) and repeating
unit of O1 (B).
A conjugate of the core pentasaccharide was shown to induce functional
antibodies. The conjugate of the O1 fragment was recognized by anti-O1
chicken serum. The &#946;-Rha-(1&#8211;3)-GlcNAc linkage was successfully
generated by boron mediated insertion of the GlcNAc building block
in the rhamnose-1,2-epoxide intermediate. The assembled structure
was deprotected and conjugated to BSA (<bold>40</bold>). This conjugate
was shown to recognize chicken anti-O1 serum, using an ELISA assay.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr9" position="float" orientation="portrait" xlink:href="cr2c00021_0009.jpg"/></fig><p>Conjugation of this glycan, using a disuccinimidyl
suberate linker,
to the common carrier protein CRM<sub>197</sub> delivered a model
vaccine (<bold>33</bold>) carrying &#177;18 oligosaccharides per protein.
Immunization of mice in a mixture with Freund&#8217;s complete adjuvant
(FCA), led to the generation of sera with increased IgM, IgG1, IgG2a,
IgG2b, and IgG3 levels. The sera were shown to have bactericidal activity
against the <italic toggle="yes">E. coli</italic> O157:H7 strain, with 50% killing
at 160-fold dilution.</p><p>Recently, Toshima&#8217;s group reported
on the synthesis of a
pentasaccharide from the LPS of avian pathogenic <italic toggle="yes">E. coli</italic> O1, which is considered problematic because of its zoonotic potential.<sup><xref ref-type="bibr" rid="ref193">193</xref></sup> The structure (<bold>39</bold>) presents a
&#946;-ManNAc residue at the upstream end and a &#946;-Rha linked
to the downstream GlcNAc (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>). The synthesis was achieved through a [2+3] strategy,
wherein the &#946;-ManNAc-(1&#8211;3)-Rha was built using a Glc
donor, followed by inversion of configuration at the Glc-C2 via an
azide displacement of a triflate intermediate.</p></sec><sec id="sec3.4"><label>3.4</label><title><italic toggle="yes">Enterococci</italic> spp</title><p><italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">faecium</italic> are Gram-positive bacteria that are
associated with infections worldwide. <italic toggle="yes">Enterococci</italic> account for 11% of nosocomial bloodstream isolates,
and an increasing trend has been recorded over the last decades.<sup><xref ref-type="bibr" rid="ref194">194</xref>,<xref ref-type="bibr" rid="ref195">195</xref></sup> In the US about 66,000 enterococcal infections occur each year,
of which 20,000 are due to multiple drug-resistant strains, with about
1,300 deaths per year.<sup><xref ref-type="bibr" rid="ref196">196</xref></sup></p><p><italic toggle="yes">E. faecalis</italic> is particularly worrisome because of vancomycin
resistance, which also occurs in the community, with risk factors
including non-heme residence, chronic skin ulcers, previous invasive
procedures, exposure to antibiotics, and the presence of indwelling
devices.<sup><xref ref-type="bibr" rid="ref197">197</xref></sup> Four different serotypes (CPS-A
to CPS-D) have been described for <italic toggle="yes">E. faecalis</italic> by
mapping their immunoreactivities with ELISA and the opsonophagocytic
capacity of antisera raised against the different CPS of prototype
strains combined with analysis of their CPS locus.<sup><xref ref-type="bibr" rid="ref198">198</xref></sup> One of the capsules produced by the CPS locus is diheteroglycan
(DHG), which is present in CPS-C and CPS-D strains. DHG masks LTA
in the bacteria and prevents opsonization by anti-LTA antibodies.
The structure of DHG from the <italic toggle="yes">E. faecalis</italic> type 2
strain has been described by Theilacker and co-workers, where the
polysaccharide repeating unit [&#8594;6)-&#946;-<sc>d</sc>-Gal<italic toggle="yes">f</italic>-(1&#8211;3)-&#946;-<sc>d</sc>-Glc<italic toggle="yes">p</italic>-(1&#8594;]
is decorated at C-5 of the Galf residue with an O-acetyl and at C-3
with an R-lactic acid (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>).<sup><xref ref-type="bibr" rid="ref198">198</xref>,<xref ref-type="bibr" rid="ref199">199</xref></sup></p><fig id="fig10" position="float" orientation="portrait"><label>Figure 10</label><caption><p><italic toggle="yes">Enterococcus
faecalis</italic> and <italic toggle="yes">faecium</italic> synthetic antigens,
including capsular polysaccharides (DHG), as
well as lipoteichoic acids (LTA) and wall teichoic acids (WTA). Glycoconjugates
of synthetic DHG (<bold>45</bold> and <bold>46</bold>) and LTA (<bold>51</bold>) fragments elicited antibodies in rabbit, inducing bacterial
opsonophagocytic killing (OPK) in vitro and providing protection from
bacterial colonization in vivo.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr10" position="float" orientation="portrait" xlink:href="cr2c00021_0010.jpg"/></fig><p>Recently, Laverde et al. described the synthesis of a library of
DHG-oligomers up to an 8-mer in length, lacking the <italic toggle="yes">O</italic>-acetyl and lactic acid residues.<sup><xref ref-type="bibr" rid="ref200">200</xref></sup> The
fragments (<bold>43</bold> and <bold>44</bold>) were built up using
either Gal<italic toggle="yes">f</italic>-Glc<italic toggle="yes">p</italic> or Glc<italic toggle="yes">p</italic>-Gal<italic toggle="yes">f</italic> dimers to explore whether the type of frameshift
played an important role in immunogenicity. The assembled library
of DHG-fragments was functionalized with a biotin handle and printed
on a streptavidin glycan array. It was revealed that the longer fragments
were more immunoreactive with the frameshifts having the &#8220;non-self&#8221;
galactofuranose terminus appearing as better antigens. The octasaccharides
were selected for conjugation, and the two octamer frameshifts were
coupled to BSA through squarate chemistry (<bold>45</bold> and <bold>46</bold>). Antibodies raised in mice with the two conjugates showed
opsonophagocytic killing activities of <italic toggle="yes">E. faecalis</italic> type 2 strains and CPS-C and CPS-D strains expressing DHG. In a
mouse sepsis model, it was shown that the raised sera offered protection
in a passive immunization strategy. As the evaluated synthetic fragments
were not decorated with acetyl or lactic acid substituents, the role
of these functional groups remains to be established. The cell wall
of <italic toggle="yes">E. faecalis</italic> A and B is not protected by a CPS,
and the LTA of these species is thus more exposed. LTA is built up
from a poly(1&#8211;3)-glycerol phosphate (GroP) backbone and has
attracted attention for its potential as an universal antigen as it
is shared with other Gram-positive pathogens such as <italic toggle="yes">S. aureus</italic>.<sup><xref ref-type="bibr" rid="ref201">201</xref>&#8722;<xref ref-type="bibr" rid="ref203">203</xref></sup> Initial studies conducted with isolated
LTA from <italic toggle="yes">E. faecalis</italic> showed that opsonophagocytic
antibodies could be raised against type 1 LTA, and cross-reactivity
was observed against <italic toggle="yes">E. faecalis</italic>, <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">S. epidermidis</italic> strains.<sup><xref ref-type="bibr" rid="ref204">204</xref></sup> Different synthetic approaches
toward well-defined LTA fragments have been developed using both solution
phase<sup><xref ref-type="bibr" rid="ref205">205</xref></sup> and solid phase chemistry,<sup><xref ref-type="bibr" rid="ref206">206</xref>,<xref ref-type="bibr" rid="ref207">207</xref></sup> and these have been recently reviewed.<sup><xref ref-type="bibr" rid="ref203">203</xref></sup><italic toggle="yes">E. faecalis</italic> GroP LTA can be decorated with &#945;-<sc>d</sc>-glucosyl or &#945;-kojibiosyl residues at the C-2 of the
GroP residues. This position can also carry labile <sc>d</sc>-alanine
esters. Building on contemporary DNA chemistry, Hogendorf et al. assembled
a small library of LTA fragments, out of which (<bold>50</bold>) was
identified as a potent antigen, able to inhibit the opsonic killing
of antibodies raised against LTA from <italic toggle="yes">E. faecalis</italic> 12030.<sup><xref ref-type="bibr" rid="ref208">208</xref></sup> The BSA conjugates of <bold>(50)</bold> induced specific IgG antibodies in rabbits, that were
directed to the native LTA. These antibodies showed cross-reactivity
against other types of Gram-positive strains and could be used in
a passive immunization scheme to protect mice in an endocarditis (heart
valve infection) model.</p><p>To generate a broader and more diverse
library of TA oligomers
presenting different carbohydrate appendages at different positions
on the TA chain, van der Es et al. developed a second generation automated
solid phase approach using a universal linker system and fluorous-tagging
strategy.<sup><xref ref-type="bibr" rid="ref209">209</xref></sup> These TA fragments were used
to create a TA glycan array to characterize the binding specificity
of sera raised against isolated LTA from <italic toggle="yes">E. faecalis</italic> and the well-defined TA conjugate (<bold>51</bold>). The arrays
revealed that the serum raised against the native LTA bound various
TA fragments and no specificity for any carbohydrate pattern became
clear. The serum raised against conjugate (<bold>51</bold>) proved
to be very selective in binding, showing that it is possible to selectively
raise antibodies to recognize specific and well-defined TA epitopes,
which is not possible for TAs isolated from bacterial sources.</p><p>The effect of the &#945;-glycosylation has been recently more
thoroughly explored.<sup><xref ref-type="bibr" rid="ref210">210</xref></sup> Using an improved
method for the assembly of the glycosylated GroP building block, a
series of glucosylated GroP hexamers was assembled, varying in the
position of the glucose residue. Besides, a series of glucosylated
GroP of the opposite stereochemistry (sn-1-GroP) was generated as
well. Using glycan array binding studies, it was revealed that antibodies
raised against (<bold>52</bold>) selectively recognized the sequence
to which they were raised with binding decreasing as the glucose moiety
moved down the chain. The GroP hexamers of the opposite stereochemistry
were poorly recognized. The serum raised against the native LTA bound
the opposite stereochemistry GroP better as it better resembles how
LTA is anchored in the bacterial cell wall. A follow-up study elucidated
the interactions of a mAb generated against <bold>(52)</bold> and
a library of LTA structures through a combination of glycan array,
ELISA, SPR-analyses, and STD-NMR spectroscopy to show that the number
of GroP residues was important for affinity of the mAb and that binding
was indirectly effected by the presence of the glucose residue.<sup><xref ref-type="bibr" rid="ref211">211</xref></sup> This study confirmed the importance of the
backbone chirality.</p><p><italic toggle="yes">Enterococci</italic> also express
different types of WTA,
where several type 2 WTAs have been described for <italic toggle="yes">E. faecalis</italic>. A WTA from <italic toggle="yes">E. faecium</italic> strain U0317 was found to
consist of &#8594;6)-&#945;-GalNAc-(1&#8211;3)-&#946;-<sc>d</sc>-GalNAc-(1&#8211;2)-GroP-(3&#8594; repeating units, and this complex
WTA can shield the LTA from opsonophagocytic antibodies.<sup><xref ref-type="bibr" rid="ref198">198</xref>,<xref ref-type="bibr" rid="ref203">203</xref>,<xref ref-type="bibr" rid="ref212">212</xref></sup> While the biosynthesis of LTA
includes GroP units consisting of phosphatidyl glycerol having sn-1-glycerol
phosphate stereochemistry, the WTA is generated using cytidine sn-3-glycerol
phosphate. The stereochemistry of the GroP moiety from the WTA was
unambiguously established by van der Es et al.<sup><xref ref-type="bibr" rid="ref213">213</xref></sup> through the synthesis of two sets of oligomers using either
an sn-glycerol-1-phosphate or an sn-glycerol-3-phosphate constituent.
From comparison of the NMR spectra of the synthesized fragments and
naturally occurring WTA, the stereochemistry of <italic toggle="yes">E. faecium</italic> WTA GroP was established to be sn-3-glycerol phosphate.</p><p>Zhou
et al. also reported a synthesis of the <italic toggle="yes">E. faecium</italic> U0317 repeating unit for investigation of a WTA-based vaccine. However,
this report did not describe the stereochemistry of the GroP moiety.
The target structure was synthesized using H-phosphonate chemistry
to insert the phosphodiester bridged linker for conjugation. The trimer
was conjugated with the carrier proteins KLH and HSA (<bold>53</bold>) using a bifunctional glutaryl ester, and the conjugates could be
used to generate antibodies that were capable of recognizing the sequence
to which they were raised. Binding to naturally sourced WTA or <italic toggle="yes">E. faecium</italic> was not reported, nor were any opsonic properties
evaluated.<sup><xref ref-type="bibr" rid="ref214">214</xref></sup></p></sec><sec id="sec3.5"><label>3.5</label><title>Group
A <italic toggle="yes">Streptococcus</italic></title><p><italic toggle="yes">Streptococcus pyogenes</italic>, commonly known as group
A <italic toggle="yes">Streptococcus</italic> (GAS), is a Gram-positive &#946;-haemoliticum
bacterium that can cause a variety of diseases, varying from minor
illnesses (pharyngitis and cellulitis) to very serious (glomerulonephritis,
necrotizing fasciitis, and rheumatic fever) and deadly diseases (sepsis).<sup><xref ref-type="bibr" rid="ref215">215</xref></sup> It, thus, represents a significant threat to
human health.</p><p>Currently GAS infections are treated with antibiotic
therapy, but the increased emergence of antibiotic resistance renders
new effective treatment and prevention strategies urgent.<sup><xref ref-type="bibr" rid="ref216">216</xref></sup> The GAS cell wall is decorated with a surface
polysaccharide, classified as the Lancefield antigen,<sup><xref ref-type="bibr" rid="ref217">217</xref></sup> that consists of trisaccharide repeating units
of [&#8594;3)-&#945;-<sc>l</sc>-Rha<italic toggle="yes">-</italic>(1&#8211;2)-[&#946;-<sc>d</sc>-GlcNAc-(1&#8211;3)]-&#945;-<sc>l</sc>-Rha-(1&#8594;]. This
polysaccharide is a bacterial virulence factor and has been recognized
as a promising target to develop GAS vaccines.<sup><xref ref-type="bibr" rid="ref218">218</xref></sup> Its expression is conserved across a variety of bacterial
strains,<sup><xref ref-type="bibr" rid="ref219">219</xref></sup> and protective properties of
anti-GAS-PS antibodies have been demonstrated.<sup><xref ref-type="bibr" rid="ref220">220</xref></sup> Pinto and co-workers have reported several syntheses of
GAS-PS fragments and their protein conjugates.<sup><xref ref-type="bibr" rid="ref221">221</xref>&#8722;<xref ref-type="bibr" rid="ref226">226</xref></sup> To gain insight into the epitope of GAS-PS, oligosaccharides were
used to study interactions with an IgG3 mAb generated against the
natural polysaccharide. It was found that &#946;-<sc>d</sc>-GlcNAc-(1&#8211;3)-[&#945;-<sc>l</sc>-Rha-(1&#8211;2)]-&#945;-<sc>l</sc>-Rha and an extended surface
were the key components for epitope recognition.<sup><xref ref-type="bibr" rid="ref227">227</xref></sup> Homology-based molecular modeling of the Fv region of the
mAb indicated that two pockets could accommodate two GlcNAc residues
on adjacent trisaccharide units, which was further supported with
data from STD-NMR studies.<sup><xref ref-type="bibr" rid="ref228">228</xref></sup></p><p>Using
naturally sourced CPS in combination with well-defined synthetic
fragments, it was revealed that polyclonal rabbit serum and serum
of children recovered from a GAS infection showed different binding
specificities.<sup><xref ref-type="bibr" rid="ref229">229</xref></sup></p><p>The human sera
required a hexasaccharide binding motif with at
least two GlcNAc residues for adequate binding, while the rabbit sera
also bound well to shorter fragments. Likely, repeated exposure to
the bacterium led to affinity maturation of the human antibodies and
a much narrower binding specificity. The GAS PS adopts a helical structure
with the backbone polyrhamnose forming a helix placing the GlcNAc
residues on the periphery.<sup><xref ref-type="bibr" rid="ref230">230</xref></sup></p><p>Based
on these detailed structural and binding studies it was proposed
that an effective oligosaccharide conjugate vaccine would require
the presentation of a contiguous series of GAS-PS helical motifs and
would likely be comprised of, at least, a doubly branched hexasaccharide.
Indeed, when the immunogenicity of TT conjugates of a synthetic hexasaccharide,
conjugated through squarate chemistry (<bold>55</bold>), and the native
cell-wall polysaccharide (CWPS) were compared in mice, similar IgG
titers were elicited (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig">11</xref></xref> panel A).<sup><xref ref-type="bibr" rid="ref231">231</xref></sup> In a more recent
work by Costantino and co-workers, a series of GAS oligosaccharides
with different frameshifts were chemically synthesized and the immunogenicities
of their CRM<sub>197</sub> conjugates were tested in mice.<sup><xref ref-type="bibr" rid="ref232">232</xref></sup> All the structures induced robust production
of functional IgGs, and the dodecasaccharide (<bold>56</bold>) with
a terminal Rha residue induced the highest opsonophagocytic titer.
A similar trend was observed in a GAS infection model, indicating
the correlation of opsonic antibodies with protection. Gu and co-workers
have tested synthetic GAS-PS with different carrier proteins, including
BSA, CRM<sub>197</sub>, TT, and GAS C5a peptidase (ScpA, <bold>57</bold>).<sup><xref ref-type="bibr" rid="ref233">233</xref></sup> The use of a streptococcal protein
could increase protection and could avoid potential epitope suppression
with CRM<sub>197</sub>,<sup><xref ref-type="bibr" rid="ref234">234</xref></sup> as this latter
protein is used in many commercial vaccines. Mono-, di-, and trimers
of the trisaccharide repeating unit of GAS PS were synthesized by
a convergent and efficient strategy and conjugated to an enzymatically
inactive ScpA mutant through a bifunctional glutaryl linker.<sup><xref ref-type="bibr" rid="ref233">233</xref></sup> The ScpA-neoglycoconjugate induced an anti-carbohydrate
immune response in mice, that was comparable to the one elicited by
the related CRM<sub>197</sub> and TT conjugates. In addition, robust
ScpA193-specific antibodies were observed, making the ScpA193&#8211;oligosaccharide
conjugates promising bivalent anti-GAS vaccine candidates.</p><fig id="fig11" position="float" orientation="portrait"><label>Figure 11</label><caption><p>Synthetic
strategies for group A <italic toggle="yes">Streptococcus</italic> antigens and
collected immune data. (A) Immunization with a GAS
cell wall hexasaccharide conjugated to BSA through squarate chemistry
induced antibodies identical to a natural CPS-TT conjugate. In silico
conformational analysis of the immunogenic fragment suggested that
the polyrhamnose backbone forms a helix with the GlcNAc moieties on
the periphery. Adapted with permission from ref (<xref ref-type="bibr" rid="ref230">230</xref>). Copyright 2004 Elsevier).
(B) The GAS dodecasaccharide conjugated to CRM<sub>197</sub> elicited
a high titer of anti-GAS opsonic antibodies. (C) Chemoenzymatically
assembled nonasaccharide conjugated to the GAS protein ScpA (GAS C5a
peptidase) induced antibodies against both antigens. (D) Site-selective
conjugation of natural GAS polysaccharide to the streptococcal protein
SpyAD induced antibodies able to provide in vivo protection in mice.
(E) GAS trisaccharide conjugated to a synthetic peptidolipid, containing
the T-cell peptide epitope PADRE.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr11" position="float" orientation="portrait" xlink:href="cr2c00021_0011.jpg"/></fig><p>In another study a more in-depth immunological characterization
of the ScpA193 conjugates was conducted. Of the tri-, hexa-, and nonasaccharides,
the latter two nonasaccharide&#8211;ScpA193 conjugates in a mouse
model revealed that the latter conjugate could effectively protect
structures, leading to a better in vitro recognition of GAS cells
and opsonophagocytosis.<sup><xref ref-type="bibr" rid="ref235">235</xref></sup></p><p>Evaluation
of the hexasaccharides and the animals from GAS challenge
and GAS-induced pulmonary damage showed significantly increased animal
survival. Further studies suggested that the two ScpA193 conjugates
could function through activation of CD4+ T-cells and promotion of
T-cell help, which would trigger differentiation into antigen-specific
Th1 and Th2 cells, which, in turn, would provoke strong B-cell activation
and IgG production.</p><p>It has been proposed that antibodies directed
at the immunodominant
GlcNAc residues may give rise to autoimmunity directed at GlcNAc residues
on self-tissue. Therefore, polyrhamnose has been proposed as a possible
alternative to GAS PS,<sup><xref ref-type="bibr" rid="ref236">236</xref>,<xref ref-type="bibr" rid="ref237">237</xref></sup> and it has been shown
that an immune response can be invoked against the polyrhamnose backbone,
lacking the GlcNAc branches, and that sera raised against this backbone
PS can promote opsonophagocytic killing of multiple GAS strains to
offer protection against a systemic GAS challenge after passive immunization.<sup><xref ref-type="bibr" rid="ref236">236</xref></sup> Nanoparticles generated by conjugation of a
rhamnohexaose, corresponding to three consecutive GAS PS epitopes,
devoid of the GlcNAc moieties, to gold beads have been shown to inhibit
binding of anti-GAS murine serum in an ELISA setup, indicating that
this hexasaccharide may be an adequate antigen in a synthetic anti-GAS
vaccine.<sup><xref ref-type="bibr" rid="ref238">238</xref></sup> Naturally sourced GAS-polyrhamnose
has been conjugated to the streptococcal protein SpyAD (<bold>58</bold>) and explored as a vaccine modality.<sup><xref ref-type="bibr" rid="ref239">239</xref></sup> Conjugation was achieved in a site-selective fashion by expressing
the protein in the so-called Xpress cell-free expression system, to
incorporate a non-natural amino acid enabling click chemistry of the
polysaccharides. The conjugated SpyAD-GACPR elicited antibodies that
bound the surface of various GAS strains and promoted opsonophagocytic
killing by human neutrophils. Active immunization of mice with a multivalent
vaccine consisting of SpyAD-polyrhamnose, together with the candidate
vaccine antigens streptolysin O and C5a peptidase, protected against
a GAS challenge in a systemic infection model and localized skin infection
model. No evidence for cross-reactivity to human heart or brain tissue
epitopes was found, indicating this approach can circumvent potential
safety concerns of the GlcNAc carrying GAS PS. Furthermore, the inactive
mutant of SpyAD is suited for site-selective conjugation, thereby
preserving critical protective immune epitopes of the carrier protein.</p><p>An innovative design has been proposed by Stephenson and co-workers,
who conjugated small GAS PS fragments to a synthetic peptidolipid,
containing the PADRE peptide, known to trigger T-cell responses.<sup><xref ref-type="bibr" rid="ref240">240</xref></sup> By this approach a fully synthetic nanoparticle
vaccine (<bold>59</bold>) of 300&#8211;500 nm was formulated. The
di- and trirhamnosyl as well as the GlcNAc dirhamnosyl lipopeptides
were able to produce statistically significant GAC-specific IgG responses
in comparison to unconjugated structures.<sup><xref ref-type="bibr" rid="ref241">241</xref></sup> Mice were immunized with the glycopeptidolipids, and the serum raised
against the di- and trirhamnoside constructs showed opsonic activity.</p></sec><sec id="sec3.6"><label>3.6</label><title>Group B <italic toggle="yes">Streptococcus</italic></title><p><italic toggle="yes">Streptococcus agalactiae</italic>, also known as group B <italic toggle="yes">Streptococcus</italic> (GBS), is a Gram-positive pathogen that colonizes
the recto-vaginal tract and represents a major cause of neonatal and
maternal infections.<sup><xref ref-type="bibr" rid="ref242">242</xref></sup> There is an estimate
of 2.6 million stillbirths each year, many of which are due to GBS
infections, especially in low and middle income contexts.<sup><xref ref-type="bibr" rid="ref243">243</xref></sup> The bacterial capsule is surrounded by sialylated
branched polysaccharides, which share great structural similarity
to one another, based on which 10 serotypes are defined (Ia, Ib, II,
III, IV, V, VI, VII, VIII, and IX).</p><p>All GBS polysaccharides
are sialylated, and most of them share the same monosaccharide residues.<sup><xref ref-type="bibr" rid="ref244">244</xref>,<xref ref-type="bibr" rid="ref245">245</xref></sup> The GBS CPS is a fundamental virulence factor and is promising for
the development of a vaccine for maternal immunization,<sup><xref ref-type="bibr" rid="ref242">242</xref></sup> in which the vaccine would be administered
to pregnant women to elicit serum antibodies that are then transferred
to the baby through the placenta. Data on the global distribution
of GBS clinical isolates show that a hexavalent vaccine including
serotypes Ia, Ib, II, III, IV, and V could provide a protection over
95% for all virulent GBS strains, and multicomponent CRM<sub>197</sub> conjugates have been tested in phase I and II clinical trials.<sup><xref ref-type="bibr" rid="ref246">246</xref>,<xref ref-type="bibr" rid="ref247">247</xref></sup> Vaccines currently under development exploit polysaccharides extracted
from bacteria conjugated to CRM<sub>197</sub>, which yield complex
heterogeneous mixtures.</p><p>Synthetic GBS oligosaccharides have
been prepared and evaluated
at a preclinical level, being mainly used to understand the chemical
features correlating with immunogenicity. Among all GBS serotypes,
type III has been most studied, because of its seroprevalence.<sup><xref ref-type="bibr" rid="ref243">243</xref></sup></p><p>Various approaches to produce short PSIII
fragments have been based
on either depolymerization or approaches employing organic synthesis
or chemoenzymatic tools.<sup><xref ref-type="bibr" rid="ref243">243</xref></sup> GBS type III
PS has for a long time been regarded to be a length-dependent conformational
epitope. Molecular dynamics simulations and NMR studies<sup><xref ref-type="bibr" rid="ref248">248</xref>,<xref ref-type="bibr" rid="ref249">249</xref></sup> showed that the GBS PSIII is able to form extended helical structures
formed of at least four repeating units (RUs), that are stabilized
by the presence of the charged sialic acids.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup></p><p>This hypothesis has been based on the length-dependent recognition
of the PS polymer with a high affinity anti-PSIII mAb. The presumed
conformational epitope has hampered the development of anti PSIII
vaccines based on short synthetic glycans, which have only recently
emerged as useful tools to effectively mimic the GBS PSIII in its
immunogenicity.</p><p>Syntheses of structures related to the linear
form of the GBSIII
repeating unit, a glycan that has also been found as part of viral
glycans, have been reported;<sup><xref ref-type="bibr" rid="ref99">99</xref>,<xref ref-type="bibr" rid="ref250">250</xref></sup> however, these linear
structures have been found to be poorly immunogenic. The synthesis
of GBS structures poses several challenges, one of which is the &#945;-sialylation
of the Gal residues. Significant advances have been made to achieve
stereoselective sialylations with the development of new building
blocks and glycosylation methodologies, summarized in <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>.<sup><xref ref-type="bibr" rid="ref251">251</xref></sup></p><table-wrap id="tbl3" position="float" orientation="portrait"><label>Table 3</label><caption><title>Synthetic GBS Structures and Corresponding
Synthetic Strategies</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr20" position="float" orientation="portrait" xlink:href="cr2c00021_0020.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="GRAPHIC-d7e2607-autogenerated" position="float" orientation="portrait" xlink:href="cr2c00021_0021.jpg"/></table-wrap><p>An early synthesis of a
more complex branched GBSIII oligosaccharide
was based on a chemoenzymatic approach where a tetrasaccharide fragment<sup><xref ref-type="bibr" rid="ref252">252</xref></sup> was sialylated using a specific rat liver sialyltransferase
to obtain the branched repeating unit <bold>(60)</bold>.</p><p>A completely
chemical assembly of a PSIII heptasaccharide (<bold>61</bold>) using
a highly convergent strategy has been described
by Demchenko and Boons,<sup><xref ref-type="bibr" rid="ref253">253</xref></sup> who used a highly
convergent strategy which also provided the hexasaccharide fragment
without the sialic acid.<sup><xref ref-type="bibr" rid="ref254">254</xref></sup> Zou et al.
used a chemoenzymatic approach to assemble the decasaccharide, representing
two repeating units of GBSIII.<sup><xref ref-type="bibr" rid="ref255">255</xref></sup></p><p>The octasaccharide precursor was enzymatically sialylated by reaction
with an &#945;-(2&#8211;3)-sialyltransferase and CMP-Neu5Ac as donor.
Using the same octasaccharide, an <italic toggle="yes">N</italic>-propionyl substituted
sialic acid analog of the GBSIII dimer was also prepared. A similar
enzymatic approach has been utilized to transform oligosaccharides
from pneumococcal ST14 to their PSIII counterparts.<sup><xref ref-type="bibr" rid="ref256">256</xref></sup> More recently, a thorough study on the immunogenicity of
the three different repeating unit frameshifts has been conducted
by Adamo and co-workers.<sup><xref ref-type="bibr" rid="ref257">257</xref></sup> A branched
(<bold>66</bold>) and &#8220;Y-shaped&#8221; (<bold>67</bold>) pentasaccharide,
along with the linear frameshift (<bold>65</bold>), bearing a linker
for conjugation to carrier proteins were generated through a convergent
[3+2] approach employing a sialogalactosyl imidate donor.</p><p>The
pentasaccharides were coupled to CRM<sub>197</sub> and the
conjugates bound to polyclonal antibodies in anti-PSIII murine serum
in an ELISA. The branching &#946;-(1&#8211;6) glucose, linked to
the GlcNAc residue, proved to be an important motif for antibody recognition.
Next, structural studies, including STD-NMR and X-ray experiments,
indicated that a hexasaccharide fragment spanning across two repeating
units is responsible for interactions with a protective mAb.<sup><xref ref-type="bibr" rid="ref258">258</xref></sup></p><p>It was found that oligosaccharides, obtained
from nitrosylation
of the polymer, with a length between 2 and 6 repeating units and
conjugated to CRM<sub>197</sub>, were able to elicit a functional
immune response, comparable to CRM<sub>197</sub>-PSIII, when conjugated
with high glycodensity.<sup><xref ref-type="bibr" rid="ref259">259</xref></sup> Following these
studies, the synthetic hexasaccharide (<bold>76</bold>) corresponding
to the identified minimal structural epitope was synthesized using
a regioselective glycosylation approach (<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig">12</xref></xref>), and this structure was conjugated to
CRM<sub>197</sub> for in vivo evaluation. The resulting neoglycoconjugate
elicited a strong protective immune response, similar the GBSIII conjugate
that is currently in clinical trials, confirming that the hexasaccharide
is the minimal GBS serotype III epitope and indicating the potential
of the synthetic carbohydrate-based vaccine targeting these complex
polysaccharides.<sup><xref ref-type="bibr" rid="ref260">260</xref></sup></p><fig id="fig12" position="float" orientation="portrait"><label>Figure 12</label><caption><p>(A) X-ray crystallography
of semisynthetic GBS III-DP2 (<bold>76</bold>) complexed with an anti
PSIII rabbit Fab. (B) Combining data from
STD-NMR and X-ray crystallography led to the identification of GBSIII
structural minimal epitope highlighted in blue corresponding to hexasaccharide
(<bold>76</bold>), which was synthesized accordingly. (C) The hexasaccharide
(<bold>76</bold>) was conjugated to CRM<sub>197</sub> carrier protein
through the SIDEA activation chemistry and tested in mice. (D) Hexa-CRM<sub>197</sub> conjugate elicited functional antibodies comparable to
the positive control PSIII-CRM<sub>197</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr12" position="float" orientation="portrait" xlink:href="cr2c00021_0012.jpg"/></fig><p>Over the years, various syntheses of other GBS serotype glycans
have been reported, with a focus on serotype Ia, which&#8212;after
type III&#8212;is one of the most prevalent serotypes. The GBSIa
hexasaccharide (<bold>68</bold>) was prepared using a chemoenzymatic
synthesis starting from a synthetic pentasaccharide, using an enzymatic
sialylation.<sup><xref ref-type="bibr" rid="ref261">261</xref></sup></p><p>In 2015 a total chemical
synthesis of the pentasaccharide corresponding
to the branched repeating unit of GBSIa (<bold>69</bold>) was accomplished
using a convergent [2+3] route using a sialogalactosyl thioglycoside
donor and a branched trisaccharide acceptor.<sup><xref ref-type="bibr" rid="ref262">262</xref></sup> An investigation on the reactivity of the galactose acceptor in
the glycosylation reaction showed that the presence of a sugar at
the 4-O-position had a big impact on the reactivity of the C-3-hydroxy
group, since it made the 3-O position inaccessible for further glycosylation.</p><p>Glycosylating the 3-<italic toggle="yes">O</italic>-position had a smaller impact
on the 4-<italic toggle="yes">O</italic>-position, and for this reason the most
effective sequence to glycosylate the galactose C-3 and C-4 hydroxy
groups was to glycosylate the 3-<italic toggle="yes">O</italic>-position before
introduction of a glycan to the C-4-OH. This approach was extended
to the synthesis of a GBSIa decasaccharide (<bold>70</bold>), corresponding
to two repeating units, which was prepared using a highly convergent
strategy. First, a key intermediate trisaccharide was constructed
via a one-pot iterative glycosylation; then, it was elongated to provide
the hexasaccharide intermediate to which two side chains were attached
by dual glycosylation with a sialogalactoside donor.<sup><xref ref-type="bibr" rid="ref264">264</xref></sup></p><p>Both the GBS Ia monomer and dimer were conjugated
to CRM<sub>197</sub>, and the resulting glycoconjugates were evaluated
in mice, showing
that both conjugates induced robust IgM and IgG antibodies, which
were cross-reactive with both the monomeric and dimeric haptens, offering
the first proof of principle for the use of synthetic glycans for
an anti GBS Ia vaccine. Another convergent synthesis of branched GBS
Ia and Ib repeating units ((<bold>71</bold>) and (<bold>72</bold>),
respectively) has recently been described by our group, along with
their linear frameshifts. NMR studies of these structures in combination
with molecular dynamic simulations on the PSIa and PSIb polysaccharides
were used to explain the origin of the highly specific immune response
against these structurally very similar PSs, which differ only in
one linkage in the repeating unit.</p><p>These conformational studies
indicated that they place the disaccharide
Neu5Ac(2&#8211;3)Gal motifs in a different spatial orientation, leading
to the presentation of different epitopes.<sup><xref ref-type="bibr" rid="ref265">265</xref></sup> Other GBS serotypes have also been synthesized, but data on their
immunogenicity are not yet available. Gao et al. described the first
synthesis of a GBS type V repeating unit, consisting of a heptasaccharide
fragment.</p><p>The target structure (<bold>73</bold>) was prepared
using a preactivation-based
one-pot [2+1+4] glycosylation strategy, which not only resulted in
the reduction of the number of steps to the final oligosaccharide
but also minimized manipulations of the glycosyl donor.<sup><xref ref-type="bibr" rid="ref267">267</xref></sup> A GBS type II branched heptasaccharide (<bold>74</bold>), corresponding to a frameshift of the repeating unit,
was prepared by a convergent [4+2+1] glycosylation strategy.<sup><xref ref-type="bibr" rid="ref266">266</xref></sup> Recently, Guo and co-workers also assembled
a hexasaccharide repeating unit of GBS type VII and the corresponding
dimer (<bold>75</bold>). The synthesis was achieved by means of a
preactivation-based iterative one-pot glycosylation protocol, which
was made possible by optimization of the challenging stereoselective
&#945;-glucosylation reaction.<sup><xref ref-type="bibr" rid="ref263">263</xref></sup></p><p>These synthetic efforts will pave the way for the preparation of
even more complex GBS oligosaccharides from different serotypes. These
structurally well-defined oligosaccharides can be used to map the
relevant epitopes expressed by the capsular polysaccharides and be
used as potential antigens in GBS glycoconjugate vaccines.</p></sec><sec id="sec3.7"><label>3.7</label><title><italic toggle="yes">Klebsiella pneumoniae</italic></title><p><italic toggle="yes">K. pneumoniae</italic> (Kp) is a commensal Gram-negative
bacterium that can cause chronic urinary tract and soft tissue infections,
pneumonia, and sepsis, particularly in elderly and immunocompromised
subjects.<sup><xref ref-type="bibr" rid="ref197">197</xref>,<xref ref-type="bibr" rid="ref268">268</xref>,<xref ref-type="bibr" rid="ref269">269</xref></sup><italic toggle="yes">Klebsiella</italic> spp. are the third most frequent cause
of healthcare-associated infections, and the occurrence of multidrug-resistant
Kp strains is considered as an urgent threat worldwide.<sup><xref ref-type="bibr" rid="ref269">269</xref></sup> Carbapenem-resistant (CR-Kp) and extended spectrum
&#946;-lactamase (ESBL-Kp) Kp are major causes of concern due to
the lack of therapeutic options; therefore, prevention of Kp infections
by vaccination has become of paramount importance.<sup><xref ref-type="bibr" rid="ref270">270</xref></sup> Synthetic vaccines targeting the sugar armory of Kp are
currently under preclinical development. Kp surface oligosaccharide
molecules, the capsular polysaccharide (CPS, K-antigen), and the lipopolysaccharide
(LPS, with the O-antigen as the main target) are major virulence factors
and promising targets for the development of vaccines.<sup><xref ref-type="bibr" rid="ref271">271</xref></sup></p><p>The CPS is mainly involved in colonization,
adhesion, perpetuation, and proliferation in the host, while the LPS
plays a main role in conferring resistance to the bactericidal activity
of the complement.<sup><xref ref-type="bibr" rid="ref272">272</xref></sup></p><p>Kp K-antigen
is anchored to the outer membrane through a lipid
A tail. The structural variability of the CPS is extremely high, with
more than 77 serotypes identified. This heterogeneity challenges the
development of vaccines based on the CPS, which should comprise at
least 24 serotypes to ensure adequate coverage against the most virulent
strains. Proof of concept of the use of the K-antigen as a vaccine
target has been provided in late &#8217;80s and &#8217;90s, when
a six-valent and a 24-valent vaccine based on different Kp CPS were
tested in humans, showing it to be safe and to induce serospecific
IgGs in all vaccines.<sup><xref ref-type="bibr" rid="ref273">273</xref></sup> Due to the complexity
in manufacturing these vaccines, the development was discontinued.
It did, however, provide the proof of principle for the use of K-antigens
in anti-Kp vaccines. Besides the use of full-length, high molecular
weight extracted polysaccharides, in 1985 Zigterman et al. demonstrated
the efficacy of a vaccine based on an octasaccharide, obtained by
depolymerization of the Kp capsular polysaccharide serotype 11.<sup><xref ref-type="bibr" rid="ref274">274</xref></sup> K1 and K2 are the most virulent Kp serotypes,
often present in antibiotic resistance strains, and these have, therefore,
been recently targeted for vaccine design through different technologies.
In 2019, expression of K1 and K2 polysaccharides conjugated to EPA
was achieved in <italic toggle="yes">E. coli</italic>, and the bioconjugates proved
to be immunogenic in mice and provided protection from lethal infections
by two hypervirulent Kp strains.<sup><xref ref-type="bibr" rid="ref275">275</xref></sup> Recently,
the synthesis of oligosaccharides derived from K2 CPS was described
and the obtained oligosaccharides were used as tools to elucidate
the structure of the minimal epitope.<sup><xref ref-type="bibr" rid="ref276">276</xref></sup> The repeating unit of the K2 antigen is built up from a [&#8594;3)-&#946;-<sc>d</sc>-Glc-(1&#8211;4)-&#946;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>d</sc>-Glc-(1&#8594;] backbone carrying &#945;-<sc>d</sc>-GlcpA
branches at the O3 of the mannoses. The main challenge of the synthesis
is presented by the two 1,2-<italic toggle="yes">cis</italic> linkages (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref>A). First, the
tetrasaccharide repeating unit was assembled; then, it was elongated
through [1+4], [2+4], [3+4], and [4+4] glycosylations to obtain the
penta-, the hexa-, the hepta-, and the octasaccharides. The &#945;-selective
glycosylation, key for the elongation process, was achieved using
glycosyl fluoride donors using Cp<sub>2</sub>HfCl<sub>2</sub>/AgOTf
mediated catalysis. The synthetic hexa-, hepta-, and octasaccharides
(<bold>81</bold>) were conjugated to DT and tested in mice. Sera against
the heptasaccharide were able to cross-react with all synthetic glycans,
including the longer octasaccharide (<bold>81</bold>), and antisera
against the hepta- and the octasaccharide DT conjugates showed a high
titer of functional antibodies in a serum bactericidal assay.</p><fig id="fig13" position="float" orientation="portrait"><label>Figure 13</label><caption><p>Synthetic
routes for <italic toggle="yes">K. pneumoniae</italic> glycans for
immunological testing: (A) Design of conjugates from synthetic fragments
of the K2 capsule used for immunization of rabbits. (B) Conjugates
from Kp ST238 CPS, that have been tested in rabbits, providing antibodies
with opsonophagocytic killing (OPK) activity in vitro. (C) Structures
related to O1 and O2 O-antigens used in the glycan array.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr13" position="float" orientation="portrait" xlink:href="cr2c00021_0013.jpg"/></fig><p>A synthetic approach to the repeating unit of Kp ST238 CPS,
a carbapenem-resistant
(CR) strain which has been responsible for several outbreaks in hospitals
in the US,<sup><xref ref-type="bibr" rid="ref277">277</xref></sup> has been described by Seeberger&#8217;s
team.<sup><xref ref-type="bibr" rid="ref278">278</xref></sup> The target hexasaccharide was
synthesized using a [3+3] convergent approach based on three monosaccharide
building blocks, of which the GalA building block was obtained by
a de novo route (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref>B). The synthetic hexasaccharide (<bold>86</bold>) and shorter
fragments were anchored to a glycan array and assayed against the
protective mouse IgM mAb 1C9, raised against the CR-Kp CPS. The specific
recognition of the hexasaccharide was demonstrated by inhibition of
the binding of the mAb preincubated with Kp CPS. The hexasaccharide
was then conjugated to the carrier protein CRM<sub>197</sub> and tested
in mice in two adjuvanted formulations, one with the Freund adjuvant
(FA) and the other with Alum, which both elicited antibodies reactive
against the hexasaccharide. However, only the conjugate formulated
with FA induced antibodies that were cross-reactive with the Kp CPS.
The formulation with Alum was also tested in rabbits and induced antibodies
that were able to bind Kp cells and promoted the uptake and killing
by phagocytic cells, indicating that the hexasaccharide-CRM<sub>197</sub> conjugate represents a promising vaccine against hypervirulent CR-Kp.
Two mAbs, 17H12 and 8F12, binding the synthetic glycan epitope, were
shown to agglutinate all clade 2 strains and were also shown to promote
inhibition of biofilm formation and extracellular killing of these
bacteria, by complement deposition and the deployment of neutrophil
extracellular traps.<sup><xref ref-type="bibr" rid="ref279">279</xref></sup> The mAbs also promoted
opsonophagocytic and intracellular killing of Kp by human derived
neutrophils and cultured murine macrophages, indicating that this
structure can be targeted to develop therapeutics.</p><p>The Kp LPS
is composed of a conserved core oligosaccharide linked
to the terminal lipid A portion and to the O-antigen, whose composition
is highly variable across different strains. As opposed to the K-antigens,
only 11 O-antigens have been identified, and these have been used
for Kp typing; four of these O-antigens (O1, O2, O3, and O5) are found
in clinically relevant strains, and therefore, it has been proposed
that a vaccine comprising these four serotypes would ensure a 80%
coverage against Kp infections.<sup><xref ref-type="bibr" rid="ref280">280</xref></sup> O1 and
O2 consist of <sc>d</sc>-galactose and <sc>d</sc>-galactofuranose,
while O3 (including the related serotype O3b) and O5 are composed
of <sc>d</sc>-mannoses. The O1 polysaccharide is the most prevalent
serotype in clinical isolates, followed by the O2 and the O3 polysaccharides;
therefore, most preclinical development of potential vaccines focused
on these serotypes.</p><p>The O1-antigen is built of two polysaccharide
types: Galactan (Gal)
I, located at the inner part of the O-chain, shared also with other
Kp serotypes (O2 and O2ac) and formed by a [&#8594;3)-Gal<italic toggle="yes">p</italic>-&#946;-(1&#8211;3)-Gal<italic toggle="yes">f</italic>-&#945;-(1&#8594;]
repeating unit, and Galactan II, constituting the capping sequences
and formed by a [&#8594;3)-Gal<italic toggle="yes">p</italic>-&#946;-(1&#8211;3)-Gal<italic toggle="yes">p</italic>-&#945;-(1&#8594;] repeating unit.<sup><xref ref-type="bibr" rid="ref281">281</xref></sup> Extracted O-antigens have been tested in animal models
as stand-alone polysaccharide antigen<sup><xref ref-type="bibr" rid="ref282">282</xref></sup> or conjugated to Tetanus Toxoid<sup><xref ref-type="bibr" rid="ref283">283</xref></sup> and <italic toggle="yes">P. aeruginosa</italic> flagellins FlaA and FlaB.<sup><xref ref-type="bibr" rid="ref284">284</xref></sup> The syntheses of O-antigens belonging to serotypes O1 and
O2 have been described. The first synthesis of the Galactan I disaccharide
&#946;-Gal<italic toggle="yes">f</italic>-(1&#8211;3)-Gal<italic toggle="yes">p</italic>,
corresponding to the repeating unit of O2 LPS, was reported by Wang
et al.<sup><xref ref-type="bibr" rid="ref427">427</xref></sup> Longer Gal I oligosaccharides
(a tetra- and hexasaccharide), bearing a <italic toggle="yes">p</italic>-methoxyphenyl
aglycone at the reducing end, were prepared by Zhu et al.<sup><xref ref-type="bibr" rid="ref285">285</xref></sup> The synthetic design was based on the preparation
of a Gal<italic toggle="yes">f</italic>-&#946;-(1&#8211;3)-Gal<italic toggle="yes">p</italic> disaccharide intermediate bearing a <italic toggle="yes">p</italic>-methoxyphenyl
group at the reducing end and a levulinoyl group to mask the Galf
3-OH. The key step in the synthesis was the &#945;-selective galactopyranosylation
of the 3-OH of the di- and tetrasaccharide acceptor in solvent controlled
glycosylation reactions. Further advances in the synthesis of Gal
I (<bold>90</bold>) and II (<bold>91</bold>) hexasaccharide fragments
were reported by Nifantiev and co-workers (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref>C).<sup><xref ref-type="bibr" rid="ref286">286</xref>,<xref ref-type="bibr" rid="ref287">287</xref></sup> A [2+2+2] synthetic
approach was developed, and a pyranoside-into-furanoside (PIF) rearrangement
was used to generate the galactofuranose building block. The synthesized
di-, tetra-, and hexasaccharides of both serotypes were biotinylated
for immobilization on a streptavidin-coated glycan array plate to
screen sera against Kp O1 of serotypes K1, K2, and K16. All tested
sera showed significant concentration-dependent reactivity with the
Gal II hexasaccharide while less interaction was observed with the
Gal II tetrasaccharide and the disaccharide was poorly recognized.
The Gal I tetra- and hexasaccharides were specifically recognized
by antibodies in sera against the Kp type 16, but not types 1 and
2, showing domination of Gal II antibodies over anti Gal I antibodies.</p><p>O1 and O2 oligosaccharides (and related subtypes O2afg and O2ac)
with a length ranging from one to eight repeating units were synthesized
recently using a highly convergent strategy based on a key di-galactose
building block with a 3-Nap protecting group. Oligosaccharides from
these serotypes were conjugated to CRM<sub>197</sub> and tested in
vivo in rabbit and mice. After immunization, functional antibodies
against the homologous oligosaccharides used for the immunization
and against the natural O-polysaccharides of Kp serotypes O1, O2,
and O2ac and carbapenem-resistant ST258 were detected, indicating
the potential of these vaccines to confer protection against Kp infections.<sup><xref ref-type="bibr" rid="ref288">288</xref></sup></p><p>O3, O3b, and O5 polysaccharides represent
other clinically relevant
Kp O-antigen serotypes which should be included in a vaccine to ensure
adequate coverage against circulating strains. The repeating units
of these polysaccharides are composed of mannoses and vary in the
length of the repeating unit and the linkages between the monosaccharides.
Syntheses of oligosaccharides from O3 to O3b to O5 have been recently
described both in solution phase and by automated glycan assembly
on a polymer matrix. O3 oligosaccharides spanning from one to four
RUs (from pentamer to 20-mer), O3b hexa- and dodecasaccharides (corresponding
to two and four RUs), and O5 tri-, hexa-, and nonasaccharides (one,
two, and three RUs) were assembled and equipped with a chemical handle
suitable for conjugation. Key building blocks for the solid phase
synthesis were the two mannoses reported in bearing temporary protections
on 2-OH and/or 3-OH, giving access to all the target O-antigen structures.
The O3 pentasaccharide and O5 hexasaccharide were activated as <italic toggle="yes">p</italic>-nitrophenyl esters and conjugated to CRM<sub>197</sub> and BSA. The CRM<sub>197</sub>-conjugates were formulated with Alum
for mice immunization and incomplete Freund adjuvant for rabbit immunization.
Sera from immunized rabbits cross-reacted in ELISA with the corresponding
O-antigens as BSA conjugates, while sera from mice were able to selectively
recognize the homologous LPS.<sup><xref ref-type="bibr" rid="ref288">288</xref></sup></p></sec><sec id="sec3.8"><label>3.8</label><title><italic toggle="yes">Neisseria gonorrhoeae</italic></title><p><italic toggle="yes">N. gonorrhoeae</italic> is a Gram-negative diplococcus bacterium
closely related to other human <italic toggle="yes">Neisseria</italic> spp. <italic toggle="yes">N. gonorrhoeae</italic> only infects humans and most commonly leads
to urethritis in men and cervicitis in women.<sup><xref ref-type="bibr" rid="ref289">289</xref></sup> It causes the sexually transmitted genitourinary infection
gonorrhea and other forms of gonococcal disease including disseminated
gonococcemia, septic arthritis, and gonococcal ophthalmia neonatorum.
Among these, the sexually transmitted infection (STI) gonorrhea remains
a major global public health concern, causing 87 million cases globally
and being the second most commonly reported infection in the United
States.<sup><xref ref-type="bibr" rid="ref290">290</xref></sup> To date, there is no vaccine
for gonorrhea in humans, and efforts to develop it are becoming increasingly
important, given the growing threat of gonococcal antimicrobial resistance
(AMR) and increased incidence of STI gonorrhea. Recent studies have
shown that vaccines against a closely related pathogen, such as the <italic toggle="yes">N. meningitidis</italic> serogroup B vaccine Bexsero, containing
outer membrane vesicle (OMV) components can reduce the incidence of
gonorrhea.<sup><xref ref-type="bibr" rid="ref291">291</xref></sup> Several approaches for the
identification of a candidate vaccine from outer membrane or pilin
proteins are currently in preclinical development.<sup><xref ref-type="bibr" rid="ref292">292</xref></sup></p><p><italic toggle="yes">N. gonorrhoeae</italic> lipooligosaccharides
(LOS) play a major role in pathogenesis by inducing host inflammatory
responses, including resistance to complement, adhesion, and entry
into cells, and also enabling evasion of host innate immunity through
sialylation.<sup><xref ref-type="bibr" rid="ref293">293</xref></sup> The LOS is located in the
outer membrane of the pathogen and constitutes about 50% of its mass.
LOS are composed of three oligosaccharide (OS) chains, made up of
glucose, galactose, and <italic toggle="yes">N</italic>-acetylglucosamine, which
are linked to two heptose residues, which in turn are attached to
lipid A through two molecules of 2-keto-3-deoxy-mannooctulosonic acid
(Kdo) (<xref rid="fig14" ref-type="fig">Figure <xref rid="fig14" ref-type="fig">14</xref></xref>).</p><fig id="fig14" position="float" orientation="portrait"><label>Figure 14</label><caption><p>Chemical
structure of <italic toggle="yes">N. gonorroheae</italic> LOS, composed
of three characteristic &#945;, &#946; and &#947; chains. Highlighted
is the epitope identified through the C27 mAb.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr14" position="float" orientation="portrait" xlink:href="cr2c00021_0014.jpg"/></fig><p>One OS chain, the &#945;-chain, extends from the first heptose
(Hep-I), while the second and third chains, the &#946;- and &#947;-chains,
are attached to the second heptose (Hep-II) (<xref rid="fig14" ref-type="fig">Figure <xref rid="fig14" ref-type="fig">14</xref></xref>). The compositions of the oligosaccharides
are highly variable, in length, carbohydrate content, and number of
chains. Phosphoethanolamines, acetyl esters, glycines, <italic toggle="yes">N</italic>-acetylneuraminic acid, and Kdo can also be present, resulting in
heterogeneity of the LOS and different antigenic epitopes.<sup><xref ref-type="bibr" rid="ref294">294</xref>,<xref ref-type="bibr" rid="ref295">295</xref></sup></p><p>In the last decade the so-called peptide mimotope approach
has
been applied to resemble the carbohydrate epitope structure, recognized
by the opsonophagocytic mAb 2C7.<sup><xref ref-type="bibr" rid="ref296">296</xref></sup> By
screening a random peptide library, the Octa-MAP1 peptide was identified
as an immunological surrogate of the 2C7-oligosaccharide epitope.
The 2C7 epitope mainly includes the &#945;-lactoside on Hep and may
also contain a &#946;-lactoside on Hep-I. In vivo evaluation of the
Octa-MAP1 peptide in a mouse model demonstrated that it is capable
of generating cross-reactive anti-LOS antibodies with complement-dependent
bactericidal activity against gonococci.<sup><xref ref-type="bibr" rid="ref294">294</xref></sup></p></sec><sec id="sec3.9"><label>3.9</label><title><italic toggle="yes">Pseudomonas aeruginosa</italic></title><p><italic toggle="yes">P. aeruginosa</italic> (PA) is a ubiquitous, Gram-negative
bacterium that can grow under both aerobic and anaerobic conditions.
Serious infections with PA are primarily encountered in the hospital
setting,<sup><xref ref-type="bibr" rid="ref297">297</xref></sup> such as fulminant and acute
ventilator-associated pneumonia.<sup><xref ref-type="bibr" rid="ref298">298</xref>,<xref ref-type="bibr" rid="ref299">299</xref></sup> PA causes
slowly progressive deterioration of pulmonary function in cystic fibrosis
(CF) patients<sup><xref ref-type="bibr" rid="ref297">297</xref></sup> as well as non-CF bronchiectasis
in COPD patients.<sup><xref ref-type="bibr" rid="ref300">300</xref>,<xref ref-type="bibr" rid="ref301">301</xref></sup> Antibiotic resistance of PA
is a major concern, and consequently, attempts have been made to obtain
a vaccine, amongst others targeting the OAg. There are 20 different
OAg structures, of which about 11 are expressed in the majority of
PA clinical isolates.</p><p>The most commonly isolated serotypes in
acute infection are O1, 6, and 11, although there are also isolates
lacking the OAg.<sup><xref ref-type="bibr" rid="ref302">302</xref></sup> A challenge associated
with the OAg is the structural variability of the lipid A in the transition
from acute to chronic infections, when the LPS changes from smooth
(with OAg) to rough (without OAg). An eight-valent vaccine consisting
of OAgs conjugated to exotoxin A (EPA), Aerugen, was initially demonstrated
to be safe and immunogenic in plasma donors, as well as bone marrow
transplant and noncolonized CF patients.<sup><xref ref-type="bibr" rid="ref303">303</xref>&#8722;<xref ref-type="bibr" rid="ref306">306</xref></sup> In a larger trial in European CF patients, however, Aerugen showed
good safety but no significant difference in clinical outcome compared
to the placebo control group.<sup><xref ref-type="bibr" rid="ref307">307</xref></sup> In bronchiectasis
patients, eliciting high titers of IgG2, specific against the OAg,
resulted in impaired serum mediated PA killing,<sup><xref ref-type="bibr" rid="ref308">308</xref></sup> which could explain the inconsistent results of LPS-based
vaccination approaches.</p><p>Synthesis of fragments lacking Lipid
A contaminants could be a
means to better understand the reasons behind this inconsistent data.
PA expresses two distinct lipopolysaccharide (LPS) molecules, also
known as the A-band and B-band.<sup><xref ref-type="bibr" rid="ref309">309</xref></sup> The
B-band is the serospecific LPS, while the A-band is the common LPS
antigen composed of a <sc>d</sc>-rhamnose O-polysaccharide chain.
Ghosh&#8217;s group constructed synthetic routes toward the trisaccharide
repeating unit [&#8594;2)-&#945;-<sc>d</sc>-Rha-(1&#8211;3)-&#945;-<sc>d</sc>-Rha-(1&#8211;3)-&#945;-<sc>d</sc>-Rha-(1&#8594;] of the
A-band polysaccharide.<sup><xref ref-type="bibr" rid="ref310">310</xref></sup> The total synthesis
of the PA 1244 pilin trisaccharide &#945;-5N-&#946;OHC4-7N-FmPse-(2&#8211;4)-&#946;-Xyl-(1&#8211;3)-FucNAc
was achieved by Liu<sup><xref ref-type="bibr" rid="ref311">311</xref></sup> and co-workers.
Kulkarni and co-workers have accomplished the challenging synthesis
of the PA O11 trisaccharide &#946;-<sc>d</sc>-Glc-(1&#8211;3)-&#945;-<sc>l</sc>-FucNAc-(1&#8211;3)-&#946;-<sc>d</sc>-FucNAc,<sup><xref ref-type="bibr" rid="ref312">312</xref></sup> where the highly stereoselective 1,2-<italic toggle="yes">cis</italic> incorporation of the <sc>l</sc>-fucosamine and <sc>d</sc>-fucosamine residues was achieved using fucosazide thioglycosyl building
blocks.</p><p>PA also expresses exopolysaccharides, such as Psl, which
is found
in 76% of all analyzed clinical isolates. Its expression occurs in
the primary infecting strains but seems to play a role also in establishing
a persistent infection.<sup><xref ref-type="bibr" rid="ref313">313</xref>&#8722;<xref ref-type="bibr" rid="ref315">315</xref></sup> Psl is responsible for the formation
and maintenance of biofilms, and an anti-Psl monoclonal antibody exhibited
opsonophagocytic killing of a number of strains and conferred significant
protection in multiple animal models.</p><p>Boons and co-workers reported
the synthesis of a Psl tetra-, penta-,
hexa-, and decasaccharide<sup><xref ref-type="bibr" rid="ref316">316</xref></sup> (<xref rid="fig15" ref-type="fig">Figure <xref rid="fig15" ref-type="fig">15</xref></xref>) to map the epitope
of three different classes of mAbs, developed as therapeutics to treat
PA infections.<sup><xref ref-type="bibr" rid="ref317">317</xref></sup> The synthetic strategy
enabled the efficient stereoselective installation of the challenging
&#946;-mannosyl linkages as well as the construction of the very
crowded mannoside that is glycosylated at C-1, C-2, and C-3.<sup><xref ref-type="bibr" rid="ref316">316</xref></sup> The class II mAb reacted potently with each
oligosaccharide, indicating its epitope to reside within the tetrasaccharide,
indicating no need for a branched mannoside. The class III antibody
well recognized the hexasaccharide and weakly interacted with the
decasaccharide, while no binding was observed with the tetra- or pentasaccharide,
suggesting a terminal glucoside as a requirement for mAb recognition.
Finally, the class I mAb did not react with any of the oligosaccharides,
suggesting that some missing structural feature is needed for binding.</p><fig id="fig15" position="float" orientation="portrait"><label>Figure 15</label><caption><p>Synthetic
strategy for <italic toggle="yes">P. aeruginosa</italic> Psl oligosaccharides
and immune evaluation with class I, II, and II mAbs. Of these three
mAbs, while class II and III allowed epitope mapping, class I did
not map any epitope, suggesting that the structure is lacking motifs
relevant for antibody recognition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr15" position="float" orientation="portrait" xlink:href="cr2c00021_0015.jpg"/></fig></sec><sec id="sec3.10"><label>3.10</label><title><italic toggle="yes">Salmonella enterica</italic></title><p><italic toggle="yes">Salmonella enterica</italic> is a Gram-negative bacterium
that is most widespread in developing countries, and it is responsible
for severe gastroenteritis and systemic illnesses.<sup><xref ref-type="bibr" rid="ref318">318</xref></sup></p><p>Human infections are generally due to the ingestion
of contaminated food or water and can generally be attributed to four
key serovars: <italic toggle="yes">S.</italic> Typhi and <italic toggle="yes">S</italic>. Paratyphi
(Typhoidal Salmonellae), the causative agents of typhoid and paratyphoid
fever, and <italic toggle="yes">S</italic>. Typhymurium and <italic toggle="yes">S</italic>.
Enteritidis (non-typhoidal Salmonellae, NTS), responsible for gastroenteritis
and bloodstream infections.<sup><xref ref-type="bibr" rid="ref319">319</xref>,<xref ref-type="bibr" rid="ref320">320</xref></sup> Conventionally, <italic toggle="yes">Salmonella</italic> infections are treated with antibiotics, but
the rise of multidrug-resistant strains demands the development of
effective vaccines.<sup><xref ref-type="bibr" rid="ref321">321</xref></sup></p><p>The Vi capsular
polysaccharide (Vi PS) is the most important virulence
factor of <italic toggle="yes">S.</italic> Typhi, making it the principal target
of vaccines. A Vi polysaccharide-based vaccine<sup><xref ref-type="bibr" rid="ref322">322</xref></sup> and an oral typhoid vaccine, Ty21a,<sup><xref ref-type="bibr" rid="ref323">323</xref></sup> consisting of an attenuated strain of <italic toggle="yes">S</italic>. Typhi, have been available for many years, but they are poorly
immunogenic in young children, where the burden of invasive salmonella
disease is highest.<sup><xref ref-type="bibr" rid="ref319">319</xref></sup> More recently, a
conjugate vaccine against typhoid fever caused by <italic toggle="yes">S</italic>. <italic toggle="yes">typhi</italic> has been licensed in India.<sup><xref ref-type="bibr" rid="ref318">318</xref></sup> A variety of glycoconjugate Vi vaccines differing
in the carrier protein (TT, DT, CRM<sub>197</sub>, and EPA) have been
developed and have been tested at different clinical stages.<sup><xref ref-type="bibr" rid="ref324">324</xref></sup> The Vi PS is a linear homopolymer of [&#8594;4)-&#945;-<sc>d</sc>-GalNAcA-1&#8594;], predominantly O-acetylated at C<sub>3</sub>-OH<sub>3</sub>,<sup><xref ref-type="bibr" rid="ref325">325</xref></sup> and the synthesis
of Vi oligomers is challenging because of the presence of the 1,2-<italic toggle="yes">cis</italic> glycosidic linkages.<sup><xref ref-type="bibr" rid="ref326">326</xref></sup> Yang
et al. reported an effective synthesis involving the use of a carbamate
protecting group masking the C-2-NH<sub>2</sub> and C-3-OH, that allows
for stereoselective glycosylation reactions and easy removal.<sup><xref ref-type="bibr" rid="ref326">326</xref></sup> This protective group was used in syntheses
of both acceptor (<bold>100</bold>) and donor (<bold>101</bold>) di-,
tri-, and tetrasaccharides bearing an extra acetyl group in the C4-OH
position of the terminal repeating unit (<xref rid="fig16" ref-type="fig">Figure <xref rid="fig16" ref-type="fig">16</xref></xref>A). It has been shown that short oligosaccharides
having an acetyl group are considerably more immunogenic than the
methylated analogs previously reported in the literature,<sup><xref ref-type="bibr" rid="ref327">327</xref></sup> suggesting that the OAc groups are an important
antigenic determinant.<sup><xref ref-type="bibr" rid="ref328">328</xref></sup> In a subsequent
study, the authors used the same approach to extend the oligosaccharide
chain of the Vi antigen. Penta-, hexa-, hepta-, and octasaccharides
were synthesized, and a competitive ELISA showed that the hexasaccharide
could represent the minimal epitope of the Vi antigen.<sup><xref ref-type="bibr" rid="ref329">329</xref></sup> Despite numerous efforts to develop typhoid
vaccines, there are no approved products against the other serotypes.<sup><xref ref-type="bibr" rid="ref330">330</xref>,<xref ref-type="bibr" rid="ref331">331</xref></sup></p><fig id="fig16" position="float" orientation="portrait"><label>Figure 16</label><caption><p>Synthetic approaches for conjugates from <italic toggle="yes">Salmonella</italic> oligosaccharides: (A) Fragments of <italic toggle="yes">S.</italic> Typhi capsular
polysaccharide used to identify the minimal epitope length. (B) Design
of conjugates against <italic toggle="yes">S</italic>. Enteritidis and Paratyphi
and immunological evaluation in animal models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr16" position="float" orientation="portrait" xlink:href="cr2c00021_0016.jpg"/></fig><p>Over the years, studies have been performed to identify protective
antigens and evaluate the best strategy to develop an efficient vaccine. <italic toggle="yes">S</italic>. Paratyphi, as well as <italic toggle="yes">S.</italic> Enteritidis
and <italic toggle="yes">S</italic>. Typhimurium, does not express the Vi antigen,
leaving the cell surface-exposed lipopolysaccharide (LPS) as a promising
vaccine target. The OAg portion of LPS is responsible for <italic toggle="yes">Salmonella</italic> serovar specificity and is considered to be an
excellent protective antigen.<sup><xref ref-type="bibr" rid="ref332">332</xref></sup> The OAg
moiety of <italic toggle="yes">S.</italic> Paratyphi A that is composed of [&#8594;2)-&#945;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>l</sc>-Rha-(1&#8211;3)-&#945;-<sc>d</sc>-Gal-(1&#8594;] repeats with an &#945;-<sc>d</sc>-paratose
branch at the mannose C3 was proven to be immunogenic in mice (<xref rid="fig15" ref-type="fig">Figure <xref rid="fig15" ref-type="fig">15</xref></xref>B).<sup><xref ref-type="bibr" rid="ref333">333</xref></sup> Acetylation of the rhamnose C-3-OH is known
to be an important factor for antigenicity.<sup><xref ref-type="bibr" rid="ref334">334</xref></sup> The first synthesis of a tetrasaccharide representing the <italic toggle="yes">S</italic>. Paratyphi A repeating unit (<bold>105</bold>) has recently
been achieved following a stereoselective [2+2] glycosylation strategy.<sup><xref ref-type="bibr" rid="ref335">335</xref></sup> After conjugation to the bacteriophage Q&#946;-carrier
(<bold>106</bold>), its immunogenicity was tested in mice and rabbits,
highlighting the importance of the paratose residue and <italic toggle="yes">O</italic>-acetyl modifications on the backbone for antibody recognition. It
was demonstrated that one repeating unit is sufficient to elicit protective
antibodies, suggesting a promising direction for the development of
synthetic antigen-based <italic toggle="yes">Salmonella</italic> vaccines.<sup><xref ref-type="bibr" rid="ref335">335</xref></sup> Vaccines are under development against other <italic toggle="yes">Salmonella</italic> species, and a bivalent <italic toggle="yes">S</italic>. Typhimurium
and <italic toggle="yes">S</italic>. Enteritidis vaccine formulation based on vesicle-based
technology that involves the use of generalized modules for membrane
antigens (GMMA), naturally expressing the OAg, has shown promising
results in mice.<sup><xref ref-type="bibr" rid="ref336">336</xref></sup></p><p>The <italic toggle="yes">S</italic>. Enteritidis and <italic toggle="yes">S.</italic> Typhimurium
OAg share the same trisaccharide backbone of <italic toggle="yes">S</italic>. Paratyphi
but differ in the structure of the mannose C-3 side chains, in glucosylation,
and in <italic toggle="yes">O</italic>-acetylation. <italic toggle="yes">S</italic>. Enteritidis
presents two oligosaccharides corresponding to two representations
of the repeating unit &#8594;3)-&#945;-<sc>d</sc>-Galp-(1&#8211;2)-[&#945;-<sc>d</sc>-Tyv-(1&#8211;3)]-&#945;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>l</sc>-Rha-(1&#8594; and &#945;-<sc>d</sc>-Tyv-(1&#8211;3)-&#945;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>l</sc>-Rha-(1&#8211;3)-&#945;-<sc>d</sc>-Gal-(1&#8594;.<sup><xref ref-type="bibr" rid="ref337">337</xref></sup> Both structures
present a rare tyvelose monosaccharide which was shown to play an
important role in pathogenesis.<sup><xref ref-type="bibr" rid="ref338">338</xref></sup> The
first synthesis of the &#945;-<sc>d</sc>-Gal-(1&#8211;2)-[&#945;-<sc>d</sc>-Tyv-(1&#8211;3)]-&#945;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>l</sc>-Rha tetrasaccharide repeating unit was achieved by using a
key dodecylthioglycosyl donor.<sup><xref ref-type="bibr" rid="ref339">339</xref></sup> Recently,
Huang&#8217;s group reported the synthesis of the tetrasaccharide
frameshift &#945;-<sc>d</sc>-Tyv-(1&#8211;3)-&#945;-<sc>d</sc>-Man-(1&#8211;4)-&#945;-<sc>l</sc>-Rhap-(1&#8211;3)-&#945;-<sc>d</sc>-Gal (<bold>107</bold>) following a [2+2] glycosylation strategy. The tetrasaccharide conjugated
to Q&#946; (<bold>108</bold>) proved to be immunogenic in mice and
rabbits, suggesting that one repeating unit is sufficient to produce
anti-OPS antibodies.<sup><xref ref-type="bibr" rid="ref340">340</xref></sup> A synthetic approach
was also reported for a methyl 3-<italic toggle="yes">O</italic>-(3,6-dideoxy-<italic toggle="yes">&#945;</italic>-<sc>d</sc>-xylopyranosyl)-&#945;-<sc>d</sc>-mannopyranoside
disaccharide from <italic toggle="yes">S</italic>. Typhimurium, which upon conjugation
was immunogenic in rabbits.<sup><xref ref-type="bibr" rid="ref341">341</xref></sup> Subsequently,
this synthetic disaccharide and tetra-, octa-, and dodecasaccharides,
corresponding to one, two, and three repeating units, respectively,
generated by fragmentation of <italic toggle="yes">S</italic>. Typhimurium OPS,
were conjugated to BSA to evaluate the influence of glycan size on
antibody response in rabbits and mice.<sup><xref ref-type="bibr" rid="ref342">342</xref>,<xref ref-type="bibr" rid="ref343">343</xref></sup> It was proposed
that an optimal <italic toggle="yes">S</italic>. Typhimurium antigen should be
composed of an octa- or dodecasaccharide and that the conjugate vaccine
carries approximately 20 saccharide molecules per protein molecule.<sup><xref ref-type="bibr" rid="ref343">343</xref></sup></p></sec><sec id="sec3.11"><label>3.11</label><title><italic toggle="yes">Staphylococcus
aureus</italic></title><p><italic toggle="yes">S. aureus</italic> is a commensal
Gram-positive bacterium
and one of the most important hospital pathogens. Multidrug-resistant
strains pose a significant health threat, and <italic toggle="yes">S. aureus</italic> invasion can lead to toxic shock, bacteremia, endocarditis, and
osteomyelis. Glycopolymers are prime constituents of the <italic toggle="yes">S.
aureus</italic> cell wall, as part of the biofilm, capsular polysaccharides,
wall teichoic acids, and lipoteichoic acids and the thick peptidoglycan
layer. All these glycopolymers have been found to be promising antigen
candidates.</p><p>To date, 13 different serotypes of capsular polysaccharides
(CPs) have been identified from clinical isolates, with capsular polysaccharide
type 5 (CP5) and type 8 (CP8) being the most abundant.<sup><xref ref-type="bibr" rid="ref344">344</xref></sup> These two polysaccharides have been targeted
for vaccine development, and conjugates of the natural polymers have
been tested in clinical trials,<sup><xref ref-type="bibr" rid="ref345">345</xref>&#8722;<xref ref-type="bibr" rid="ref347">347</xref></sup> unfortunately without
demonstrated efficacy. A pentavalent vaccine is currently in a Ph1
clinical trial.<sup><xref ref-type="bibr" rid="ref348">348</xref></sup> The structures of CP5
and CP8 are quite similar. The RU of CP5 is composed of &#8594;(4-&#946;-<sc>d</sc>-ManNAcA-(1&#8211;4)-&#945;-<sc>l</sc>-FucNAc(3-<italic toggle="yes">O</italic>-Ac)-(1&#8211;3)-&#946;-<sc>d</sc>-FucNAc-(1&#8594; and the RU
of CP8 of &#8594;(3-&#946;-<sc>d</sc>-ManNAcA(4-<italic toggle="yes">O</italic>-Ac)-(1&#8211;3)-&#945;-<sc>l</sc>-FucNAc-(1&#8211;3)-&#946;-<sc>d</sc>-FucNAc-(1&#8594; units. The syntheses of CP5 and CP8 are
very challenging because of the presence of the 1,2-<italic toggle="yes">cis</italic> glycosylic linkages and the presence of unusual amino sugars as
well as the critical O-acetyl group. In 2012 Adamo et al.<sup><xref ref-type="bibr" rid="ref349">349</xref></sup> reported the first synthesis of a CP5 trisaccharide
(<xref rid="fig17" ref-type="fig">Figure <xref rid="fig17" ref-type="fig">17</xref></xref>). The &#946;-ManNAcA
residue was generated using a 2-O-levulinoyl glucuronate donor (<bold>107</bold>), which was used to first create a &#946;-glucuronic
acid linkage, after which a C-2- azide was introduced through a substitution
reaction at C-2. Although a spacer was introduced at the reducing
end terminus, this linker could not be used for conjugation purposes
as an acetamide (<bold>111</bold>) was generated during the deprotection
steps. Competitive ELISA and dot blot studies, with murine anti-CP5
serum, generated against the conjugated polysaccharide, showed recognition
of the synthetic structure, representing a first proof that the trisaccharide
contains the minimal elements for antibody binding.</p><fig id="fig17" position="float" orientation="portrait"><label>Figure 17</label><caption><p>Assembly and immunological
evaluation of staphylococcal surface
carbohydrates, including capsular polysaccharides and teichoic acids.
(A) Repeating unit structure of capsular polysaccharides CP8 and CP5.
(B) Synthesis of CP5 trisaccharide, which was recognized by murine
anti-CP5 serum. (C) Synthesis of the CP8 trisaccharide repeating unit,
which, conjugated to CRM<sub>197</sub>, elicited anti-glycan antibodies
in mice. (D) Assembly of a 10-mer glycerol phosphate (GroP) polymer
and conjugation to TT for immunological evaluation. (E) Synthesis
of ribitol-phosphate (RboP) oligomers. (F) Solution phase synthesis
of 8-mer and 12-mer RboP oligomers and conjugation to BSA. (G) Example
of WTA RboP substituted tetramer tested in mice. (H) Wall teichoic
acid (WTA) fragments conjugated to recombinant <italic toggle="yes">P. aeruginosa</italic> exotoxin A (rEPA) induced murine antibodies providing in vitro opsonophagocytic
killing (OPK).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr17" position="float" orientation="portrait" xlink:href="cr2c00021_0017.jpg"/></fig><p>However, in comparison to the
natural polysaccharide, significantly
weaker interaction was observed, suggesting that longer fragments
will be necessary to function as adequate synthetic antigens. To address
the need for longer conjugation-ready structures, different approaches
have been reported. Demchenko and co-workers<sup><xref ref-type="bibr" rid="ref350">350</xref></sup> developed another synthetic route, based on inversion of configuration
of a glucose building block to obtain the ManNAc residue, while Boons,<sup><xref ref-type="bibr" rid="ref351">351</xref></sup> Cod&#233;e,<sup><xref ref-type="bibr" rid="ref352">352</xref></sup> and Kulkarni<sup><xref ref-type="bibr" rid="ref312">312</xref></sup> exploited a direct &#946;-mannosylation
reaction. However, no further immunological evaluation has been reported.</p><p>The synthesis of a CP8-fragment has been achieved by Demchenko&#8217;s
group, who managed to synthesize both a trisaccharide and a protected
hexasaccharide (<xref rid="fig17" ref-type="fig">Figure <xref rid="fig17" ref-type="fig">17</xref></xref>),<sup><xref ref-type="bibr" rid="ref353">353</xref>,<xref ref-type="bibr" rid="ref354">354</xref></sup> equipped with capping methyl
groups at the points of propagation of the polysaccharide sequence.
No immunological evaluation has thus far been reported. In 2020 Hu
et al.<sup><xref ref-type="bibr" rid="ref355">355</xref></sup> reported a synthesis of a CP8
trisaccharide (<bold>116</bold>) and the initial immunological evaluation
thereof. The introduction of the &#946;-ManNAcA moiety was achieved
by a late-stage epimerization of a glucose precursor. The carboxylic
acid functionality was introduced at the trisaccharide level. To test
the immunogenicity of the trisaccharide, it was conjugated to the
carrier protein CRM<sub>197</sub>. After immunization of mice with
the glycoconjugate, a glycan array showed the induction of anti-glycan
IgGs. Hybridoma development and subcloning of the secreted antibodies
was used to prepare mAbs. The purified mAbs and serum antibodies were
analyzed for recognition of bacteria by immunofluorescence. Confocal
laser scanning microscopy showed recognition of the bacterial surface
of <italic toggle="yes">S. aureus</italic>. This data suggests that conjugates
from the synthetic structures could be tested for functional activity
and in infection models to assess their potential as vaccine candidates.
Not only the CPs but also the teichoic acids (TA) of <italic toggle="yes">S. aureus</italic> have been considered to be promising vaccine candidates.<sup><xref ref-type="bibr" rid="ref356">356</xref></sup> TAs are anionic glycopolymers, which are either
covalently attached to the peptidoglycan, as in WTA, or anchored in
the lipid bilayer through hydrophobic interactions, as in LTA. <italic toggle="yes">S. aureus</italic> WTA is composed of 20&#8211;-40 ribitol phosphate
(RboP) repeats, which can be substituted with either &#945;- or &#946;-linked
GlcNAc residues or <sc>d</sc>-alanine esters.<sup><xref ref-type="bibr" rid="ref357">357</xref>,<xref ref-type="bibr" rid="ref358">358</xref></sup> The most common type of LTA consists of a GroP backbone randomly
decorated with <sc>d</sc>-alanine or &#945;-GlcNAc moieties. Schmidt
and co-workers have reported a significant amount of work to generate
LTA fragments to probe their innate immune-stimulation activity,<sup><xref ref-type="bibr" rid="ref359">359</xref>&#8722;<xref ref-type="bibr" rid="ref361">361</xref></sup> finding that the glycolipid anchor and positively charged alanine
esters on the GroP units were required for full innate immune-stimulation
activity. The potential effect of these fragments in an adaptive immune
response setting has not been investigated. In 2013 Snapper and co-workers
reported a synthesis of a GroP oligomer for potential use in a conjugate
vaccine.<sup><xref ref-type="bibr" rid="ref362">362</xref></sup> A 10-mer (<bold>119</bold>)
was synthesized taking a solid phase approach using a glycerol phosphoramidite
building block (<bold>118</bold>), where a dimethoxytrityl (DMTr)
was used to protect primary alcohols and a benzoyl (Bz) group to mask
the secondary alcohols, even though these groups can readily migrate
to the neighboring primary hydroxy groups under both basic and acidic
reaction conditions. No characterization data have been provided for
the generated structure.<sup><xref ref-type="bibr" rid="ref363">363</xref></sup> The crude product
was conjugated to a TT carrier protein to generate a model vaccine.</p><p>Administration in mice of the unconjugated and the TT-conjugated
GroP oligomer adjuvanted with CpG-ODN, a strong TLR9 activator, showed
that a high IgG level was only induced by the conjugate form. The
pooled serum was able to mediate opsonic killing of both the Lowenstein
and the USA300 strains of <italic toggle="yes">S. aureus</italic>.</p><p>An approach
leading to a set of glycosylated LTA fragments has
been reported by Cod&#233;e&#8217;s group as described above.<sup><xref ref-type="bibr" rid="ref210">210</xref></sup> Cross-reactivity of serum generated against
a glucosylated GroP hexamer, designed to mimic enterococcal LTA, was
shown.</p><p>The glycosylation pattern of RboP-based WTA has been
found to be
critical for the fitness and virulence of bacteria. Different approaches
toward the generation of well-defined WTA fragments have been investigated
including solution and solid phase syntheses. In 2006 Pozsgay and
co-workers successfully synthesized a Rbo-P-8-mer and a Rbo-P-12-mer
using solution phase chemistry. The solid phase assembly of these
fragments proved unsuccessful. The octamer and dodecamer were conjugated
to a BSA carrier protein via an ethanol amine linker introducing 10
to 18 oligomers per protein (<bold>130</bold>).<sup><xref ref-type="bibr" rid="ref364">364</xref></sup> However, the immunogenicity of the conjugates was not studied.
Another approach for the synthesis of <italic toggle="yes">S. aureus</italic> WTA
RboP was reported by Lee et al.<sup><xref ref-type="bibr" rid="ref365">365</xref></sup> Four
building blocks were used to enable the incorporation of different
GlcNAc and <sc>d</sc>-Ala substitution patterns. The very labile <sc>d</sc>-Ala ester linkage was replaced in these structures by a robust
amide linkage. The syntheses were achieved using a solution phase
strategy, because attempts to use a solid phase nucleotide synthesizer
required prohibitively large amounts of monomers. The synthesized
tetramers (i.e. <bold>131</bold>) were tested in BALB/c mice, where
increased levels of interleukin-6, as a marker of innate immunity
activation, were measured.</p><p>Recently, Cod&#233;e et al. reported
a method to synthesize well-defined
unsubstituted RboP oligomers using both solution and automated solid
phase synthesis approaches.<sup><xref ref-type="bibr" rid="ref366">366</xref></sup> The assembled
library of structures consisted of oligomers with and without carbohydrate
substituents, varying in length from hexa- to dodecamers. The phosporamidite
building blocks (<bold>121</bold>&#8211;<bold>123</bold>) were used
for synthesis with dimethoxytrityl (DMtr) protecting groups to mask
the sites for elongation, in line with contemporary DNA synthesis.
The use of mild acidic deprotection conditions enabled the solid phase
assembly of RboP WTA fragments. For conjugation purposes a phosphoramidite
hexanolamine spacer (<bold>125</bold>) was used.</p><p>Binding studies
with the obtained molecules were conducted by conjugating
the hexamers through a biotin handle to streptavidin-coated magnetic
dynabeads M280 followed by interrogation with monoclonal antibodies.
For this purpose mAbs were generated toward the &#945;-GlcNAc functionalized
RboP WTAs (clones 4461 and 4624) or &#946;-1,4-GlcNAc carrying RboP
WTA (clones 4497 and 6292).<sup><xref ref-type="bibr" rid="ref367">367</xref></sup> The antibodies
selectively recognized the glycosylated WTA fragments. Cross-reactivity
of mAbs generated against &#946;-(1&#8211;4)-GlcNAc RboP WTA against
the corresponding &#946;-1,3-GlcNAc RboP WTA could be demonstrated.
The nonglycosylated WTA fragments could also be used as substrates
for the <italic toggle="yes">S. aureus</italic> glycosyl transferases TarM, TarS,
and TarP, capable of introducing &#945;-(1&#8211;4)-GlcNAc, &#946;-(1&#8211;4)-GlcNAc,
or &#946;-(1&#8211;3)-GlcNAc residues. The magnetic bead assay with
these enzymatically glycosylated fragments was used to interrogate
human sera to probe the presence of circulating anti-WTA antibodies.
The &#946;-(1&#8211;4)-GlcNAc- and &#946;-(1&#8211;3)-GlcNAc-functionlized
WTAs were found to be the most important targets for circulating antibodies,
with significantly less recognition of the &#945;-(1&#8211;4)-GlcNAc
WTA. The nonglycosylated RboP WTA was not bound at all by the sera
used.</p><p>These findings somewhat contrasted the findings of Gerlach
et al.,<sup><xref ref-type="bibr" rid="ref368">368</xref></sup> who reported that &#946;-(1&#8211;3)-GlcNAc
WTA was significantly less immunogenic than &#946;-(1&#8211;4)-GlcNAc
WTA in a mouse model. The enzymatically glycosylated WTA magnetic
beads were also used to investigate Langerin binding.<sup><xref ref-type="bibr" rid="ref369">369</xref></sup> This C-type lectin receptor can be found on
Langerhans cells, that play an important role in sensing the environment
in the skin and kick-start an immune response against invading pathogens.
The synthetic WTA fragments carrying &#946;-GlcNAc substituents bound
Langerin effectively, leading to cellular uptake in an in vitro model,
showing that WTA may be a target for immune surveillance by Langerhans
cells.</p><p>A team from Sanofi Pasteur generated three different
WTA fragments,
using a highly convergent synthesis approach, having either an &#945;-(1&#8211;4)-GlcNAc
(<bold>133</bold>), &#946;-(1&#8211;4)-GlcNAc (<bold>133</bold>),
or &#946;-(1&#8211;3)-GlcNAc (<bold>132</bold>) substituent on each
RboP monomer.<sup><xref ref-type="bibr" rid="ref370">370</xref></sup> These fragments were conjugated
to detoxified <italic toggle="yes">S. aureus</italic> &#945;-hemolysin (HladM)
or <italic toggle="yes">P. aeruginosa</italic> detoxified recombinant exotoxin
A (rEPA) using hydrazide conjugation chemistry. Immunization using
the AF04 adjuvant provided a strong immune response against the conjugates,
while the use of nonconjugated WTA provided a poor response. The use
of the adjuvant was important to raise a high level of antibodies.
Interestingly, the sera raised against the &#946;-(1&#8211;4)-GlcNAc-WTA
conjugate proved to be more cross-reactive against different <italic toggle="yes">S. aureus</italic> strains than the &#945;-(1&#8211;4)-GlcNAc-WTA
and &#946;-(1&#8211;3)-GlcNAc-WTA conjugate. The immune response
against the latter conjugate was not cross-reactive. The exact reason
for the different binding specificities of the raised antibodies remains
unclear and will require detailed structural studies with well-defined
synthetic WTA fragments.</p><p>Overall, the &#946;-(1&#8211;4)-GlcNAc-RboP
WTA appears to be
a promising candidate for further development. The role of the labile <sc>d</sc>-Ala residues in immunogenicity remains to be established.
These positively charged groups may play an important role as they
introduce zwitterionic moieties in the WTA that may render these glycopolymers&#8217;
T-cell-independent antigens, in line with the zwitterionic polysaccharides
described above.</p></sec></sec><sec id="sec4"><label>4</label><title>&#8220;Universal&#8221;
Carbohydrate Antigens</title><p>Cross-reactive antigens have been explored
for their capacity to
target multiple bacteria, thereby &#8220;killing more birds with
one stone&#8221;. The cell wall of <italic toggle="yes">S. aureus</italic> as
well as other bacterial species, fungi, and protozoal parasites produces
the cell surface polysaccharide poly-&#946;-(1&#8211;6)-<italic toggle="yes">N</italic>-acetylglucosamine (PNAG, <xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig">18</xref></xref>A), which in the past decade has been investigated
as a potential application in vaccine development (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> The structure of PNAG consists of &#946;-linked <italic toggle="yes">N</italic>-acetylglucosamine, of which 10&#8211;20% of the amino groups are
not <italic toggle="yes">N</italic>-acetylated (dPNAG).<sup><xref ref-type="bibr" rid="ref371">371</xref></sup> Animal models using native PNAG and chemically deacetylated dPNAG
have shown that antibodies against dPNAG were more effective in mediating
opsonophagotic killing<sup><xref ref-type="bibr" rid="ref372">372</xref></sup> and protected
mice from staphylococcal infection.<sup><xref ref-type="bibr" rid="ref373">373</xref></sup> Chemically
synthesized well-defined structures could be used to define the structure&#8211;immunogenicity
relationship and, thus, find the best candidate for a vaccine. In
2007 Nifantiev and co-workers reported a route based on building blocks
(<bold>133</bold>&#8211;<bold>135</bold>) toward well-defined GlcNAc
and GlcN fragments up to the undecamer level.<sup><xref ref-type="bibr" rid="ref374">374</xref></sup> These were equipped with an aminopropyl linker for functionalization.
The synthesis relied on three building blocks, where an <italic toggle="yes">N</italic>-phthalimide directed the stereochemistry of the glycosylation reactions
via neighboring group participation. For the immunogenicity studies
the acetylated and non-acetylated pentasaccharide and nonasaccharide
were coupled to TT (<bold>138</bold>).<sup><xref ref-type="bibr" rid="ref375">375</xref></sup> Sera from mice immunized with the conjugates of the non-acetylated
oligomers showed higher opsonic activity than the sera obtained from
the acetylated ones. A conjugate of the pentamer has been tested in
a phase I clinical trial, demonstrating the scalability of this synthetic
conjugate for vaccine development.<sup><xref ref-type="bibr" rid="ref376">376</xref></sup> Antibodies
to dPNAG have been shown to be highly cross-reactive with numerous
species including AMR pathogens such as <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">C. difficile</italic>, <italic toggle="yes">E. coli</italic>, and <italic toggle="yes">K. pneumoniae</italic> and, therefore, are very attractive to further
develop as therapeutic monoclonal antibodies.<sup><xref ref-type="bibr" rid="ref377">377</xref>&#8722;<xref ref-type="bibr" rid="ref379">379</xref></sup> The mAb F598 is currently in clinical development, and it has been
tested in a human challenge model against <italic toggle="yes">N. gonorrhoeae</italic> infection. The X-ray structure of the Fab fragment of the mAb in
complex with synthetic dPNAG oligomers has elucidated that F598 recognizes
PNAG through a large groove-shaped binding site that traverses the
entire light and heavy chain interface and accommodates at least five
GlcNAc residues, defining the dPNAG structural epitope.<sup><xref ref-type="bibr" rid="ref380">380</xref></sup></p><fig id="fig18" position="float" orientation="portrait"><label>Figure 18</label><caption><p>(A) PNAG structure and design of a universal
PNAG-based universal
vaccine and therapeutic mAb. (B) Synthetic route to the enterobacterial
common antigen (ECA) conjugate used to generate specific sera and
mAbs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr18" position="float" orientation="portrait" xlink:href="cr2c00021_0018.jpg"/></fig><p><italic toggle="yes">E. coli</italic> shares
with all <italic toggle="yes">Enterobacteriaceae</italic> a polysaccharide known
as the enterobacterial common antigen (ECA),
which is composed of &#8594;3)-&#945;-<sc>d</sc>-Fuc4NAc-(1&#8211;4)-&#946;-<sc>d</sc>-ManNAcA-(1&#8211;4)-&#945;-<sc>d</sc>-GlcNAc-(1&#8594;
repeating units that are substoichiometrically (&#8764;70%) decorated
at the GlcNAc C-6 with acetyl esters.<sup><xref ref-type="bibr" rid="ref381">381</xref></sup> ECA is important for cell envelope integrity and has been suggested
as a virulence factor, since bacteria that cannot produce ECA exhibit
attenuated infections in oral and intraperitoneal mouse models.<sup><xref ref-type="bibr" rid="ref382">382</xref></sup> Therefore, ECA represents an attractive target
for the development of cross-protective vaccines or mAbs. The challenging
synthesis involves the formation of multiple 1,2-<italic toggle="yes">cis</italic>- glycosyl linkages and the presence of rare monosaccharide constituents.
Boons and co-workers achieved the synthesis of an ECA hexasaccharide
through a [3+3] strategy, using an <italic toggle="yes">N</italic>-phenyltrifluoroacetimidate
donor readily attainable from (<bold>142</bold>) (<xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig">18</xref></xref>B). The assembled oligosaccharide
(<bold>143</bold>) was conjugated to BSA (<bold>145</bold>) and shown
to recognize antibodies in sera of mice, exposed to different <italic toggle="yes">K. pneumonia</italic> strains as well as a mAb, SM250-1A5, raised
against a mixture of six <italic toggle="yes">Shigella</italic> strains. These
studies have revealed the potential of the ECA trisaccharide and hexasaccharide
in the development of a conjugate vaccine and their potential to raise
potentially cross-reactive mAbs. The effectivity of the ECA antigens
remains to be assessed with respect to capsule and O-antigen expression
of the different bacterial strains.</p></sec><sec id="sec5"><label>5</label><title>Fungal
Glycans: <italic toggle="yes">Candida</italic> spp.
and Emergence of <italic toggle="yes">C. auris</italic></title><sec id="sec5.1"><label>5.1</label><title><italic toggle="yes">Candida</italic> spp</title><p><italic toggle="yes">Candida</italic> spp. are fungi
(yeasts) that are part of the microbiome
on human skin, mucous membranes, the female genital tract, and the
gastrointestinal tract. Worldwide, recurrent vulvovaginal candidiasis
affects about &#8764;140M women annually, with the highest prevalence
on the 25&#8211;34 years age group and an increasing trend of incidence.<sup><xref ref-type="bibr" rid="ref383">383</xref></sup><italic toggle="yes">Candida</italic> spp. are also among
the major causes of nosocomial infection, with invasive candidiasis
gaining increasing prevalence worldwide in parallel with mortality
rates ranging from 10 to 49%.<sup><xref ref-type="bibr" rid="ref384">384</xref></sup> The epidemiology
of candidemia has changed due to the increased number of patients
receiving transplants and immunosuppressive therapy, use of broad
spectrum antimicrobials, and number of AIDS patients.<sup><xref ref-type="bibr" rid="ref385">385</xref></sup> Particularly, invasive candidiasis was mainly
caused by <italic toggle="yes">Candida albicans</italic>, but in the past decade
there has been a shift toward <italic toggle="yes">Candida</italic> spp. non-albicans,
essentially due to the advent of <italic toggle="yes">Candida auris</italic>, identified
in Japan in 2009 and recently recognized as an emerging multidrug-resistant
pathogen that poses a major global health threat, including in the
US. <italic toggle="yes">C. auris</italic> can cause invasive infections and outbreaks
with high mortality rates in hospitalized patients, particularly among
patients with multiple comorbidities and who have been admitted to
intensive care or other special care facilities.<sup><xref ref-type="bibr" rid="ref386">386</xref>&#8722;<xref ref-type="bibr" rid="ref388">388</xref></sup></p><p>Polysaccharides on the fungal surface have been targeted for
vaccine discovery,<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> and carbohydrate synthesis
has become a powerful tool to provide pure and well-defined glycan
as opposite to highly variable structures from purification and aid
elucidating protective epitopes and obtaining glycoconjugate vaccines
with an optimized immunological response.<sup><xref ref-type="bibr" rid="ref389">389</xref>,<xref ref-type="bibr" rid="ref390">390</xref></sup></p><p>Many syntheses of mannan oligomers<sup><xref ref-type="bibr" rid="ref391">391</xref>&#8722;<xref ref-type="bibr" rid="ref393">393</xref></sup> are reported which
have allowed identification of the structure and dimensions of the
protective epitope required for the development of promising vaccine
antigens.<sup><xref ref-type="bibr" rid="ref394">394</xref>,<xref ref-type="bibr" rid="ref395">395</xref></sup> Synthetic conjugates of trisaccharide
&#946;-(1&#8211;2)-mannan to TT (<bold>146</bold>) showed a robust
secondary antibody response in rabbits but poor immunogenicity in
mice (<xref rid="fig19" ref-type="fig">Figure <xref rid="fig19" ref-type="fig">19</xref></xref>).<sup><xref ref-type="bibr" rid="ref396">396</xref></sup> A conjugate with a synthetic 14-mer Fba peptide,
derived from the <italic toggle="yes">C. albicans</italic> cell wall protein, elicited
a strong antibody response and provided protection against a lethal
challenge of <italic toggle="yes">C. albicans</italic>.<sup><xref ref-type="bibr" rid="ref397">397</xref></sup> A tricomponent vaccine where the &#946;-(1&#8211;2)-mannan was
conjugated along with the &#946;-glucan Laminarin, as immunopotentiator,
was also constructed and shown to favor the conjugate&#8217;s uptake
from dendritic cells in mice, thus increasing its immunogenicity.<sup><xref ref-type="bibr" rid="ref398">398</xref></sup> Lately, a fully synthetic conjugated vaccine
(<bold>146</bold>) (<xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig">18</xref></xref>A) was constructed from a &#946;-(1&#8211;2)-linked mannose
trisaccharide conjugated to a T-cell peptide and an asymmetric dendrimer
component bearing four copies of a &#946;-(1&#8211;3)-linked hexaglucan
dendritic cell epitope by click chemistry, yielding a conjugate vaccine
that induced antibodies to all three epitopes of the fully synthetic
construct.<sup><xref ref-type="bibr" rid="ref399">399</xref></sup> Other researchers investigated
a series of synthetic oligo &#945;-mannosides containing branches
or not. These synthetic structures were conjugated to BSA via squarate
chemistry, and the immunological evaluation revealed that the linear
oligomannoside structure could influence the quality of the antibody
response.<sup><xref ref-type="bibr" rid="ref400">400</xref></sup> Recently, synthetic biotinylated
&#945;-mannooligosaccharides mimicking <italic toggle="yes">Candida</italic> antigenic
factors using RAW264.7 macrophages have been used to demonstrate their
ability to induce a release of Th1, Th2, Th17, and Treg cytokine signature
patterns.<sup><xref ref-type="bibr" rid="ref401">401</xref></sup> It should be noted that &#945;-mannooligosaccharides
decorate human cells and their immunogenicity in humans could not
be optimal. Subsequently, the mannose trisaccharide conjugated to
&#946;-glucan is an essential component of the <italic toggle="yes">Candida</italic> cell wall and has attracted attention for vaccine development because
of its accessibility to antibodies.<sup><xref ref-type="bibr" rid="ref402">402</xref></sup> Antibodies
directed to &#946;-glucan have been shown to confer protection to
mice following challenge with <italic toggle="yes">C. albicans</italic>,<sup><xref ref-type="bibr" rid="ref403">403</xref></sup> and the linear &#946;-(1&#8211;3) glucan
with sporadic &#946;-(1&#8211;6) branches, Laminarin, which is extracted
from the brown alga Laminaria digitata, has been proposed as an alternative
to fungal glycans in order to avoid any possible contamination from
the microorganism.<sup><xref ref-type="bibr" rid="ref403">403</xref>,<xref ref-type="bibr" rid="ref404">404</xref></sup> Laminarin conjugated to CRM<sub>197</sub> induced in mice antibodies which recognized <italic toggle="yes">C.
albicans</italic> and protected it from lethal challenge with fungal
cells.<sup><xref ref-type="bibr" rid="ref404">404</xref></sup> Synthetic oligosaccharides have
been used to elucidate the structural features needed for optimal
immunogenicity. By comparing a linear 15-mer with a branched 17-mer
(<bold>147</bold>) it was observed that &#946;-(1&#8211;6) branches
need to be separated by at least six &#946;-(1&#8211;3) residues
for efficient antibody production (<xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig">18</xref></xref>B).<sup><xref ref-type="bibr" rid="ref404">404</xref></sup> Based
on this data, a linear synthetic &#946;-(1&#8211;3)-glucan hexamer
(<bold>148</bold>) was synthesized and conjugated to CRM<sub>197</sub>, which was shown to elicit in mice anti &#946;-glucan IgGs in a
comparable manner to Lam-CRM<sub>197</sub>.<sup><xref ref-type="bibr" rid="ref405">405</xref></sup> Further investigations were carried out with the &#946;-(1&#8211;3)
glucan hexamer regioselectivity conjugated via tyrosine-selective
alkynylation with a 4-phenyl-1,2,4-triazoline-3,5-dione spacer followed
by a click chemistry mediated carbohydrate installation (<bold>149</bold>),<sup><xref ref-type="bibr" rid="ref406">406</xref></sup> which was compared to a conjugate
obtained by controlled reaction at the four more surface exposed lysine
residues and the random conjugate (<bold>148</bold>). In vivo studies
showed that conjugation to four tyrosines is sufficient for a strong
production of antibodies that inhibit the adhesion of <italic toggle="yes">C. albicans</italic> to human epithelial cells.<sup><xref ref-type="bibr" rid="ref407">407</xref>,<xref ref-type="bibr" rid="ref408">408</xref></sup> More recently, synthetic
octa-, deca-, and dodeca-&#946;-glucans were synthesized and, after
conjugation to KLM, shown to be more immunogenic than the hexamer
with the octamer being the best among these lengths.<sup><xref ref-type="bibr" rid="ref409">409</xref></sup></p><fig id="fig19" position="float" orientation="portrait"><label>Figure 19</label><caption><p>Vaccine candidates against <italic toggle="yes">Candida</italic> infections:
(A) Different types of synthesized &#946;-(1&#8211;2)-mannan conjugates
used tested in animal models. (B) &#946;-(1&#8211;3)-Glucan conjugates
of different lengths enabling identification of a minimal hexamer
epitope.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr19" position="float" orientation="portrait" xlink:href="cr2c00021_0019.jpg"/></fig><p><italic toggle="yes">C. auris</italic> shares
a cell wall glycan composition
with the other <italic toggle="yes">Candida</italic> spp. However, mannans seem
to avoid triggering the antifungal activity of neutrophils, which
would evoke the innate immune cells to respond to fungal infections,
which could explain a different mechanism of immune evasion for this
pathogen.<sup><xref ref-type="bibr" rid="ref410">410</xref></sup> In a recent study, passive
transfer of C3.1, a mAb that targets &#946;-(1&#8211;2)-mannotriose
(&#946;-Man3) in the A/J mouse model, which mimics disseminated infection
of human candidiasis, demonstrated a significantly extended survival
and reduced burdens from <italic toggle="yes">C. auris</italic> in kidney, brain,
and heart.<sup><xref ref-type="bibr" rid="ref411">411</xref></sup> The data underpins the potential
of glycan targeting for the design of therapeutics against multidrug-resistant <italic toggle="yes">C. auris</italic>.</p><p>Also, unlike <italic toggle="yes">C. albicans</italic>, which forms a heterogeneous
architecture of biofilms combined with blastoconidia and hyphae embedded
within the extracellular matrix, <italic toggle="yes">C. auris</italic> produces
thin biofilms composed mostly of blastoconidia and occasionally pseudohyphae
embedded within a very limited extracellular matrix, which show less
susceptibility to antifungals than those of <italic toggle="yes">C. albicans</italic>.<sup><xref ref-type="bibr" rid="ref412">412</xref></sup> Adhesion plays a key role in <italic toggle="yes">C. auris</italic> virulence and biofilm formation, and proteins of
the agglutinin-like sequence (Als), in particular Als3393, are involved
in the adhesion of <italic toggle="yes">C. auris</italic>.<sup><xref ref-type="bibr" rid="ref413">413</xref></sup> Recently, the efficacy of the NDV-3A vaccine,<sup><xref ref-type="bibr" rid="ref414">414</xref></sup> already tested in women for the prevention
of recurrent vulvovaginal candidiasis, has been reported to protect
neutropenic mice from <italic toggle="yes">C. auris</italic> infection, with an
additive protective effect when combined with micafungin mice.<sup><xref ref-type="bibr" rid="ref415">415</xref></sup></p></sec></sec><sec id="sec6"><label>6</label><title>Conclusions and Future Directions</title><p>The ongoing SARS-Cov2 pandemic has clearly highlighted the need
for vaccines for pandemic preparedness, capable of inducing sterilizing
antibodies and providing herd immunity.<sup><xref ref-type="bibr" rid="ref416">416</xref></sup> Glycoconjugate vaccines represent preventive therapeutics that have
been shown able to induce killing (opsonic or bactericidal) antibodies
and to achieve herd immunity.<sup><xref ref-type="bibr" rid="ref417">417</xref></sup> Carbohydrate
targeting for the design of vaccines to combat the possible next pandemic,
AMR, therefore, appears crucial. The combination of synthesis with
structural glycobiology is rationalizing vaccine design, enabling
the generation of a more focused immune response against the most
relevant polysaccharide epitopes.<sup><xref ref-type="bibr" rid="ref134">134</xref>,<xref ref-type="bibr" rid="ref418">418</xref></sup></p><p>Further
advances in the synthesis of complex bacterial glycans
will allow the faster generation of more and more complex glycans,
making carbohydrate antigen production faster and more scalable.<sup><xref ref-type="bibr" rid="ref71">71</xref>,<xref ref-type="bibr" rid="ref419">419</xref></sup> Key challenges include not only further optimization of stereoselective
glycosylation methodology and automated synthesis techniques (a technique
that, if sufficiently matured, will also ensure reproducibility of
oligosaccharide synthesis) but also the incorporation of functional
groups, including labile esters, differently functionalized amines/amides,
pyruvate ketals, and phosphates and phosphonates, which often provide
microheterogeneity to the bacterial polysaccharide chains.<sup><xref ref-type="bibr" rid="ref420">420</xref></sup> A clear advantage of organic synthesis is the
improvement of specific properties of the glycans, such as stability
(as shown above for carbaMenA,<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Hib,<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> and ST5<sup><xref ref-type="bibr" rid="ref158">158</xref></sup> pneumococcal
analogues). In some examples, chemically derived structures have the
potential to improve the vaccine design for those polysaccharides
that have been proven less efficacious in humans (e.g. pneumococcal
ST3<sup><xref ref-type="bibr" rid="ref154">154</xref></sup>).</p><p>Due to the complexity of
the synthetic routes for glycans antigens,
large scale manufacturability has historically been considered a challenge
associated with this approach. Today, the success of the Cuban Quimi-Hib
conjugate and scalability for GMP production of <italic toggle="yes">Shigella</italic> and PNAG vaccines increase the confidence in chemical synthesis
as a tool to supply carbohydrate antigens at the industrial level.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Also, the need for minimal amounts per vaccine dose, as compared
to other chemical therapeutics and the increased availability of
commercial building blocks resulting in reduced cost of goods are
positively contributing to the large scale manufacturability of this
approach. Finally, various glycomimetic drugs and a synthetic heparin
(Fondaparinux) are manufactured at the industrial level and available
in the market.<sup><xref ref-type="bibr" rid="ref421">421</xref></sup></p><p>A more effective
synthesis methodology will enable the generation
of larger and more complex glycans, which may adopt crucial three-dimensional
structures presenting conformational epitopes that will further resemble
the natural polymers. From this perspective, the use of enzymatic
glycosylations will significantly speed up the assembly of naturally
occurring bacterial oligosaccharides and close analogues thereof,
as has been shown for the production of the MenX CPS.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> At present, the vast majority of the reported enzymatic
oligosaccharide syntheses have been directed at the assembly of mammalian
glycans, featuring the most common monosaccharide donors. Bacteria
use a much wider monosaccharide panel for the construction of their
polysaccharides. Expression of the relevant biosynthesis enzymes (besides
the transferases also the enzymes that generate the nucleotide donor
monosaccharides) and their use in the assembly of bacterial glycan
epitopes will streamline bacterial glycan assembly.</p><p>Novel nanosized
carriers favoring multimeric and optimal spatial
presentation of short glycans may improve the immunogenicity of glycoconjugate
vaccines, increasing the antibody avidity or breadth of the immune
response. Novel site-selective protein conjugation chemistries are
emerging to achieve better control over the carbohydrate&#8211;protein
linkages. Not only the number of glycans per carrier protein but also
the position on the protein may impact vaccine efficacy. Improved,
site-selective ligation chemistry will allow the generation of multivalent
conjugate vaccines, in which several epitopes can be connected to
a single protein carrier, which can be a pathogen derived protein,
also playing the role of antigen.</p><p>Very few adjuvants have been
so far tested with conjugated synthetic
carbohydrates (Freund adjuvant, Alum salts, and MF59 to mention some),
and the effect of adjuvantation on this type of structures has not
been thoroughly explored. The combination with well-defined molecular
adjuvants (such as TLR, NLR, RIG, and STING ligands) and targeting
devices is expected to further improve vaccine efficiency.<sup><xref ref-type="bibr" rid="ref422">422</xref>&#8722;<xref ref-type="bibr" rid="ref424">424</xref></sup> In particular, there is a need for potent and effective adjuvants
to be combined with glycoconjugate vaccines in elderly, hospitalized,
and immunocompromised patients where the need for therapies counteracting
AMR is higher.<sup><xref ref-type="bibr" rid="ref425">425</xref></sup> In combination with better
defined delivery vehicles, such as polymers or supramolecular architectures,
another level of control is introduced. The availability of well-defined
glycans is mandatory to allow optimization of all these important
vaccine parameters.</p><p>Finally, synthetic chemistry, in combination
with chemical biology
techniques and advanced microscopy, will enable studies to provide
insight into how conjugate vaccines are taken up and processed by
the host immune system.<sup><xref ref-type="bibr" rid="ref426">426</xref></sup> This will enable
the rational optimization of all steps required in the immunization
process to achieve optimal delivery, uptake, processing, and presentation
to the right partners of the immune system alongside optimal activation
of all players involved. We believe that all these advancements will
render carbohydrates a major player to defeat emerging AMR. While
the RNA platform will be used more and more for the expression of
protein antigens, progress in carbohydrate synthesis and conjugation
will allow better exploitation of the peculiar role of carbohydrates
as vaccine targets and create the next generation of glycovaccines.</p></sec></body><back><notes notes-type="" id="notes1"><title>Author Contributions</title><p>The manuscript
was written through contributions of all authors. All authors have
given approval to the final version of the manuscript.</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare the following competing financial interest(s): L.D.B., F.N.,
M.R.R., and R.A. are employees of the GSK group of companies. Bexsero
is a trademark from GSK. Trumemeba is a trademark of Pfizer. QumiHib
is a trademark of CIGB.</p></notes><bio id="BIO-d7e4126-autogenerated" rid="ath1"><p>Linda
Del Bino obtained her Master&#8217;s Degree in Chemistry
and Pharmaceutical Technology at the University of Pisa (Italy) in
2014 with a thesis on organic chemistry. She joined for two years
the AstraZeneca IMED Graduate Programme in G&#246;teborg (Sweden).
In 2020 she obtained her Ph.D. Program at the University of Leiden
working in GSK Siena (Italy) within the framework of the Horizon 2020
Marie Curie International Training Network Glycovax. Linda is currently
working as Scientist in the Glycoconjugate Synthesis and Analytical
Lab in Preclinical R&amp;D at GSK Siena, focusing on glycan and glycoconjugate
synthesis.</p></bio><bio id="BIO-d7e4129-autogenerated" rid="ath2"><p>Kitt Emilie &#216;sterlid obtained
her Master&#8217;s Degree at
University of Copenhagen (Denmark) in 2020. She is currently doing
her Ph.D. at Leiden University under the supervision of Prof. Dr.
J. D. C. Cod&#233;e. Her current research focuses on synthesis of
glycans from <italic toggle="yes">S. aureus</italic> for vaccine development.</p></bio><bio id="BIO-d7e4135-autogenerated" rid="ath3"><p>Dung-Yeh Wu received his M.S. degree in chemistry
from National
Tsing Hua University in 2018. Presently, he is a Ph.D. student in
Chemistry at Leiden University under the supervision of Dr. Jeroen
Cod&#233;e. His current research focuses on oligosaccharide syntheses
and bacterial vaccine development.</p></bio><bio id="BIO-d7e4138-autogenerated" rid="ath4"><p>Francesca
Nonne studied Pharmaceutical Chemistry and Technologies
at the University of Sassari (Italy), where she graduated in 2015.
After a Master&#8217;s Program in Drug Design and Synthesis at the
University of Siena, she joined GSK first for an internship in carbohydrate
synthesis and then for a Ph.D. Program in Chemical and Pharmaceutical
Sciences in collaboration with the University of Siena. Since January
2022 she has been Associate Scientist at GSK Vaccines Institute for
Global Health.</p></bio><bio id="BIO-d7e4141-autogenerated" rid="ath5"><p>Maria Rosaria Romano obtained
her Ph.D. in Pharmaceutical Sciences
at the University of Pisa on the synthesis of glycal derivatives in
2006. In 2007 she joined Novartis Vaccines as an Associate Researcher,
and in 2016 she became Head of Glycoconjugates Synthesis &amp; Analytic
Laboratory in GSK Vaccines. Her research is focused on polysaccharide
derived glycoconjugate vaccines, generation of new vaccines from synthetic
carbohydrates, nanoparticle technologies, and carbohydrate epitope
characterization for optimized vaccine design.</p></bio><bio id="BIO-d7e4144-autogenerated" rid="ath6"><p>Jeroen Cod&#233;e obtained his Ph.D. from Leiden University in
2004. After a post-doctoral stay at the ETH in Zurich, he returned
to Leiden, where he now is a Full Professor in Organic Chemistry.
The research in his group revolves around the many aspects of carbohydrate
chemistry, ranging from fundamental mechanistic studies to the assembly
of complex bacterial glycans, that are used as biosynthesis probes
and vaccine entities, and the generation of carbohydrate-based adjuvants
and biosynthesis inhibitors.</p></bio><bio id="BIO-d7e4147-autogenerated" rid="ath7"><p>Roberto Adamo
obtained his Ph.D. in Pharmaceutical Science from
the University of Catania (Italy) in 2003, working on the synthesis
of biologically relevant inositols. After two post-doctoral fellowships
at the NIH in Bethesda (USA) and at Utrecht University (The Netherlands),
in 2007 he joined Novartis, where he was later appointed Head of the
Carbohydrate Chemistry Laboratory and Leader of the Conjugation &amp;
Synthesis Platform. Following the company acquisition by GSK, he has
covered the role of Conjugation Platform Leader and, currently, of
Discovery Project Leader. His research interests vary from the synthesis
of glycans, glycoconjugates, and glyconanoparticles to structural
glycobiology for the design of carbohydrate-based therapeutics.</p></bio><ack><title>Acknowledgments</title><p>We are grateful to Giorgio Corsi
for his artwork
in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. EU Horizon
2020 program provided support with the grant No 861194 (PAVax). This
work was sponsored by GlaxoSmithKline Biologicals SA.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name><article-title>A 2020 vision for vaccines
against HIV, tuberculosis
and malaria</article-title>. <source>Nature</source><year>2011</year>, <volume>473</volume>, <fpage>463</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1038/nature10124</pub-id>.<pub-id pub-id-type="pmid">21614073</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Peltola</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>K&#228;ythy</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Sivonen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>M&#228;kel&#228;</surname><given-names>P. H.</given-names></name><article-title><italic toggle="yes">Haemophilus
influenzae</italic> type b capsular polysaccharide vaccine
in children: a double-blind field study of 100,000 vaccinees 3 months
to 5 years of age in Finland</article-title>. <source>Pediatrics</source><year>1977</year>, <volume>60</volume>, <fpage>686</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1542/peds.60.5.730</pub-id>.<pub-id pub-id-type="pmid">335348</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Peltola</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>M&#228;kel&#228;</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>K&#228;yhty</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Jousimies</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Herva</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>H&#228;llstr&#246;m</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Sivonen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Renkonen</surname><given-names>O. V.</given-names></name>; <name name-style="western"><surname>Pettay</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Karanko</surname><given-names>V.</given-names></name>; et al. <article-title>Clinical
efficacy of meningococcus group A capsular polysaccharide vaccine
in children three months to five years of age</article-title>. <source>N. Engl. J. Med.</source><year>1977</year>, <volume>297</volume>, <fpage>686</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM197709292971302</pub-id>.<pub-id pub-id-type="pmid">408682</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name><article-title>The design of semi-synthetic
and
synthetic glycoconjugate vaccines</article-title>. <source>Expert Opin.
Drug Discovery</source><year>2011</year>, <volume>6</volume>, <fpage>1045</fpage>&#8211;<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1517/17460441.2011.609554</pub-id>.<pub-id pub-id-type="pmid">22646863</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Stacey</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Rosen</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Peterson</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Williams-Diaz</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gakhar</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Sterling</surname><given-names>T. M.</given-names></name>; <name name-style="western"><surname>Acosta</surname><given-names>C. J.</given-names></name>; <name name-style="western"><surname>Nolan</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Pedley</surname><given-names>A.</given-names></name>; et al. <article-title>Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults</article-title>. <source>Hum. Vaccin. Immunother.</source><year>2019</year>, <fpage>530</fpage>&#8211;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2018.1532249</pub-id>.<pub-id pub-id-type="pmcid">PMC6605726</pub-id><pub-id pub-id-type="pmid">30648919</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Klein</surname><given-names>N. P.</given-names></name>; <name name-style="western"><surname>Peyrani</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Yacisin</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Caldwell</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Scully</surname><given-names>I. L.</given-names></name>; <name name-style="western"><surname>Scott</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Jansen</surname><given-names>K. U.</given-names></name>; <name name-style="western"><surname>Gruber</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>Watson</surname><given-names>W.</given-names></name><article-title>A phase 3, randomized, double-blind study to evaluate
the immunogenicity and safety of 3 lots of 20-valent pneumococcal
conjugate vaccine in pneumococcal vaccine-naive adults 18 through
49 years of age</article-title>. <source>Vaccine</source><year>2021</year>, <volume>39</volume>, <fpage>5428</fpage>&#8211;<lpage>5435</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.004</pub-id>.<pub-id pub-id-type="pmid">34315611</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Pichichero</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kaur</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Scott</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Gruber</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>Trammel</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Almudevar</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Center</surname><given-names>K. J.</given-names></name><article-title>Effectiveness of 13-valent pneumococcal
conjugate vaccination for protection against acute otitis media caused
by Streptococcus pneumoniae in healthy young children: a prospective
observational study</article-title>. <source>Lancet Child Adolesc. Health</source><year>2018</year>, <volume>2</volume>, <fpage>561</fpage>&#8211;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-4642(18)30168-8</pub-id>.<pub-id pub-id-type="pmid">30119715</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Potential targets for next generation
anti-microbial glycoconjugate vaccines</article-title>. <source>FEMS
Microbiol. Rev.</source><year>2018</year>, <volume>42</volume>, <fpage>388</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fuy011</pub-id>.<pub-id pub-id-type="pmid">29547971</pub-id><pub-id pub-id-type="pmcid">PMC5995208</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name name-style="western"><surname>de
Kraker</surname><given-names>M. E. A.</given-names></name>; <name name-style="western"><surname>Stewardson</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Harbarth</surname><given-names>S.</given-names></name><article-title>Will 10 million people
die a year due to antimicrobial resistance by 2050?</article-title>. <source>PLoS Medicine</source><year>2016</year>, <volume>13</volume>, <elocation-id>e1002184</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1002184</pub-id>.<pub-id pub-id-type="pmid">27898664</pub-id><pub-id pub-id-type="pmcid">PMC5127510</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="weblink" id="cit10"><person-group person-group-type="allauthors"><collab>CDC</collab></person-group>. <article-title>Antibiotic resistance threats in
the United States,
2019</article-title>. <year>2019</year>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf">https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf</uri>.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name>; <name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Navarro</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Edara</surname><given-names>V. V.</given-names></name>; et al. <article-title>Adjuvanting
a subunit COVID-19 vaccine to induce protective immunity</article-title>. <source>Nature</source><year>2021</year>, <volume>594</volume>, <fpage>253</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id>.<pub-id pub-id-type="pmid">33873199</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><person-group person-group-type="allauthors"><name name-style="western"><surname>Murray</surname><given-names>C. J. L.</given-names></name>; <name name-style="western"><surname>Ikuta</surname><given-names>K. S.</given-names></name>; <name name-style="western"><surname>Sharara</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Swetschinski</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Robles Aguilar</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Gray</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Han</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Bisignano</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Rao</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Wool</surname><given-names>E.</given-names></name></person-group>; <etal/><article-title>Global burden of bacterial antimicrobial
resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source><year>2022</year>, <volume>399</volume>, <fpage>629</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id>.<pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Garcia-Quintanilla</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pulido</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Carretero-Ledesma</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>McConnell</surname><given-names>M. J.</given-names></name><article-title>Vaccines
for antibiotic-resistant bacteria: possibility or pipe dream?</article-title>. <source>Trends Pharmacol. Sci.</source><year>2016</year>, <volume>37</volume>, <fpage>143</fpage>&#8211;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2015.10.003</pub-id>.<pub-id pub-id-type="pmid">26574183</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Siber</surname><given-names>G. R.</given-names></name><article-title>How can vaccines contribute to solving
the antimicrobial
resistance problem?</article-title>. <source>MBio</source><year>2016</year>, <volume>7</volume>, <elocation-id>e00428-e00416</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00428-16</pub-id>.<pub-id pub-id-type="pmid">27273824</pub-id><pub-id pub-id-type="pmcid">PMC4959668</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bagnoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Serruto</surname><given-names>D.</given-names></name><article-title>The role of vaccines
in combatting antimicrobial resistance</article-title>. <source>Nature
Rev. Microbiol.</source><year>2021</year>, <volume>19</volume>, <fpage>287</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-020-00506-3</pub-id>.<pub-id pub-id-type="pmid">33542518</pub-id><pub-id pub-id-type="pmcid">PMC7861009</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name name-style="western"><surname>David</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Reuter</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Harris</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Glasner</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Feltwell</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Argimon</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Abudahab</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Goater</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Giani</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Errico</surname><given-names>G.</given-names></name>; et al. <article-title>Epidemic of carbapenem-resistant <italic toggle="yes">Klebsiella
pneumoniae</italic> in Europe is driven by nosocomial spread</article-title>. <source>Nature Microbiol.</source><year>2019</year>, <volume>4</volume>, <fpage>1919</fpage>&#8211;<lpage>1929</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-019-0492-8</pub-id>.<pub-id pub-id-type="pmid">31358985</pub-id><pub-id pub-id-type="pmcid">PMC7244338</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Alfini</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Glycoconjugate vaccines: current
approaches towards faster vaccine
design</article-title>. <source>Expert Rev. Vaccines</source><year>2019</year>, <volume>18</volume>, <fpage>881</fpage>&#8211;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2019.1657012</pub-id>.<pub-id pub-id-type="pmid">31475596</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Verez-Bencomo</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Fernandez-Santana</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Hardy</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Toledo</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Rodriguez</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>Heynngnezz</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Baly</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Herrera</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Izquierdo</surname><given-names>M.</given-names></name>; et al. <article-title>A synthetic conjugate polysaccharide vaccine
against <italic toggle="yes">Haemophilus influenzae</italic> type b</article-title>. <source>Science</source><year>2004</year>, <volume>305</volume>, <fpage>522</fpage>&#8211;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1126/science.1095209</pub-id>.<pub-id pub-id-type="pmid">15273395</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Atsmon</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Artaud</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Meron-Sudai</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gougeon</surname><given-names>M.-L.</given-names></name>; <name name-style="western"><surname>Bialik</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Goren</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Asato</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Ariel-Cohen</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Reizis</surname><given-names>A.</given-names></name>; et al. <article-title>Safety and immunogenicity
of a synthetic carbohydrate conjugate vaccine against <italic toggle="yes">Shigella
flexneri</italic> 2a in healthy adult volunteers: a phase 1, dose-escalating,
single-blind, randomised, placebo-controlled study</article-title>. <source>Lancet Infect. Dis.</source><year>2020</year>, <volume>21</volume>, <fpage>735</fpage>&#8211;<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30488-6</pub-id>.<pub-id pub-id-type="pmid">33186516</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><person-group person-group-type="allauthors"><name name-style="western"><surname>van der
Put</surname><given-names>R. M. F.</given-names></name>; <name name-style="western"><surname>Smitsman</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>de Haan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hamzink</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Timmermans</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Uittenbogaard</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Westdijk</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Stork</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ophorst</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Thouron</surname><given-names>F.</given-names></name></person-group>; <etal/><article-title>The first-in-human synthetic glycan-based conjugate vaccine candidate
against <italic toggle="yes">Shigella</italic></article-title>. <source>ACS Cent.
Sci.</source><year>2022</year>, <volume>8</volume>, <fpage>449</fpage>&#8211;<lpage>460</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.1c01479</pub-id>.<pub-id pub-id-type="pmid">35559427</pub-id><pub-id pub-id-type="pmcid">PMC9088300</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Soliman</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name>; <name name-style="western"><surname>Ramsland</surname><given-names>P. A.</given-names></name><article-title>Antibody recognition
of bacterial
surfaces and extracellular polysaccharides</article-title>. <source>Curr. Opin. Struct. Biol.</source><year>2020</year>, <volume>62</volume>, <fpage>48</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2019.12.001</pub-id>.<pub-id pub-id-type="pmid">31874385</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Chemical
biology approaches to designing defined carbohydrate vaccines</article-title>. <source>Chem. Biol.</source><year>2014</year>, <volume>21</volume>, <fpage>38</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2014.01.002</pub-id>.<pub-id pub-id-type="pmid">24439205</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Hendrickx</surname><given-names>A. P.</given-names></name>; <name name-style="western"><surname>Budzik</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Oh</surname><given-names>S. Y.</given-names></name>; <name name-style="western"><surname>Schneewind</surname><given-names>O.</given-names></name><article-title>Architects
at the bacterial surface - sortases and the assembly of pili with
isopeptide bonds</article-title>. <source>Nat. Rev. Microbiol.</source><year>2011</year>, <volume>9</volume>, <fpage>166</fpage>&#8211;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2520</pub-id>.<pub-id pub-id-type="pmid">21326273</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Filloux</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name><article-title>Editorial:
The many wonders of the bacterial cell surface</article-title>. <source>FEMS Microbiol. Rev.</source><year>2016</year>, <volume>40</volume>, <fpage>161</fpage>&#8211;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fuv047</pub-id>.<pub-id pub-id-type="pmid">26684539</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Costerton</surname><given-names>J. W.</given-names></name>; <name name-style="western"><surname>Irvin</surname><given-names>R. T.</given-names></name><article-title>The bacterial glycocalix in nature and disease</article-title>. <source>Annu. Rev. Microbiol.</source><year>1981</year>, <volume>35</volume>, <fpage>299</fpage>&#8211;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.mi.35.100181.001503</pub-id>.<pub-id pub-id-type="pmid">7027902</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Willis</surname><given-names>L. M.</given-names></name>; <name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name><article-title>Structure,
biosynthesis, and function of bacterial
capsular polysaccharides synthesized by ABC transporter-dependent
pathways</article-title>. <source>Carbohydr. Res.</source><year>2013</year>, <volume>378</volume>, <fpage>35</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2013.05.007</pub-id>.<pub-id pub-id-type="pmid">23746650</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Williams</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Kelly</surname><given-names>S. D.</given-names></name><article-title>Lipopolysaccharide
O-antigens-bacterial
glycans made to measure</article-title>. <source>J. Biol. Chem.</source><year>2020</year>, <volume>295</volume>, <fpage>10593</fpage>&#8211;<lpage>10609</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.REV120.009402</pub-id>.<pub-id pub-id-type="pmid">32424042</pub-id><pub-id pub-id-type="pmcid">PMC7397119</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Greenfield</surname><given-names>L. K.</given-names></name>; <name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name><article-title>Synthesis
of lipopolysaccharide O-antigens by ABC transporter-dependent
pathways</article-title>. <source>Carbohydr. Res.</source><year>2012</year>, <volume>356</volume>, <fpage>12</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2012.02.027</pub-id>.<pub-id pub-id-type="pmid">22475157</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Knirel</surname><given-names>Y. A.</given-names></name>; <name name-style="western"><surname>Bystrova</surname><given-names>O. V.</given-names></name>; <name name-style="western"><surname>Shashkov</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Lindner</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Kocharova</surname><given-names>N. A.</given-names></name>; <name name-style="western"><surname>Senchenkova</surname><given-names>S. N.</given-names></name>; <name name-style="western"><surname>Moll</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zahringer</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Kazue</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Structural
analysis of the lipopolysaccharide
core of a rough, cystic fibrosis isolate of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Eur. J. Biochem.</source><year>2001</year>, <volume>268</volume>, <fpage>4708</fpage>&#8211;<lpage>4719</lpage>. <pub-id pub-id-type="doi">10.1046/j.1432-1327.2001.02396.x</pub-id>.<pub-id pub-id-type="pmid">11532007</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Vollmer</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Blanot</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>de Pedro</surname><given-names>M. A.</given-names></name><article-title>Peptidoglycan
structure and architecture</article-title>. <source>FEMS Microbiol.
Rev.</source><year>2008</year>, <volume>32</volume>, <fpage>149</fpage>&#8211;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00094.x</pub-id>.<pub-id pub-id-type="pmid">18194336</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Armstrong</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Baddiley</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Buchanan</surname><given-names>J. G.</given-names></name>; <name name-style="western"><surname>Carss</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Greenberg</surname><given-names>G. R.</given-names></name><article-title>Isolation
and structure of ribitol phosphate derivatives (teichoic acids) from
bacterial cell walls</article-title>. <source>J. Chem. Soc.</source><year>1958</year>, <fpage>4344</fpage>&#8211;<lpage>4354</lpage>. <pub-id pub-id-type="doi">10.1039/jr9580004344</pub-id>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Neuhaus</surname><given-names>F. C.</given-names></name>; <name name-style="western"><surname>Baddiley</surname><given-names>J.</given-names></name><article-title>A continuum of anionic
charge: structures and functions
of D-alanyl-teichoic acids in Gram-positive bacteria</article-title>. <source>Microbiol. Mol. Biol. Rev.</source><year>2003</year>, <volume>67</volume>, <fpage>686</fpage>&#8211;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.67.4.686-723.2003</pub-id>.<pub-id pub-id-type="pmid">14665680</pub-id><pub-id pub-id-type="pmcid">PMC309049</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Collins</surname><given-names>L. V.</given-names></name>; <name name-style="western"><surname>Kristian</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Weidenmaier</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Faigle</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Van Kessel</surname><given-names>K. P. M.</given-names></name>; <name name-style="western"><surname>Van Strijp</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>G&#246;tz</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Neumeister</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Peschel</surname><given-names>A.</given-names></name><article-title><italic toggle="yes">Staphylococcus
aureus</italic> strains lacking D-alanine modifications of teichoic
acids are highly
susceptible to human neutrophil killing and are virulence attenuated
in mice</article-title>. <source>J. Infect. Dis.</source><year>2002</year>, <volume>186</volume>, <fpage>214</fpage>&#8211;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1086/341454</pub-id>.<pub-id pub-id-type="pmid">12134257</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Fischer</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Behr</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hartmann</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Peter-Katalinic</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Egge</surname><given-names>H.</given-names></name><article-title>Teichoic acid and lipoteichoic acid
of <italic toggle="yes">Streptococcus pneumoniae</italic> possess identical chain
structures. A reinvestigation of teichoid
acid (C polysaccharide)</article-title>. <source>Eur. J. Biochem.</source><year>1993</year>, <volume>215</volume>, <fpage>851</fpage>&#8211;<lpage>857</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1993.tb18102.x</pub-id>.<pub-id pub-id-type="pmid">8354290</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Donlan</surname><given-names>R. M.</given-names></name><article-title>Biofilm
formation: a clinically relevant microbiological process</article-title>. <source>Clin. Infect. Dis.</source><year>2001</year>, <volume>33</volume>, <fpage>1387</fpage>&#8211;<lpage>1392</lpage>. <pub-id pub-id-type="doi">10.1086/322972</pub-id>.<pub-id pub-id-type="pmid">11565080</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Maira-Litran</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Abeygunawardana</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Joyce</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mark</surname><given-names>G.</given-names><suffix>III</suffix></name>; <name name-style="western"><surname>Goldmann</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Immunochemical properties
of the staphylococcal poly-N-Acetylglucosamine surface polysaccharide</article-title>. <source>Infect. Immun.</source><year>2002</year>, <volume>70</volume>, <fpage>4433</fpage>&#8211;<lpage>4440</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.8.4433-4440.2002</pub-id>.<pub-id pub-id-type="pmid">12117954</pub-id><pub-id pub-id-type="pmcid">PMC128161</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Ryder</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Byrd</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wozniak</surname><given-names>D. J.</given-names></name><article-title>Role of
polysaccharides in <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm
development</article-title>. <source>Curr. Opin. Microbiol.</source><year>2007</year>, <volume>10</volume>, <fpage>644</fpage>&#8211;<lpage>648</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2007.09.010</pub-id>.<pub-id pub-id-type="pmid">17981495</pub-id><pub-id pub-id-type="pmcid">PMC2176169</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Masuoka</surname><given-names>J.</given-names></name><article-title>Surface glycans
of <italic toggle="yes">Candida albicans</italic> and other pathogenic fungi: physiological
roles, clinical uses, and experimental challenges</article-title>. <source>Clin. Microbiol. Rev.</source><year>2004</year>, <volume>17</volume>, <fpage>281</fpage>&#8211;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.17.2.281-310.2004</pub-id>.<pub-id pub-id-type="pmid">15084502</pub-id><pub-id pub-id-type="pmcid">PMC387410</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><person-group person-group-type="allauthors"><name name-style="western"><surname>Gow</surname><given-names>N. A. R.</given-names></name>; <name name-style="western"><surname>Latge</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Munro</surname><given-names>C. A.</given-names></name></person-group><article-title>The fungal
cell wall: structure, biosynthesis, and function</article-title>. <source>Microbiol. Spectrosc.</source><year>2017</year>, <volume>5</volume>, <pub-id pub-id-type="doi">10.1128/microbiolspec.FUNK-0035-2016</pub-id>.<pub-id pub-id-type="pmcid">PMC11687499</pub-id><pub-id pub-id-type="pmid">28513415</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Khatun</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Stephenson</surname><given-names>R. J.</given-names></name>; <name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name><article-title>An overview of structural features
of antibacterial glycoconjugate vaccines that influence their immunogenicity</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2017</year>, <volume>23</volume>, <fpage>4233</fpage>&#8211;<lpage>4254</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201603599</pub-id>.<pub-id pub-id-type="pmid">28097690</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="book" id="cit41"><person-group person-group-type="allauthors"><name name-style="western"><surname>Ravenscroft</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Talaga</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Rodriguez</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Egan</surname><given-names>W.</given-names></name></person-group><article-title>Glycoconjugate
vaccines</article-title>. In <source>Vaccine Analysis: Strategies,
Principles, and Control</source>; <person-group person-group-type="editor"><name name-style="western"><surname>Nunnally</surname><given-names>B. K.</given-names></name></person-group>, <etal/>, Eds.; <publisher-name>Springer-Verlag</publisher-name>: <publisher-loc>Berlin Heidelberg</publisher-loc>, <year>2015</year>; pp <fpage>301</fpage>&#8211;<lpage>381</lpage>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><person-group person-group-type="allauthors"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name></person-group><article-title>Protein
carriers for glycoconjugate
vaccines: history, selection criteria, characterization and new trends</article-title>. <source>Molecules</source><year>2018</year>, <volume>23</volume>, <fpage>1451</fpage><pub-id pub-id-type="doi">10.3390/molecules23061451</pub-id>.<pub-id pub-id-type="pmcid">PMC6100388</pub-id><pub-id pub-id-type="pmid">29914046</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Broker</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Schneider</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vojtek</surname><given-names>I.</given-names></name><article-title>Polysaccharide conjugate
vaccine protein carriers as a &#8243;neglected valency&#8243; -
Potential and limitations</article-title>. <source>Vaccine</source><year>2017</year>, <volume>35</volume>, <fpage>3286</fpage>&#8211;<lpage>3294</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.04.078</pub-id>.<pub-id pub-id-type="pmid">28487056</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Broker</surname><given-names>M.</given-names></name><article-title>Potential
protective immunogenicity of tetanus toxoid, diphtheria toxoid and
Cross Reacting Material 197 (CRM197) when used as carrier proteins
in glycoconjugates</article-title>. <source>Hum. Vaccin. Immunother.</source><year>2016</year>, <volume>12</volume>, <fpage>664</fpage>&#8211;<lpage>667</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1086048</pub-id>.<pub-id pub-id-type="pmid">26327602</pub-id><pub-id pub-id-type="pmcid">PMC4964734</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Zambonelli</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Bottomley</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; et al. <article-title>Comparison of CRM197,
diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal
glycoconjugate vaccines</article-title>. <source>Vaccine</source><year>2013</year>, <volume>31</volume>, <fpage>4827</fpage>&#8211;<lpage>4833</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.078</pub-id>.<pub-id pub-id-type="pmid">23965218</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Marburg</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Jorn</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Tolman</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Arison</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>McCauley</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kniskern</surname><given-names>P. J.</given-names></name>; <name name-style="western"><surname>Hagopian</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Vella</surname><given-names>P. P.</given-names></name><article-title>Bimolecular chemistry
of macromolecules: synthesis of bacterial polysaccharide conjugates
with <italic toggle="yes">Neisseria meningitidis</italic> membrane protein</article-title>. <source>J. Am. Chem. Soc.</source><year>1986</year>, <volume>108</volume>, <fpage>5282</fpage>&#8211;<lpage>5287</lpage>. <pub-id pub-id-type="doi">10.1021/ja00277a037</pub-id>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name></person-group><article-title>Preparation
of glycoconjugate vaccines</article-title>. In <source>Carbohydrate-Based
Vaccines and Immunotherapies</source>; <person-group person-group-type="editor"><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Boons</surname><given-names>G.-J.</given-names></name></person-group>, Eds.; <publisher-name>John Wiley &amp; Sons,
Inc</publisher-name>; <publisher-loc>Hoboken, NJ</publisher-loc>, <year>2009</year>; pp <fpage>55</fpage>&#8211;<lpage>88</lpage>.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Anderson</surname><given-names>P. W.</given-names></name>; <name name-style="western"><surname>Pichichero</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Insel</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Betts</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Eby</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Smith</surname><given-names>D. H.</given-names></name><article-title>Vaccines consisting of periodate-cleaved oligosaccharides
from the capsule of <italic toggle="yes">Haemophilus influenzae</italic> type b
coupled to protein carrier: structural and temporal a requirements
for priming in the human infant</article-title>. <source>J. Immunol.</source><year>1986</year>, <volume>137</volume>, <fpage>1181</fpage>&#8211;<lpage>1186</lpage>.<pub-id pub-id-type="pmid">3016088</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="book" id="cit49"><person-group person-group-type="allauthors"><collab>CDC</collab></person-group>. <article-title>Food and Drug Administration approval
for use of
Hiberix as a 3-dose primary <italic toggle="yes">Haemophilus influenzae</italic> type b (Hib) vaccination series</article-title>. <source>MMWR Morb.
Mortal. Wkly Rep.</source><year>2016</year>, <volume>65</volume>, <fpage>418</fpage>&#8211;<lpage>419</lpage>.<pub-id pub-id-type="pmid">27124887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6516a3</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Broker</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Dull</surname><given-names>P. M.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name><article-title>Chemistry
of a new investigational quadrivalent meningococcal conjugate vaccine
that is immunogenic at all ages</article-title>. <source>Vaccine</source><year>2009</year>, <volume>27</volume>, <fpage>5574</fpage>&#8211;<lpage>5580</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.036</pub-id>.<pub-id pub-id-type="pmid">19619500</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Bardotti</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Averani</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Carinci</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>D&#8217;Ascenzi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Fabbri</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Giannini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Giannozzi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Magagnoli</surname><given-names>C.</given-names></name>; et al. <article-title>Physicochemical characterisation of glycoconjugate
vaccines for prevention of meningococcal diseases</article-title>. <source>Vaccine</source><year>2008</year>, <volume>26</volume>, <fpage>2284</fpage>&#8211;<lpage>2296</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.022</pub-id>.<pub-id pub-id-type="pmid">18378363</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Norelli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Giannozzi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>D&#8217;Ascenzi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bartoloni</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Kaur</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Seid</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Viti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Paffetti</surname><given-names>R.</given-names></name>; et al. <article-title>Size fractionation
of
bacterial capsular polysaccharides for their use in conjugate vaccines</article-title>. <source>Vaccine</source><year>1999</year>, <volume>17</volume>, <fpage>1251</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(98)00348-X</pub-id>.<pub-id pub-id-type="pmid">10195638</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Antimicrobial glycoconjugate vaccines:
an overview of classic and
modern approaches for protein modification</article-title>. <source>Chem. Soc. Rev.</source><year>2018</year>, <volume>47</volume>, <fpage>9015</fpage>&#8211;<lpage>9025</lpage>. <pub-id pub-id-type="doi">10.1039/C8CS00495A</pub-id>.<pub-id pub-id-type="pmid">30277489</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Wacker</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Linton</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Hitchen</surname><given-names>P. G.</given-names></name>; <name name-style="western"><surname>Nita-Lazar</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Haslam</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>North</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Panico</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Morris</surname><given-names>H. R.</given-names></name>; <name name-style="western"><surname>Dell</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Wren</surname><given-names>B. W.</given-names></name>; et al. <article-title>N-Linked glycosylation
in <italic toggle="yes">Campylobacter jejuni</italic> and its functional transfer
into <italic toggle="yes">E. coli</italic></article-title>. <source>Science</source><year>2002</year>, <volume>298</volume>, <fpage>1790</fpage>&#8211;<lpage>1793</lpage>. <pub-id pub-id-type="doi">10.1126/science.298.5599.1790</pub-id>.<pub-id pub-id-type="pmid">12459590</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Wacker</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Feldman</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Callewaert</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Kowarik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Clarke</surname><given-names>B. R.</given-names></name>; <name name-style="western"><surname>Pohl</surname><given-names>N. L.</given-names></name>; <name name-style="western"><surname>Hernandez</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Vines</surname><given-names>E. D.</given-names></name>; <name name-style="western"><surname>Valvano</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name>; et al. <article-title>Substrate specificity of bacterial oligosaccharyltransferase
suggests a common transfer mechanism for the bacterial and eukaryotic
systems</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2006</year>, <volume>103</volume>, <fpage>7088</fpage>&#8211;<lpage>7093</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0509207103</pub-id>.<pub-id pub-id-type="pmid">16641107</pub-id><pub-id pub-id-type="pmcid">PMC1459022</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Feldman</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Wacker</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hernandez</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hitchen</surname><given-names>P. G.</given-names></name>; <name name-style="western"><surname>Marolda</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Kowarik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Morris</surname><given-names>H. R.</given-names></name>; <name name-style="western"><surname>Dell</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Valvano</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Aebi</surname><given-names>M.</given-names></name><article-title>Engineering N-linked
protein glycosylation with diverse O antigen
lipopolysaccharide structures in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2005</year>, <volume>102</volume>, <fpage>3016</fpage>&#8211;<lpage>3021</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0500044102</pub-id>.<pub-id pub-id-type="pmid">15703289</pub-id><pub-id pub-id-type="pmcid">PMC549450</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Kowarik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Young</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Numao</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Schulz</surname><given-names>B. L.</given-names></name>; <name name-style="western"><surname>Hug</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Callewaert</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Mills</surname><given-names>D. C.</given-names></name>; <name name-style="western"><surname>Watson</surname><given-names>D. C.</given-names></name>; <name name-style="western"><surname>Hernandez</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kelly</surname><given-names>J. F.</given-names></name>; et al. <article-title>Definition of the bacterial N-glycosylation
site consensus sequence</article-title>. <source>EMBO J.</source><year>2006</year>, <volume>25</volume>, <fpage>1957</fpage>&#8211;<lpage>1966</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7601087</pub-id>.<pub-id pub-id-type="pmid">16619027</pub-id><pub-id pub-id-type="pmcid">PMC1456941</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Talaat</surname><given-names>K. R.</given-names></name>; <name name-style="western"><surname>Alaimo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Bourgeois</surname><given-names>A. L.</given-names></name>; <name name-style="western"><surname>Dreyer</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Kaminski</surname><given-names>R. W.</given-names></name>; <name name-style="western"><surname>Porter</surname><given-names>C. K.</given-names></name>; <name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Clarkson</surname><given-names>K. A.</given-names></name>; <name name-style="western"><surname>Brubaker</surname><given-names>J.</given-names></name>; et al. <article-title>Human
challenge study
with a <italic toggle="yes">Shigella</italic> bioconjugate vaccine: analyses of
clinical efficacy and correlate of protection</article-title>. <source>EBioMedicine</source><year>2021</year>, <volume>66</volume>, <fpage>103310</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103310</pub-id>.<pub-id pub-id-type="pmid">33862589</pub-id><pub-id pub-id-type="pmcid">PMC8054157</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>van den
Dobbelsteen</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Abbanat</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Hornacek</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fr&#246;lich</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Dreyer</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Davies</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Fae</surname><given-names>K.</given-names></name>; et al. <article-title>Safety, immunogenicity, and preliminary clinical efficacy
of a vaccine against extraintestinal pathogenic <italic toggle="yes">Escherichia
coli</italic> in women with a history of recurrent urinary tract infection:
a randomised, single-blind, placebo-controlled phase 1b trial</article-title>. <source>Lancet Infect. Dis.</source><year>2017</year>, <volume>17</volume>, <fpage>528</fpage>&#8211;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30108-1</pub-id>.<pub-id pub-id-type="pmid">28238601</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Wals</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Ovaa</surname><given-names>H.</given-names></name><article-title>Unnatural amino acid incorporation
in <italic toggle="yes">E. coli</italic>: current
and future applications in the design of therapeutic proteins</article-title>. <source>Front. Chem.</source><year>2014</year>, <volume>2</volume>, <fpage>15</fpage><pub-id pub-id-type="doi">10.3389/fchem.2014.00015</pub-id>.<pub-id pub-id-type="pmid">24790983</pub-id><pub-id pub-id-type="pmcid">PMC3982533</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Machida</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Lang</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Xue</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Chin</surname><given-names>J. W.</given-names></name>; <name name-style="western"><surname>Winssinger</surname><given-names>N.</given-names></name><article-title>Site-specific
glycoconjugation of protein via bioorthogonal tetrazine cycloaddition
with a genetically encoded trans-cyclooctene or bicyclononyne</article-title>. <source>Bioconjugate Chem.</source><year>2015</year>, <volume>26</volume>, <fpage>802</fpage>&#8211;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00101</pub-id>.<pub-id pub-id-type="pmcid">PMC4673905</pub-id><pub-id pub-id-type="pmid">25897481</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Fairman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Agarwal</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Barbanel</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Behrens</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Berges</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Burky</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Davey</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Fernsten</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Grainger</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name>; et al. <article-title>Non-clinical
immunological comparison of a next-generation
24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific
carrier protein conjugation to the current standard of care (PCV13
and PPV23)</article-title>. <source>Vaccine</source><year>2021</year>, <volume>39</volume>, <fpage>3197</fpage>&#8211;<lpage>3206</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.070</pub-id>.<pub-id pub-id-type="pmid">33965258</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Thanawastien</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Cartee</surname><given-names>R. T.</given-names></name>; <name name-style="western"><surname>Griffin</surname><given-names>T. J.</given-names></name>; <name name-style="western"><surname>Killeen</surname><given-names>K. P.</given-names></name>; <name name-style="western"><surname>Mekalanos</surname><given-names>J. J.</given-names></name><article-title>Conjugate-like
immunogens produced as protein capsular matrix vaccines</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2015</year>, <volume>112</volume>, <fpage>E1143</fpage>&#8211;<lpage>E1151</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1425005112</pub-id>.<pub-id pub-id-type="pmid">25699685</pub-id><pub-id pub-id-type="pmcid">PMC4364189</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>Y.-J.</given-names></name>; <name name-style="western"><surname>Malley</surname><given-names>R.</given-names></name><article-title>Multiple antigen-presenting
system
(MAPS) to induce comprehensive B- and T-cell immunity</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2013</year>, <volume>110</volume>, <fpage>13564</fpage>&#8211;<lpage>13569</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1307228110</pub-id>.<pub-id pub-id-type="pmid">23898212</pub-id><pub-id pub-id-type="pmcid">PMC3746895</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="weblink" id="cit65"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://affinivax.com">http://affinivax.com</uri>.</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Advancing
homogeneous antimicrobial glycoconjugate vaccines</article-title>. <source>Acc. Chem. Res.</source><year>2017</year>, <volume>50</volume>, <fpage>1270</fpage>&#8211;<lpage>1279</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.7b00106</pub-id>.<pub-id pub-id-type="pmid">28463499</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Ye</surname><given-names>X. S.</given-names></name><article-title>Iterative
one-pot
synthesis of oligosaccharides</article-title>. <source>Angew. Chem.
Int. Ed. Engl.</source><year>2004</year>, <volume>43</volume>, <fpage>5221</fpage>&#8211;<lpage>5224</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200460176</pub-id>.<pub-id pub-id-type="pmid">15455432</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Fiebig</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Berger</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>De Ricco</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Santini</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; et al. <article-title>Combined chemical synthesis and tailored enzymatic
elongation provide fully synthetic and conjugation-ready Neisseria
meningitidis serogroup X vaccine antigens</article-title>. <source>ACS
Chem. Biol.</source><year>2018</year>, <volume>13</volume>, <fpage>984</fpage>&#8211;<lpage>994</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.7b01057</pub-id>.<pub-id pub-id-type="pmid">29481045</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Hahm</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Schlegel</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Hurevich</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Eller</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Schuhmacher</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hofmann</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Pagel</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Automated
glycan assembly using the Glyconeer 2.1 synthesizer</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2017</year>, <volume>114</volume>, <fpage>E3385</fpage>&#8211;<lpage>E3389</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1700141114</pub-id>.<pub-id pub-id-type="pmid">28396442</pub-id><pub-id pub-id-type="pmcid">PMC5410834</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Automated
oligosaccharide synthesis</article-title>. <source>Chem. Soc. Rev.</source><year>2008</year>, <volume>37</volume>, <fpage>19</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1039/B511197H</pub-id>.<pub-id pub-id-type="pmid">18197330</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Panza</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pistorio</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Stine</surname><given-names>K. J.</given-names></name>; <name name-style="western"><surname>Demchenko</surname><given-names>A. V.</given-names></name><article-title>Automated
chemical oligosaccharide synthesis: novel approach to traditional
challenges</article-title>. <source>Chem. Rev.</source><year>2018</year>, <volume>118</volume>, <fpage>8105</fpage>&#8211;<lpage>8150</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00051</pub-id>.<pub-id pub-id-type="pmid">29953217</pub-id><pub-id pub-id-type="pmcid">PMC6522228</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Nilo</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Castagner</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Boutureira</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bernardes</surname><given-names>G. J. L.</given-names></name><article-title>Synthetically
defined glycoprotein
vaccines: current status and future directions</article-title>. <source>Chem. Sci.</source><year>2013</year>, <volume>4</volume>, <fpage>2995</fpage>&#8211;<lpage>3008</lpage>. <pub-id pub-id-type="doi">10.1039/c3sc50862e</pub-id>.<pub-id pub-id-type="pmid">25893089</pub-id><pub-id pub-id-type="pmcid">PMC4396375</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Stefanetti</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>Q. Y.</given-names></name>; <name name-style="western"><surname>Usera</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Robinson</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Allan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Imase</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Cobb</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Zhai</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Quinn</surname><given-names>D.</given-names></name>; et al. <article-title>Sugar-protein connectivity impacts on the immunogenicity
of site-selective Salmonella O-Antigen glycoconjugate vaccines</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year>, <volume>54</volume>, <fpage>13198</fpage>&#8211;<lpage>13203</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201506112</pub-id>.<pub-id pub-id-type="pmid">26350581</pub-id><pub-id pub-id-type="pmcid">PMC4648054</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Slack</surname><given-names>M. P. E.</given-names></name><article-title>Long
term impact of conjugate vaccines on <italic toggle="yes">Haemophilus influenzae</italic> meningitis: narrative review</article-title>. <source>Microorganisms</source><year>2021</year>, <volume>9</volume>, <fpage>886</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9050886</pub-id>.<pub-id pub-id-type="pmid">33919149</pub-id><pub-id pub-id-type="pmcid">PMC8143157</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Zon</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Robbins</surname><given-names>J. D.</given-names></name><article-title><sup>31</sup>P and <sup>13</sup>C NMR spectral and
chemical characterization of the end-group and repeating-unit components
of oligosaccharides derived by acid hydrolysis of <italic toggle="yes">Haemophilus
influenzae</italic> type b capsular polysaccharide</article-title>. <source>Carbohydr. Res.</source><year>1983</year>, <volume>114</volume>, <fpage>103</fpage>&#8211;<lpage>121</lpage>.<pub-id pub-id-type="pmid">6601988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(83)88177-4</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Schneerson</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Barrera</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Sutton</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Robbins</surname><given-names>J. B.</given-names></name><article-title>Preparation, characterization,
and immunogenicity of <italic toggle="yes">Haemophilus influenzae</italic> type
b polysaccharide-protein conjugates</article-title>. <source>J. Exp.
Med.</source><year>1980</year>, <volume>152</volume>, <fpage>361</fpage>&#8211;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1084/jem.152.2.361</pub-id>.<pub-id pub-id-type="pmid">6967514</pub-id><pub-id pub-id-type="pmcid">PMC2185954</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Anderson</surname><given-names>P.</given-names></name><article-title>Antibody responses
to <italic toggle="yes">Haemophilus influenzae</italic> type b and diphtheria toxin
induced by conjugates of oligosaccharides of the type b capsule with
the nontoxic protein CRM197</article-title>. <source>Infect. Immun.</source><year>1983</year>, <volume>39</volume>, <fpage>233</fpage>&#8211;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1128/iai.39.1.233-238.1983</pub-id>.<pub-id pub-id-type="pmid">6600444</pub-id><pub-id pub-id-type="pmcid">PMC347931</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Heath</surname><given-names>P. T.</given-names></name><article-title><italic toggle="yes">Haemophilus influenzae</italic> type b conjugate vaccines: a review
of efficacy data</article-title>. <source>Pediatr. Infect. Dis. J.</source><year>1998</year>, <volume>17</volume>, <fpage>S117</fpage>&#8211;<lpage>S122</lpage>. <pub-id pub-id-type="doi">10.1097/00006454-199809001-00005</pub-id>.<pub-id pub-id-type="pmid">9781743</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Khatuntseva</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Glycoconjugate
vaccines for prevention of <italic toggle="yes">Haemophilus
influenzae</italic> type b diseases</article-title>. <source>Russ. J.
Bioorg. Chem.</source><year>2021</year>, <volume>47</volume>, <fpage>26</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1134/S1068162021010106</pub-id>.<pub-id pub-id-type="pmid">33776394</pub-id><pub-id pub-id-type="pmcid">PMC7980804</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Anderson</surname><given-names>P. W.</given-names></name>; <name name-style="western"><surname>Pichichero</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Stein</surname><given-names>E. C.</given-names></name>; <name name-style="western"><surname>Porcelli</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Betts</surname><given-names>R. F.</given-names></name>; <name name-style="western"><surname>Connuck</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Korones</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Insel</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Zahradnik</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Eby</surname><given-names>R.</given-names></name><article-title>Effect of oligosaccharide chain length, exposed terminal group, and
hapten loading on the antibody response of human adults and infants
to vaccines consisting of <italic toggle="yes">Haemophilus influenzae</italic> type
b capsular antigen unterminally coupled to the diphtheria protein
CRM197</article-title>. <source>J. Immunol.</source><year>1989</year>, <volume>142</volume>, <fpage>2464</fpage>&#8211;<lpage>2468</lpage>.<pub-id pub-id-type="pmid">2784464</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Rana</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Dalal</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Hanif</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Joshi</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Chhikara</surname><given-names>M. K.</given-names></name><article-title>Development and
characterization
of <italic toggle="yes">Haemophilus influenzae</italic> type b conjugate vaccine
prepared using different polysaccharide chain lengths</article-title>. <source>Vaccine</source><year>2015</year>, <volume>33</volume>, <fpage>2646</fpage>&#8211;<lpage>2654</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.031</pub-id>.<pub-id pub-id-type="pmid">25907408</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Hoogerhout</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Evenberg</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>van Boeckel</surname><given-names>C. A. A.</given-names></name>; <name name-style="western"><surname>Poolman</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Beuvery</surname><given-names>E. C.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>van Boom</surname><given-names>J. H.</given-names></name><article-title>Synthesis of the capsular polysaccharide
of <italic toggle="yes">Haemophilus influenzae</italic> type b, comprising two
or three repeating units</article-title>. <source>Tetrahedron Lett.</source><year>1987</year>, <volume>28</volume>, <fpage>1553</fpage>&#8211;<lpage>1556</lpage>. <pub-id pub-id-type="doi">10.1016/S0040-4039(01)81040-6</pub-id>.</mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Hoogerhout</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Funke</surname><given-names>C. W.</given-names></name>; <name name-style="western"><surname>Mellema</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Wagenaars</surname><given-names>G. N. A.</given-names></name>; <name name-style="western"><surname>van Boeckel</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Evenberg</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Poolman</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Lefeber</surname><given-names>A. W. M.</given-names></name>; <name name-style="western"><surname>Van Der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Van Booma</surname><given-names>J. H.</given-names></name><article-title>Synthesis
of fragments of the capsular polysaccharide of <italic toggle="yes">Haemophilus
influnzae</italic> type b part II. Preparation and structural analysis
of fragments comprising two and three repeating units</article-title>. <source>J. Carbohydr. Chem.</source><year>1988</year>, <volume>7</volume>, <fpage>399</fpage>&#8211;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1080/07328308808058933</pub-id>.</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Garegg</surname><given-names>P. J.</given-names></name>; <name name-style="western"><surname>Samuelsson</surname><given-names>B.</given-names></name><article-title>Synthesis of 1-O-&#946;-D-ribofuranosyl-D-ribitol
5-(disodium phosphate)</article-title>. <source>Carbohydr. Res.</source><year>1980</year>, <volume>86</volume>, <fpage>293</fpage>&#8211;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(00)85906-6</pub-id>.</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rathwell</surname><given-names>D. C. K.</given-names></name>; <name name-style="western"><surname>Meierhofer</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>A modular
synthetic route to size-defined
immunogenic <italic toggle="yes">Haemophilus influenzae</italic> b antigens is
key to the identification of an octasaccharide lead vaccine candidate</article-title>. <source>Chem. Sci.</source><year>2018</year>, <volume>9</volume>, <fpage>1279</fpage>&#8211;<lpage>1288</lpage>. <pub-id pub-id-type="doi">10.1039/C7SC04521B</pub-id>.<pub-id pub-id-type="pmid">29675174</pub-id><pub-id pub-id-type="pmcid">PMC5887106</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Egan</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Schneerson</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Werner</surname><given-names>K. E.</given-names></name>; <name name-style="western"><surname>Zon</surname><given-names>G.</given-names></name><article-title>Structural studies
and chemistry of bacterial capsular polysaccharides. Investigations
of phosphodiester-linked capsular polysaccharides isolated from H<italic toggle="yes">aemophilus influenzae</italic> types a, b, c, and f: NMR spectroscopic
identification and chemical modification of end groups and the nature
of base-catalyzed hydrolytic depolymerization</article-title>. <source>J. Am. Chem. Soc.</source><year>1982</year>, <volume>104</volume>, <fpage>2898</fpage>&#8211;<lpage>2910</lpage>. <pub-id pub-id-type="doi">10.1021/ja00374a033</pub-id>.</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="patent" id="cit87"><person-group person-group-type="allauthors"><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C.</given-names></name></person-group><article-title>Stable hydrolysis-resistant
synthetic polyribosylribitolphosphate derivatives as vaccines against <italic toggle="yes">Haemphilus influenzae</italic> type b</article-title>. US <patent>11,014,952</patent> B2, <year>2021</year>.</mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Collins</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Litt</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Flynn</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Ramsay</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Slack</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Ladhani</surname><given-names>S. N.</given-names></name><article-title>Neonatal invasive <italic toggle="yes">Haemophilus influenzae</italic> disease in England and Wales: epidemiology,
clinical characteristics,
and outcome</article-title>. <source>Clin. Infect. Dis.</source><year>2015</year>, <volume>60</volume>, <fpage>1786</fpage>&#8211;<lpage>1792</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ194</pub-id>.<pub-id pub-id-type="pmid">25784720</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Grzeszczyk</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Banaszek</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Zamojski</surname><given-names>A.</given-names></name><article-title>The synthesis
of the two repeating
units of <italic toggle="yes">Haemophilus influenzae</italic> type a capsular antigen</article-title>. <source>Carbohyd. Res.</source><year>1988</year>, <volume>175</volume>, <fpage>215</fpage>&#8211;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1016/0008-6215(88)84144-2</pub-id>.<pub-id pub-id-type="pmid">3261200</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Alderson</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Welsch</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>Regan</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Newhouse</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Bhat</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Marfin</surname><given-names>A. A.</given-names></name><article-title>Vaccines to prevent meningitis: historical
perspectives
and future directions</article-title>. <source>Microorganisms</source><year>2021</year>, <volume>9</volume>, <fpage>771</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9040771</pub-id>.<pub-id pub-id-type="pmid">33917003</pub-id><pub-id pub-id-type="pmcid">PMC8067733</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name name-style="western"><surname>Ulanova</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tsang</surname><given-names>R. S. W.</given-names></name><article-title><italic toggle="yes">Haemophilus
influenzae</italic> serotype a
as a cause of serious invasive infections</article-title>. <source>Lancet
Infect. Dis.</source><year>2014</year>, <volume>14</volume>, <fpage>70</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70170-1</pub-id>.<pub-id pub-id-type="pmid">24268829</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name name-style="western"><surname>Cox</surname><given-names>A. D.</given-names></name>; <name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Cairns</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>St. Michael</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Fleming</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Vinogradov</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Arbour</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Masson</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><article-title>Investigating the candidacy
of a capsular polysaccharide-based glycoconjugate
as a vaccine to combat <italic toggle="yes">Haemophilus influenzae</italic> type
a disease: a solution for an unmet public health need</article-title>. <source>Vaccine</source><year>2017</year>, <volume>35</volume>, <fpage>6129</fpage>&#8211;<lpage>6136</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.055</pub-id>.<pub-id pub-id-type="pmid">28951087</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name name-style="western"><surname>Slattegard</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Teodorovic</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Kinfe</surname><given-names>H. H.</given-names></name>; <name name-style="western"><surname>Ravenscroft</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Gammon</surname><given-names>D. W.</given-names></name>; <name name-style="western"><surname>Oscarson</surname><given-names>S.</given-names></name><article-title>Synthesis of structures corresponding
to the capsular polysaccharide of <italic toggle="yes">Neisseria meningitidis</italic> group A</article-title>. <source>Org. Biomol. Chem.</source><year>2005</year>, <volume>3</volume>, <fpage>3782</fpage>&#8211;<lpage>3787</lpage>. <pub-id pub-id-type="doi">10.1039/b507898a</pub-id>.<pub-id pub-id-type="pmid">16211114</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name name-style="western"><surname>Harale</surname><given-names>K. R.</given-names></name>; <name name-style="western"><surname>Rout</surname><given-names>J. K.</given-names></name>; <name name-style="western"><surname>Chhikara</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Gill</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Misra</surname><given-names>A. K.</given-names></name><article-title>Synthesis
and immunochemical evaluation of a novel <italic toggle="yes">Neisseria meningitidis</italic> serogroup A tetrasaccharide and its conjugate</article-title>. <source>Org. Chem. Front.</source><year>2017</year>, <volume>4</volume>, <fpage>2348</fpage>&#8211;<lpage>2357</lpage>. <pub-id pub-id-type="doi">10.1039/C7QO00468K</pub-id>.</mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><article-title>Synthesis of <italic toggle="yes">Neisseria meningitidis</italic> X capsular polysaccharide
fragments</article-title>. <source>Arkivoc</source><year>2013</year>, <fpage>166</fpage>&#8211;<lpage>184</lpage>.</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Cancogni</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Nilo</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Filippini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><article-title>Synthesis and immunological evaluation of protein conjugates of <italic toggle="yes">Neisseria meningitidis</italic> X capsular polysaccharide fragments</article-title>. <source>Beilstein J. Org. Chem.</source><year>2014</year>, <volume>10</volume>, <fpage>2367</fpage>&#8211;<lpage>2376</lpage>. <pub-id pub-id-type="doi">10.3762/bjoc.10.247</pub-id>.<pub-id pub-id-type="pmid">25383107</pub-id><pub-id pub-id-type="pmcid">PMC4222376</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name name-style="western"><surname>Harale</surname><given-names>K. R.</given-names></name>; <name name-style="western"><surname>Dumare</surname><given-names>N. B.</given-names></name>; <name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Misra</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Chhikara</surname><given-names>M. K.</given-names></name><article-title>Synthesis
of a tetrasaccharide and its glycoconjugate corresponding to the capsular
polysaccharide of <italic toggle="yes">Neisseria meningitidis</italic> serogroup
X and its immunochemical studies</article-title>. <source>RSC Adv.</source><year>2015</year>, <volume>5</volume>, <fpage>41332</fpage>&#8211;<lpage>41340</lpage>. <pub-id pub-id-type="doi">10.1039/C5RA02993G</pub-id>.</mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name name-style="western"><surname>Pietri</surname><given-names>G. P.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Robakiewicz</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Henriques</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Calloni</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Abramova</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Santini</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Mali&#263;</surname><given-names>S.</given-names></name>; et al. <article-title>Elucidating the structural and minimal protective
epitope of the serogroup X meningococcal capsular polysaccharide</article-title>. <source>Front. Mol. Biosci.</source><year>2021</year>, <volume>8</volume>, <fpage>745360</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2021.745360</pub-id>.<pub-id pub-id-type="pmid">34722634</pub-id><pub-id pub-id-type="pmcid">PMC8551719</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name name-style="western"><surname>Hsu</surname><given-names>C.-H.</given-names></name>; <name name-style="western"><surname>Chu</surname><given-names>K.-C.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>Y.-S.</given-names></name>; <name name-style="western"><surname>Han</surname><given-names>J.-L.</given-names></name>; <name name-style="western"><surname>Peng</surname><given-names>Y.-S.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>C.-T.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>C.-Y.</given-names></name>; <name name-style="western"><surname>Wong</surname><given-names>C.-H.</given-names></name><article-title>Highly alpha-selective
sialyl phosphate donors for efficient preparation of natural sialosides</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2010</year>, <volume>16</volume>, <fpage>1754</fpage>&#8211;<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200903035</pub-id>.<pub-id pub-id-type="pmid">20066711</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Synthesis and immunological
study of alpha-2,9-oligosialic acid conjugates as anti-group C meningitis
vaccines</article-title>. <source>Chem. Commun. (Camb)</source><year>2015</year>, <volume>51</volume>, <fpage>9647</fpage>&#8211;<lpage>9650</lpage>. <pub-id pub-id-type="doi">10.1039/C5CC01794G</pub-id>.<pub-id pub-id-type="pmid">25973942</pub-id><pub-id pub-id-type="pmcid">PMC4526240</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name name-style="western"><surname>Chu</surname><given-names>K. C.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>C. T.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>C. P.</given-names></name>; <name name-style="western"><surname>Hsu</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Sun</surname><given-names>T. H.</given-names></name>; <name name-style="western"><surname>Han</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Pal</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Chao</surname><given-names>T. A.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>Y. F.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>S. H.</given-names></name>; et al. <article-title>Efficient
and stereoselective
synthesis of &#945;-(2&#8594;9) oligosialic acids: from monomers
to dodecamers</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><year>2011</year>, <volume>50</volume>, <fpage>9391</fpage>&#8211;<lpage>9395</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201101794</pub-id>.<pub-id pub-id-type="pmid">21948436</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name name-style="western"><surname>Dalal</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Rana</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Harale</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Hanif</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Chhikara</surname><given-names>M. K.</given-names></name><article-title>Development
and
pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate
vaccine against <italic toggle="yes">Neisseria meningitidis</italic> serogroup
C</article-title>. <source>Vaccine</source><year>2019</year>, <volume>37</volume>, <fpage>5297</fpage>&#8211;<lpage>5306</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.053</pub-id>.<pub-id pub-id-type="pmid">31371227</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Suryawanshi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mondal</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Fully synthetic self-adjuvanting
alpha-2,9-oligosialic acid based conjugate vaccines against group
C meningitis</article-title>. <source>ACS Cent. Sci.</source><year>2016</year>, <volume>2</volume>, <fpage>210</fpage>&#8211;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.5b00364</pub-id>.<pub-id pub-id-type="pmid">27163051</pub-id><pub-id pub-id-type="pmcid">PMC4850515</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name name-style="western"><surname>Wang</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>S. T.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>Y. Y.</given-names></name>; <name name-style="western"><surname>Sun</surname><given-names>T. H.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>T. J.</given-names></name>; <name name-style="western"><surname>Mong</surname><given-names>K. K.</given-names></name>; <name name-style="western"><surname>Wong</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>C. Y.</given-names></name><article-title>Synthesis of <italic toggle="yes">Neisseria meningitidis</italic> serogroup W135 capsular oligosaccharides
for immunogenicity comparison
and vaccine development</article-title>. <source>Angew. Chem. Int. Ed.
Engl.</source><year>2013</year>, <volume>52</volume>, <fpage>9157</fpage>&#8211;<lpage>9161</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201302540</pub-id>.<pub-id pub-id-type="pmid">23843313</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name name-style="western"><surname>Finne</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Leinonen</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>M&#228;kel&#228;</surname><given-names>P. H.</given-names></name><article-title>Antigenic
similarities between brain components and bacteria causing meningitidis:
implications for vaccine development and pathogenesis</article-title>. <source>Lancet</source><year>1983</year>, <volume>322</volume>, <fpage>355</fpage>&#8211;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(83)90340-9</pub-id>.<pub-id pub-id-type="pmid">6135869</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name name-style="western"><surname>Flitter</surname><given-names>B. A.</given-names></name>; <name name-style="western"><surname>Ing</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Moe</surname><given-names>G. R.</given-names></name><article-title>Effect of human
serum on de-<italic toggle="yes">N</italic>-acetyl sialic acid epitope expression
and antibody activity against <italic toggle="yes">N. meningitidis</italic> group
B</article-title>. <source>Vaccine</source><year>2010</year>, <volume>28</volume>, <fpage>5967</fpage>&#8211;<lpage>5972</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.119</pub-id>.<pub-id pub-id-type="pmid">20637761</pub-id><pub-id pub-id-type="pmcid">PMC2924676</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name name-style="western"><surname>Moe</surname><given-names>G. R.</given-names></name>; <name name-style="western"><surname>Dave</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Granoff</surname><given-names>D. M.</given-names></name><article-title>Molecular
analysis
of anti-<italic toggle="yes">N</italic>-propionyl <italic toggle="yes">Neisseria meningitidis</italic> group B polysaccharide monoclonal antibodies</article-title>. <source>Mol. Immunol.</source><year>2006</year>, <volume>43</volume>, <fpage>1424</fpage>&#8211;<lpage>1431</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2005.07.033</pub-id>.<pub-id pub-id-type="pmid">16140379</pub-id><pub-id pub-id-type="pmcid">PMC2245894</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name name-style="western"><surname>Cox</surname><given-names>A. D.</given-names></name>; <name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Gidney</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Lacelle</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Plested</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Makepeace</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Wright</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Coull</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Moxon</surname><given-names>E. R.</given-names></name>; <name name-style="western"><surname>Richards</surname><given-names>J. C.</given-names></name><article-title>Candidacy of LPS-based glycoconjugates
to prevent invasive meningococcal disease: developmental chemistry
and investigation of immunological responses following immunization
of mice and rabbits</article-title>. <source>Vaccine</source><year>2005</year>, <volume>23</volume>, <fpage>5045</fpage>&#8211;<lpage>5054</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.06.011</pub-id>.<pub-id pub-id-type="pmid">16046037</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Vijayakrishnan</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Kowarik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Park</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Zakharova</surname><given-names>A. N.</given-names></name>; <name name-style="western"><surname>Neiwert</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Faridmoayer</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Davis</surname><given-names>B. G.</given-names></name><article-title>An antibacterial
vaccination strategy based on a glycoconjugate
containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2</article-title>. <source>Nat. Chem.</source><year>2016</year>, <volume>8</volume>, <fpage>242</fpage>&#8211;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2432</pub-id>.<pub-id pub-id-type="pmid">26892556</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name name-style="western"><surname>Masignani</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Moxon</surname><given-names>E. R.</given-names></name><article-title>The development
of a vaccine against meningococcus B using reverse vaccinology</article-title>. <source>Front. Immunol.</source><year>2019</year>, <volume>10</volume>, <fpage>751</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00751</pub-id>.<pub-id pub-id-type="pmid">31040844</pub-id><pub-id pub-id-type="pmcid">PMC6477034</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name name-style="western"><surname>Sierra</surname><given-names>G. V.</given-names></name>; <name name-style="western"><surname>Campa</surname><given-names>H. C.</given-names></name>; <name name-style="western"><surname>Varcacel</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Garcia</surname><given-names>I. L.</given-names></name>; <name name-style="western"><surname>Izquierdo</surname><given-names>P. L.</given-names></name>; <name name-style="western"><surname>Sotolongo</surname><given-names>P. F.</given-names></name>; <name name-style="western"><surname>Casanueva</surname><given-names>G. V.</given-names></name>; <name name-style="western"><surname>Rico</surname><given-names>C. O.</given-names></name>; <name name-style="western"><surname>Rodriguez</surname><given-names>C. R.</given-names></name>; <name name-style="western"><surname>Terry</surname><given-names>M. H.</given-names></name><article-title>Vaccine against
group B <italic toggle="yes">Neisseria meningitidis</italic>: protection trial
and mass vaccination results in Cuba</article-title>. <source>NIPH Annals</source><year>1991</year>, <volume>14</volume>, <fpage>195</fpage>&#8211;<lpage>207</lpage>.<pub-id pub-id-type="pmid">1812432</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name name-style="western"><surname>Fiebig</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Freiberger</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Claus</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Stummeyer</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Berger</surname><given-names>M.</given-names></name>; et al. <article-title>Functional
expression of the capsule polymerase of <italic toggle="yes">Neisseria meningitidis</italic> serogroup X: a new perspective for vaccine development</article-title>. <source>Glycobiology</source><year>2014</year>, <volume>24</volume>, <fpage>150</fpage>&#8211;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cwt102</pub-id>.<pub-id pub-id-type="pmid">24259400</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name name-style="western"><surname>Fiebig</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Cramer</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Bethe</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Baruch</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Curth</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>F&#252;hring</surname><given-names>J. I.</given-names></name>; <name name-style="western"><surname>Buettner</surname><given-names>F. F. R.</given-names></name>; <name name-style="western"><surname>Vogel</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Schubert</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fedorov</surname><given-names>R.</given-names></name>; et al. <article-title>Structural and mechanistic
basis of capsule O-acetylation in N<italic toggle="yes">eisseria meningitidis</italic> serogroup A</article-title>. <source>Nat. Commun.</source><year>2020</year>, <volume>11</volume>, <fpage>4723</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18464-y</pub-id>.<pub-id pub-id-type="pmid">32948778</pub-id><pub-id pub-id-type="pmcid">PMC7501274</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name name-style="western"><surname>Fiebig</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Litschko</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Freiberger</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bethe</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Berger</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Gerardy-Schahn</surname><given-names>R.</given-names></name><article-title>Efficient solid-phase synthesis of meningococcal capsular
oligosaccharides enables simple and fast chemoenzymatic vaccine production</article-title>. <source>J. Biol. Chem.</source><year>2017</year>, <volume>93</volume>, <fpage>953</fpage>&#8211;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA117.000488</pub-id>.<pub-id pub-id-type="pmcid">PMC5777266</pub-id><pub-id pub-id-type="pmid">29187601</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name name-style="western"><surname>Fiebig</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Santini</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Berger</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; et al. <article-title>An efficient cell free
enzyme-based total synthesis of a meningococcal vaccine candidate</article-title>. <source>npj Vaccines</source><year>2016</year>, <volume>1</volume>, <fpage>16017</fpage><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.17</pub-id>.<pub-id pub-id-type="pmid">29263856</pub-id><pub-id pub-id-type="pmcid">PMC5707881</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name name-style="western"><surname>McCarthy</surname><given-names>P. C.</given-names></name>; <name name-style="western"><surname>Saksena</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Peterson</surname><given-names>D. C.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name>; <name name-style="western"><surname>An</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Cipollo</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Vann</surname><given-names>W. F.</given-names></name><article-title>Chemoenzymatic
synthesis of immunogenic
meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates</article-title>. <source>Glycoconj. J.</source><year>2013</year>, <volume>30</volume>, <fpage>857</fpage>&#8211;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1007/s10719-013-9490-x</pub-id>.<pub-id pub-id-type="pmid">23949787</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Kooner</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Muthana</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><article-title>A chemoenzymatic synthon strategy for synthesizing
N-Acetyl analogues
of O-Acetylated <italic toggle="yes">N. meningitidis</italic> W capsular polysaccharide
oligosaccharides</article-title>. <source>J. Org. Chem.</source><year>2020</year>, <volume>85</volume>, <fpage>16157</fpage>&#8211;<lpage>16165</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.0c02134</pub-id>.<pub-id pub-id-type="pmid">33164526</pub-id><pub-id pub-id-type="pmcid">PMC7811823</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Cappelletti</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Gavini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pluschke</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>MacLennan</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name><article-title>Relative stability
of meningococcal
serogroup A and X polysaccharides</article-title>. <source>Vaccine</source><year>2012</year>, <volume>30</volume>, <fpage>6409</fpage>&#8211;<lpage>6415</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.08.021</pub-id>.<pub-id pub-id-type="pmid">22921741</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name name-style="western"><surname>Torres-Sanchez</surname><given-names>M. I.</given-names></name>; <name name-style="western"><surname>Zaccaria</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Buzzi</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Miglio</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Lombardi</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><article-title>Synthesis
and biological evaluation of phosphono analogues of capsular polysaccharide
fragments from <italic toggle="yes">Neisseria meningitidis</italic> A</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2007</year>, <volume>13</volume>, <fpage>6623</fpage>&#8211;<lpage>6635</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200601743</pub-id>.<pub-id pub-id-type="pmid">17508372</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name name-style="western"><surname>Fallarini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Buzzi</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Giovarruscio</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lombardi</surname><given-names>G.</given-names></name><article-title>A synthetic disaccharide
analogue from <italic toggle="yes">Neisseria meningitidis</italic> A capsular polysaccharide
stimulates immune cell responses and induces Immunoglobulin G (IgG)
production in mice when protein-conjugated</article-title>. <source>ACS Infect. Dis.</source><year>2015</year>, <volume>1</volume>, <fpage>487</fpage>&#8211;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00071</pub-id>.<pub-id pub-id-type="pmid">27623315</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Zaccaria</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Poletti</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><article-title>Synthesis and preliminary biological
evaluation of carba analogues
from <italic toggle="yes">Neisseria meningitidis</italic> A capsular polysaccharide</article-title>. <source>Org. Biomol. Chem.</source><year>2012</year>, <volume>10</volume>, <fpage>6673</fpage>&#8211;<lpage>6681</lpage>. <pub-id pub-id-type="doi">10.1039/c2ob25222h</pub-id>.<pub-id pub-id-type="pmid">22850927</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Nilo</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Filippini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Harfouche</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; et al. <article-title>Immunoactivity of protein conjugates of carba analogues
from <italic toggle="yes">Neisseria meningitidis</italic> A capsular polysaccharide</article-title>. <source>ACS Chem. Biol.</source><year>2013</year>, <volume>8</volume>, <fpage>2561</fpage>&#8211;<lpage>2567</lpage>. <pub-id pub-id-type="doi">10.1021/cb400463u</pub-id>.<pub-id pub-id-type="pmid">24000773</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name name-style="western"><surname>Hlozek</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kuttel</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Ravenscroft</surname><given-names>N.</given-names></name><article-title>Conformations
of <italic toggle="yes">Neisseria meningitidis</italic> serogroup A and X polysaccharides:
The effects of chain length and O-acetylation</article-title>. <source>Carbohydr. Res.</source><year>2018</year>, <volume>465</volume>, <fpage>44</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2018.06.007</pub-id>.<pub-id pub-id-type="pmid">29940397</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name name-style="western"><surname>Hlozek</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ravenscroft</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Kuttel</surname><given-names>M. M.</given-names></name><article-title>Modeling the conformations
of <italic toggle="yes">Neisseria meningitidis</italic> serogroup a CPS and a carba-analogue:
implications for vaccine development</article-title>. <source>Carbohydr.
Res.</source><year>2019</year>, <volume>486</volume>, <fpage>107838</fpage><pub-id pub-id-type="doi">10.1016/j.carres.2019.107838</pub-id>.<pub-id pub-id-type="pmid">31654945</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name name-style="western"><surname>Calloni</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Unione</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Jim&#233;nez-Os&#233;s</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Corzana</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Corrado</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Pitirollo</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Colombo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; et al. <article-title>The conformation
of the mannopyranosyl phosphate repeating unit of the capsular polysaccharide
of Neisseria meningitidis serogroup A and its carba-mimetic</article-title>. <source>European J. Org. Chem.</source><year>2018</year>, <volume>2018</volume> (<issue>33</issue>), <fpage>4548</fpage>&#8211;<lpage>4555</lpage>. <pub-id pub-id-type="doi">10.1002/ejoc.201801003</pub-id>.<pub-id pub-id-type="pmcid">PMC6220853</pub-id><pub-id pub-id-type="pmid">30443159</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name name-style="western"><surname>Enotarpi</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Balocchi</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>van der
Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Auberger</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Balducci</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Casini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Filippov</surname><given-names>D. V.</given-names></name>; et al. <article-title>A stabilized glycomimetic
conjugate vaccine inducing protective antibodies against Neisseria
meningitidis serogroup A</article-title>. <source>Nat. Commun.</source><year>2020</year>, <volume>11</volume>, <fpage>4434</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18279-x</pub-id>.<pub-id pub-id-type="pmid">32895393</pub-id><pub-id pub-id-type="pmcid">PMC7477203</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name name-style="western"><surname>Henriques</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Dello Iacono</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Gimeno</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Biolchi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Arda</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bernardes</surname><given-names>G. J. L.</given-names></name>; <name name-style="western"><surname>Jimenez-Barbero</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; et al. <article-title>Structure of a protective epitope reveals the importance of acetylation
of <italic toggle="yes">Neisseria meningitidis</italic> serogroup A capsular polysaccharide</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2020</year>, <volume>117</volume>, <fpage>29795</fpage>&#8211;<lpage>29802</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2011385117</pub-id>.<pub-id pub-id-type="pmid">33158970</pub-id><pub-id pub-id-type="pmcid">PMC7703565</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Nilo</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Harfouche</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Pecetta</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Balducci</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Filippini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mori</surname><given-names>E.</given-names></name>; et al. <article-title>Investigating
the immunodominance of carbohydrate antigens in a bivalent unimolecular
glycoconjugate vaccine against serogroup A and C meningococcal disease</article-title>. <source>Glycoconj. J.</source><year>2014</year>, <volume>31</volume>, <fpage>637</fpage>&#8211;<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1007/s10719-014-9559-1</pub-id>.<pub-id pub-id-type="pmid">25256065</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Balducci</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Balocchi</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Santini</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Masignani</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name><article-title>Preclinical studies on new proteins
as carrier for glycoconjugate vaccines</article-title>. <source>Vaccine</source><year>2016</year>, <volume>34</volume>, <fpage>4235</fpage>&#8211;<lpage>4242</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.06.039</pub-id>.<pub-id pub-id-type="pmid">27317455</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Alfini</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Di Benedetto</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Necchi</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Schiavo</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Mancini</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Carducci</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Palmieri</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Balocchi</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Gasperini</surname><given-names>G.</given-names></name>; et al. <article-title>GMMA is a versatile platform to design effective multivalent combination
vaccines</article-title>. <source>Vaccines</source><year>2020</year>, <volume>8</volume>, <fpage>540</fpage><pub-id pub-id-type="doi">10.3390/vaccines8030540</pub-id>.<pub-id pub-id-type="pmcid">PMC7564227</pub-id><pub-id pub-id-type="pmid">32957610</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><article-title>Development of meningococcal polysaccharide conjugate
vaccine that can elicit long-lasting and strong cellular immune response
with hepatitis B core antigen virus-like particles as a novel carrier
protein</article-title>. <source>Vaccine</source><year>2019</year>, <volume>37</volume>, <fpage>956</fpage>&#8211;<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.12.073</pub-id>.<pub-id pub-id-type="pmid">30655174</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name name-style="western"><surname>Grijalva</surname><given-names>C. G.</given-names></name>; <name name-style="western"><surname>Nuorti</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Arbogast</surname><given-names>P. G.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>S. W.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Griffin</surname><given-names>M. R.</given-names></name><article-title>Decline in pneumonia
admissions after
routine childhood immunisation with pneumococcal conjugate vaccine
in the USA: a time-series analysis</article-title>. <source>Lancet</source><year>2007</year>, <volume>369</volume>, <fpage>1179</fpage>&#8211;<lpage>1186</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60564-9</pub-id>.<pub-id pub-id-type="pmid">17416262</pub-id></mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name name-style="western"><surname>Bechini</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Boccalini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bonanni</surname><given-names>P.</given-names></name><article-title>Immunization with the
7-valent conjugate pneumococcal vaccine: impact evaluation, continuing
surveillance and future perspectives</article-title>. <source>Vaccine</source><year>2009</year>, <volume>27</volume>, <fpage>3285</fpage>&#8211;<lpage>3290</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.058</pub-id>.<pub-id pub-id-type="pmid">19200829</pub-id></mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Discovery of semi- and fully-synthetic
carbohydrate
vaccines against bacterial infections using a medicinal chemistry
approach</article-title>. <source>Chem. Rev.</source><year>2021</year>, <volume>121</volume>, <fpage>3598</fpage>&#8211;<lpage>3626</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01210</pub-id>.<pub-id pub-id-type="pmid">33794090</pub-id><pub-id pub-id-type="pmcid">PMC8154330</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name name-style="western"><surname>Javed</surname></name>; <name name-style="western"><surname>Mandal</surname><given-names>P. K.</given-names></name><article-title>Bacterial
surface capsular polysaccharides from <italic toggle="yes">Streptococcus pneumoniae</italic>: a systematic review on structures, syntheses, and glycoconjugate
vaccines</article-title>. <source>Carbohydr. Res.</source><year>2021</year>, <volume>502</volume>, <fpage>108277</fpage><pub-id pub-id-type="doi">10.1016/j.carres.2021.108277</pub-id>.<pub-id pub-id-type="pmid">33743443</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal" id="cit136"><name name-style="western"><surname>Gening</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Kurbatova</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Development
of approaches to a conjugated carbohydrate vaccine of the third generation
against <italic toggle="yes">Streptococcus pneumoniae</italic>: the search for
optimal oligosaccharide ligands</article-title>. <source>Russ. Chem.
Rev.</source><year>2015</year>, <volume>84</volume>, <fpage>1100</fpage>&#8211;<lpage>1113</lpage>. <pub-id pub-id-type="doi">10.1070/RCR4574</pub-id>.</mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal" id="cit137"><name name-style="western"><surname>Gening</surname><given-names>M.
L.</given-names></name>; <name name-style="western"><surname>Kurbatova</surname><given-names>E A.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Synthetic
Analogs of Streptococcus pneumoniae Capsular Polysaccharides and Immunogenic
Activities of Glycoconjugates</article-title>. <source>Russ. J. Bioorg.
Chem.</source><year>2021</year>, <volume>47</volume>, <fpage>1</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1134/S1068162021010076</pub-id>.<pub-id pub-id-type="pmid">33776393</pub-id><pub-id pub-id-type="pmcid">PMC7980793</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal" id="cit138"><name name-style="western"><surname>Jansen</surname><given-names>W. T.</given-names></name>; <name name-style="western"><surname>Hogenboom</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Thijssen</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Vliegenthart</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Verhoef</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Verheul</surname><given-names>A. F.</given-names></name><article-title>Synthetic
6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal
type 6A and 6B common and 6B-specific epitopes that elicit protective
antibodies in mice</article-title>. <source>Infect. Immun.</source><year>2001</year>, <volume>69</volume>, <fpage>787</fpage>&#8211;<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.69.2.787-793.2001</pub-id>.<pub-id pub-id-type="pmid">11159969</pub-id><pub-id pub-id-type="pmcid">PMC97953</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name name-style="western"><surname>Mawas</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Niggemann</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Jones</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Corbel</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Vliegenthart</surname><given-names>J. F. G.</given-names></name><article-title>Immunogenicity in a mouse model of
a conjugate vaccine made with a synthetic single repeating unit of
type 14 pneumococcal polysaccharide coupled to CRM197</article-title>. <source>Infect. Immun.</source><year>2002</year>, <volume>70</volume>, <fpage>5107</fpage>&#8211;<lpage>5114</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.9.5107-5114.2002</pub-id>.<pub-id pub-id-type="pmid">12183560</pub-id><pub-id pub-id-type="pmcid">PMC128223</pub-id></mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name name-style="western"><surname>Safari</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Dekker</surname><given-names>H. A.</given-names></name>; <name name-style="western"><surname>Joosten</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>Michalik</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>de Souza</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lahmann</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sundgren</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Oscarson</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; et al. <article-title>Identification of the
smallest structure capable of evoking opsonophagocytic antibodies
against <italic toggle="yes">Streptococcus pneumoniae</italic> type 14</article-title>. <source>Infect. Immun.</source><year>2008</year>, <volume>76</volume>, <fpage>4615</fpage>&#8211;<lpage>4623</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00472-08</pub-id>.<pub-id pub-id-type="pmid">18678667</pub-id><pub-id pub-id-type="pmcid">PMC2546832</pub-id></mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal" id="cit141"><name name-style="western"><surname>Lou&#231;ano</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Both</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Marchesi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Flitsch</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Salwiczek</surname><given-names>M.</given-names></name><article-title>Automated
glycan assembly of <italic toggle="yes">Streptococcus pneumoniae</italic> type
14 capsular polysaccharide fragments</article-title>. <source>RSC Adv.</source><year>2020</year>, <volume>10</volume>, <fpage>23668</fpage>&#8211;<lpage>23674</lpage>. <pub-id pub-id-type="doi">10.1039/D0RA01803A</pub-id>.<pub-id pub-id-type="pmid">35517348</pub-id><pub-id pub-id-type="pmcid">PMC9054924</pub-id></mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal" id="cit142"><name name-style="western"><surname>Safari</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Marradi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Chiodo</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Th Dekker</surname><given-names>H. A.</given-names></name>; <name name-style="western"><surname>Shan</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Oscarson</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rijkers</surname><given-names>G. T.</given-names></name>; <name name-style="western"><surname>Lahmann</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; et al. <article-title>Gold nanoparticles as
carriers for a synthetic <italic toggle="yes">Streptococcus pneumoniae</italic> type 14 conjugate vaccine</article-title>. <source>Nanomedicine (Lond)</source><year>2012</year>, <volume>7</volume>, <fpage>651</fpage>&#8211;<lpage>662</lpage>. <pub-id pub-id-type="doi">10.2217/nnm.11.151</pub-id>.<pub-id pub-id-type="pmid">22630149</pub-id></mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal" id="cit143"><name name-style="western"><surname>Seco</surname><given-names>B. M. S.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>F.-F.</given-names></name>; <name name-style="western"><surname>Grafmueller</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Kottari</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Sequential
linkage of carbohydrate antigens to mimic capsular polysaccharides:
towards semisynthetic glycoconjugate vaccine candidates against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 14</article-title>. <source>ACS Chem. Biol.</source><year>2020</year>, <volume>15</volume>, <fpage>2395</fpage>&#8211;<lpage>2405</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.0c00360</pub-id>.<pub-id pub-id-type="pmid">32835479</pub-id><pub-id pub-id-type="pmcid">PMC7506939</pub-id></mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal" id="cit144"><name name-style="western"><surname>Akhmatova</surname><given-names>N. K.</given-names></name>; <name name-style="western"><surname>Kurbatova</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Akhmatov</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Egorova</surname><given-names>N. B.</given-names></name>; <name name-style="western"><surname>Logunov</surname><given-names>D. Y.</given-names></name>; <name name-style="western"><surname>Gening</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Sukhova</surname><given-names>E. V.</given-names></name>; <name name-style="western"><surname>Yashunsky</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>The Effect of a BSA Conjugate of
a synthetic hexasaccharide related to the fragment of capsular polysaccharide
of <italic toggle="yes">Streptococcus pneumoniae</italic> type 14 on the activation
of innate and adaptive immune responses</article-title>. <source>Front.
Immunol.</source><year>2016</year>, <volume>7</volume>, <fpage>248</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00248</pub-id>.<pub-id pub-id-type="pmid">27446078</pub-id><pub-id pub-id-type="pmcid">PMC4919334</pub-id></mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal" id="cit145"><person-group person-group-type="allauthors"><name name-style="western"><surname>Pillot</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Defontaine</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fateh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lambert</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Prasanna</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fanuel</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pipelier</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Csaba</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Violo</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Camberlein</surname><given-names>E.</given-names></name></person-group>; <etal/><article-title>Site-specific
conjugation for fully
controlled glycoconjugate vaccine preparation</article-title>. <source>Front. Chem.</source><year>2019</year>, <volume>7</volume>, <pub-id pub-id-type="doi">10.3389/fchem.2019.00726</pub-id>.<pub-id pub-id-type="pmcid">PMC6839274</pub-id><pub-id pub-id-type="pmid">31737603</pub-id></mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal" id="cit146"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Cui</surname><given-names>L. L. T.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D.R.</given-names></name><article-title>Synthesis of monomeric and dimeric
repeating units of the zwitterionic type 1 capsular polysaccharide
from <italic toggle="yes">Streptococcus pneumoniae</italic></article-title>. <source>Chem.&#8212;Eur. J.</source><year>2010</year>, <volume>16</volume>, <fpage>3476</fpage>&#8211;<lpage>3488</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200902460</pub-id>.<pub-id pub-id-type="pmid">20146269</pub-id></mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal" id="cit147"><name name-style="western"><surname>Christina</surname><given-names>A. E.</given-names></name>; <name name-style="western"><surname>van den Bos</surname><given-names>L. J.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D.</given-names></name><article-title>Galacturonic acid lactones in the
synthesis of all trisaccharide repeating units of the zwitterionic
polysaccharide Sp1</article-title>. <source>J. Org. Chem.</source><year>2011</year>, <volume>76</volume>, <fpage>1692</fpage>&#8211;<lpage>1706</lpage>. <pub-id pub-id-type="doi">10.1021/jo102363d</pub-id>.<pub-id pub-id-type="pmid">21341806</pub-id></mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal" id="cit148"><name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Pragani</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Synthesis of conjugation-ready zwitterionic
oligosaccharides
by chemoselective thioglycoside activation</article-title>. <source>Chem. Sci.</source><year>2014</year>, <volume>5</volume>, <fpage>1992</fpage>&#8211;<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1039/C3SC53362J</pub-id>.</mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal" id="cit149"><name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kaplonek</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Wahlbrink</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Development
of an efficacious, semisynthetic glycoconjugate vaccine candidate
against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 1</article-title>. <source>ACS Cent. Sci.</source><year>2018</year>, <volume>4</volume>, <fpage>357</fpage>&#8211;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.7b00504</pub-id>.<pub-id pub-id-type="pmid">29632881</pub-id><pub-id pub-id-type="pmcid">PMC5879475</pub-id></mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal" id="cit150"><name name-style="western"><surname>Cobb</surname><given-names>B. A.</given-names></name>; <name name-style="western"><surname>Kasper</surname><given-names>D. L.</given-names></name><article-title>Zwitterionic capsular polysaccharides:
the new MHCII-dependent antigens</article-title>. <source>Cellular Microbiology</source><year>2005</year>, <volume>7</volume>, <fpage>1398</fpage>&#8211;<lpage>1403</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2005.00591.x</pub-id>.<pub-id pub-id-type="pmid">16153240</pub-id></mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal" id="cit151"><name name-style="western"><surname>Benaissa-Trouw</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Lefeber</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Vliegenthart</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Kraaijeveld</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name><article-title>Synthetic polysaccharide
type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates
induce protection against <italic toggle="yes">Streptococcus pneumoniae</italic> type 3 in mice</article-title>. <source>Infect. Immun.</source><year>2001</year>, <volume>69</volume>, <fpage>4698</fpage>&#8211;<lpage>4701</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.69.7.4698-4701.2001</pub-id>.<pub-id pub-id-type="pmid">11402020</pub-id><pub-id pub-id-type="pmcid">PMC98553</pub-id></mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal" id="cit152"><name name-style="western"><surname>Lefeber</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Vliegenthart</surname><given-names>J. F. G.</given-names></name><article-title>Synthesis
of <italic toggle="yes">Streptococcus pneumoniae</italic> type 3 neoglycoproteins
varying in oligosaccharide chain length, loading and carrier Protein</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2001</year>, <volume>7</volume>, <fpage>4411</fpage>&#8211;<lpage>4421</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-3765(20011015)7:20&amp;#x0003c;4411::AID-CHEM4411&amp;#x0003e;3.0.CO;2-T</pub-id>.<pub-id pub-id-type="pmid">11695675</pub-id></mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal" id="cit153"><name name-style="western"><surname>Xiong</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Gu</surname><given-names>G.</given-names></name><article-title>Synthesis and immunological studies of oligosaccharides
that consist
of the repeating unit of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 3 capsular polysaccharide</article-title>. <source>Chem.&#8212;Eur.
J.</source><year>2018</year>, <volume>24</volume>, <fpage>8205</fpage>&#8211;<lpage>8216</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201800754</pub-id>.<pub-id pub-id-type="pmid">29528515</pub-id></mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal" id="cit154"><name name-style="western"><surname>Parameswarappa</surname><given-names>S.G.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>M&#233;nov&#225;</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Govindan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Calow</surname><given-names>A. D. J.</given-names></name>; et al. <article-title>A Semisynthetic oligosaccharide
conjugate vaccine candidate confers protection against <italic toggle="yes">Streptococcus
pneumoniae</italic> serotype 3 infection</article-title>. <source>Cell
Chem. Biol.</source><year>2016</year>, <volume>23</volume>, <fpage>1407</fpage>&#8211;<lpage>1416</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2016.09.016</pub-id>.<pub-id pub-id-type="pmid">27818299</pub-id><pub-id pub-id-type="pmcid">PMC5234679</pub-id></mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal" id="cit155"><name name-style="western"><surname>Emmadi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Lykke</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Parameswarappa</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Lisboa</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Wienhold</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C.L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P.H.</given-names></name><article-title>A <italic toggle="yes">Streptococcus pneumoniae</italic> type 2 oligosaccharide glycoconjugate elicits opsonic antibodies
and is protective in an animal model of invasive pneumococcal disease</article-title>. <source>J. Am. Chem. Soc.</source><year>2017</year>, <volume>139</volume>, <fpage>14783</fpage>&#8211;<lpage>14791</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.7b07836</pub-id>.<pub-id pub-id-type="pmid">28945368</pub-id></mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal" id="cit156"><name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Hahm</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Parameswarappa</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Wahlbrink</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Govindan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kaplone</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Pirofski</surname><given-names>L.-A.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; et al. <article-title>A semisynthetic
S<italic toggle="yes">treptococcus pneumoniae</italic> serotype 8 glycoconjugate
vaccine</article-title>. <source>Sci. Transl. Med.</source><year>2017</year>, <volume>9</volume>, <elocation-id>eaaf5347</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf5347</pub-id>.<pub-id pub-id-type="pmid">28275152</pub-id><pub-id pub-id-type="pmcid">PMC5573155</pub-id></mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="journal" id="cit157"><name name-style="western"><surname>Kaplonek</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Emmadi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lisboa</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>F. F.</given-names></name>; <name name-style="western"><surname>Calow</surname><given-names>A. D. J.</given-names></name>; <name name-style="western"><surname>Parameswarappa</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name>; et al. <article-title>Improving vaccines against <italic toggle="yes">Streptococcus pneumoniae</italic> using synthetic glycans</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source><year>2018</year>, <volume>115</volume>, <fpage>13353</fpage>&#8211;<lpage>13358</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1811862115</pub-id>.<pub-id pub-id-type="pmid">30530654</pub-id><pub-id pub-id-type="pmcid">PMC6310808</pub-id></mixed-citation></ref><ref id="ref158"><mixed-citation publication-type="journal" id="cit158"><name name-style="western"><surname>Lisboa</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>F.-F.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Govindan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Semisynthetic glycoconjugate vaccine
candidate against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype
5</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2017</year>, <volume>114</volume>, <fpage>11063</fpage>&#8211;<lpage>11068</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1706875114</pub-id>.<pub-id pub-id-type="pmid">28973947</pub-id><pub-id pub-id-type="pmcid">PMC5651752</pub-id></mixed-citation></ref><ref id="ref159"><mixed-citation publication-type="journal" id="cit159"><name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Fallarini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lombardi</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Colombo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Compostella</surname><given-names>F.</given-names></name><article-title>Synthesis
and biological evaluation of a trisaccharide
repeating unit derivative of <italic toggle="yes">Streptococcus pneumoniae</italic> 19A capsular polysaccharide</article-title>. <source>Bioorg. Med.
Chem.</source><year>2018</year>, <volume>26</volume>, <fpage>5682</fpage>&#8211;<lpage>5690</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2018.10.016</pub-id>.<pub-id pub-id-type="pmid">30449426</pub-id></mixed-citation></ref><ref id="ref160"><mixed-citation publication-type="journal" id="cit160"><name name-style="western"><surname>Sanapala</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Seco</surname><given-names>B. M. S.</given-names></name>; <name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Awan</surname><given-names>S. I.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Chimeric oligosaccharide conjugate
induces opsonic antibodies against Streptococcus pneumoniae serotypes
19A and 19F</article-title>. <source>Chem. Sci.</source><year>2020</year>, <volume>11</volume>, <fpage>7401</fpage>&#8211;<lpage>7407</lpage>. <pub-id pub-id-type="doi">10.1039/D0SC02230F</pub-id>.<pub-id pub-id-type="pmid">34123020</pub-id><pub-id pub-id-type="pmcid">PMC8159444</pub-id></mixed-citation></ref><ref id="ref161"><mixed-citation publication-type="journal" id="cit161"><name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Santana-Mederos</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Valdes-Balbin</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Verez Bencomo</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>van Diepen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hokke</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Chiodo</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Compostella</surname><given-names>F.</given-names></name><article-title>Glycan Array
Evaluation of Synthetic Epitopes between the Capsular Polysaccharides
from Streptococcus pneumoniae 19F and 19A</article-title>. <source>ACS
Chem. Biol.</source><year>2021</year>, <volume>16</volume>, <fpage>1671</fpage>&#8211;<lpage>1679</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.1c00347</pub-id>.<pub-id pub-id-type="pmid">34469105</pub-id><pub-id pub-id-type="pmcid">PMC8453487</pub-id></mixed-citation></ref><ref id="ref162"><mixed-citation publication-type="journal" id="cit162"><name name-style="western"><surname>Vetro</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Safari</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Fallarini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Salsabila</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Lahmann</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Penad&#233;s</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Marradi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Compostella</surname><given-names>F.</given-names></name><article-title>Preparation and immunogenicity of
gold glyco-nanoparticles as antipneumococcal vaccine model</article-title>. <source>Nanomedicine</source><year>2017</year>, <volume>12</volume>, <fpage>13</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2016-0306</pub-id>.<pub-id pub-id-type="pmid">27879152</pub-id></mixed-citation></ref><ref id="ref163"><mixed-citation publication-type="journal" id="cit163"><name name-style="western"><surname>Fournier</surname><given-names>P. E.</given-names></name>; <name name-style="western"><surname>Richet</surname><given-names>H.</given-names></name><article-title>The epidemiology and control of <italic toggle="yes">Acinetobacter baumannii</italic> in health care facilities</article-title>. <source>Clin. Infect. Dis.</source><year>2006</year>, <volume>42</volume>, <fpage>692</fpage>&#8211;<lpage>699</lpage>. <pub-id pub-id-type="doi">10.1086/500202</pub-id>.<pub-id pub-id-type="pmid">16447117</pub-id></mixed-citation></ref><ref id="ref164"><mixed-citation publication-type="journal" id="cit164"><name name-style="western"><surname>Peleg</surname><given-names>A. Y.</given-names></name>; <name name-style="western"><surname>Seifert</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Paterson</surname><given-names>D. L.</given-names></name><article-title><italic toggle="yes">Acinetobacter
baumannii</italic>: emergence of a successful pathogen</article-title>. <source>Clin. Microbiol. Rev.</source><year>2008</year>, <volume>21</volume>, <fpage>538</fpage>&#8211;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00058-07</pub-id>.<pub-id pub-id-type="pmid">18625687</pub-id><pub-id pub-id-type="pmcid">PMC2493088</pub-id></mixed-citation></ref><ref id="ref165"><mixed-citation publication-type="journal" id="cit165"><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Chu</surname><given-names>X.</given-names></name>; et al. <article-title>Immunization with a 22-kDa outer membrane protein
elicits protective immunity to multidrug-resistant <italic toggle="yes">Acinetobacter
baumannii</italic></article-title>. <source>Sci. Rep.</source><year>2016</year>, <volume>6</volume>, <fpage>20724</fpage><pub-id pub-id-type="doi">10.1038/srep20724</pub-id>.<pub-id pub-id-type="pmid">26853590</pub-id><pub-id pub-id-type="pmcid">PMC4745112</pub-id></mixed-citation></ref><ref id="ref166"><mixed-citation publication-type="journal" id="cit166"><name name-style="western"><surname>Russo</surname><given-names>T. A.</given-names></name>; <name name-style="western"><surname>Beanan</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Olson</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>MacDonald</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Cox</surname><given-names>A. D.</given-names></name>; <name name-style="western"><surname>St. Michael</surname><given-names>F. S.</given-names></name>; <name name-style="western"><surname>Vinogradov</surname><given-names>E. V.</given-names></name>; <name name-style="western"><surname>Spellberg</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Luke-Marshall</surname><given-names>N. R.</given-names></name>; <name name-style="western"><surname>Campagnaric</surname><given-names>A. A.</given-names></name><article-title>The K1
Capsular polysaccharide from <italic toggle="yes">Acinetobacter baumannii</italic> is a potential therapeutic target via passive immunization</article-title>. <source>Infect. Immun.</source><year>2013</year>, <volume>81</volume>, <fpage>915</fpage>&#8211;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01184-12</pub-id>.<pub-id pub-id-type="pmid">23297385</pub-id><pub-id pub-id-type="pmcid">PMC3584894</pub-id></mixed-citation></ref><ref id="ref167"><mixed-citation publication-type="journal" id="cit167"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><article-title>Current advances and challenges in the development of <italic toggle="yes">Acinetobacter</italic> vaccines</article-title>. <source>Hum. Vaccin. Immunother.</source><year>2015</year>, <volume>11</volume>, <fpage>2495</fpage>&#8211;<lpage>2500</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1052354</pub-id>.<pub-id pub-id-type="pmid">26158773</pub-id><pub-id pub-id-type="pmcid">PMC4635877</pub-id></mixed-citation></ref><ref id="ref168"><mixed-citation publication-type="journal" id="cit168"><name name-style="western"><surname>Giguere</surname><given-names>D.</given-names></name><article-title>Surface polysaccharides from <italic toggle="yes">Acinetobacter
baumannii</italic>: structures and syntheses</article-title>. <source>Carbohydr. Res.</source><year>2015</year>, <volume>418</volume>, <fpage>29</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2015.10.001</pub-id>.<pub-id pub-id-type="pmid">26531136</pub-id></mixed-citation></ref><ref id="ref169"><mixed-citation publication-type="journal" id="cit169"><name name-style="western"><surname>Lee</surname><given-names>I. M.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>F. L.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Liao</surname><given-names>K. S.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>C. T.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>N. T.</given-names></name>; <name name-style="western"><surname>Chang</surname><given-names>Y. P.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>C. Y.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>S. H.</given-names></name><article-title>Pseudaminic acid on exopolysaccharide of A<italic toggle="yes">cinetobacter baumannii</italic> plays a critical role in phage-assisted preparation of glycoconjugate
vaccine with high antigenicity</article-title>. <source>J. Am. Chem.
Soc.</source><year>2018</year>, <volume>140</volume>, <fpage>8639</fpage>&#8211;<lpage>8643</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.8b04078</pub-id>.<pub-id pub-id-type="pmid">29965749</pub-id></mixed-citation></ref><ref id="ref170"><mixed-citation publication-type="journal" id="cit170"><name name-style="western"><surname>Pepin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Valiquette</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Alary</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Villemure</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Pelletier</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Forget</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Pepin</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Chouinard</surname><given-names>D.</given-names></name><article-title><italic toggle="yes">Clostridium
difficile</italic>-associated diarrhea in a region of Quebec from
1991 to 2003: a changing pattern of disease severity</article-title>. <source>CMAJ.</source><year>2004</year>, <volume>171</volume>, <fpage>466</fpage>&#8211;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.1041104</pub-id>.<pub-id pub-id-type="pmid">15337727</pub-id><pub-id pub-id-type="pmcid">PMC514643</pub-id></mixed-citation></ref><ref id="ref171"><mixed-citation publication-type="journal" id="cit171"><name name-style="western"><surname>Guh</surname><given-names>A. Y.</given-names></name>; <name name-style="western"><surname>Mu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Winston</surname><given-names>L. G.</given-names></name>; <name name-style="western"><surname>Johnston</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Olson</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Farley</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Wilson</surname><given-names>L. E.</given-names></name>; <name name-style="western"><surname>Holzbauer</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Phipps</surname><given-names>E. C.</given-names></name>; <name name-style="western"><surname>Dumyati</surname><given-names>G. K.</given-names></name>; <name name-style="western"><surname>Beldavs</surname><given-names>Z. G.</given-names></name>; <name name-style="western"><surname>Kainer</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Karlsson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Gerding</surname><given-names>D. N.</given-names></name>; <name name-style="western"><surname>McDonald</surname><given-names>L. C.</given-names></name><article-title>Trends in U.S. Burden
of <italic toggle="yes">Clostridioides difficile</italic> infection and out-comes</article-title>. <source>N. Engl. J. Med.</source><year>2020</year>, <volume>382</volume>, <fpage>1320</fpage>&#8211;<lpage>1330</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910215</pub-id>.<pub-id pub-id-type="pmid">32242357</pub-id><pub-id pub-id-type="pmcid">PMC7861882</pub-id></mixed-citation></ref><ref id="ref172"><mixed-citation publication-type="journal" id="cit172"><name name-style="western"><surname>Sch&#228;ffler</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Breitr&#252;ck</surname><given-names>A.</given-names></name><article-title><italic toggle="yes">Clostridium difficile</italic> - From colonization to infection</article-title>. <source>Front. Microbiol.</source><year>2018</year>, <volume>9</volume>, <fpage>646</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00646</pub-id>.<pub-id pub-id-type="pmid">29692762</pub-id><pub-id pub-id-type="pmcid">PMC5902504</pub-id></mixed-citation></ref><ref id="ref173"><mixed-citation publication-type="journal" id="cit173"><name name-style="western"><surname>Smits</surname><given-names>W. K.</given-names></name>; <name name-style="western"><surname>Lyras</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lacy</surname><given-names>D. B.</given-names></name>; <name name-style="western"><surname>Wilcox</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Kuijper</surname><given-names>E. J.</given-names></name><article-title><italic toggle="yes">Clostridium difficile</italic> infection</article-title>. <source>Nat. Rev. Dis. Primers</source><year>2016</year>, <volume>2</volume>, <fpage>16020</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.20</pub-id>.<pub-id pub-id-type="pmid">27158839</pub-id><pub-id pub-id-type="pmcid">PMC5453186</pub-id></mixed-citation></ref><ref id="ref174"><mixed-citation publication-type="journal" id="cit174"><name name-style="western"><surname>Ganeshapillai</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vinogradov</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Rousseau</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Weese</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Monteiro</surname><given-names>M. A.</given-names></name><article-title><italic toggle="yes">Clostridium
difficile</italic> cell-surface
polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate
repeating units</article-title>. <source>Carbohydr. Res.</source><year>2008</year>, <volume>343</volume>, <fpage>703</fpage>&#8211;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2008.01.002</pub-id>.<pub-id pub-id-type="pmid">18237724</pub-id></mixed-citation></ref><ref id="ref175"><mixed-citation publication-type="journal" id="cit175"><name name-style="western"><surname>Bertolo</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Boncheff</surname><given-names>A. G.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>Y. H.</given-names></name>; <name name-style="western"><surname>Wakeford</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Friendship</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Rosseau</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Weese</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Chu</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Mallozzi</surname><given-names>M.</given-names></name>; et al. <article-title><italic toggle="yes">Clostridium difficile</italic> carbohydrates: glucan in spores,
PSII common antigen in cells, immunogenicity
of PSII in swine and synthesis of a dual <italic toggle="yes">C. difficile</italic>-ETEC conjugate vaccine</article-title>. <source>Carbohydr. Res.</source><year>2012</year>, <volume>354</volume>, <fpage>79</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2012.03.032</pub-id>.<pub-id pub-id-type="pmid">22533919</pub-id></mixed-citation></ref><ref id="ref176"><mixed-citation publication-type="journal" id="cit176"><name name-style="western"><surname>P&#233;chin&#233;</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bruxelle</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Janoir</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Collignon</surname><given-names>A.</given-names></name><article-title>Targeting <italic toggle="yes">Clostridium difficile</italic> surface
components to develop immunotherapeutic strategies against <italic toggle="yes">Clostridium difficile</italic> infection</article-title>. <source>Front.
Microbiol.</source><year>2018</year>, <volume>9</volume>, <fpage>1009</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01009</pub-id>.<pub-id pub-id-type="pmid">29875742</pub-id><pub-id pub-id-type="pmcid">PMC5974105</pub-id></mixed-citation></ref><ref id="ref177"><mixed-citation publication-type="journal" id="cit177"><name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Oberli</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Komor</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mattner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Immunological
evaluation of a synthetic <italic toggle="yes">Clostridium difficile</italic> oligosaccharide
conjugate vaccine candidate and identification of a minimal epitope</article-title>. <source>J. Am. Chem. Soc.</source><year>2013</year>, <volume>135</volume>, <fpage>9713</fpage>&#8211;<lpage>9722</lpage>. <pub-id pub-id-type="doi">10.1021/ja401410y</pub-id>.<pub-id pub-id-type="pmid">23795894</pub-id></mixed-citation></ref><ref id="ref178"><mixed-citation publication-type="journal" id="cit178"><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Hodgins</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pequegnat</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Bertolo</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Arroyo</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Monteiro</surname><given-names>M. A.</given-names></name><article-title><italic toggle="yes">Clostridium
difficile</italic> PSI polysaccharide: synthesis of pentasaccharide
repeating block, conjugation to exotoxin B subunit, and detection
of natural anti-PSI IgG antibodies in horse serum</article-title>. <source>Carbohydr. Res.</source><year>2013</year>, <volume>378</volume>, <fpage>15</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2013.03.018</pub-id>.<pub-id pub-id-type="pmid">23597587</pub-id></mixed-citation></ref><ref id="ref179"><mixed-citation publication-type="journal" id="cit179"><name name-style="western"><surname>Danieli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>First synthesis of <italic toggle="yes">C. difficile</italic> PS-II cell wall polysaccharide repeating unit</article-title>. <source>Org. Lett.</source><year>2011</year>, <volume>13</volume> (<issue>3</issue>), <fpage>378</fpage>&#8211;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1021/ol1026188</pub-id>.<pub-id pub-id-type="pmid">21190352</pub-id></mixed-citation></ref><ref id="ref180"><mixed-citation publication-type="journal" id="cit180"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Leuzzi</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Danieli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Cappelletti</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Cakici</surname><given-names>O. S.</given-names></name>; <name name-style="western"><surname>Swennen</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; et al. <article-title>Phosphorylation
of the synthetic hexasaccharide repeating unit is essential for the
induction of antibodies to <italic toggle="yes">Clostridium difficile</italic> PSII
cell wall polysaccharide</article-title>. <source>ACS Chem. Biol.</source><year>2012</year>, <volume>7</volume>, <fpage>1420</fpage>&#8211;<lpage>1428</lpage>. <pub-id pub-id-type="doi">10.1021/cb300221f</pub-id>.<pub-id pub-id-type="pmid">22620974</pub-id></mixed-citation></ref><ref id="ref181"><mixed-citation publication-type="journal" id="cit181"><name name-style="western"><surname>Oberli</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Hecht</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Bindschadler</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Adibekian</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Adam</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>A possible
oligosaccharide-conjugate vaccine candidate for <italic toggle="yes">Clostridium
difficile</italic> is antigenic and immunogenic</article-title>. <source>Chem. Biol.</source><year>2011</year>, <volume>18</volume>, <fpage>580</fpage>&#8211;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2011.03.009</pub-id>.<pub-id pub-id-type="pmid">21609839</pub-id></mixed-citation></ref><ref id="ref182"><mixed-citation publication-type="journal" id="cit182"><name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Eller</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Oberli</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Glycan
arrays containing synthetic <italic toggle="yes">Clostridium difficile</italic> lipoteichoic acid oligomers as tools toward a carbohydrate vaccine</article-title>. <source>Chem. Commun. (Camb)</source><year>2013</year>, <volume>49</volume>, <fpage>7159</fpage>&#8211;<lpage>7161</lpage>. <pub-id pub-id-type="doi">10.1039/c3cc43545h</pub-id>.<pub-id pub-id-type="pmid">23836132</pub-id></mixed-citation></ref><ref id="ref183"><mixed-citation publication-type="journal" id="cit183"><name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Wegner</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Mattner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Synthetic
lipoteichoic acid glycans are potential vaccine candidates to protect
from <italic toggle="yes">Clostridium difficile</italic> infections</article-title>. <source>Cell Chem. Biol.</source><year>2016</year>, <volume>23</volume>, <fpage>1014</fpage>&#8211;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2016.07.009</pub-id>.<pub-id pub-id-type="pmid">27524293</pub-id></mixed-citation></ref><ref id="ref184"><mixed-citation publication-type="journal" id="cit184"><name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hanske</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Wahlbrink</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Wojcik</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hartmann</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Rademacher</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Multivalent
display of minimal <italic toggle="yes">Clostridium difficile</italic> glycan epitopes
mimics antigenic properties
of larger glycans</article-title>. <source>Nat. Commun.</source><year>2016</year>, <volume>7</volume>, <fpage>11224</fpage><pub-id pub-id-type="doi">10.1038/ncomms11224</pub-id>.<pub-id pub-id-type="pmid">27091615</pub-id><pub-id pub-id-type="pmcid">PMC4838876</pub-id></mixed-citation></ref><ref id="ref185"><mixed-citation publication-type="journal" id="cit185"><name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Wegner</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Seco</surname><given-names>B. M. S.</given-names></name>; <name name-style="western"><surname>Kaplonek</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Brautigam</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ensser</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Pfister</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Daniel</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Mattner</surname><given-names>J.</given-names></name>; et al. <article-title>Synthetic
oligosaccharide-based
vaccines protect mice from <italic toggle="yes">Clostridioides difficile</italic> infections</article-title>. <source>ACS Chem. Biol.</source><year>2019</year>, <volume>14</volume>, <fpage>2720</fpage>&#8211;<lpage>2728</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.9b00642</pub-id>.<pub-id pub-id-type="pmid">31692324</pub-id><pub-id pub-id-type="pmcid">PMC6929054</pub-id></mixed-citation></ref><ref id="ref186"><mixed-citation publication-type="journal" id="cit186"><name name-style="western"><surname>Croxen</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Finlay</surname><given-names>B. B.</given-names></name><article-title>Molecular mechanisms
of Escherichia
coli pathogenicity</article-title>. <source>Nat. Rev. Microbiol.</source><year>2010</year>, <volume>8</volume>, <fpage>26</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2265</pub-id>.<pub-id pub-id-type="pmid">19966814</pub-id></mixed-citation></ref><ref id="ref187"><mixed-citation publication-type="journal" id="cit187"><name name-style="western"><surname>Bonten</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>van den
Biggelaar</surname><given-names>A. H. J.</given-names></name>; <name name-style="western"><surname>Georgalis</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Geurtsen</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>de Palacios</surname><given-names>P. I.</given-names></name>; <name name-style="western"><surname>Gravenstein</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Verstraeten</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hermans</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Poolman</surname><given-names>J. T.</given-names></name><article-title>Epidemiology
of <italic toggle="yes">Escherichia coli</italic> bacteremia: a systematic literature
review</article-title>. <source>Clin. Infect. Dis.</source><year>2021</year>, <volume>72</volume>, <fpage>1211</fpage>&#8211;<lpage>1219</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa210</pub-id>.<pub-id pub-id-type="pmid">32406495</pub-id></mixed-citation></ref><ref id="ref188"><mixed-citation publication-type="journal" id="cit188"><name name-style="western"><surname>Lee</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>S.-J.</given-names></name>; <name name-style="western"><surname>Choe</surname><given-names>H.-S.</given-names></name><article-title>Community-acquired
urinary tract infection by <italic toggle="yes">Escherichia coli</italic> in the
era of antibiotic resistance</article-title>. <source>BioMed. Res. Int.</source><year>2018</year>, <volume>2018</volume>, <fpage>7656752</fpage><pub-id pub-id-type="doi">10.1155/2018/7656752</pub-id>.<pub-id pub-id-type="pmid">30356438</pub-id><pub-id pub-id-type="pmcid">PMC6178185</pub-id></mixed-citation></ref><ref id="ref189"><mixed-citation publication-type="journal" id="cit189"><name name-style="western"><surname>Whitfield</surname><given-names>C.</given-names></name><article-title>Biosynthesis and assembly of capsular
polysaccharides
in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Annu.
Rev. Biochem.</source><year>2006</year>, <volume>75</volume>, <fpage>39</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.75.103004.142545</pub-id>.<pub-id pub-id-type="pmid">16756484</pub-id></mixed-citation></ref><ref id="ref190"><mixed-citation publication-type="journal" id="cit190"><name name-style="western"><surname>Szijarto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Pal</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Nagy</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Nagy</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Ghazawi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>al-Haj</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>El Kurdi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sonnevend</surname><given-names>A.</given-names></name><article-title>The rapidly
emerging ESBL-producing <italic toggle="yes">Escherichia coli</italic> O25-ST131
clone carries LPS core synthesis genes of the K-12 type</article-title>. <source>FEMS Microbiol. Lett.</source><year>2012</year>, <volume>332</volume>, <fpage>131</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.2012.02585.x</pub-id>.<pub-id pub-id-type="pmid">22537083</pub-id></mixed-citation></ref><ref id="ref191"><mixed-citation publication-type="journal" id="cit191"><name name-style="western"><surname>Saade</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Gravenstein</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Donskey</surname><given-names>C. J.</given-names></name>; <name name-style="western"><surname>Wilson</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Spiessens</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Abbanat</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Poolman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>de Palacios</surname><given-names>P. I.</given-names></name>; <name name-style="western"><surname>Hermans</surname><given-names>P.</given-names></name><article-title>Characterization of <italic toggle="yes">Escherichia coli</italic> isolates potentially covered by ExPEC4V and ExPEC10V, that were
collected from post-transrectal ultrasound-guided prostate needle
biopsy invasive urinary tract and bloodstream infections</article-title>. <source>Vaccine</source><year>2020</year>, <volume>38</volume>, <fpage>5100</fpage>&#8211;<lpage>5104</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.06.024</pub-id>.<pub-id pub-id-type="pmid">32561123</pub-id></mixed-citation></ref><ref id="ref192"><mixed-citation publication-type="journal" id="cit192"><name name-style="western"><surname>Shang</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Wei</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Wei</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>P. G.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><article-title>Chemical synthesis of the outer core
oligosaccharide of <italic toggle="yes">Escherichia coli</italic> R3 and immunological
evaluation</article-title>. <source>Org. Biomol. Chem.</source><year>2015</year>, <volume>13</volume>, <fpage>4321</fpage>&#8211;<lpage>4330</lpage>. <pub-id pub-id-type="doi">10.1039/C5OB00177C</pub-id>.<pub-id pub-id-type="pmid">25764373</pub-id><pub-id pub-id-type="pmcid">PMC4481194</pub-id></mixed-citation></ref><ref id="ref193"><mixed-citation publication-type="journal" id="cit193"><name name-style="western"><surname>Nishi</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Seki</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Takahashi</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Toshima</surname><given-names>K.</given-names></name><article-title>Synthesis of a pentasaccharide repeating unit of lipopolysaccharide
derived from virulent <italic toggle="yes">E. coli</italic> O1 and identification
of a glycotope candidate of avian pathogenic <italic toggle="yes">E. coli</italic> O1</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><year>2021</year>, <volume>60</volume>, <fpage>1789</fpage>&#8211;<lpage>1796</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202013729</pub-id>.<pub-id pub-id-type="pmid">33124093</pub-id></mixed-citation></ref><ref id="ref194"><mixed-citation publication-type="journal" id="cit194"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Krueger</surname><given-names>W. A.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name><article-title>Rationale
for the development of immunotherapy regimens against enterococcal
infections</article-title>. <source>Vaccine</source><year>2004</year>, <volume>22</volume>, <fpage>S31</fpage>&#8211;<lpage>S38</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.08.014</pub-id>.<pub-id pub-id-type="pmid">15576199</pub-id></mixed-citation></ref><ref id="ref195"><mixed-citation publication-type="journal" id="cit195"><name name-style="western"><surname>Blot</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Hammami</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Blot</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Vogelaers</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lambert</surname><given-names>M.-L.</given-names></name><article-title>Increasing burden of <italic toggle="yes">Escherichia
coli</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, and <italic toggle="yes">Enterococcus
faecium</italic> in hospital-acquired bloodstream infections (2000-2014):
a national dynamic cohort study</article-title>. <source>Infect. Control.
Hosp. Epidemiol.</source><year>2019</year>, <volume>40</volume>, <fpage>705</fpage>&#8211;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1017/ice.2019.59</pub-id>.<pub-id pub-id-type="pmid">31012402</pub-id></mixed-citation></ref><ref id="ref196"><mixed-citation publication-type="journal" id="cit196"><name name-style="western"><surname>Reyes</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Bardossy</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Zervos</surname><given-names>M.</given-names></name><article-title>Vancomycin-resistant <italic toggle="yes">Enterococci</italic>: epidemiology, infection prevention, and control</article-title>. <source>Infect. Dis. Clin. North Am.</source><year>2016</year>, <volume>30</volume>, <fpage>953</fpage>&#8211;<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1016/j.idc.2016.07.009</pub-id>.<pub-id pub-id-type="pmid">27660091</pub-id></mixed-citation></ref><ref id="ref197"><mixed-citation publication-type="journal" id="cit197"><name name-style="western"><surname>Flores-Mireles</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hreha</surname><given-names>T. N.</given-names></name>; <name name-style="western"><surname>Hunstad</surname><given-names>D. A.</given-names></name><article-title>Pathophysiology,
treatment, and prevention of catheter-associated urinary tract infection</article-title>. <source>Top Spinal Cord. Inj. Rehabil.</source><year>2019</year>, <volume>25</volume>, <fpage>228</fpage>&#8211;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1310/sci2503-228</pub-id>.<pub-id pub-id-type="pmid">31548790</pub-id><pub-id pub-id-type="pmcid">PMC6743745</pub-id></mixed-citation></ref><ref id="ref198"><mixed-citation publication-type="journal" id="cit198"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kaczy&#324;ski</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sava</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Bychowska</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Holst</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name><article-title>Serodiversity of opsonic
antibodies against <italic toggle="yes">Enterococcus faecalis</italic> - Glycans
of the cell wall revisited</article-title>. <source>PLoS One</source><year>2011</year>, <volume>6</volume>, <elocation-id>e17839</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017839</pub-id>.<pub-id pub-id-type="pmid">21437253</pub-id><pub-id pub-id-type="pmcid">PMC3060912</pub-id></mixed-citation></ref><ref id="ref199"><mixed-citation publication-type="journal" id="cit199"><name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Gerbst</surname><given-names>A. G.</given-names></name>; <name name-style="western"><surname>Argunov</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Dmitrenok</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Shashkov</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Kaczynski</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Holst</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Definitive
structural assessment of enterococcal diheteroglycan</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2015</year>, <volume>21</volume>, <fpage>1749</fpage>&#8211;<lpage>1754</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201405857</pub-id>.<pub-id pub-id-type="pmid">25421964</pub-id></mixed-citation></ref><ref id="ref200"><mixed-citation publication-type="journal" id="cit200"><name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Romero-Saavedra</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Argunov</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Enotarpi</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Kalfopoulou</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Torelli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Sanguinetti</surname><given-names>M.</given-names></name>; et al. <article-title>Synthetic oligomers
mimicking capsular polysaccharide di-heteroglycan are potential vaccine
candidates against encapsulated enterococcal infections</article-title>. <source>ACS Infect. Dis.</source><year>2020</year>, <volume>6</volume>, <fpage>1816</fpage>&#8211;<lpage>1826</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00063</pub-id>.<pub-id pub-id-type="pmid">32364376</pub-id></mixed-citation></ref><ref id="ref201"><mixed-citation publication-type="journal" id="cit201"><name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Krueger</surname><given-names>W. A.</given-names></name>; <name name-style="western"><surname>Madoff</surname><given-names>L. C.</given-names></name>; <name name-style="western"><surname>Martirosian</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Boisot</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Goldmann</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Kasper</surname><given-names>D. L.</given-names></name>; <name name-style="western"><surname>Tzianabos</surname><given-names>A. O.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Isolation and chemical characterization
of a capsular polysaccharide antigen shared by clinical isolates of <italic toggle="yes">Enterococcus faecalis</italic> and vancomycin-resistant <italic toggle="yes">Enterococcus
faecium</italic></article-title>. <source>Infect. Immun.</source><year>1999</year>, <volume>67</volume>, <fpage>1213</fpage>&#8211;<lpage>1219</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.67.3.1213-1219.1999</pub-id>.<pub-id pub-id-type="pmid">10024563</pub-id><pub-id pub-id-type="pmcid">PMC96449</pub-id></mixed-citation></ref><ref id="ref202"><mixed-citation publication-type="journal" id="cit202"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Tzianabos</surname><given-names>A. O.</given-names></name>; <name name-style="western"><surname>Martirosian</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kasper</surname><given-names>D. L.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Structure of an
antigenic teichoic acid shared by clinical isolates of <italic toggle="yes">Enterococcus
faecalis</italic> and vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic></article-title>. <source>Carbohydr. res.</source><year>1999</year>, <volume>316</volume>, <fpage>155</fpage><pub-id pub-id-type="doi">10.1016/S0008-6215(99)00046-4</pub-id>.<pub-id pub-id-type="pmid">10420594</pub-id></mixed-citation></ref><ref id="ref203"><mixed-citation publication-type="journal" id="cit203"><name name-style="western"><surname>van der Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Hogendorf</surname><given-names>W. F. J.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D. C.</given-names></name><article-title>Teichoic acids: synthesis and applications</article-title>. <source>Chem. Soc. Rev.</source><year>2017</year>, <volume>46</volume>, <fpage>1464</fpage>&#8211;<lpage>1482</lpage>. <pub-id pub-id-type="doi">10.1039/C6CS00270F</pub-id>.<pub-id pub-id-type="pmid">27990523</pub-id></mixed-citation></ref><ref id="ref204"><mixed-citation publication-type="journal" id="cit204"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hammer</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Sava</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Wobser</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Sakinc</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Hogendorf</surname><given-names>W. F.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name><article-title>Protection against <italic toggle="yes">Staphylococcus
aureus</italic> by antibody to the polyglycerolphosphate backbone
of heterologous lipoteichoic acid</article-title>. <source>J. Infect.
Dis.</source><year>2012</year>, <volume>205</volume>, <fpage>1076</fpage>&#8211;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis022</pub-id>.<pub-id pub-id-type="pmid">22362863</pub-id></mixed-citation></ref><ref id="ref205"><mixed-citation publication-type="journal" id="cit205"><name name-style="western"><surname>Hogendorf</surname><given-names>W. F.</given-names></name>; <name name-style="western"><surname>Bos</surname><given-names>L. J.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Marel</surname><given-names>G. A.</given-names></name><article-title>Synthesis
of an alpha-kojibiosyl
substituted glycerol teichoic acid hexamer</article-title>. <source>Bioorg. Med. Chem.</source><year>2010</year>, <volume>18</volume>, <fpage>3668</fpage>&#8211;<lpage>3678</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2010.03.071</pub-id>.<pub-id pub-id-type="pmid">20409722</pub-id></mixed-citation></ref><ref id="ref206"><mixed-citation publication-type="journal" id="cit206"><name name-style="western"><surname>Hogendorf</surname><given-names>W. F.</given-names></name>; <name name-style="western"><surname>Meeuwenoord</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Filippov</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J. D.</given-names></name><article-title>Automated solid phase synthesis of
teichoic acids</article-title>. <source>Chem. Commun. (Camb)</source><year>2011</year>, <volume>47</volume>, <fpage>8961</fpage>&#8211;<lpage>8963</lpage>. <pub-id pub-id-type="doi">10.1039/c1cc13132j</pub-id>.<pub-id pub-id-type="pmid">21734985</pub-id></mixed-citation></ref><ref id="ref207"><mixed-citation publication-type="journal" id="cit207"><name name-style="western"><surname>Hogendorf</surname><given-names>W. F.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Filippov</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J. D.</given-names></name><article-title>Light fluorous synthesis
of glucosylated glycerol teichoic acids</article-title>. <source>Carbohydr.
Res.</source><year>2012</year>, <volume>356</volume>, <fpage>142</fpage>&#8211;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2012.02.023</pub-id>.<pub-id pub-id-type="pmid">22429772</pub-id></mixed-citation></ref><ref id="ref208"><mixed-citation publication-type="journal" id="cit208"><name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wobser</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Romero-Saavedra</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hogendorf</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Berthold</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name><article-title>Synthetic teichoic acid conjugate
vaccine against nosocomial Gram-positive bacteria</article-title>. <source>PLoS One</source><year>2014</year>, <volume>9</volume>, <elocation-id>e110953</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0110953</pub-id>.<pub-id pub-id-type="pmid">25333799</pub-id><pub-id pub-id-type="pmcid">PMC4205086</pub-id></mixed-citation></ref><ref id="ref209"><mixed-citation publication-type="journal" id="cit209"><name name-style="western"><surname>van der Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Berni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hogendorf</surname><given-names>W. F. J.</given-names></name>; <name name-style="western"><surname>Meeuwenoord</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>van Diepen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Filippov</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>Hokke</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; et al. <article-title>Streamlined synthesis and evaluation of teichoic acid fragments</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2018</year>, <volume>24</volume>, <fpage>4014</fpage>&#8211;<lpage>4018</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201800153</pub-id>.<pub-id pub-id-type="pmid">29389054</pub-id><pub-id pub-id-type="pmcid">PMC5887911</pub-id></mixed-citation></ref><ref id="ref210"><mixed-citation publication-type="journal" id="cit210"><name name-style="western"><surname>Berni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Kalfopoulou</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Nguyen</surname><given-names>D. L.</given-names></name>; <name name-style="western"><surname>van der Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Hokke</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>van Diepen</surname><given-names>A.</given-names></name>; et al. <article-title>Generation of glucosylated sn-1-glycerolphosphate teichoic acids:
glycerol stereochemistry affects synthesis and antibody interaction</article-title>. <source>RSC Chem. Biol.</source><year>2021</year>, <volume>2</volume>, <fpage>187</fpage>&#8211;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1039/D0CB00206B</pub-id>.<pub-id pub-id-type="pmid">34458781</pub-id><pub-id pub-id-type="pmcid">PMC8341164</pub-id></mixed-citation></ref><ref id="ref211"><mixed-citation publication-type="journal" id="cit211"><name name-style="western"><surname>Berni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Kalfopoulou</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Gimeno Cardells</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>van der
Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Romero-Saavedra</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Miklic</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Malic</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rovis</surname><given-names>T. L.</given-names></name>; et al. <article-title>Epitope recognition
of a monoclonal antibody raised against a synthetic
glycerol phosphate based teichoic acid</article-title>. <source>ACS
Chem. Biol.</source><year>2021</year>, <volume>16</volume>, <fpage>1344</fpage>&#8211;<lpage>1349</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.1c00422</pub-id>.<pub-id pub-id-type="pmid">34255482</pub-id><pub-id pub-id-type="pmcid">PMC8389533</pub-id></mixed-citation></ref><ref id="ref212"><mixed-citation publication-type="journal" id="cit212"><name name-style="western"><surname>Wanner</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Schade</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Keinhorster</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Weller</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>George</surname><given-names>S. E.</given-names></name>; <name name-style="western"><surname>Kull</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Bauer</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Grau</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Winstel</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Stoy</surname><given-names>H.</given-names></name>; et al. <article-title>Wall teichoic
acids mediate increased virulence in Staphylococcus aureus</article-title>. <source>Nat. Microbiol.</source><year>2017</year>, <volume>2</volume>, <fpage>16257</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.257</pub-id>.<pub-id pub-id-type="pmid">28112716</pub-id></mixed-citation></ref><ref id="ref213"><mixed-citation publication-type="journal" id="cit213"><name name-style="western"><surname>van der Es</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Groenia</surname><given-names>N. A.</given-names></name>; <name name-style="western"><surname>Laverde</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D. C.</given-names></name><article-title>Synthesis
of <italic toggle="yes">E. faecium</italic> wall teichoic acid fragments</article-title>. <source>Bioorg. Med. Chem.</source><year>2016</year>, <volume>24</volume>, <fpage>3893</fpage>&#8211;<lpage>3907</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2016.03.019</pub-id>.<pub-id pub-id-type="pmid">26993744</pub-id></mixed-citation></ref><ref id="ref214"><mixed-citation publication-type="journal" id="cit214"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Ding</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><article-title>Synthesis
and immunological study of a wall teichoic acid-based vaccine against
E. faecium U0317</article-title>. <source>J. Carbohydr. Chem.</source><year>2017</year>, <volume>36</volume>, <fpage>205</fpage>&#8211;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1080/07328303.2017.1390576</pub-id>.</mixed-citation></ref><ref id="ref215"><mixed-citation publication-type="journal" id="cit215"><name name-style="western"><surname>Cunningham</surname><given-names>M. W.</given-names></name><article-title>Pathogenesis of group A streptococcal
infections</article-title>. <source>Clin. Microbiol. Rev.</source><year>2000</year>, <volume>13</volume>, <fpage>470</fpage>&#8211;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.13.3.470</pub-id>.<pub-id pub-id-type="pmid">10885988</pub-id><pub-id pub-id-type="pmcid">PMC88944</pub-id></mixed-citation></ref><ref id="ref216"><mixed-citation publication-type="journal" id="cit216"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><article-title>Molecular epidemiology and antimicrobial
resistance of group a streptococcus
recovered from patients in Beijing, China</article-title>. <source>BMC
Infect. Dis.</source><year>2020</year>, <volume>20</volume>, <fpage>507</fpage><pub-id pub-id-type="doi">10.1186/s12879-020-05241-x</pub-id>.<pub-id pub-id-type="pmid">32660436</pub-id><pub-id pub-id-type="pmcid">PMC7359455</pub-id></mixed-citation></ref><ref id="ref217"><mixed-citation publication-type="journal" id="cit217"><name name-style="western"><surname>Lancefield</surname><given-names>R. C.</given-names></name><article-title>A Serological differentiation of
human and other groups
of hemolytic streptococci</article-title>. <source>J. Exp. Med.</source><year>1933</year>, <volume>57</volume>, <fpage>571</fpage>&#8211;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1084/jem.57.4.571</pub-id>.<pub-id pub-id-type="pmid">19870148</pub-id><pub-id pub-id-type="pmcid">PMC2132252</pub-id></mixed-citation></ref><ref id="ref218"><mixed-citation publication-type="journal" id="cit218"><name name-style="western"><surname>Henningham</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Davies</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Uchiyama</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>van Sorge</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Lund</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>K. T.</given-names></name>; <name name-style="western"><surname>Walker</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Cole</surname><given-names>J. N.</given-names></name>; <name name-style="western"><surname>Nizet</surname><given-names>V.</given-names></name><article-title>Virulence role of the GlcNAc side
chain of the Lancefield cell wall
carbohydrate antigen in non-M1-serotype group A <italic toggle="yes">Streptococcus</italic></article-title>. <source>MBio</source><year>2018</year>, <volume>9</volume>, <elocation-id>e02294-17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02294-17</pub-id>.<pub-id pub-id-type="pmid">29382733</pub-id><pub-id pub-id-type="pmcid">PMC5790915</pub-id></mixed-citation></ref><ref id="ref219"><mixed-citation publication-type="journal" id="cit219"><name name-style="western"><surname>McCarty</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lancefield</surname><given-names>R. C.</given-names></name><article-title>Variation in the group-specific carbohydrate
of group A streptococci. Immunochemical studies on the carbohydrates
of variant strains</article-title>. <source>J. Exp. Med.</source><year>1955</year>, <volume>102</volume>, <fpage>11</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1084/jem.102.1.11</pub-id>.<pub-id pub-id-type="pmid">14392237</pub-id><pub-id pub-id-type="pmcid">PMC2136495</pub-id></mixed-citation></ref><ref id="ref220"><mixed-citation publication-type="journal" id="cit220"><name name-style="western"><surname>Sabharwal</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Michon</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Nelson</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Fuchs</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Carre&#241;o Manjarrez</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Uitz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Viteri-Jackson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Suarez</surname><given-names>R. S. R.</given-names></name>; et al. <article-title>Group A <italic toggle="yes">Streptococcus</italic> (GAS)
carbohydrate as an immunogen
for protection against GAS Infection</article-title>. <source>J. Infect.
Dis.</source><year>2006</year>, <volume>193</volume>, <fpage>129</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1086/498618</pub-id>.<pub-id pub-id-type="pmid">16323141</pub-id></mixed-citation></ref><ref id="ref221"><mixed-citation publication-type="journal" id="cit221"><name name-style="western"><surname>Andrews</surname><given-names>J.
S.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Oligosaccharides
corresponding to
the antigenic determinants of the &#946;-haemolytic <italic toggle="yes">Streptococci</italic> Group A. Part 2. Synthesis and 2D nuclear magnetic resonance analysis
of a branched tetrasaccharide hapten</article-title>. <source>J. Chem.
Soc., Perkin Trans. 1</source><year>1990</year>, <volume>6</volume>, <fpage>1785</fpage>&#8211;<lpage>1792</lpage>. <pub-id pub-id-type="doi">10.1039/P19900001785</pub-id>.</mixed-citation></ref><ref id="ref222"><mixed-citation publication-type="journal" id="cit222"><name name-style="western"><surname>Reimer</surname><given-names>K. B.</given-names></name>; <name name-style="western"><surname>Harris</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Varma</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Convergent
synthesis of higher-order oligosaccharides corre-sponding to the cell-wall
polysaccharide of the &#946;-hemolytic <italic toggle="yes">Streptococcus</italic> group A. A branched hexasaccharide hapten</article-title>. <source>Carbohydr. Res.</source><year>1992</year>, <volume>228</volume>, <fpage>399</fpage>&#8211;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1016/0008-6215(92)84133-D</pub-id>.<pub-id pub-id-type="pmid">1525784</pub-id></mixed-citation></ref><ref id="ref223"><mixed-citation publication-type="journal" id="cit223"><name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name>; <name name-style="western"><surname>Buiting</surname><given-names>M. M. W.</given-names></name>; <name name-style="western"><surname>Reimer</surname><given-names>K. B.</given-names></name><article-title>Use of the [beta-(trimethylsilyl)ethoxy]methyl
(SEM) protecting group in carbohydrate chemistry. Fully functionalized
rhamnose acceptors and donors for use in oligosaccharide synthesis</article-title>. <source>J. Org. Chem.</source><year>1990</year>, <volume>55</volume>, <fpage>2177</fpage><pub-id pub-id-type="doi">10.1021/jo00294a036</pub-id>.</mixed-citation></ref><ref id="ref224"><mixed-citation publication-type="journal" id="cit224"><name name-style="western"><surname>Marino-Albernas</surname><given-names>J.-R.</given-names></name>; <name name-style="western"><surname>Harris</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Varma</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Convergent
synthesis of an elusive hexasaccharide corre-sponding to the cell-wall
polysaccharide of the &#946;-hemolytic Streptococcus Group A</article-title>. <source>Carbohydr. Res.</source><year>1993</year>, <volume>245</volume>, <fpage>245</fpage>&#8211;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/0008-6215(93)80075-P</pub-id>.<pub-id pub-id-type="pmid">8370024</pub-id></mixed-citation></ref><ref id="ref225"><mixed-citation publication-type="journal" id="cit225"><name name-style="western"><surname>Auzanneau</surname><given-names>F.-I.</given-names></name>; <name name-style="western"><surname>Forooghian</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Efficient, convergent
syntheses of oligosaccharide allyl glycosides corresponding to the <italic toggle="yes">Streptococcus</italic> group A cell-wall poly-saccharide</article-title>. <source>Carbohydr. Res.</source><year>1996</year>, <volume>291</volume>, <fpage>21</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(96)00152-8</pub-id>.<pub-id pub-id-type="pmid">8864221</pub-id></mixed-citation></ref><ref id="ref226"><mixed-citation publication-type="journal" id="cit226"><name name-style="western"><surname>Auzanneau</surname><given-names>F.-I.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Preparation of antigens and immunoadsorbents
corresponding to the <italic toggle="yes">Streptococcus</italic> group A cell-wall
polysaccharide</article-title>. <source>Bioorg. Med. Chem.</source><year>1996</year>, <volume>4</volume>, <fpage>2003</fpage>&#8211;<lpage>2010</lpage>. <pub-id pub-id-type="doi">10.1016/S0968-0896(96)00183-6</pub-id>.<pub-id pub-id-type="pmid">9007283</pub-id></mixed-citation></ref><ref id="ref227"><mixed-citation publication-type="journal" id="cit227"><name name-style="western"><surname>Pitner</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Beyer</surname><given-names>W. F.</given-names></name>; <name name-style="western"><surname>Venetta</surname><given-names>T. M.</given-names></name>; <name name-style="western"><surname>Nycz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Harris</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Marino-Albernas</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Auzanneau</surname><given-names>F.-I.</given-names></name>; <name name-style="western"><surname>Forooghian</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Bivalency and epitope
specifici-ty of a high-affinity IgG3 monoclonal antibody to the <italic toggle="yes">Strep-tococcus</italic> group A carbohydrate antigen. Molecular modeling
of a Fv fragment</article-title>. <source>Carbohydr. Res.</source><year>2000</year>, <volume>324</volume>, <fpage>17</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(99)00279-7</pub-id>.<pub-id pub-id-type="pmid">10723608</pub-id></mixed-citation></ref><ref id="ref228"><mixed-citation publication-type="journal" id="cit228"><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Saturation transfer
difference 1D-TOCSY
experiments to map the topography of oligosaccharides recognized by
a monoclonal antibody directed against the cell-wall polysaccharide
of group A <italic toggle="yes">Streptococcus</italic></article-title>. <source>J.
Am. Chem. Soc.</source><year>2002</year>, <volume>124</volume>, <fpage>15368</fpage>&#8211;<lpage>15374</lpage>. <pub-id pub-id-type="doi">10.1021/ja020983v</pub-id>.<pub-id pub-id-type="pmid">12487612</pub-id></mixed-citation></ref><ref id="ref229"><mixed-citation publication-type="journal" id="cit229"><name name-style="western"><surname>Michon</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Moore</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Blake</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Auzanneau</surname><given-names>F. I.</given-names></name>; <name name-style="western"><surname>Johnston</surname><given-names>B. D.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Doubly
branched hexasaccharide epitope on the cell wall polysaccharide of
group A <italic toggle="yes">Streptococci</italic> recognized by human and rabbit
antisera</article-title>. <source>Infect. Immun.</source><year>2005</year>, <volume>73</volume>, <fpage>6383</fpage>&#8211;<lpage>6389</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.73.10.6383-6389.2005</pub-id>.<pub-id pub-id-type="pmid">16177309</pub-id><pub-id pub-id-type="pmcid">PMC1230941</pub-id></mixed-citation></ref><ref id="ref230"><mixed-citation publication-type="journal" id="cit230"><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>NMR spectroscopic
and molecular modeling
studies of protein-carbohydrate and protein-peptide interactions</article-title>. <source>Carbohydr. Res.</source><year>2004</year>, <volume>339</volume>, <fpage>907</fpage>&#8211;<lpage>928</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2003.12.028</pub-id>.<pub-id pub-id-type="pmid">15010299</pub-id></mixed-citation></ref><ref id="ref231"><mixed-citation publication-type="journal" id="cit231"><name name-style="western"><surname>Auzanneau</surname><given-names>F. I.</given-names></name>; <name name-style="western"><surname>Borrelli</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>B. M.</given-names></name><article-title>Synthesis and immunological
activity of an oligosaccharide-conjugate as a vaccine candidate against
Group A <italic toggle="yes">Streptococcus</italic></article-title>. <source>Bioorg.
Med. Chem. Lett.</source><year>2013</year>, <volume>23</volume>, <fpage>6038</fpage>&#8211;<lpage>6042</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2013.09.042</pub-id>.<pub-id pub-id-type="pmid">24103300</pub-id></mixed-citation></ref><ref id="ref232"><mixed-citation publication-type="journal" id="cit232"><name name-style="western"><surname>Kabanova</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Margarit</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Grandi</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Bensi</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Chiarot</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Proiettigou</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Swennen</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Cappelletti</surname><given-names>E.</given-names></name>; et al. <article-title>Evaluation of a group
A <italic toggle="yes">Streptococcus</italic> synthetic oligosaccharide as vaccine
candidate</article-title>. <source>Vaccine</source><year>2010</year>, <volume>29</volume>, <fpage>104</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.018</pub-id>.<pub-id pub-id-type="pmid">20870056</pub-id></mixed-citation></ref><ref id="ref233"><mixed-citation publication-type="journal" id="cit233"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Gu</surname><given-names>G.</given-names></name><article-title>Synthesis and immunological studies
of group A <italic toggle="yes">Streptococcus</italic> cell-wall oligosaccharide-streptococcal
C5a
peptidase conjugates as bivalent vaccines</article-title>. <source>Org.
Chem. Front.</source><year>2019</year>, <volume>6</volume>, <fpage>3589</fpage>&#8211;<lpage>3596</lpage>. <pub-id pub-id-type="doi">10.1039/C9QO00651F</pub-id>.</mixed-citation></ref><ref id="ref234"><mixed-citation publication-type="journal" id="cit234"><name name-style="western"><surname>Dagan</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Poolman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Siegrist</surname><given-names>C. A.</given-names></name><article-title>Glycoconjugate vaccines
and immune interference: a review</article-title>. <source>Vaccine</source><year>2010</year>, <volume>28</volume>, <fpage>5513</fpage>&#8211;<lpage>5523</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.026</pub-id>.<pub-id pub-id-type="pmid">20600514</pub-id></mixed-citation></ref><ref id="ref235"><mixed-citation publication-type="journal" id="cit235"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Gu</surname><given-names>G.</given-names></name><article-title>Group A <italic toggle="yes">Streptococcus</italic> cell wall oligosaccharide-streptococcal
C5a peptidase conjugates as effective antibacterial vaccines</article-title>. <source>ACS Infect. Dis.</source><year>2020</year>, <volume>6</volume>, <fpage>281</fpage>&#8211;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00347</pub-id>.<pub-id pub-id-type="pmid">31872763</pub-id></mixed-citation></ref><ref id="ref236"><mixed-citation publication-type="journal" id="cit236"><name name-style="western"><surname>van Sorge</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Cole</surname><given-names>J. N.</given-names></name>; <name name-style="western"><surname>Kuipers</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Henningham</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Aziz</surname><given-names>R. K.</given-names></name>; <name name-style="western"><surname>Kasirer-Friede</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Berends</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Davies</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Dougan</surname><given-names>G.</given-names></name>; et al. <article-title>The classical Lancefield
antigen of group A <italic toggle="yes">Streptococcus</italic> is a virulence determinant
with implications for vaccine design</article-title>. <source>Cell Host
Microbe</source><year>2014</year>, <volume>15</volume>, <fpage>729</fpage>&#8211;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2014.05.009</pub-id>.<pub-id pub-id-type="pmid">24922575</pub-id><pub-id pub-id-type="pmcid">PMC4078075</pub-id></mixed-citation></ref><ref id="ref237"><mixed-citation publication-type="journal" id="cit237"><name name-style="western"><surname>Goldstein</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Rebeyrotte</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Parlebas</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Halpern</surname><given-names>B.</given-names></name><article-title>Isolation
from heart valves of glycopeptides which share immunological properties
with <italic toggle="yes">Streptococcus haemolyticus</italic> group A polysaccharides</article-title>. <source>Nature</source><year>1968</year>, <volume>219</volume>, <fpage>866</fpage>&#8211;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1038/219866a0</pub-id>.<pub-id pub-id-type="pmid">4970577</pub-id></mixed-citation></ref><ref id="ref238"><mixed-citation publication-type="journal" id="cit238"><name name-style="western"><surname>Pitirollo</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Necchi</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Mancini</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Carducci</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Evangelisti</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><article-title>Gold nanoparticles
morphology does not affect the multivalent presentation and antibody
recognition of group A <italic toggle="yes">Streptococcus</italic> synthetic oligorhamnans</article-title>. <source>Bioorg. Chem.</source><year>2020</year>, <volume>99</volume>, <fpage>103815</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103815</pub-id>.<pub-id pub-id-type="pmid">32289587</pub-id></mixed-citation></ref><ref id="ref239"><mixed-citation publication-type="journal" id="cit239"><name name-style="western"><surname>Gao</surname><given-names>N. J.</given-names></name>; <name name-style="western"><surname>Uchiyama</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pill</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Dahesh</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Olson</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bau-tista</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Maroju</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Berges</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>J. Z.</given-names></name>; <name name-style="western"><surname>Zurich</surname><given-names>R. H.</given-names></name><article-title>Site-Specific conjugation of cell
wall polyrhamnose to protein SpyAD envisioning a safe universal group
A streptococcal vaccine</article-title>. <source>Infect. Microb. Dis.</source><year>2021</year>, <volume>3</volume>, <fpage>87</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1097/IM9.0000000000000044</pub-id>.</mixed-citation></ref><ref id="ref240"><mixed-citation publication-type="journal" id="cit240"><name name-style="western"><surname>Belot</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Guerreiro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Baleux</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Mulard</surname><given-names>L. A.</given-names></name><article-title>Synthesis
of two linear PADRE conjugates bearing a deca- or pentadecasaccharide
B epitope as potential synthetic vaccines against Shigella flexneri
serotype 2a infection</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2005</year>, <volume>11</volume>, <fpage>1625</fpage>&#8211;<lpage>1635</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200400903</pub-id>.<pub-id pub-id-type="pmid">15669066</pub-id></mixed-citation></ref><ref id="ref241"><mixed-citation publication-type="journal" id="cit241"><name name-style="western"><surname>Khatun</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Dai</surname><given-names>C. C.</given-names></name>; <name name-style="western"><surname>Rivera-Hernandez</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hussein</surname><given-names>W. M.</given-names></name>; <name name-style="western"><surname>Khalil</surname><given-names>Z. G.</given-names></name>; <name name-style="western"><surname>Capon</surname><given-names>R. J.</given-names></name>; <name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Stephenson</surname><given-names>R. J.</given-names></name><article-title>Immunogenicity assessment of cell wall carbohydrates
of group A <italic toggle="yes">Streptococcus</italic> via self-adjuvanted glyco-lipopeptides</article-title>. <source>ACS Infect. Dis.</source><year>2021</year>, <volume>7</volume>, <fpage>390</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00722</pub-id>.<pub-id pub-id-type="pmid">33533246</pub-id></mixed-citation></ref><ref id="ref242"><mixed-citation publication-type="journal" id="cit242"><name name-style="western"><surname>Oster</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Edelsberg</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Hennegan</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Lewin</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Narasimhan</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Slobod</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Baker</surname><given-names>C. J.</given-names></name><article-title>Prevention
of group B streptococcal disease in the first 3 months of life: would
routine maternal immunization during pregnancy be cost-effective?</article-title>. <source>Vaccine</source><year>2014</year>, <volume>32</volume>, <fpage>4778</fpage>&#8211;<lpage>4785</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.003</pub-id>.<pub-id pub-id-type="pmid">24992717</pub-id></mixed-citation></ref><ref id="ref243"><mixed-citation publication-type="journal" id="cit243"><name name-style="western"><surname>Seale</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Blencowe</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Bianchi-Jassir</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Embleton</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Bassat</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Ordi</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Men&#233;ndez</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Cutland</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Briner</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Berkley</surname><given-names>J. A.</given-names></name>; et al. <article-title>Stillbirth
with group B <italic toggle="yes">Streptococcus</italic> disease worldwide: systematic
review and meta-analyses</article-title>. <source>Clin. Infect. Dis.</source><year>2017</year>, <volume>65</volume>, <fpage>S125</fpage>&#8211;<lpage>S132</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix585</pub-id>.<pub-id pub-id-type="pmid">29117322</pub-id><pub-id pub-id-type="pmcid">PMC5850020</pub-id></mixed-citation></ref><ref id="ref244"><mixed-citation publication-type="journal" id="cit244"><name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Structure-based glycoconjugate
vaccine
design: the example of group B <italic toggle="yes">Streptococcus</italic> type
III capsular polysaccharide</article-title>. <source>Drug Discovery
Today Technol.</source><year>2020</year>, <volume>35-36</volume>, <fpage>23</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.11.003</pub-id>.<pub-id pub-id-type="pmid">33388125</pub-id></mixed-citation></ref><ref id="ref245"><mixed-citation publication-type="journal" id="cit245"><name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Campisi</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Toniolo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Crotti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rosini</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Torricelli</surname><given-names>G.</given-names></name>; et al. <article-title>Structure of the type
IX group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide
and its evolutionary relationship with types V and VII</article-title>. <source>J. Biol. Chem.</source><year>2014</year>, <volume>289</volume>, <fpage>23437</fpage>&#8211;<lpage>23448</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.567974</pub-id>.<pub-id pub-id-type="pmid">24990951</pub-id><pub-id pub-id-type="pmcid">PMC4156066</pub-id></mixed-citation></ref><ref id="ref246"><mixed-citation publication-type="journal" id="cit246"><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Segall</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Block</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Center</surname><given-names>K. J.</given-names></name>; <name name-style="western"><surname>Scully</surname><given-names>I. L.</given-names></name>; <name name-style="western"><surname>Giardina</surname><given-names>P. C.</given-names></name>; <name name-style="western"><surname>Peterson</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Watson</surname><given-names>W. J.</given-names></name>; <name name-style="western"><surname>Gruber</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>Jansen</surname><given-names>K. U.</given-names></name>; et al. <article-title>Safety and immunogenicity
of a novel hexavalent group B <italic toggle="yes">Streptococcus</italic> conjugate
vaccine in healthy, non-pregnant adults: a phase 1/2, randomised,
placebo-controlled, observer-blinded, dose-escalation trial</article-title>. <source>Lancet Infect. Dis.</source><year>2021</year>, <volume>21</volume>, <fpage>263</fpage>&#8211;<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30478-3</pub-id>.<pub-id pub-id-type="pmid">32891191</pub-id><pub-id pub-id-type="pmcid">PMC9760110</pub-id></mixed-citation></ref><ref id="ref247"><mixed-citation publication-type="journal" id="cit247"><name name-style="western"><surname>Madhi</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Cutland</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Jose</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Koen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Govender</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Wittke</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Olugbosi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Meulen</surname><given-names>A. S.-t.</given-names></name>; <name name-style="western"><surname>Baker</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Dull</surname><given-names>P. M.</given-names></name>; et al. <article-title>Safety and immunogenicity
of an investigational maternal trivalent group B <italic toggle="yes">Streptococcus</italic> vaccine in healthy women and their infants: a randomised phase 1b/2
trial</article-title>. <source>Lancet Infect. Dis.</source><year>2016</year>, <volume>16</volume>, <fpage>923</fpage>&#8211;<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)00152-3</pub-id>.<pub-id pub-id-type="pmid">27139805</pub-id></mixed-citation></ref><ref id="ref248"><mixed-citation publication-type="journal" id="cit248"><name name-style="western"><surname>Gonz&#225;lez-Outeiri&#241;o</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kadirvelraj</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Woods</surname><given-names>R. J.</given-names></name><article-title>Structural elucidation of type III
group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide using
molecular dynamics
simulations: the role of sialic acid</article-title>. <source>Carbohydr.
Res.</source><year>2005</year>, <volume>340</volume>, <fpage>1007</fpage>&#8211;<lpage>1018</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2004.12.034</pub-id>.<pub-id pub-id-type="pmid">15780265</pub-id></mixed-citation></ref><ref id="ref249"><mixed-citation publication-type="journal" id="cit249"><name name-style="western"><surname>Kuttel</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Ravenscroft</surname><given-names>N.</given-names></name><article-title>Conformation and cross-protection
in group B <italic toggle="yes">Streptococcus</italic> serotype III and <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 14: a molecular modeling
study</article-title>. <source>Pharmaceuticals (Basel)</source><year>2019</year>, <volume>12</volume>, <fpage>28</fpage><pub-id pub-id-type="doi">10.3390/ph12010028</pub-id>.<pub-id pub-id-type="pmcid">PMC6469160</pub-id><pub-id pub-id-type="pmid">30781826</pub-id></mixed-citation></ref><ref id="ref250"><mixed-citation publication-type="journal" id="cit250"><name name-style="western"><surname>Hanashima</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Total synthesis
of sialylated glycans
related to avian and human influenza virus infection</article-title>. <source>Chem. Asian J.</source><year>2007</year>, <volume>2</volume>, <fpage>1447</fpage>&#8211;<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1002/asia.200600424</pub-id>.<pub-id pub-id-type="pmid">17963282</pub-id></mixed-citation></ref><ref id="ref251"><mixed-citation publication-type="journal" id="cit251"><name name-style="western"><surname>Crotti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>New strategies for the synthesis
of bio-medically relevant oligosaccharides: recent updates on 1,2-<italic toggle="yes">cis</italic>-O-glycosylation and &#945;-O-sialylation</article-title>. <source>Curr. Org. Chem.</source><year>2013</year>, <volume>10</volume>, <fpage>501</fpage>&#8211;<lpage>524</lpage>.</mixed-citation></ref><ref id="ref252"><mixed-citation publication-type="journal" id="cit252"><name name-style="western"><surname>Pozsgay</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Gaudino</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Paulson</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name><article-title>Chemo-enzymatic
synthesis of a branching decasaccharide fragment of the capsular polysaccharide
of type III group B <italic toggle="yes">Streptococcus</italic></article-title>. <source>Bioorg. Med. Chem. Lett.</source><year>1991</year>, <volume>1</volume>, <fpage>391</fpage>&#8211;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-894X(00)80262-0</pub-id>.</mixed-citation></ref><ref id="ref253"><mixed-citation publication-type="journal" id="cit253"><name name-style="western"><surname>Demchenko</surname><given-names>A. V.</given-names></name>; <name name-style="western"><surname>Boons</surname><given-names>G.-J.</given-names></name><article-title>A highly convergent synthesis of
a complex oligosaccharide derived from group B type III <italic toggle="yes">Streptococcus</italic></article-title>. <source>J. Org. Chem.</source><year>2001</year>, <volume>66</volume>, <fpage>2547</fpage>&#8211;<lpage>2554</lpage>. <pub-id pub-id-type="doi">10.1021/jo001477w</pub-id>.<pub-id pub-id-type="pmid">11304169</pub-id></mixed-citation></ref><ref id="ref254"><mixed-citation publication-type="journal" id="cit254"><name name-style="western"><surname>Demchenko</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Boons</surname><given-names>G.-J.</given-names></name><article-title>A highly convergent
synthesis of
a hexasaccharide derived from the oligosaccharide of group B type
III <italic toggle="yes">Streptococcus</italic></article-title>. <source>Tetrahedron
Lett.</source><year>1997</year>, <volume>38</volume>, <fpage>1629</fpage>&#8211;<lpage>1632</lpage>. <pub-id pub-id-type="doi">10.1016/S0040-4039(97)00106-8</pub-id>.</mixed-citation></ref><ref id="ref255"><mixed-citation publication-type="journal" id="cit255"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Brisson</surname><given-names>J.-R.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>Q.-L.</given-names></name>; <name name-style="western"><surname>van der Zwan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name><article-title>Synthesis and NMR assignment of two repeating units
(decasaccharide) of the type III group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide and its <sup>13</sup>C-labeled and N-propionyl
substituted sialic acid analogues</article-title>. <source>Carbohydr.
Res.</source><year>1996</year>, <volume>295</volume>, <fpage>209</fpage>&#8211;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(96)90144-5</pub-id>.<pub-id pub-id-type="pmid">9002193</pub-id></mixed-citation></ref><ref id="ref256"><mixed-citation publication-type="journal" id="cit256"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Laferriere</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name><article-title>Oligosaccharide
fragments of the type III group B streptococcal polysaccharide derived
from <italic toggle="yes">S. pneumoniae</italic> type 14 capsular polysaccharide
by a chemoenzymatic method</article-title>. <source>Carbohydr. Res.</source><year>1998</year>, <volume>309</volume>, <fpage>297</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(98)00134-7</pub-id>.<pub-id pub-id-type="pmid">9742691</pub-id></mixed-citation></ref><ref id="ref257"><mixed-citation publication-type="journal" id="cit257"><name name-style="western"><surname>Cattaneo</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>De Ricco</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Donadio</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Ros</surname><given-names>I. M. Y.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Synthesis
of group B <italic toggle="yes">Streptococcus</italic> type III polysaccharide
fragments for evaluation of their interactions with monoclonal antibodies</article-title>. <source>Pure Appl. Chem.</source><year>2017</year>, <volume>89</volume>, <fpage>855</fpage>&#8211;<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1515/pac-2016-0918</pub-id>.</mixed-citation></ref><ref id="ref258"><mixed-citation publication-type="journal" id="cit258"><name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Fabbrini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>De Ricco</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Cattaneo</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Veggi</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Passalacqua</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; et al. <article-title>Structure of a protective
epitope of group B Streptococcus type III capsular polysaccharide</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2017</year>, <volume>114</volume>, <fpage>5017</fpage>&#8211;<lpage>5022</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1701885114</pub-id>.<pub-id pub-id-type="pmid">28439022</pub-id><pub-id pub-id-type="pmcid">PMC5441712</pub-id></mixed-citation></ref><ref id="ref259"><mixed-citation publication-type="journal" id="cit259"><name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Angiolini</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Fabbrini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Corrado</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Margarit</surname><given-names>I.</given-names></name><article-title>Evaluation
of immune responses to group B <italic toggle="yes">Streptococcus</italic> type
III oligosaccharides containing a minimal protective epitope</article-title>. <source>J. Infect. Dis.</source><year>2020</year>, <volume>221</volume>, <fpage>943</fpage>&#8211;<lpage>947</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiz551</pub-id>.<pub-id pub-id-type="pmid">31641758</pub-id></mixed-citation></ref><ref id="ref260"><mixed-citation publication-type="journal" id="cit260"><name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Arda</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Carboni</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Henriques</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Angiolini</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Quintana</surname><given-names>J. I.</given-names></name>; <name name-style="western"><surname>Calloni</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; et al. <article-title>Structure-guided design
of a group B <italic toggle="yes">Streptococcus</italic> type III synthetic glycan-conjugate
vaccine</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2020</year>, <volume>26</volume>, <fpage>7018</fpage>&#8211;<lpage>7025</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202000284</pub-id>.<pub-id pub-id-type="pmid">32058627</pub-id><pub-id pub-id-type="pmcid">PMC7317837</pub-id></mixed-citation></ref><ref id="ref261"><mixed-citation publication-type="journal" id="cit261"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name><article-title>Chemical-enzymatic
synthesis of a branched hexasaccharide
fragment of type Ia group B <italic toggle="yes">Streptococcus</italic> capsular
polysaccharide</article-title>. <source>J. Carbohydr. Chem.</source><year>1996</year>, <volume>15</volume>, <fpage>925</fpage>&#8211;<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1080/07328309608005699</pub-id>.</mixed-citation></ref><ref id="ref262"><mixed-citation publication-type="journal" id="cit262"><name name-style="western"><surname>Mondal</surname><given-names>P. K.</given-names></name>; <name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Mondal</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Chemical synthesis
of the repeating unit of type Ia group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide</article-title>. <source>Org. Lett.</source><year>2015</year>, <volume>17</volume>, <fpage>1102</fpage>&#8211;<lpage>1105</lpage>. <pub-id pub-id-type="doi">10.1021/ol5036563</pub-id>.<pub-id pub-id-type="pmid">25674920</pub-id><pub-id pub-id-type="pmcid">PMC4664191</pub-id></mixed-citation></ref><ref id="ref263"><mixed-citation publication-type="journal" id="cit263"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Shao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><article-title>One-pot synthesis of
the repeating unit of type VII
group B <italic toggle="yes">Streptococcus</italic> polysaccharide and the dimer</article-title>. <source>Org. Lett.</source><year>2019</year>, <volume>21</volume>, <fpage>2374</fpage>&#8211;<lpage>2377</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.9b00653</pub-id>.<pub-id pub-id-type="pmid">30888190</pub-id></mixed-citation></ref><ref id="ref264"><mixed-citation publication-type="journal" id="cit264"><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Synthesis of a dimer of the repeating unit of type
Ia group B <italic toggle="yes">Streptococcus</italic> extracellular capsular polysaccharide
and immunological evaluations of related protein conjugates</article-title>. <source>Org. Chem. Front.</source><year>2019</year>, <volume>6</volume>, <fpage>2833</fpage>&#8211;<lpage>2838</lpage>. <pub-id pub-id-type="doi">10.1039/C9QO00486F</pub-id>.<pub-id pub-id-type="pmid">32274071</pub-id><pub-id pub-id-type="pmcid">PMC7144420</pub-id></mixed-citation></ref><ref id="ref265"><mixed-citation publication-type="journal" id="cit265"><name name-style="western"><surname>Del
Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Calloni</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Oldrini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Raso</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Cuffaro</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Ard&#225;</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D. C.</given-names></name>; <name name-style="western"><surname>Jim&#233;nez-Barbero</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Regioselective glycosylation
strategies for the synthesis of group Ia and Ib <italic toggle="yes">Streptococcus</italic> related glycans enable elucidating unique conformations of the capsular
polysaccharides</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2019</year>, <volume>25</volume>, <fpage>16277</fpage>&#8211;<lpage>16287</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201903527</pub-id>.<pub-id pub-id-type="pmid">31506992</pub-id><pub-id pub-id-type="pmcid">PMC6972993</pub-id></mixed-citation></ref><ref id="ref266"><mixed-citation publication-type="journal" id="cit266"><name name-style="western"><surname>Shao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Gu</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><article-title>Chemical synthesis
of the repeating
unit of type II group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide</article-title>. <source>J. Org. Chem.</source><year>2018</year>, <volume>83</volume>, <fpage>5920</fpage>&#8211;<lpage>5930</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.8b00396</pub-id>.<pub-id pub-id-type="pmid">29709182</pub-id></mixed-citation></ref><ref id="ref267"><mixed-citation publication-type="journal" id="cit267"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Chemical synthesis of the repeating unit of type V
group B <italic toggle="yes">Streptococcus</italic> capsular polysaccharide</article-title>. <source>Org. Lett.</source><year>2016</year>, <volume>18</volume>, <fpage>5552</fpage>&#8211;<lpage>5555</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.6b02796</pub-id>.<pub-id pub-id-type="pmid">27809549</pub-id><pub-id pub-id-type="pmcid">PMC5645073</pub-id></mixed-citation></ref><ref id="ref268"><mixed-citation publication-type="journal" id="cit268"><person-group person-group-type="allauthors"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Margarit</surname><given-names>I.</given-names></name></person-group><article-title>Fighting
Antibiotic-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> with &#8243;Sweet&#8243;
Immune
Targets</article-title>. <source>mBio</source><year>2018</year>, <volume>9</volume>, <pub-id pub-id-type="doi">10.1128/mbio.00874-18</pub-id>.<pub-id pub-id-type="pmcid">PMC5954227</pub-id><pub-id pub-id-type="pmid">29764953</pub-id></mixed-citation></ref><ref id="ref269"><mixed-citation publication-type="journal" id="cit269"><name name-style="western"><surname>Wenzel</surname><given-names>R. P.</given-names></name>; <name name-style="western"><surname>Edmond</surname><given-names>M. B.</given-names></name><article-title>The Impact of hospital-acquired
bloodstream
infections</article-title>. <source>Emerg. Infect. Dis.</source><year>2001</year>, <volume>7</volume>, <fpage>174</fpage>&#8211;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.3201/eid0702.010203</pub-id>.<pub-id pub-id-type="pmid">11294700</pub-id><pub-id pub-id-type="pmcid">PMC2631709</pub-id></mixed-citation></ref><ref id="ref270"><mixed-citation publication-type="journal" id="cit270"><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tennant</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Simon</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Cross</surname><given-names>A. S.</given-names></name><article-title>Progress
towards the development of <italic toggle="yes">Klebsiella</italic> vaccines</article-title>. <source>Expert Rev. Vaccines</source><year>2019</year>, <volume>18</volume>, <fpage>681</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2019.1635460</pub-id>.<pub-id pub-id-type="pmid">31250679</pub-id><pub-id pub-id-type="pmcid">PMC6656602</pub-id></mixed-citation></ref><ref id="ref271"><mixed-citation publication-type="journal" id="cit271"><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hegerle</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Nkeze</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Jamindar</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Nasrin</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Permala-Booth</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Sinclair</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Tapia</surname><given-names>M. D.</given-names></name>; et al. <article-title>The diversity of lipopolysaccharide
(O) and capsular polysaccharide (K) antigens of invasive <italic toggle="yes">Klebsiella
pneumoniae</italic> in a multi-country collection</article-title>. <source>Front. Immunol.</source><year>2020</year>, <volume>11</volume>, <fpage>1249</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.01249</pub-id>.<pub-id pub-id-type="pmid">32595624</pub-id><pub-id pub-id-type="pmcid">PMC7303279</pub-id></mixed-citation></ref><ref id="ref272"><mixed-citation publication-type="journal" id="cit272"><name name-style="western"><surname>Tom&#225;s</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Camprubi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Merino</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Davey</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Williams</surname><given-names>P.</given-names></name><article-title>Surface exposure
of O1 serotype lipopolysaccharide
in <italic toggle="yes">Klebsiella pneumoniae</italic> strains expressing different
K antigens</article-title>. <source>Infect. Immunol.</source><year>1991</year>, <volume>59</volume>, <fpage>2006</fpage>&#8211;<lpage>2011</lpage>. <pub-id pub-id-type="doi">10.1128/iai.59.6.2006-2011.1991</pub-id>.<pub-id pub-id-type="pmid">1709919</pub-id><pub-id pub-id-type="pmcid">PMC257957</pub-id></mixed-citation></ref><ref id="ref273"><mixed-citation publication-type="journal" id="cit273"><name name-style="western"><surname>Cryz</surname><given-names>S. J.</given-names></name><article-title>Progress in immunization against <italic toggle="yes">Klebsiella</italic> Infections</article-title>. <source>Eur. J. Clin.
Microbiol.</source><year>1983</year>, <volume>2</volume>, <fpage>523</fpage>&#8211;<lpage>528</lpage>. <pub-id pub-id-type="doi">10.1007/BF02016559</pub-id>.<pub-id pub-id-type="pmid">6365535</pub-id></mixed-citation></ref><ref id="ref274"><mixed-citation publication-type="journal" id="cit274"><name name-style="western"><surname>Zigterman</surname><given-names>J. W.</given-names></name>; <name name-style="western"><surname>van Dam</surname><given-names>J. E.</given-names></name>; <name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Rotteveel</surname><given-names>F. T.</given-names></name>; <name name-style="western"><surname>Jansze</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Willers</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Kamerling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Vliegenthart</surname><given-names>J. F.</given-names></name><article-title>Immunogenic properties of octasaccharide-protein conjugates
derived from <italic toggle="yes">Klebsiella</italic> serotype 11 capsular polysaccharide</article-title>. <source>Infect. Immunol.</source><year>1985</year>, <volume>47</volume>, <fpage>421</fpage>&#8211;<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1128/iai.47.2.421-428.1985</pub-id>.<pub-id pub-id-type="pmid">3881349</pub-id><pub-id pub-id-type="pmcid">PMC263186</pub-id></mixed-citation></ref><ref id="ref275"><mixed-citation publication-type="journal" id="cit275"><name name-style="western"><surname>Feldman</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Mayer Bridwell</surname><given-names>A. E.</given-names></name>; <name name-style="western"><surname>Scott</surname><given-names>N. E.</given-names></name>; <name name-style="western"><surname>Vinogradov</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>McKee</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Chavez</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Twentyman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Stallings</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Rosen</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Harding</surname><given-names>C. M.</given-names></name><article-title>A promising bioconjugate
vaccine against hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2019</year>, <volume>116</volume>, <fpage>18655</fpage>&#8211;<lpage>18663</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1907833116</pub-id>.<pub-id pub-id-type="pmid">31455739</pub-id><pub-id pub-id-type="pmcid">PMC6744904</pub-id></mixed-citation></ref><ref id="ref276"><mixed-citation publication-type="journal" id="cit276"><name name-style="western"><surname>Ravinder</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Liao</surname><given-names>K. S.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>Y. Y.</given-names></name>; <name name-style="western"><surname>Pawar</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>C. Y.</given-names></name><article-title>A synthetic
carbohydrate-protein
conjugate vaccine candidate against <italic toggle="yes">Klebsiella pneumoniae</italic> serotype K2</article-title>. <source>J. Org. Chem.</source><year>2020</year>, <volume>85</volume>, <fpage>15964</fpage>&#8211;<lpage>15997</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.0c01404</pub-id>.<pub-id pub-id-type="pmid">33108196</pub-id></mixed-citation></ref><ref id="ref277"><mixed-citation publication-type="journal" id="cit277"><person-group person-group-type="allauthors"><name name-style="western"><surname>Satlin</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Patel</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Gomez-Simmonds</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Weston</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Seo</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Rosenthal</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Sperber</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Jenkins</surname><given-names>S. G.</given-names></name></person-group>; <etal/><article-title>Multicenter
clinical and molecular epidemiological analysis of bacteremia due
to Carbapenem-Resistant <italic toggle="yes">Enterobacteriaceae</italic> (CRE)
in the CRE epicenter of the United States</article-title>. <source>Antimicrob. Agents Chemother.</source><year>2017</year>, <volume>61</volume>, AAC.02349-16.<pub-id pub-id-type="doi">10.1128/AAC.02349-16</pub-id><pub-id pub-id-type="pmcid">PMC5365653</pub-id><pub-id pub-id-type="pmid">28167547</pub-id></mixed-citation></ref><ref id="ref278"><mixed-citation publication-type="journal" id="cit278"><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Diago-Navarro</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Reppe</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Opitz</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Fries</surname><given-names>B. C.</given-names></name>; <name name-style="western"><surname>Witzenrath</surname><given-names>M.</given-names></name><article-title>A semi-synthetic
glycoconjugate vaccine candidate for
carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><year>2017</year>, <volume>56</volume>, <fpage>13973</fpage>&#8211;<lpage>13978</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201700964</pub-id>.<pub-id pub-id-type="pmid">28815890</pub-id><pub-id pub-id-type="pmcid">PMC5819008</pub-id></mixed-citation></ref><ref id="ref279"><mixed-citation publication-type="journal" id="cit279"><name name-style="western"><surname>Diago-Navarro</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Motley</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Ruiz-Per&#233;z</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Austin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Seco</surname><given-names>B. M. S.</given-names></name>; <name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Chikhalya</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Fries</surname><given-names>B. C.</given-names></name><article-title>Novel, Broadly reactive anticapsular
antibodies against carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> protect from infection</article-title>. <source>mBio</source><year>2018</year>, <volume>9</volume>, <elocation-id>e00091</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00091-18</pub-id>.<pub-id pub-id-type="pmid">29615497</pub-id><pub-id pub-id-type="pmcid">PMC5885035</pub-id></mixed-citation></ref><ref id="ref280"><mixed-citation publication-type="journal" id="cit280"><name name-style="western"><surname>Follador</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Heinz</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Wyres</surname><given-names>K. L.</given-names></name>; <name name-style="western"><surname>Ellington</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Kowarik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Holt</surname><given-names>K. E.</given-names></name>; <name name-style="western"><surname>Thomson</surname><given-names>N. R.</given-names></name><article-title>The diversity
of <italic toggle="yes">Klebsiella pneumoniae</italic> surface polysaccharides</article-title>. <source>Microb. Genom.</source><year>2016</year>, <volume>2</volume>, <elocation-id>e000073</elocation-id><pub-id pub-id-type="doi">10.1099/mgen.0.000073</pub-id>.<pub-id pub-id-type="pmid">28348868</pub-id><pub-id pub-id-type="pmcid">PMC5320592</pub-id></mixed-citation></ref><ref id="ref281"><mixed-citation publication-type="journal" id="cit281"><name name-style="western"><surname>Clarke</surname><given-names>B. R.</given-names></name>; <name name-style="western"><surname>Ovchinnikova</surname><given-names>O. G.</given-names></name>; <name name-style="western"><surname>Kelly</surname><given-names>S. D.</given-names></name>; <name name-style="western"><surname>Williamson</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Butler</surname><given-names>J. E.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Gou</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Follador</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lowary</surname><given-names>T. L.</given-names></name>; et al. <article-title>Molecular basis for
the structural diversity in serogroup O2-antigen polysaccharides in <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>J. Biol. Chem.</source><year>2018</year>, <volume>293</volume>, <fpage>4666</fpage>&#8211;<lpage>4679</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA117.000646</pub-id>.<pub-id pub-id-type="pmid">29602878</pub-id><pub-id pub-id-type="pmcid">PMC5880124</pub-id></mixed-citation></ref><ref id="ref282"><mixed-citation publication-type="journal" id="cit282"><name name-style="western"><surname>Clements</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Jenney</surname><given-names>A. W.</given-names></name>; <name name-style="western"><surname>Farn</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Brown</surname><given-names>L. E.</given-names></name>; <name name-style="western"><surname>Deliyannis</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Hartland</surname><given-names>E. L.</given-names></name>; <name name-style="western"><surname>Pearse</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Maloney</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Wesselingh</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Wijburg</surname><given-names>O. L.</given-names></name>; et al. <article-title>Targeting
subcapsular
antigens for prevention of <italic toggle="yes">Klebsiella pneumoniae</italic> infections</article-title>. <source>Vaccine</source><year>2008</year>, <volume>26</volume>, <fpage>5649</fpage>&#8211;<lpage>5653</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.100</pub-id>.<pub-id pub-id-type="pmid">18725260</pub-id></mixed-citation></ref><ref id="ref283"><mixed-citation publication-type="journal" id="cit283"><name name-style="western"><surname>Chhibber</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rani</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Vanashree</surname><given-names>Y.</given-names></name><article-title>Immunoprotective
potential of polysaccharide-tetanus toxoid conjugate in <italic toggle="yes">Klebsiella
pneumoniae</italic> induced lobar pneumonia in rats</article-title>. <source>Indian J. Exp. Biol.</source><year>2005</year>, <volume>43</volume>, <fpage>40</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">15691064</pub-id></mixed-citation></ref><ref id="ref284"><mixed-citation publication-type="journal" id="cit284"><name name-style="western"><surname>Hegerle</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sinclair</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Amin</surname><given-names>M. N.</given-names></name>; <name name-style="western"><surname>Ollivault-Shiflett</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Curtis</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Laufer</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Shridhar</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Brammer</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Toapanta</surname><given-names>F. R.</given-names></name>; et al. <article-title>Development of a broad
spectrum glycoconjugate vaccine to prevent wound and disseminated
infections with <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>PLoS One</source><year>2018</year>, <volume>13</volume>, <elocation-id>e0203143</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0203143</pub-id>.<pub-id pub-id-type="pmid">30188914</pub-id><pub-id pub-id-type="pmcid">PMC6126813</pub-id></mixed-citation></ref><ref id="ref427"><mixed-citation publication-type="journal" id="cit427"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Ning</surname><given-names>J.</given-names></name><article-title>First synthesis
of
&#946;-d-Galf-(1&#8594;3)-d-Galp&#8212;the repeating unit of the
backbone structure of the O-antigenic polysaccharide present in the
lipopolysaccharide (LPS) of the genus Klebsiella</article-title>. <source>Carbohydr. Res.</source><year>2003</year>, <volume>338</volume>, <fpage>1033</fpage>&#8211;<lpage>1037</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(03)00076-4</pub-id>.<pub-id pub-id-type="pmid">12706968</pub-id></mixed-citation></ref><ref id="ref285"><mixed-citation publication-type="journal" id="cit285"><name name-style="western"><surname>Zhu</surname><given-names>S.-Y.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>J.-S.</given-names></name><article-title>Synthesis of tetra- and hexasaccharide
fragments corresponding to the O-antigenic polysaccharide of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Tetrahedron</source><year>2012</year>, <volume>68</volume>, <fpage>3795</fpage>&#8211;<lpage>3801</lpage>. <pub-id pub-id-type="doi">10.1016/j.tet.2012.03.074</pub-id>.</mixed-citation></ref><ref id="ref286"><mixed-citation publication-type="journal" id="cit286"><name name-style="western"><surname>Verkhnyatskaya</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Pyranoside-into-furanoside
rearrangement of 4-pentenyl glycosides in the synthesis of a tetrasaccharide-related
to Galactan I of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Eur. J. Org. Chem.</source><year>2017</year>, <volume>3</volume>, <fpage>710</fpage>&#8211;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1002/ejoc.201601413</pub-id>.</mixed-citation></ref><ref id="ref287"><mixed-citation publication-type="journal" id="cit287"><name name-style="western"><surname>Argunov</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Trostianetskaia</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Kurbatova</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Convergent synthesis of oligosaccharides structurally
related to Galactan I and Galactan II of <italic toggle="yes">Klebsiella pneumoniae</italic> and their use in screening of antibody specificity</article-title>. <source>Eur. J. Org. Chem.</source><year>2019</year>, <volume>2019</volume> (<issue>26</issue>), <fpage>4226</fpage>&#8211;<lpage>4232</lpage>. <pub-id pub-id-type="doi">10.1002/ejoc.201900389</pub-id>.</mixed-citation></ref><ref id="ref288"><mixed-citation publication-type="patent" id="cit288"><person-group person-group-type="allauthors"><name name-style="western"><surname>Parameswarappa</surname><given-names>S. G.-h.</given-names></name>; <name name-style="western"><surname>Lisboa</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Ciestreich</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pryzigodda</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Monnanda</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name></person-group><article-title>Vaccine against <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. Int. Patent Appl. WO <patent>2019/106201</patent> A1, <year>2019</year>.</mixed-citation></ref><ref id="ref289"><mixed-citation publication-type="journal" id="cit289"><name name-style="western"><surname>Unemo</surname><given-names>M.</given-names></name><article-title>Current and future antimicrobial
treatment of gonorrhoea - the rapidly
evolving <italic toggle="yes">Neisseria gonorrhoeae</italic> continues to challenge</article-title>. <source>BMC Infect. Dis.</source><year>2015</year>, <volume>15</volume>, <fpage>364</fpage><pub-id pub-id-type="doi">10.1186/s12879-015-1029-2</pub-id>.<pub-id pub-id-type="pmid">26293005</pub-id><pub-id pub-id-type="pmcid">PMC4546108</pub-id></mixed-citation></ref><ref id="ref290"><mixed-citation publication-type="journal" id="cit290"><name name-style="western"><surname>Quillin</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Seifert</surname><given-names>H. S.</given-names></name><article-title><italic toggle="yes">Neisseria gonorrhoeae</italic> host adaptation
and pathogenesis</article-title>. <source>Nat. Rev.
Microbiol.</source><year>2018</year>, <volume>16</volume>, <fpage>226</fpage>&#8211;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2017.169</pub-id>.<pub-id pub-id-type="pmid">29430011</pub-id><pub-id pub-id-type="pmcid">PMC6329377</pub-id></mixed-citation></ref><ref id="ref291"><mixed-citation publication-type="journal" id="cit291"><name name-style="western"><surname>Semchenko</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Borrow</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Seib</surname><given-names>K. L.</given-names></name><article-title>The serogroup
B meningococcal vaccine Bexsero elicits antibodies to <italic toggle="yes">Neisseria
gonorrhoeae</italic></article-title>. <source>Clin. Infect. Dis.</source><year>2019</year>, <volume>69</volume>, <fpage>1101</fpage>&#8211;<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy1061</pub-id>.<pub-id pub-id-type="pmid">30551148</pub-id><pub-id pub-id-type="pmcid">PMC6743822</pub-id></mixed-citation></ref><ref id="ref292"><mixed-citation publication-type="journal" id="cit292"><name name-style="western"><surname>Hill</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Masters</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Wachter</surname><given-names>J.</given-names></name><article-title>Gonorrhea
- an evolving
disease of the new millennium</article-title>. <source>Microbial. Cell.
(Graz, Austria)</source><year>2016</year>, <volume>3</volume>, <fpage>371</fpage>&#8211;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.15698/mic2016.09.524</pub-id>.<pub-id pub-id-type="pmcid">PMC5354566</pub-id><pub-id pub-id-type="pmid">28357376</pub-id></mixed-citation></ref><ref id="ref293"><mixed-citation publication-type="journal" id="cit293"><name name-style="western"><surname>Gulati</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Shaughnessy</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rice</surname><given-names>P. A.</given-names></name><article-title>Targeting
lipooligosaccharide (LOS) for a gonococcal vaccine</article-title>. <source>Front. Immunol.</source><year>2019</year>, <volume>10</volume>, <fpage>321</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00321</pub-id>.<pub-id pub-id-type="pmid">30873172</pub-id><pub-id pub-id-type="pmcid">PMC6400993</pub-id></mixed-citation></ref><ref id="ref294"><mixed-citation publication-type="journal" id="cit294"><name name-style="western"><surname>Gulati</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Reed</surname><given-names>G. W.</given-names></name>; <name name-style="western"><surname>Su</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Cox</surname><given-names>A. D.</given-names></name>; <name name-style="western"><surname>St. Michael</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Stupak</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lewis</surname><given-names>L. A.</given-names></name>; <name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rice</surname><given-names>P. A.</given-names></name><article-title>Immunization against a saccharide epitope accelerates
clearance of experimental gonococcal infection</article-title>. <source>PLoS Pathogens</source><year>2013</year>, <volume>9</volume>, <elocation-id>e1003559</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003559</pub-id>.<pub-id pub-id-type="pmid">24009500</pub-id><pub-id pub-id-type="pmcid">PMC3757034</pub-id></mixed-citation></ref><ref id="ref295"><mixed-citation publication-type="journal" id="cit295"><name name-style="western"><surname>Mandrell</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Schneider</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Apicella</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zollinger</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Rice</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Griffiss</surname><given-names>J. M.</given-names></name><article-title>Antigenic and physical diversity
of Neisseria gonorrhoeae lipooligosaccharides</article-title>. <source>Infect. Immun.</source><year>1986</year>, <volume>54</volume>, <fpage>63</fpage>&#8211;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1128/iai.54.1.63-69.1986</pub-id>.<pub-id pub-id-type="pmid">2428752</pub-id><pub-id pub-id-type="pmcid">PMC260117</pub-id></mixed-citation></ref><ref id="ref296"><mixed-citation publication-type="journal" id="cit296"><name name-style="western"><surname>Gulati</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>McQuillen</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Mandrell</surname><given-names>R. E.</given-names></name>; <name name-style="western"><surname>Jani</surname><given-names>D. B.</given-names></name>; <name name-style="western"><surname>Rice</surname><given-names>P. A.</given-names></name><article-title>Immunogenicity of <italic toggle="yes">Neisseria gonorrhoeae</italic> lipooligosaccharide epitope 2C7, widely expressed in vivo with no
immunochemical similarity to human glycosphingolipids</article-title>. <source>J. Infect. Dis.</source><year>1996</year>, <volume>174</volume>, <fpage>1223</fpage>&#8211;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/174.6.1223</pub-id>.<pub-id pub-id-type="pmid">8940213</pub-id></mixed-citation></ref><ref id="ref297"><mixed-citation publication-type="journal" id="cit297"><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Krause</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name><article-title>Recent developments
for <italic toggle="yes">Pseudomonas</italic> vaccines</article-title>. <source>Hum.
Vaccines</source><year>2011</year>, <volume>7</volume>, <fpage>999</fpage>&#8211;<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.4161/hv.7.10.16369</pub-id>.<pub-id pub-id-type="pmcid">PMC3360073</pub-id><pub-id pub-id-type="pmid">21941090</pub-id></mixed-citation></ref><ref id="ref298"><mixed-citation publication-type="journal" id="cit298"><name name-style="western"><surname>Klompas</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Kleinman</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Evans</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Lloyd</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Stevenson</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Samore</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Platt</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Program</surname><given-names>C. D. C. P. E.</given-names></name><article-title>Multicenter evaluation of a novel surveillance paradigm
for complications of mechanical ventilation</article-title>. <source>PLoS One</source><year>2011</year>, <volume>6</volume>, <elocation-id>e18062</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018062</pub-id>.<pub-id pub-id-type="pmid">21445364</pub-id><pub-id pub-id-type="pmcid">PMC3062570</pub-id></mixed-citation></ref><ref id="ref299"><mixed-citation publication-type="journal" id="cit299"><name name-style="western"><surname>Sandiumenge</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><article-title>Ventilator-associated pneumonia caused
by ESKAPE organisms: cause, clinical features, and management</article-title>. <source>Curr. Opin. Pulm. Med.</source><year>2012</year>, <volume>18</volume>, <fpage>187</fpage>&#8211;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1097/MCP.0b013e328351f974</pub-id>.<pub-id pub-id-type="pmid">22366995</pub-id></mixed-citation></ref><ref id="ref300"><mixed-citation publication-type="journal" id="cit300"><name name-style="western"><surname>Veesenmeyer</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Hauser</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Lisboa</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><article-title>Pseudomonas
aeruginosa virulence and therapy: evolving translational strategies</article-title>. <source>Crit. Care. Med.</source><year>2009</year>, <volume>37</volume>, <fpage>1777</fpage>&#8211;<lpage>1786</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e31819ff137</pub-id>.<pub-id pub-id-type="pmid">19325463</pub-id><pub-id pub-id-type="pmcid">PMC2749241</pub-id></mixed-citation></ref><ref id="ref301"><mixed-citation publication-type="journal" id="cit301"><name name-style="western"><surname>Talbot</surname><given-names>G. H.</given-names></name>; <name name-style="western"><surname>Bradley</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>J. E. J.</given-names></name>; <name name-style="western"><surname>Gilbert</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Scheld</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Bartlett</surname><given-names>J. G.</given-names></name><article-title>Bad bugs need drugs: an update on
the development pipeline from the antimicrobial availability task
force of the Infectious Diseases Society of America</article-title>. <source>Clin. Infect. Dis.</source><year>2006</year>, <volume>42</volume>, <fpage>657</fpage>&#8211;<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1086/499819</pub-id>.<pub-id pub-id-type="pmid">16447111</pub-id></mixed-citation></ref><ref id="ref302"><mixed-citation publication-type="journal" id="cit302"><name name-style="western"><surname>Jennings</surname><given-names>L. K.</given-names></name>; <name name-style="western"><surname>Storek</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Ledvina</surname><given-names>H. E.</given-names></name>; <name name-style="western"><surname>Coulon</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Marmont</surname><given-names>L. S.</given-names></name>; <name name-style="western"><surname>Sadovskaya</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Secor</surname><given-names>P. R.</given-names></name>; <name name-style="western"><surname>Tseng</surname><given-names>B. S.</given-names></name>; <name name-style="western"><surname>Scian</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Filloux</surname><given-names>A.</given-names></name>; et al. <article-title>Pel is a cationic exopolysaccharide
that cross-links extracellular DNA in the <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm matrix</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2015</year>, <volume>112</volume>, <fpage>11353</fpage>&#8211;<lpage>11358</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1503058112</pub-id>.<pub-id pub-id-type="pmid">26311845</pub-id><pub-id pub-id-type="pmcid">PMC4568648</pub-id></mixed-citation></ref><ref id="ref303"><mixed-citation publication-type="journal" id="cit303"><name name-style="western"><surname>Cryz</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Sadojr</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Cross</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Furer</surname><given-names>E.</given-names></name><article-title>Safety and
Immunogenicity of a polyvalent <italic toggle="yes">Pseudomonas aeruginosa</italic> O-polysaccharide Toxin A vaccine in humans</article-title>. <source>Antibiot. Chemother.</source><year>1989</year>, <volume>42</volume>, <fpage>177</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1159/000417618</pub-id>.<pub-id pub-id-type="pmid">2512836</pub-id></mixed-citation></ref><ref id="ref304"><mixed-citation publication-type="journal" id="cit304"><name name-style="western"><surname>Cryz</surname><given-names>S. J. J.</given-names></name>; <name name-style="western"><surname>Wedgwood</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lang</surname><given-names>A. B.</given-names></name>; <name name-style="western"><surname>Ruedeberg</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Que</surname><given-names>J. U.</given-names></name>; <name name-style="western"><surname>Furer</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Schaad</surname><given-names>U. B.</given-names></name><article-title>Immunization of
noncolonized cystic fibrosis patients against <italic toggle="yes">Pseudomonas
aeruginosa</italic></article-title>. <source>J. Infect. Dis.</source><year>1994</year>, <volume>169</volume>, <fpage>1159</fpage>&#8211;<lpage>1162</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/169.5.1159</pub-id>.<pub-id pub-id-type="pmid">8169414</pub-id></mixed-citation></ref><ref id="ref305"><mixed-citation publication-type="journal" id="cit305"><name name-style="western"><surname>Schaad</surname><given-names>U.B</given-names></name>; <name name-style="western"><surname>Wedgwood</surname><given-names>J</given-names></name>; <name name-style="western"><surname>Ruedeberg</surname><given-names>A</given-names></name>; <name name-style="western"><surname>Lang</surname><given-names>A.B</given-names></name>; <name name-style="western"><surname>Que</surname><given-names>J.U</given-names></name>; <name name-style="western"><surname>Furer</surname><given-names>E</given-names></name>; <name name-style="western"><surname>Cryz</surname><given-names>S.J</given-names></name><article-title>Safety and
immunogenicity of <italic toggle="yes">Pseudomonas aeruginosa</italic> conjugate
A vaccine in cystic fibrosis</article-title>. <source>Lancet</source><year>1991</year>, <volume>338</volume>, <fpage>1236</fpage>&#8211;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)92103-9</pub-id>.<pub-id pub-id-type="pmid">1682645</pub-id></mixed-citation></ref><ref id="ref306"><mixed-citation publication-type="journal" id="cit306"><name name-style="western"><surname>Lang</surname><given-names>A. B.</given-names></name>; <name name-style="western"><surname>R&#252;deberg</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sch&#246;ni</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Que</surname><given-names>J. U.</given-names></name>; <name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Schaad</surname><given-names>U. B.</given-names></name><article-title>Vaccination of cystic
fibrosis patients against <italic toggle="yes">Pseudomonas aeruginosa</italic> reduces
the proportion of patients infected and delays time to infection</article-title>. <source>Pediatr. Infect. Dis. J.</source><year>2004</year>, <volume>23</volume>, <fpage>504</fpage>&#8211;<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1097/01.inf.0000129688.50588.ac</pub-id>.<pub-id pub-id-type="pmid">15194830</pub-id></mixed-citation></ref><ref id="ref307"><mixed-citation publication-type="weblink" id="cit307"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.biospace.com/News/crucell-n-v-announces-suspension-of-aerugenr/24447">http://www.biospace.com/News/crucell-n-v-announces-suspension-of-aerugenr/24447</uri>.</mixed-citation></ref><ref id="ref308"><mixed-citation publication-type="journal" id="cit308"><name name-style="western"><surname>Wells</surname><given-names>T. J.</given-names></name>; <name name-style="western"><surname>Whitters</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Sevastsyanovich</surname><given-names>Y. R.</given-names></name>; <name name-style="western"><surname>Heath</surname><given-names>J. N.</given-names></name>; <name name-style="western"><surname>Pravin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Goodall</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Browning</surname><given-names>D. F.</given-names></name>; <name name-style="western"><surname>O&#8217;Shea</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Cranston</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>De Soyza</surname><given-names>A.</given-names></name>; et al. <article-title>Increased
severity of respiratory infections associated with elevated anti-LPS
IgG2 which inhibits serum bactericidal killing</article-title>. <source>J. Exp. Med.</source><year>2014</year>, <volume>211</volume>, <fpage>1893</fpage>&#8211;<lpage>1904</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20132444</pub-id>.<pub-id pub-id-type="pmid">25113975</pub-id><pub-id pub-id-type="pmcid">PMC4144740</pub-id></mixed-citation></ref><ref id="ref309"><mixed-citation publication-type="journal" id="cit309"><name name-style="western"><surname>Rocchetta</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Lam</surname><given-names>J. S.</given-names></name><article-title>Identification and functional characterization
of an ABC transport system involved in polysaccharide export of A-band
lipopolysaccharide in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>J. Bacteriol.</source><year>1997</year>, <volume>179</volume>, <fpage>4713</fpage>&#8211;<lpage>4724</lpage>. <pub-id pub-id-type="doi">10.1128/jb.179.15.4713-4724.1997</pub-id>.<pub-id pub-id-type="pmid">9244257</pub-id><pub-id pub-id-type="pmcid">PMC179316</pub-id></mixed-citation></ref><ref id="ref310"><mixed-citation publication-type="journal" id="cit310"><name name-style="western"><surname>Chaudhury</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Maity</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Ghosh</surname><given-names>R.</given-names></name><article-title>Efficient
routes toward
the synthesis of the D-rhamno-trisaccharide related to the A-band
polysaccharide of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Beilstein J. Org. Chem.</source><year>2014</year>, <volume>10</volume>, <fpage>1488</fpage>&#8211;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.3762/bjoc.10.153</pub-id>.<pub-id pub-id-type="pmid">25161705</pub-id><pub-id pub-id-type="pmcid">PMC4142843</pub-id></mixed-citation></ref><ref id="ref311"><mixed-citation publication-type="journal" id="cit311"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wei</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Andolina</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><article-title>Total Synthesis
of <italic toggle="yes">Pseudomonas aeruginosa</italic> 1244 pilin glycan via de
novo synthesis of Pseudaminic Acid</article-title>. <source>J. Am. Chem.
Soc.</source><year>2017</year>, <volume>139</volume>, <fpage>13420</fpage>&#8211;<lpage>13428</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.7b06055</pub-id>.<pub-id pub-id-type="pmid">28837324</pub-id></mixed-citation></ref><ref id="ref312"><mixed-citation publication-type="journal" id="cit312"><name name-style="western"><surname>Behera</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rai</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kulkarni</surname><given-names>S. S.</given-names></name><article-title>Total syntheses
of conjugation-ready trisaccharide repeating units of <italic toggle="yes">Pseudomonas
aeruginosa</italic> O11 and <italic toggle="yes">Staphylococcus aureus</italic> type 5 capsular polysaccharide for vaccine development</article-title>. <source>J. Am. Chem. Soc.</source><year>2020</year>, <volume>142</volume>, <fpage>456</fpage>&#8211;<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b11309</pub-id>.<pub-id pub-id-type="pmid">31815459</pub-id></mixed-citation></ref><ref id="ref313"><mixed-citation publication-type="journal" id="cit313"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Jackson</surname><given-names>K. D.</given-names></name>; <name name-style="western"><surname>Landry</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Parsek</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Wozniak</surname><given-names>D. J.</given-names></name><article-title>Analysis
of <italic toggle="yes">Pseudomonas aeruginosa</italic> conditional Psl variants
reveals roles for the Psl polysaccharide in adhesion and maintaining
biofilm structure postattachment</article-title>. <source>J. Bacteriol.</source><year>2006</year>, <volume>188</volume>, <fpage>8213</fpage>&#8211;<lpage>8221</lpage>. <pub-id pub-id-type="doi">10.1128/JB.01202-06</pub-id>.<pub-id pub-id-type="pmid">16980452</pub-id><pub-id pub-id-type="pmcid">PMC1698210</pub-id></mixed-citation></ref><ref id="ref314"><mixed-citation publication-type="journal" id="cit314"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Sprinkle</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Parsek</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Wozniak</surname><given-names>D. J.</given-names></name><article-title>Pseudomonas
aeruginosa Psl is a galactose- and mannose-rich exopolysaccharide</article-title>. <source>J. Bacteriol.</source><year>2007</year>, <volume>189</volume>, <fpage>8353</fpage>&#8211;<lpage>8356</lpage>. <pub-id pub-id-type="doi">10.1128/JB.00620-07</pub-id>.<pub-id pub-id-type="pmid">17631634</pub-id><pub-id pub-id-type="pmcid">PMC2168683</pub-id></mixed-citation></ref><ref id="ref315"><mixed-citation publication-type="journal" id="cit315"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Parsek</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Wozniak</surname><given-names>D. J.</given-names></name><article-title>The roles
of biofilm matrix polysaccharide Psl in mucoid <italic toggle="yes">Pseudomonas
aeruginosa</italic> biofilms</article-title>. <source>FEMS Immunol.
Med. Microbiol.</source><year>2012</year>, <volume>65</volume>, <fpage>377</fpage>&#8211;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00934.x</pub-id>.<pub-id pub-id-type="pmid">22309106</pub-id></mixed-citation></ref><ref id="ref316"><mixed-citation publication-type="journal" id="cit316"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Mo</surname><given-names>K. F.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Stover</surname><given-names>C. K.</given-names></name>; <name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Boons</surname><given-names>G. J.</given-names></name><article-title>Epitope mapping
of monoclonal antibodies using synthetic
oligosaccharides uncovers novel aspects of immune recognition of the
Psl exopolysaccharide of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Chem.&#8212;Eur. J.</source><year>2013</year>, <volume>19</volume>, <fpage>17425</fpage>&#8211;<lpage>17431</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201302916</pub-id>.<pub-id pub-id-type="pmid">24248772</pub-id></mixed-citation></ref><ref id="ref317"><mixed-citation publication-type="journal" id="cit317"><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Warrener</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Hamilton</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Guillard</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Ravn</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Minter</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Camara</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Venkatraman</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Macgill</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name>; et al. <article-title>Identification of broadly
protective human antibodies to <italic toggle="yes">Pseudomonas aeruginosa</italic> exopolysaccharide Psl by phenotypic screening</article-title>. <source>J. Exp. Med.</source><year>2012</year>, <volume>209</volume>, <fpage>1273</fpage>&#8211;<lpage>1287</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20120033</pub-id>.<pub-id pub-id-type="pmid">22734046</pub-id><pub-id pub-id-type="pmcid">PMC3405507</pub-id></mixed-citation></ref><ref id="ref318"><mixed-citation publication-type="journal" id="cit318"><name name-style="western"><surname>Andrews</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Baker</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Marks</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Alsan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Garrett</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Gellin</surname><given-names>B. G.</given-names></name>; <name name-style="western"><surname>Saha</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Qamar</surname><given-names>F. N.</given-names></name>; <name name-style="western"><surname>Yousafzai</surname><given-names>M. T.</given-names></name>; <name name-style="western"><surname>Bogoch</surname><given-names>I. I.</given-names></name>; et al. <article-title>Typhoid conjugate vaccines:
a new tool in the fight against antimicrobial resistance</article-title>. <source>Lancet Infect. Dis.</source><year>2019</year>, <volume>19</volume>, <fpage>e26</fpage>&#8211;<lpage>e30</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30350-5</pub-id>.<pub-id pub-id-type="pmid">30170987</pub-id></mixed-citation></ref><ref id="ref319"><mixed-citation publication-type="journal" id="cit319"><name name-style="western"><surname>MacLennan</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>L. B.</given-names></name>; <name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name><article-title>Vaccines against invasive <italic toggle="yes">Salmonella</italic> disease: current status and future directions</article-title>. <source>Hum. Vaccin. Immunother.</source><year>2014</year>, <volume>10</volume>, <fpage>1478</fpage>&#8211;<lpage>1493</lpage>. <pub-id pub-id-type="doi">10.4161/hv.29054</pub-id>.<pub-id pub-id-type="pmid">24804797</pub-id><pub-id pub-id-type="pmcid">PMC4185946</pub-id></mixed-citation></ref><ref id="ref320"><mixed-citation publication-type="journal" id="cit320"><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hulme</surname><given-names>J. P.</given-names></name><article-title>Recent advances
in the detection of antibiotic and
multi-drug resistant <italic toggle="yes">Salmonella</italic>: an update</article-title>. <source>Int. J. Mol. Sci.</source><year>2021</year>, <volume>22</volume>, <fpage>3499</fpage><pub-id pub-id-type="doi">10.3390/ijms22073499</pub-id>.<pub-id pub-id-type="pmid">33800682</pub-id><pub-id pub-id-type="pmcid">PMC8037659</pub-id></mixed-citation></ref><ref id="ref321"><mixed-citation publication-type="journal" id="cit321"><name name-style="western"><surname>Parry</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Thieu</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Dolecek</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Karkey</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Turner</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Dance</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Maude</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Ha</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Tran</surname><given-names>C.</given-names></name>; et al. <article-title>Clinically and microbiologically derived azithromycin
susceptibility breakpoints for <italic toggle="yes">Salmonella enterica</italic> serovars Typhi and Paratyphi A</article-title>. <source>Antimicrob.
Agents Chemother.</source><year>2015</year>, <volume>59</volume>, <fpage>2756</fpage>&#8211;<lpage>2764</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.04729-14</pub-id>.<pub-id pub-id-type="pmid">25733500</pub-id><pub-id pub-id-type="pmcid">PMC4394775</pub-id></mixed-citation></ref><ref id="ref322"><mixed-citation publication-type="journal" id="cit322"><name name-style="western"><surname>Khan</surname><given-names>M. I.</given-names></name>; <name name-style="western"><surname>Ochiai</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Clemens</surname><given-names>J. D.</given-names></name><article-title>Population impact
of Vi capsular polysaccharide vaccine</article-title>. <source>Expert
Rev. Vaccines</source><year>2010</year>, <volume>9</volume>, <fpage>485</fpage>&#8211;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1586/erv.10.43</pub-id>.<pub-id pub-id-type="pmid">20450323</pub-id></mixed-citation></ref><ref id="ref323"><mixed-citation publication-type="journal" id="cit323"><name name-style="western"><surname>Engels</surname><given-names>E.
A.</given-names></name>; <name name-style="western"><surname>Falagas</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bennish</surname><given-names>M. L.</given-names></name><article-title>Typhoid
fever vaccines: a meta-analysis of studies on efficacy and toxicity</article-title>. <source>BMJ.</source><year>1998</year>, <volume>316</volume>, <fpage>110</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.316.7125.110</pub-id>.<pub-id pub-id-type="pmid">9462316</pub-id><pub-id pub-id-type="pmcid">PMC2665386</pub-id></mixed-citation></ref><ref id="ref324"><mixed-citation publication-type="journal" id="cit324"><name name-style="western"><surname>Syed</surname><given-names>K. A.</given-names></name>; <name name-style="western"><surname>Saluja</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Hsiao</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Shaikh</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Wartel</surname><given-names>T. A.</given-names></name>; <name name-style="western"><surname>Mogasale</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Lynch</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name>; <name name-style="western"><surname>Excler</surname><given-names>J. L.</given-names></name>; et al. <article-title>Review on the recent
advances on Typhoid vaccine development and challenges ahead</article-title>. <source>Clin. Infect. Dis.</source><year>2020</year>, <volume>71</volume>, <fpage>S141</fpage>&#8211;<lpage>S150</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa504</pub-id>.<pub-id pub-id-type="pmid">32725225</pub-id><pub-id pub-id-type="pmcid">PMC7388714</pub-id></mixed-citation></ref><ref id="ref325"><mixed-citation publication-type="journal" id="cit325"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Knirel</surname><given-names>Y. A.</given-names></name>; <name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Perepelov</surname><given-names>A. V.</given-names></name>; <name name-style="western"><surname>Senchenkova</surname><given-names>S. y. N.</given-names></name>; <name name-style="western"><surname>Reeves</surname><given-names>P. R.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><article-title>Structural diversity
in <italic toggle="yes">Salmonella</italic> O-antigens and its genetic basis</article-title>. <source>FEMS Microbiol. Rev.</source><year>2014</year>, <volume>38</volume>, <fpage>56</fpage>&#8211;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1111/1574-6976.12034</pub-id>.<pub-id pub-id-type="pmid">23848592</pub-id></mixed-citation></ref><ref id="ref326"><mixed-citation publication-type="journal" id="cit326"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Zheng</surname><given-names>X. J.</given-names></name>; <name name-style="western"><surname>Tai</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Ye</surname><given-names>X. S.</given-names></name><article-title>A highly alpha-stereoselective synthesis of oligosaccharide fragments
of the Vi antigen from <italic toggle="yes">Salmonella</italic> typhi and their
antigenic activities</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2011</year>, <volume>17</volume>, <fpage>14518</fpage>&#8211;<lpage>14526</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201102615</pub-id>.<pub-id pub-id-type="pmid">22095754</pub-id></mixed-citation></ref><ref id="ref327"><mixed-citation publication-type="journal" id="cit327"><name name-style="western"><surname>Kiow Shi-Shun</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Mallet</surname><given-names>J.-M.</given-names></name>; <name name-style="western"><surname>Moreau</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sina&#255;</surname><given-names>P.</given-names></name><article-title>Synth&#232;se
d&#8217;oligom&#232;res du polysaccharide capsulaire de <italic toggle="yes">Salmonella</italic> typhi, bact&#233;rie &#224; l&#8217;origine
de la fi&#232;vre typho&#239;de</article-title>. <source>Tetrahedron</source><year>1999</year>, <volume>55</volume>, <fpage>14043</fpage>&#8211;<lpage>14068</lpage>. <pub-id pub-id-type="doi">10.1016/S0040-4020(99)00869-8</pub-id>.</mixed-citation></ref><ref id="ref328"><mixed-citation publication-type="journal" id="cit328"><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Taylor</surname><given-names>A.</given-names></name><article-title>Immunochemical properties
of Vi antigen
from <italic toggle="yes">Salmonella</italic> typhi Ty2: presence of two antigenic
determinants</article-title>. <source>Infect. Immun.</source><year>1980</year>, <volume>29</volume>, <fpage>539</fpage>&#8211;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1128/iai.29.2.539-544.1980</pub-id>.<pub-id pub-id-type="pmid">6163712</pub-id><pub-id pub-id-type="pmcid">PMC551152</pub-id></mixed-citation></ref><ref id="ref329"><mixed-citation publication-type="journal" id="cit329"><name name-style="western"><surname>Zhang</surname><given-names>G.-L.</given-names></name>; <name name-style="western"><surname>Wei</surname><given-names>M.-M.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>Y.-F.</given-names></name>; <name name-style="western"><surname>Zheng</surname><given-names>X.-J.</given-names></name>; <name name-style="western"><surname>Xiong</surname><given-names>D.-C.</given-names></name>; <name name-style="western"><surname>Ye</surname><given-names>X.-S.</given-names></name><article-title>Chemical
synthesis
and biological evaluation of penta- to octa- saccharide fragments
of Vi polysaccharide from <italic toggle="yes">Salmonella</italic> typhi</article-title>. <source>Org. Chem. Front.</source><year>2018</year>, <volume>5</volume>, <fpage>2179</fpage>&#8211;<lpage>2188</lpage>. <pub-id pub-id-type="doi">10.1039/C8QO00471D</pub-id>.</mixed-citation></ref><ref id="ref330"><mixed-citation publication-type="journal" id="cit330"><name name-style="western"><surname>Sokaribo</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Perera</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Sereggela</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Krochak</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Balezantis</surname><given-names>L. R.</given-names></name>; <name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Lam</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Deck</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Attah-Poku</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Abbott</surname><given-names>D. W.</given-names></name>; et al. <article-title>A GMMA-CPS-based
vaccine for non-Typhoidal <italic toggle="yes">Salmonella</italic></article-title>. <source>Vaccines</source><year>2021</year>, <volume>9</volume>, <fpage>165</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020165</pub-id>.<pub-id pub-id-type="pmid">33671372</pub-id><pub-id pub-id-type="pmcid">PMC7922415</pub-id></mixed-citation></ref><ref id="ref331"><mixed-citation publication-type="journal" id="cit331"><name name-style="western"><surname>Masuet-Aumatell</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Atouguia</surname><given-names>J.</given-names></name><article-title>Typhoid fever infection
- Antibiotic
resistance and vaccination strategies: a narrative review</article-title>. <source>Travel Med. Infect. Dis.</source><year>2021</year>, <volume>40</volume>, <fpage>101946</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101946</pub-id>.<pub-id pub-id-type="pmid">33301931</pub-id></mixed-citation></ref><ref id="ref332"><mixed-citation publication-type="journal" id="cit332"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Liang</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Kong</surname><given-names>Q.</given-names></name><article-title>O-Serotype
conversion
in <italic toggle="yes">Salmonella</italic> typhimurium induces protective immune
responses against invasive Non-Typhoidal <italic toggle="yes">Salmonella</italic> infections</article-title>. <source>Front. Immunol.</source><year>2017</year>, <volume>8</volume>, <fpage>1647</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01647</pub-id>.<pub-id pub-id-type="pmid">29255460</pub-id><pub-id pub-id-type="pmcid">PMC5722840</pub-id></mixed-citation></ref><ref id="ref333"><mixed-citation publication-type="journal" id="cit333"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Rondini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gavini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lanzilao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Medaglini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Saul</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>L. B.</given-names></name><article-title>O:2-CRM197
conjugates
against <italic toggle="yes">Salmonella</italic> paratyphi A</article-title>. <source>PLoS One</source><year>2012</year>, <volume>7</volume>, <elocation-id>e47039</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047039</pub-id>.<pub-id pub-id-type="pmid">23144798</pub-id><pub-id pub-id-type="pmcid">PMC3492368</pub-id></mixed-citation></ref><ref id="ref334"><mixed-citation publication-type="journal" id="cit334"><name name-style="western"><surname>Konadu</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Shiloach</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bryla</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Robbins</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Szu</surname><given-names>S. C.</given-names></name><article-title>Synthesis,
characterization, and immunological properties
in mice of conjugates composed of detoxified lipopolysaccharide of <italic toggle="yes">Salmonella</italic> paratyphi A bound to tetanus toxoid with emphasis
on the role of O acetyls</article-title>. <source>Infect. Immunol.</source><year>1996</year>, <volume>64</volume>, <fpage>2709</fpage>&#8211;<lpage>2715</lpage>. <pub-id pub-id-type="doi">10.1128/iai.64.7.2709-2715.1996</pub-id>.<pub-id pub-id-type="pmid">8698499</pub-id><pub-id pub-id-type="pmcid">PMC174130</pub-id></mixed-citation></ref><ref id="ref335"><mixed-citation publication-type="journal" id="cit335"><name name-style="western"><surname>Dhara</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Baliban</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Huo</surname><given-names>C.-X.</given-names></name>; <name name-style="western"><surname>Rashidijahanabad</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Sears</surname><given-names>K. T.</given-names></name>; <name name-style="western"><surname>Nick</surname><given-names>S. T.</given-names></name>; <name name-style="western"><surname>Misra</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Tennant</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><article-title>Syntheses of <italic toggle="yes">Salmonella</italic> paratiphy A associated oligosaccharide
antigens and development towards anti-Paratyphoid fever vaccines</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2020</year>, <volume>26</volume>, <fpage>15953</fpage>&#8211;<lpage>15968</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202002401</pub-id>.<pub-id pub-id-type="pmid">32578281</pub-id><pub-id pub-id-type="pmcid">PMC7722144</pub-id></mixed-citation></ref><ref id="ref336"><mixed-citation publication-type="journal" id="cit336"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Rondini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Alfini</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lanzilao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Necchi</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Negrea</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rossi</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Brandt</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Clare</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mastroeni</surname><given-names>P.</given-names></name>; et al. <article-title>Comparative immunogenicity
and efficacy of equivalent outer membrane vesicle and glycoconjugate
vaccines against nontyphoidal Salmonella</article-title>. <source>Proc.
Natl. Acad. Sci. U.S.A.</source><year>2018</year>, <volume>115</volume>, <fpage>10428</fpage>&#8211;<lpage>10433</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1807655115</pub-id>.<pub-id pub-id-type="pmid">30262653</pub-id><pub-id pub-id-type="pmcid">PMC6187145</pub-id></mixed-citation></ref><ref id="ref337"><mixed-citation publication-type="journal" id="cit337"><name name-style="western"><surname>Snyder</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Heiss</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kay</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Azadi</surname><given-names>P.</given-names></name><article-title>Structure of a capsular polysaccharide isolated from <italic toggle="yes">Salmonella
enteritidis</italic></article-title>. <source>Carbohydr. Res.</source><year>2006</year>, <volume>341</volume>, <fpage>2388</fpage>&#8211;<lpage>2397</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2006.06.010</pub-id>.<pub-id pub-id-type="pmid">16857179</pub-id></mixed-citation></ref><ref id="ref338"><mixed-citation publication-type="journal" id="cit338"><name name-style="western"><surname>Koropatkin</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>H.-w.</given-names></name>; <name name-style="western"><surname>Holden</surname><given-names>H. M.</given-names></name><article-title>High resolution
X-ray structure of Tyvelose epimerase from <italic toggle="yes">Salmonella typhi</italic></article-title>. <source>J. Biol. Chem.</source><year>2003</year>, <volume>278</volume>, <fpage>20874</fpage>&#8211;<lpage>20881</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M301948200</pub-id>.<pub-id pub-id-type="pmid">12642575</pub-id></mixed-citation></ref><ref id="ref339"><mixed-citation publication-type="journal" id="cit339"><name name-style="western"><surname>Son</surname><given-names>S.-H.</given-names></name>; <name name-style="western"><surname>Tano</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Furuike</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Sakairi</surname><given-names>N.</given-names></name><article-title>Synthesis
of a tetrasaccharide repeating unit of O-antigenic polysaccha-ride
of <italic toggle="yes">Salmonella enteritidis</italic> by use of unique and odorless
dodecyl thioglycosyl donors</article-title>. <source>Tetrahedron Lett.</source><year>2008</year>, <volume>49</volume>, <fpage>5289</fpage>&#8211;<lpage>5292</lpage>. <pub-id pub-id-type="doi">10.1016/j.tetlet.2008.06.097</pub-id>.</mixed-citation></ref><ref id="ref340"><mixed-citation publication-type="journal" id="cit340"><name name-style="western"><surname>Huo</surname><given-names>C. X.</given-names></name>; <name name-style="western"><surname>Dhara</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Baliban</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Tahmasebi
Nick</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Simon</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Misra</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><article-title>Synthetic
and immunological studies of <italic toggle="yes">Salmonella Enteritidis</italic> O-antigen tetrasaccharides as potential anti-<italic toggle="yes">Salmonella</italic> vaccines</article-title>. <source>Chem. Commun. (Camb)</source><year>2019</year>, <volume>55</volume>, <fpage>4519</fpage>&#8211;<lpage>4522</lpage>. <pub-id pub-id-type="doi">10.1039/C8CC08622B</pub-id>.<pub-id pub-id-type="pmid">30924468</pub-id><pub-id pub-id-type="pmcid">PMC6525565</pub-id></mixed-citation></ref><ref id="ref341"><mixed-citation publication-type="journal" id="cit341"><name name-style="western"><surname>Eklind</surname><given-names>K. I.</given-names></name>; <name name-style="western"><surname>Garegg</surname><given-names>P. J.</given-names></name>; <name name-style="western"><surname>Gotthammar</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Schaumburg</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Vialle</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Anthonsen</surname><given-names>T.</given-names></name><article-title>Synthesis
of p-Isothiocyanatophenyl-3-O-(3,6-Dideoxy-alpha-D-arabino-hexopyranosyl)-alpha-D-mannopyranoside</article-title>. <source>Acta Chem. Scand.</source><year>1975</year>, <fpage>305</fpage>&#8211;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.3891/acta.chem.scand.29b-0765</pub-id>.</mixed-citation></ref><ref id="ref342"><mixed-citation publication-type="journal" id="cit342"><name name-style="western"><surname>J&#246;rbeck</surname><given-names>H. J.</given-names></name>; <name name-style="western"><surname>Svenson</surname><given-names>S. B.</given-names></name>; <name name-style="western"><surname>Lindberg</surname><given-names>A. A.</given-names></name><article-title>Artificial <italic toggle="yes">Salmonella</italic> vaccines: <italic toggle="yes">Salmonella typhimurium</italic> O-antigen-specific
oligosaccharide-protein conjugates elicit opsonizing
antibodies that enhance phagocytosis</article-title>. <source>Infect.
Immun.</source><year>1981</year>, <volume>32</volume>, <fpage>497</fpage>&#8211;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1128/iai.32.2.497-502.1981</pub-id>.<pub-id pub-id-type="pmid">7019072</pub-id><pub-id pub-id-type="pmcid">PMC351473</pub-id></mixed-citation></ref><ref id="ref343"><mixed-citation publication-type="journal" id="cit343"><name name-style="western"><surname>Svenson</surname><given-names>S. B.</given-names></name>; <name name-style="western"><surname>Lindberg</surname><given-names>A. A.</given-names></name><article-title>Artificial Salmonella vaccines: <italic toggle="yes">Salmonella
typhimurium</italic> O-antigen-specific oligosaccharide-protein
conjugates elicit protective antibodies in rabbits and mice</article-title>. <source>Infect. Immunol.</source><year>1981</year>, <volume>32</volume>, <fpage>490</fpage>&#8211;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1128/iai.32.2.490-496.1981</pub-id>.<pub-id pub-id-type="pmid">6166555</pub-id><pub-id pub-id-type="pmcid">PMC351472</pub-id></mixed-citation></ref><ref id="ref344"><mixed-citation publication-type="journal" id="cit344"><name name-style="western"><surname>O&#8217;Riordan</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J. C.</given-names></name><article-title><italic toggle="yes">Staphylococcus
aureus</italic> capsular polysaccharides</article-title>. <source>Clin.
Microbiol.
Rev.</source><year>2004</year>, <volume>17</volume>, <fpage>218</fpage>&#8211;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.17.1.218-234.2004</pub-id>.<pub-id pub-id-type="pmid">14726462</pub-id><pub-id pub-id-type="pmcid">PMC321462</pub-id></mixed-citation></ref><ref id="ref345"><mixed-citation publication-type="journal" id="cit345"><name name-style="western"><surname>Fattom</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fuller</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Propst</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Winston</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Muenz</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>He</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Naso</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Horwith</surname><given-names>G.</given-names></name><article-title>Safety and
immunogenicity of a booster dose of <italic toggle="yes">Staphylococcus aureus</italic> types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX)
in hemodialysis patients</article-title>. <source>Vaccine</source><year>2004</year>, <volume>23</volume>, <fpage>656</fpage>&#8211;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.043</pub-id>.<pub-id pub-id-type="pmid">15542186</pub-id></mixed-citation></ref><ref id="ref346"><mixed-citation publication-type="journal" id="cit346"><name name-style="western"><surname>Fattom</surname><given-names>A. I.</given-names></name>; <name name-style="western"><surname>Horwith</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Fuller</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Propst</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Naso</surname><given-names>R.</given-names></name><article-title>Development of StaphVAX, a polysaccharide
conjugate vaccine against <italic toggle="yes">S. aureus</italic> infection: from
the lab bench to phase III clinical
trials</article-title>. <source>Vaccine</source><year>2004</year>, <volume>22</volume>, <fpage>880</fpage>&#8211;<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2003.11.034</pub-id>.<pub-id pub-id-type="pmid">15040941</pub-id></mixed-citation></ref><ref id="ref347"><mixed-citation publication-type="journal" id="cit347"><name name-style="western"><surname>Creech</surname><given-names>C. B.</given-names></name>; <name name-style="western"><surname>Frenck</surname><given-names>R. W.</given-names><suffix>Jr.</suffix></name>; <name name-style="western"><surname>Sheldon</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Seiden</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Kankam</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Zito</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Girgenti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Severs</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Immermann</surname><given-names>F. W.</given-names></name>; <name name-style="western"><surname>McNeil</surname><given-names>L. K.</given-names></name>; et al. <article-title>Safety,
tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen <italic toggle="yes">Staphylococcus aureus</italic> vaccine in healthy older adults: results
of a randomised trial</article-title>. <source>Vaccine</source><year>2017</year>, <volume>35</volume>, <fpage>385</fpage>&#8211;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.032</pub-id>.<pub-id pub-id-type="pmid">27866765</pub-id></mixed-citation></ref><ref id="ref348"><mixed-citation publication-type="weblink" id="cit348"><article-title>Safety, immunogenicity and efficacy of
GSK <italic toggle="yes">S. aureus</italic> candidate vaccine (GSK3878858A) when
administered to healthy adults
(dose-escalation) and to adults 18 to 50 years of age with a recent <italic toggle="yes">S. aureus</italic> skin and soft tissue infection (SSTI)</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04420221?term=GSK&amp;cond=s.+aureus+vaccine&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04420221?term=GSK&amp;cond=s.+aureus+vaccine&amp;draw=2&amp;rank=1</uri>.</mixed-citation></ref><ref id="ref349"><mixed-citation publication-type="journal" id="cit349"><name name-style="western"><surname>Danieli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Cappelletti</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Synthesis of <italic toggle="yes">Staphylococcus
aureus</italic> type 5 capsular polysaccharide repeating unit using
novel L-FucNAc and D-FucNAc synthons and immunochemical evaluation</article-title>. <source>Bioorg. Med. Chem.</source><year>2012</year>, <volume>20</volume>, <fpage>6403</fpage>&#8211;<lpage>6415</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2012.08.048</pub-id>.<pub-id pub-id-type="pmid">23000295</pub-id></mixed-citation></ref><ref id="ref350"><mixed-citation publication-type="journal" id="cit350"><name name-style="western"><surname>Yasomanee</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Visansirikul</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pornsuriyasak</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Thompson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kolodziej</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Demchenko</surname><given-names>A. V.</given-names></name><article-title>Synthesis
of the repeating unit of capsular polysaccharide <italic toggle="yes">Staphylococcus
aureus</italic> type 5 to study chemical activation and conjugation
of native CP5</article-title>. <source>J. Org. Chem.</source><year>2016</year>, <volume>81</volume>, <fpage>5981</fpage>&#8211;<lpage>5987</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.6b00910</pub-id>.<pub-id pub-id-type="pmid">27305525</pub-id></mixed-citation></ref><ref id="ref351"><mixed-citation publication-type="journal" id="cit351"><name name-style="western"><surname>Gagarinov</surname><given-names>I. A.</given-names></name>; <name name-style="western"><surname>Fang</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Srivastava</surname><given-names>A. D.</given-names></name>; <name name-style="western"><surname>Boons</surname><given-names>G. J.</given-names></name><article-title>Synthesis of <italic toggle="yes">Staphylococcus
aureus</italic> type 5 trisaccharide repeating unit: solving the problem
of lactamization</article-title>. <source>Org. Lett.</source><year>2015</year>, <volume>17</volume>, <fpage>928</fpage>&#8211;<lpage>931</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.5b00031</pub-id>.<pub-id pub-id-type="pmid">25658811</pub-id><pub-id pub-id-type="pmcid">PMC4507426</pub-id></mixed-citation></ref><ref id="ref352"><mixed-citation publication-type="journal" id="cit352"><name name-style="western"><surname>Hagen</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D.</given-names></name><article-title>Mapping the reactivity and selectivity
of 2-azidofucosyl donors for the assembly of N-Acetylfucosamine-containing
bacterial oligosaccharides</article-title>. <source>J. Org. Chem.</source><year>2017</year>, <volume>82</volume>, <fpage>848</fpage>&#8211;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.6b02593</pub-id>.<pub-id pub-id-type="pmid">28051314</pub-id><pub-id pub-id-type="pmcid">PMC5332126</pub-id></mixed-citation></ref><ref id="ref353"><mixed-citation publication-type="journal" id="cit353"><name name-style="western"><surname>Visansirikul</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Yasomanee</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Pornsuriyasak</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Kamat</surname><given-names>M. N.</given-names></name>; <name name-style="western"><surname>Podvalnyy</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Gobble</surname><given-names>C. P.</given-names></name>; <name name-style="western"><surname>Thompson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kolodziej</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Demchenko</surname><given-names>A. V.</given-names></name><article-title>A concise synthesis of the repeating
unit of capsular polysaccharide <italic toggle="yes">Staphylococcus aureus</italic> Type 8</article-title>. <source>Org. Lett.</source><year>2015</year>, <volume>17</volume>, <fpage>2382</fpage>&#8211;<lpage>2384</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.5b00899</pub-id>.<pub-id pub-id-type="pmid">25928124</pub-id></mixed-citation></ref><ref id="ref354"><mixed-citation publication-type="journal" id="cit354"><name name-style="western"><surname>Visansirikul</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kolodziej</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Demchenko</surname><given-names>A. V.</given-names></name><article-title>Synthesis
of oligosaccharide fragments of capsular polysaccharide <italic toggle="yes">Staphylococcus
aureus</italic> type 8</article-title>. <source>J. Carbohydr. Chem.</source><year>2020</year>, <volume>39</volume>, <fpage>301</fpage>&#8211;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1080/07328303.2020.1821042</pub-id>.</mixed-citation></ref><ref id="ref355"><mixed-citation publication-type="journal" id="cit355"><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><article-title>Conjugation
of synthetic
trisaccharide of <italic toggle="yes">Staphylococcus aureus</italic> type 8 capsular
polysaccharide elicits antibodies recognizing intact bacterium</article-title>. <source>Front. Chem.</source><year>2020</year>, <volume>8</volume>, <fpage>258</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00258</pub-id>.<pub-id pub-id-type="pmid">32411658</pub-id><pub-id pub-id-type="pmcid">PMC7199654</pub-id></mixed-citation></ref><ref id="ref356"><mixed-citation publication-type="journal" id="cit356"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kaczynski</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fabretti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Sange</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Holst</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Huebner</surname><given-names>J.</given-names></name><article-title>Opsonic antibodies
to <italic toggle="yes">Enterococcus faecalis</italic> strain 12030 are directed
against lipoteichoic acid</article-title>. <source>Infect. Immun.</source><year>2006</year>, <volume>74</volume>, <fpage>5703</fpage>&#8211;<lpage>5712</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00570-06</pub-id>.<pub-id pub-id-type="pmid">16988246</pub-id><pub-id pub-id-type="pmcid">PMC1594888</pub-id></mixed-citation></ref><ref id="ref357"><mixed-citation publication-type="journal" id="cit357"><name name-style="western"><surname>Brown</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Santa Maria</surname><given-names>J. P.</given-names><suffix>Jr.</suffix></name>; <name name-style="western"><surname>Walker</surname><given-names>S.</given-names></name><article-title>Wall teichoic
acids of gram-positive bacteria</article-title>. <source>Annu. Rev.
Microbiol.</source><year>2013</year>, <volume>67</volume>, <fpage>313</fpage>&#8211;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-092412-155620</pub-id>.<pub-id pub-id-type="pmid">24024634</pub-id><pub-id pub-id-type="pmcid">PMC3883102</pub-id></mixed-citation></ref><ref id="ref358"><mixed-citation publication-type="journal" id="cit358"><name name-style="western"><surname>Swoboda</surname><given-names>J. G.</given-names></name>; <name name-style="western"><surname>Campbell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Meredith</surname><given-names>T. C.</given-names></name>; <name name-style="western"><surname>Walker</surname><given-names>S.</given-names></name><article-title>Wall Teichoic
Acid function, biosynthesis, and inhibition</article-title>. <source>ChemBioChem</source><year>2010</year>, <volume>11</volume>, <fpage>35</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200900557</pub-id>.<pub-id pub-id-type="pmid">19899094</pub-id><pub-id pub-id-type="pmcid">PMC2798926</pub-id></mixed-citation></ref><ref id="ref359"><mixed-citation publication-type="journal" id="cit359"><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Lindner</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Z&#228;hringer</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Truog</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Schmidt</surname><given-names>R. R.</given-names></name><article-title>Synthesis
of the lipoteichoic acid
of the <italic toggle="yes">Streptococcus</italic> species DSM 8747</article-title>. <source>Bioorg. Med. Chem.</source><year>2010</year>, <volume>18</volume>, <fpage>3696</fpage>&#8211;<lpage>3702</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2010.04.006</pub-id>.<pub-id pub-id-type="pmid">20510791</pub-id></mixed-citation></ref><ref id="ref360"><mixed-citation publication-type="journal" id="cit360"><name name-style="western"><surname>Figueroa-Perez</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Stadelmaier</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Deininger</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Aulock</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hartung</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Schmidt</surname><given-names>R. R.</given-names></name><article-title>Synthesis
of <italic toggle="yes">Staphylococcus aureus</italic> lipoteichoic acid derivatives
for
determining the minimal structural requirements for cytokine induction</article-title>. <source>Carbohydr. Res.</source><year>2006</year>, <volume>341</volume>, <fpage>2901</fpage>&#8211;<lpage>2911</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2006.10.003</pub-id>.<pub-id pub-id-type="pmid">17074308</pub-id></mixed-citation></ref><ref id="ref361"><mixed-citation publication-type="journal" id="cit361"><name name-style="western"><surname>Stadelmaier</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Morath</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hartung</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Schmidt</surname><given-names>R. R.</given-names></name><article-title>Synthesis
of the first fully active lipoteichoic acid</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><year>2003</year>, <volume>42</volume>, <fpage>916</fpage>&#8211;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200390243</pub-id>.<pub-id pub-id-type="pmid">12596177</pub-id></mixed-citation></ref><ref id="ref362"><mixed-citation publication-type="journal" id="cit362"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Dintaman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lees</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sen</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Schwartz</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Shirtliff</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Park</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Mond</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Snapper</surname><given-names>C. M.</given-names></name><article-title>Novel synthetic (poly)glycerolphosphate-based
anti-staphylococcal conjugate vaccine</article-title>. <source>Infect.
Immun.</source><year>2013</year>, <volume>81</volume>, <fpage>2554</fpage>&#8211;<lpage>2561</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00271-13</pub-id>.<pub-id pub-id-type="pmid">23649092</pub-id><pub-id pub-id-type="pmcid">PMC3697627</pub-id></mixed-citation></ref><ref id="ref363"><mixed-citation publication-type="patent" id="cit363"><person-group person-group-type="allauthors"><name name-style="western"><surname>Snapper</surname><given-names>C. M.</given-names></name>; <name name-style="western"><surname>Lees</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Mond</surname><given-names>J.
J.</given-names></name>; <name name-style="western"><surname>Schwartz</surname><given-names>D.</given-names></name></person-group><article-title>(Poly)-glycerolphosphate-based
anti-gram positive bacterial vaccine</article-title>. <patent>WO/2011/060379</patent>, <year>2011</year>.</mixed-citation></ref><ref id="ref364"><mixed-citation publication-type="journal" id="cit364"><name name-style="western"><surname>Fekete</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hoogerhout</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Zomer</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kubler-Kielb</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Schneerson</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Robbins</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Pozsgay</surname><given-names>V.</given-names></name><article-title>Synthesis of octa-
and dodecamers of d-ribitol-1-phosphate and their protein conjugates</article-title>. <source>Carbohydr. Res.</source><year>2006</year>, <volume>341</volume>, <fpage>2037</fpage>&#8211;<lpage>2048</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2005.10.023</pub-id>.<pub-id pub-id-type="pmid">16458277</pub-id></mixed-citation></ref><ref id="ref365"><mixed-citation publication-type="journal" id="cit365"><name name-style="western"><surname>Jung</surname><given-names>Y.-C.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J.-H.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Schmidt</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>B. L.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>H.-S.</given-names></name><article-title>Synthesis and biological activity
tetrameric ribitol phosphate fragments of <italic toggle="yes">Staphylococcus aureus</italic> Wall Teichoic Acid</article-title>. <source>Org. Lett.</source><year>2018</year>, <volume>20</volume>, <fpage>4449</fpage>&#8211;<lpage>4452</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.8b01725</pub-id>.<pub-id pub-id-type="pmid">30028624</pub-id></mixed-citation></ref><ref id="ref366"><mixed-citation publication-type="journal" id="cit366"><name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hendriks</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>van Dalen</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Bruyning</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Meeuwenoord</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Overkleeft</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Filippov</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>van Sorge</surname><given-names>N. M.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J. D. C.</given-names></name><article-title>(Automated) synthesis of well-defined <italic toggle="yes">Staphylococcus
aureus</italic> Wall Teichoic Acid fragments</article-title>. <source>Chem.&#8212;Eur. J.</source><year>2021</year>, <volume>27</volume>, <fpage>10461</fpage>&#8211;<lpage>10469</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202101242</pub-id>.<pub-id pub-id-type="pmid">33991006</pub-id><pub-id pub-id-type="pmcid">PMC8361686</pub-id></mixed-citation></ref><ref id="ref367"><mixed-citation publication-type="journal" id="cit367"><name name-style="western"><surname>van Dalen</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Molendijk</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>van Kessel</surname><given-names>K. P. M.</given-names></name>; <name name-style="western"><surname>Aerts</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>van Strijp</surname><given-names>J. A. G.</given-names></name>; <name name-style="western"><surname>de Haas</surname><given-names>C. J. C.</given-names></name>; <name name-style="western"><surname>Cod&#233;e</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>van Sorge</surname><given-names>N. M.</given-names></name><article-title>Do not discard <italic toggle="yes">Staphylococcus aureus</italic> WTA as a vaccine antigen</article-title>. <source>Nature</source><year>2019</year>, <volume>572</volume>, <fpage>E1</fpage>&#8211;<lpage>E2</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1416-8</pub-id>.<pub-id pub-id-type="pmid">31367020</pub-id></mixed-citation></ref><ref id="ref368"><mixed-citation publication-type="journal" id="cit368"><name name-style="western"><surname>Gerlach</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>De Castro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name>; <name name-style="western"><surname>Schlatterer</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>F. F.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Codee</surname><given-names>J.</given-names></name>; et al. <article-title>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> alters cell wall glycosylation to
evade immunity</article-title>. <source>Nature</source><year>2018</year>, <volume>563</volume>, <fpage>705</fpage>&#8211;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-018-0730-x</pub-id>.<pub-id pub-id-type="pmid">30464342</pub-id></mixed-citation></ref><ref id="ref369"><mixed-citation publication-type="journal" id="cit369"><name name-style="western"><surname>Hendriks</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>van Dalen</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gerlach</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>van der Marel</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Fuchsberger</surname><given-names>F. F.</given-names></name>; <name name-style="western"><surname>Aerts</surname><given-names>P. C.</given-names></name>; <name name-style="western"><surname>de Haas</surname><given-names>C. J. C.</given-names></name>; <name name-style="western"><surname>Peschel</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rademacher</surname><given-names>C.</given-names></name>; et al. <article-title>Impact of glycan linkage
to <italic toggle="yes">Staphylococcus aureus</italic> Wall Teichoic Acid on Langerin
recognition and Langerhans cell activation</article-title>. <source>ACS Infect. Dis.</source><year>2021</year>, <volume>7</volume>, <fpage>624</fpage>&#8211;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00822</pub-id>.<pub-id pub-id-type="pmid">33591717</pub-id><pub-id pub-id-type="pmcid">PMC8023653</pub-id></mixed-citation></ref><ref id="ref370"><mixed-citation publication-type="patent" id="cit370"><person-group person-group-type="allauthors"><name name-style="western"><surname>Driguez</surname><given-names>P.-a.</given-names></name>; <name name-style="western"><surname>Guillo</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Rokbi</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Mistretta</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Talaga</surname><given-names>P.</given-names></name></person-group><article-title>Immunogenic composition
against <italic toggle="yes">S. aureus</italic></article-title>. Int. Pat. Appl.
US<patent>10772946B2</patent>, <year>2018</year>.</mixed-citation></ref><ref id="ref371"><mixed-citation publication-type="journal" id="cit371"><name name-style="western"><surname>Joyce</surname><given-names>J.
G.</given-names></name>; <name name-style="western"><surname>Abeygunawardana</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Cook</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Hepler</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Przysiecki</surname><given-names>C. T.</given-names></name>; <name name-style="western"><surname>Grimm</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Roper</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Ip</surname><given-names>C. C. Y.</given-names></name>; <name name-style="western"><surname>Cope</surname><given-names>L.</given-names></name>; et al. <article-title>Isolation, structural
characterization, and immunological evaluation of a high-molecular-weight
exopolysaccharide from <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Carbohydr. Res.</source><year>2003</year>, <volume>338</volume>, <fpage>903</fpage>&#8211;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6215(03)00045-4</pub-id>.<pub-id pub-id-type="pmid">12681914</pub-id></mixed-citation></ref><ref id="ref372"><mixed-citation publication-type="journal" id="cit372"><name name-style="western"><surname>Cerca</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Jefferson</surname><given-names>K. K.</given-names></name><article-title>Effect of growth conditions on poly-N-acetylglucosamine
expression and biofilm formation in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>FEMS Microbiol. Lett.</source><year>2008</year>, <volume>283</volume>, <fpage>36</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.2008.01142.x</pub-id>.<pub-id pub-id-type="pmid">18445167</pub-id></mixed-citation></ref><ref id="ref373"><mixed-citation publication-type="journal" id="cit373"><name name-style="western"><surname>Perez</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Prenafeta</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Valle</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Penades</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Rota</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Solano</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Marco</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Grillo</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Lasa</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Irache</surname><given-names>J. M.</given-names></name>; et al. <article-title>Protection from <italic toggle="yes">Staphylococcus aureus</italic> mastitis associated
with poly-N-acetyl
beta-1,6 glucosamine specific antibody production using biofilm-embedded
bacteria</article-title>. <source>Vaccine</source><year>2009</year>, <volume>27</volume>, <fpage>2379</fpage>&#8211;<lpage>2386</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.005</pub-id>.<pub-id pub-id-type="pmid">19428854</pub-id><pub-id pub-id-type="pmcid">PMC3024585</pub-id></mixed-citation></ref><ref id="ref374"><mixed-citation publication-type="journal" id="cit374"><name name-style="western"><surname>Gening</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Synthesis
of beta-(1&#8594;6)-linked glucosamine oligosaccharides corresponding
to fragments of the bacterial surface polysaccharide poly-N-acetylglucosamine</article-title>. <source>Carbohydr. Res.</source><year>2007</year>, <volume>342</volume>, <fpage>567</fpage>&#8211;<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2006.08.010</pub-id>.<pub-id pub-id-type="pmid">16952342</pub-id></mixed-citation></ref><ref id="ref375"><mixed-citation publication-type="journal" id="cit375"><name name-style="western"><surname>Gening</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Maira-Litran</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kropec</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Skurnik</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Synthetic -(1-&gt;6)-Linked N-Acetylated and nonacetylated
oligoglucosamines used to produce conjugate vaccines for bacterial
pathogens</article-title>. <source>Infect. Immun.</source><year>2010</year>, <volume>78</volume>, <fpage>764</fpage>&#8211;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01093-09</pub-id>.<pub-id pub-id-type="pmid">19948836</pub-id><pub-id pub-id-type="pmcid">PMC2812210</pub-id></mixed-citation></ref><ref id="ref376"><mixed-citation publication-type="journal" id="cit376"><name name-style="western"><surname>Gening</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Broadly
protective semi-synthetic glycoconjugate vaccine against pathogens
capable of producing poly-&#946;-(1&#8594;6)-N-acetyl-d-glucosamine
exopolysaccharide</article-title>. <source>Drug Discovery Today Technol.</source><year>2020</year>, <volume>35-36</volume>, <fpage>13</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.09.002</pub-id>.<pub-id pub-id-type="pmid">33388124</pub-id></mixed-citation></ref><ref id="ref377"><mixed-citation publication-type="journal" id="cit377"><name name-style="western"><surname>Cywes-Bentley</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Skurnik</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Zaidi</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Roux</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Deoliveira</surname><given-names>R. B.</given-names></name>; <name name-style="western"><surname>Garrett</surname><given-names>W. S.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>O&#8217;Malley</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kinzel</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Zaidi</surname><given-names>T.</given-names></name>; et al. <article-title>Antibody
to a conserved
antigenic target is protective against diverse prokaryotic and eukaryotic
pathogens</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2013</year>, <volume>110</volume>, <fpage>E2209</fpage>&#8211;<lpage>E2218</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1303573110</pub-id>.<pub-id pub-id-type="pmid">23716675</pub-id><pub-id pub-id-type="pmcid">PMC3683766</pub-id></mixed-citation></ref><ref id="ref378"><mixed-citation publication-type="journal" id="cit378"><name name-style="western"><surname>Bentancor</surname><given-names>L. V.</given-names></name>; <name name-style="western"><surname>O&#8217;Malley</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Bozkurt-Guzel</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name>; <name name-style="western"><surname>Maira-Litran</surname><given-names>T.</given-names></name><article-title>Poly-N-acetyl-beta-(1-6)-glucosamine
is a target for protective immunity against <italic toggle="yes">Acinetobacter
baumannii</italic> infections</article-title>. <source>Infect. Immun.</source><year>2012</year>, <volume>80</volume>, <fpage>651</fpage>&#8211;<lpage>656</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.05653-11</pub-id>.<pub-id pub-id-type="pmid">22104104</pub-id><pub-id pub-id-type="pmcid">PMC3264292</pub-id></mixed-citation></ref><ref id="ref379"><mixed-citation publication-type="journal" id="cit379"><name name-style="western"><surname>Cerca</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Maira-Litran</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Jefferson</surname><given-names>K. K.</given-names></name>; <name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Goldmann</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name><article-title>Protection
against <italic toggle="yes">Escherichia coli</italic> infection by antibody to
the <italic toggle="yes">Staphylococcus
aureus</italic> poly-N-acetylglucosamine surface polysaccharide</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source><year>2007</year>, <volume>104</volume>, <fpage>7528</fpage>&#8211;<lpage>7533</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0700630104</pub-id>.<pub-id pub-id-type="pmid">17446272</pub-id><pub-id pub-id-type="pmcid">PMC1863476</pub-id></mixed-citation></ref><ref id="ref380"><mixed-citation publication-type="journal" id="cit380"><name name-style="western"><surname>Soliman</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Walduck</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Yuriev</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Richards</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Cywes-Bentley</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pier</surname><given-names>G. B.</given-names></name>; <name name-style="western"><surname>Ramsland</surname><given-names>P. A.</given-names></name><article-title>Structural
basis
for antibody targeting of the broadly expressed microbial polysaccharide
poly-N-acetylglucosamine</article-title>. <source>J. Biol. Chem.</source><year>2018</year>, <volume>293</volume>, <fpage>5079</fpage>&#8211;<lpage>5089</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA117.001170</pub-id>.<pub-id pub-id-type="pmid">29449370</pub-id><pub-id pub-id-type="pmcid">PMC5892565</pub-id></mixed-citation></ref><ref id="ref381"><mixed-citation publication-type="journal" id="cit381"><name name-style="western"><surname>Bruix</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Jim&#233;nez-Barbero</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Cronet</surname><given-names>P.</given-names></name><article-title>Determination
by NMR spectroscopy of the structure and conformational features of
the enterobacterial common antigen isolated from <italic toggle="yes">Escherichia
coli</italic></article-title>. <source>Carbohyd. Res.</source><year>1995</year>, <volume>273</volume>, <fpage>157</fpage>&#8211;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1016/0008-6215(95)00117-C</pub-id>.<pub-id pub-id-type="pmid">8565004</pub-id></mixed-citation></ref><ref id="ref382"><mixed-citation publication-type="journal" id="cit382"><name name-style="western"><surname>Gilbreath</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Colvocoresses Dodds</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Rick</surname><given-names>P. D.</given-names></name>; <name name-style="western"><surname>Soloski</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Merrell</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Metcalf</surname><given-names>E. S.</given-names></name><article-title>Enterobacterial
common antigen mutants
of Salmonella enterica serovar Typhimurium establish a persistent
infection and provide protection against subsequent lethal challenge</article-title>. <source>Infect. Immunol.</source><year>2012</year>, <volume>80</volume>, <fpage>441</fpage>&#8211;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.05559-11</pub-id>.<pub-id pub-id-type="pmid">22025511</pub-id><pub-id pub-id-type="pmcid">PMC3255661</pub-id></mixed-citation></ref><ref id="ref383"><mixed-citation publication-type="journal" id="cit383"><name name-style="western"><surname>Denning</surname><given-names>D. W.</given-names></name>; <name name-style="western"><surname>Kneale</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sobel</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Rautemaa-Richardson</surname><given-names>R.</given-names></name><article-title>Global burden
of recurrent vulvovaginal candidiasis: a systematic review</article-title>. <source>Lancet Infect. Dis.</source><year>2018</year>, <volume>18</volume>, <fpage>e339</fpage>&#8211;<lpage>e347</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30103-8</pub-id>.<pub-id pub-id-type="pmid">30078662</pub-id></mixed-citation></ref><ref id="ref384"><mixed-citation publication-type="journal" id="cit384"><name name-style="western"><surname>Kullberg</surname><given-names>B. J.</given-names></name>; <name name-style="western"><surname>Arendrup</surname><given-names>M. C.</given-names></name><article-title>Invasive candidiasis</article-title>. <source>N. Engl. J. Med.</source><year>2015</year>, <volume>373</volume>, <fpage>1445</fpage>&#8211;<lpage>1456</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1315399</pub-id>.<pub-id pub-id-type="pmid">26444731</pub-id></mixed-citation></ref><ref id="ref385"><mixed-citation publication-type="journal" id="cit385"><name name-style="western"><surname>Nandini</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Manonmoney</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lavanya</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Leela</surname><given-names>K. V.</given-names></name>; <name name-style="western"><surname>Sujith</surname><given-names>A.</given-names></name><article-title>Study on prevalence and characterization of <italic toggle="yes">Candida</italic> species in immunocompromised patients</article-title>. <source>J. Pure Appl. Microbiol.</source><year>2021</year>, <volume>15</volume>, <fpage>2065</fpage>&#8211;<lpage>2072</lpage>. <pub-id pub-id-type="doi">10.22207/JPAM.15.4.29</pub-id>.</mixed-citation></ref><ref id="ref386"><mixed-citation publication-type="journal" id="cit386"><name name-style="western"><surname>Deorukhkar</surname><given-names>S. C.</given-names></name>; <name name-style="western"><surname>Saini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mathew</surname><given-names>S.</given-names></name><article-title>Non-albicans <italic toggle="yes">Candida</italic> infection: an emerging threat</article-title>. <source>Interdiscip. Perspect. Infect. Dis.</source><year>2014</year>, <volume>2014</volume>, <fpage>615958</fpage><pub-id pub-id-type="doi">10.1155/2014/615958</pub-id>.<pub-id pub-id-type="pmid">25404942</pub-id><pub-id pub-id-type="pmcid">PMC4227454</pub-id></mixed-citation></ref><ref id="ref387"><mixed-citation publication-type="journal" id="cit387"><name name-style="western"><surname>Ghrenassia</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Mokart</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Mayaux</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Demoule</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rezine</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Kerhuel</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Calvet</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>De Jong</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Azoulay</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Darmon</surname><given-names>M.</given-names></name><article-title>Candidemia in critically ill immunocompromised
patients: report of a retrospective multicenter cohort study</article-title>. <source>Ann. Intensive Care</source><year>2019</year>, <volume>9</volume>, <fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13613-019-0539-2</pub-id>.<pub-id pub-id-type="pmid">31161475</pub-id><pub-id pub-id-type="pmcid">PMC6546779</pub-id></mixed-citation></ref><ref id="ref388"><mixed-citation publication-type="journal" id="cit388"><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Alfouzan</surname><given-names>W.</given-names></name><article-title><italic toggle="yes">Candida auris</italic>: Epidemiology,
diagnosis, pathogenesis, anti-fungal susceptibility, and infection
control measures to combat the spread of infections in healthcare
facilities</article-title>. <source>Microorganisms</source><year>2021</year>, <volume>9</volume>, <fpage>807</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9040807</pub-id>.<pub-id pub-id-type="pmid">33920482</pub-id><pub-id pub-id-type="pmcid">PMC8069182</pub-id></mixed-citation></ref><ref id="ref389"><mixed-citation publication-type="journal" id="cit389"><name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name><article-title>Role of carbohydrate antigens in
antifungal glycoconjugate vaccines and immunotherapy</article-title>. <source>Drug Discovery Today Technol.</source><year>2020</year>, <volume>38</volume>, <fpage>45</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2021.02.002</pub-id>.<pub-id pub-id-type="pmid">34895640</pub-id></mixed-citation></ref><ref id="ref390"><mixed-citation publication-type="journal" id="cit390"><name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Synthetic carbohydrate based anti-fungal
vaccines</article-title>. <source>Drug Discovery Today Technol.</source><year>2020</year>, <volume>35-36</volume>, <fpage>35</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.11.002</pub-id>.<pub-id pub-id-type="pmid">33388126</pub-id></mixed-citation></ref><ref id="ref391"><mixed-citation publication-type="journal" id="cit391"><name name-style="western"><surname>Cartmell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Paszkiewicz</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Dziadek</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tam</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Luu</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lipinski</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name><article-title>Synthesis of antifungal
vaccines by conjugation of beta-1,2 trimannosides with T-cell peptides
and covalent anchoring of neoglycopeptide to tetanus toxoid</article-title>. <source>Carbohydr. Res.</source><year>2015</year>, <volume>403</volume>, <fpage>123</fpage>&#8211;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2014.06.024</pub-id>.<pub-id pub-id-type="pmid">25126994</pub-id></mixed-citation></ref><ref id="ref392"><mixed-citation publication-type="journal" id="cit392"><name name-style="western"><surname>Nycholat</surname><given-names>C. M.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name><article-title>Synthesis of monodeoxy and mono-O-methyl
congeners of methyl beta-D-mannopyranosyl-(1&#8594;2)-beta-D-mannopyranoside
for epitope mapping of anti-<italic toggle="yes">Candida</italic> albicans antibodies</article-title>. <source>Carbohydr. Res.</source><year>2009</year>, <volume>344</volume>, <fpage>555</fpage>&#8211;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2008.12.011</pub-id>.<pub-id pub-id-type="pmid">19249752</pub-id></mixed-citation></ref><ref id="ref393"><mixed-citation publication-type="journal" id="cit393"><name name-style="western"><surname>Xin</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Dziadek</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Cutler</surname><given-names>J. E.</given-names></name><article-title>Synthetic
glycopeptide
vaccines combining beta-mannan and peptide epitopes induce protection
against candidiasis</article-title>. <source>Proc. Natl. Acad. Sci.
U S A</source><year>2008</year>, <volume>105</volume>, <fpage>13526</fpage>&#8211;<lpage>13531</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0803195105</pub-id>.<pub-id pub-id-type="pmid">18725625</pub-id><pub-id pub-id-type="pmcid">PMC2533223</pub-id></mixed-citation></ref><ref id="ref394"><mixed-citation publication-type="journal" id="cit394"><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Cartmell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Weisser</surname><given-names>N. E.</given-names></name>; <name name-style="western"><surname>Woods</surname><given-names>R. J.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name><article-title>Molecular
recognition of <italic toggle="yes">Candida albicans</italic> (1&#8594;2)-&#946;-Mannan
oligosaccharides by a protective monoclonal
antibody reveals the immunodominance of internal saccharide residues</article-title>. <source>J. Biol. Chem.</source><year>2012</year>, <volume>287</volume>, <fpage>18078</fpage>&#8211;<lpage>18090</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.355578</pub-id>.<pub-id pub-id-type="pmid">22493450</pub-id><pub-id pub-id-type="pmcid">PMC3365708</pub-id></mixed-citation></ref><ref id="ref395"><mixed-citation publication-type="journal" id="cit395"><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name><article-title>Designing a new antifungal glycoconjugate
vaccine</article-title>. <source>Chem. Soc. Rev.</source><year>2013</year>, <volume>42</volume>, <fpage>4327</fpage>&#8211;<lpage>4344</lpage>. <pub-id pub-id-type="doi">10.1039/C2CS35382B</pub-id>.<pub-id pub-id-type="pmid">23232662</pub-id></mixed-citation></ref><ref id="ref396"><mixed-citation publication-type="journal" id="cit396"><name name-style="western"><surname>Lipinski</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kitov</surname><given-names>P. I.</given-names></name>; <name name-style="western"><surname>Szpacenko</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Paszkiewicz</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name><article-title>Synthesis and immunogenicity of a
glycopolymer conjugate</article-title>. <source>Bioconjugate Chem.</source><year>2011</year>, <volume>22</volume>, <fpage>274</fpage>&#8211;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1021/bc100397b</pub-id>.<pub-id pub-id-type="pmid">21186827</pub-id></mixed-citation></ref><ref id="ref397"><mixed-citation publication-type="journal" id="cit397"><name name-style="western"><surname>Xin</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Cartmell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bailey</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Dziadek</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Cutler</surname><given-names>J. E.</given-names></name><article-title>Self-adjuvanting
glycopeptide conjugate vaccine against
disseminated candidiasis</article-title>. <source>PLoS One</source><year>2012</year>, <volume>7</volume>, <elocation-id>e35106</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035106</pub-id>.<pub-id pub-id-type="pmid">22563378</pub-id><pub-id pub-id-type="pmcid">PMC3338514</pub-id></mixed-citation></ref><ref id="ref398"><mixed-citation publication-type="journal" id="cit398"><name name-style="western"><surname>Lipinski</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Fitieh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>St. Pierre</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ostergaard</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Touret</surname><given-names>N.</given-names></name><article-title>Enhanced immunogenicity
of a tricomponent mannan tetanus toxoid conjugate vaccine targeted
to dendritic cells via Dectin-1 by incorporating beta-glucan</article-title>. <source>J. Immunol.</source><year>2013</year>, <volume>190</volume>, <fpage>4116</fpage>&#8211;<lpage>4128</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202937</pub-id>.<pub-id pub-id-type="pmid">23514738</pub-id></mixed-citation></ref><ref id="ref399"><mixed-citation publication-type="journal" id="cit399"><name name-style="western"><surname>Bundle</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Paszkiewicz</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Elsaidi</surname><given-names>H. R. H.</given-names></name>; <name name-style="western"><surname>Mandal</surname><given-names>S. S.</given-names></name>; <name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><article-title>A three component synthetic vaccine containing a beta-Mannan
T-cell peptide epitope and a beta-glucan dendritic cell ligand</article-title>. <source>Molecules</source><year>2018</year>, <volume>23</volume>, <fpage>1961</fpage><pub-id pub-id-type="doi">10.3390/molecules23081961</pub-id>.<pub-id pub-id-type="pmcid">PMC6222438</pub-id><pub-id pub-id-type="pmid">30082627</pub-id></mixed-citation></ref><ref id="ref400"><mixed-citation publication-type="journal" id="cit400"><name name-style="western"><surname>Paulovicova</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Paulovicova</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Pilisiova</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Bystricky</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Yashunsky</surname><given-names>D. V.</given-names></name>; <name name-style="western"><surname>Karelin</surname><given-names>A. A.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Synthetically
prepared glycooligosaccharides mimicking <italic toggle="yes">Candida albicans</italic> cell wall glycan antigens-novel tools to
study host-pathogen interactions</article-title>. <source>FEMS Yeast
Res.</source><year>2013</year>, <volume>13</volume>, <fpage>659</fpage>&#8211;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1111/1567-1364.12065</pub-id>.<pub-id pub-id-type="pmid">23859640</pub-id></mixed-citation></ref><ref id="ref401"><mixed-citation publication-type="journal" id="cit401"><name name-style="western"><surname>Paulovi&#269;ov&#225;</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Paulovi&#269;ov&#225;</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Farka&#353;</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Karelin</surname><given-names>A. A.</given-names></name>; <name name-style="western"><surname>Tsvetkov</surname><given-names>Y. E.</given-names></name>; <name name-style="western"><surname>Krylov</surname><given-names>V. B.</given-names></name>; <name name-style="western"><surname>Nifantiev</surname><given-names>N. E.</given-names></name><article-title>Importance
of <italic toggle="yes">Candida</italic> antigenic factors:
structure-driven immunomodulation properties of synthetically prepared
mannooligosaccharides in RAW264.7 macrophages</article-title>. <source>Front. Cell. Infect. Microbiol.</source><year>2019</year>, <volume>9</volume>, <fpage>659</fpage>&#8211;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2019.00378</pub-id>.<pub-id pub-id-type="pmcid">PMC6856089</pub-id><pub-id pub-id-type="pmid">31788453</pub-id></mixed-citation></ref><ref id="ref402"><mixed-citation publication-type="journal" id="cit402"><name name-style="western"><surname>Torosantucci</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bromuro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Chiani</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>De Bernardis</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Galli</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Norelli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bellucci</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Polonelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; et al. <article-title>A novel glyco-conjugate
vaccine against fungal pathogens</article-title>. <source>J. Exp. Med.</source><year>2005</year>, <volume>202</volume>, <fpage>597</fpage>&#8211;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20050749</pub-id>.<pub-id pub-id-type="pmid">16147975</pub-id><pub-id pub-id-type="pmcid">PMC2212864</pub-id></mixed-citation></ref><ref id="ref403"><mixed-citation publication-type="journal" id="cit403"><name name-style="western"><surname>Bromuro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Torosantucci</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Chiani</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Conti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Polonelli</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Cassone</surname><given-names>A.</given-names></name><article-title>Interplay between protective and
inhibitory antibodies dictates the outcome of experimentally disseminated
candidiasis in recipients of a <italic toggle="yes">Candida albicans</italic> vaccine</article-title>. <source>Infect. Immunol.</source><year>2002</year>, <volume>70</volume>, <fpage>5462</fpage>&#8211;<lpage>5470</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.10.5462-5470.2002</pub-id>.<pub-id pub-id-type="pmid">12228271</pub-id><pub-id pub-id-type="pmcid">PMC128316</pub-id></mixed-citation></ref><ref id="ref404"><mixed-citation publication-type="journal" id="cit404"><name name-style="western"><surname>Bromuro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Chiani</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Mori</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Torosantucci</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; et al. <article-title>Beta-glucan-CRM197
conjugates
as candidates antifungal vaccines</article-title>. <source>Vaccine</source><year>2010</year>, <volume>28</volume>, <fpage>2615</fpage>&#8211;<lpage>2623</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.012</pub-id>.<pub-id pub-id-type="pmid">20096763</pub-id></mixed-citation></ref><ref id="ref405"><mixed-citation publication-type="journal" id="cit405"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Romano</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Costantini</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Danieli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name><article-title>Synthesis of Laminarin fragments
and evaluation of
a &#946;-(1,3) glucan hexasaccaride-CRM<sub>197</sub> conjugate as
vaccine candidate against <italic toggle="yes">Candida albicans</italic></article-title>. <source>J. Carbohydr. Chem.</source><year>2011</year>, <volume>30</volume>, <fpage>249</fpage>&#8211;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1080/07328303.2011.604453</pub-id>.</mixed-citation></ref><ref id="ref406"><mixed-citation publication-type="journal" id="cit406"><name name-style="western"><surname>Hu</surname><given-names>Q. Y.</given-names></name>; <name name-style="western"><surname>Allan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Quinn</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Zhai</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Clark</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ortiz</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name>; et al. <article-title>Synthesis of a well-defined
glycoconjugate vaccine by a tyrosine-selective conjugation strategy</article-title>. <source>Chem. Sci.</source><year>2013</year>, <volume>4</volume>, <fpage>3827</fpage>&#8211;<lpage>3832</lpage>. <pub-id pub-id-type="doi">10.1039/c3sc51694f</pub-id>.</mixed-citation></ref><ref id="ref407"><mixed-citation publication-type="journal" id="cit407"><name name-style="western"><surname>Crotti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhai</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Allan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Proietti</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pansegrau</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>Q. Y.</given-names></name>; <name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><article-title>Defined conjugation
of glycans to the lysines of CRM197 guided by
their reactivity mapping</article-title>. <source>ChemBioChem.</source><year>2014</year>, <volume>15</volume>, <fpage>836</fpage>&#8211;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201300785</pub-id>.<pub-id pub-id-type="pmid">24616190</pub-id></mixed-citation></ref><ref id="ref408"><mixed-citation publication-type="journal" id="cit408"><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>Q. Y.</given-names></name>; <name name-style="western"><surname>Torosantucci</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Crotti</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Brogioni</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Allan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Chiani</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Bromuro</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Quinn</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name>; et al. <article-title>Deciphering
the structure-immunogenicity relationship of anti-<italic toggle="yes">Candida</italic> glycoconjugate vaccines</article-title>. <source>Chem. Sci.</source><year>2014</year>, <volume>5</volume>, <fpage>4302</fpage>&#8211;<lpage>4311</lpage>. <pub-id pub-id-type="doi">10.1039/C4SC01361A</pub-id>.</mixed-citation></ref><ref id="ref409"><mixed-citation publication-type="journal" id="cit409"><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Burgula</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Yuan</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><article-title>Synthesis
and immunological
studies of linear oligosaccharides of beta-glucan as antigens for
antifungal vaccine development</article-title>. <source>Bioconjugate
Chem.</source><year>2015</year>, <volume>26</volume>, <fpage>466</fpage>&#8211;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1021/bc500575a</pub-id>.<pub-id pub-id-type="pmcid">PMC4664189</pub-id><pub-id pub-id-type="pmid">25671314</pub-id></mixed-citation></ref><ref id="ref410"><mixed-citation publication-type="journal" id="cit410"><name name-style="western"><surname>Horton</surname><given-names>M.
V.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>C. J.</given-names></name>; <name name-style="western"><surname>Zarnowski</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Andes</surname><given-names>B. D.</given-names></name>; <name name-style="western"><surname>Schoen</surname><given-names>T. J.</given-names></name>; <name name-style="western"><surname>Kernien</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Lowman</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kruppa</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Williams</surname><given-names>D. L.</given-names></name>; et al. <article-title><italic toggle="yes">Candida auris</italic> cell wall mannosylation contributes
to neutrophil
evasion through pathways divergent from <italic toggle="yes">Candida albicans</italic> and <italic toggle="yes">Candida glabrata</italic></article-title>. <source>mSphere</source><year>2021</year>, <volume>6</volume>, <elocation-id>e0040621</elocation-id><pub-id pub-id-type="doi">10.1128/mSphere.00406-21</pub-id>.<pub-id pub-id-type="pmid">34160238</pub-id><pub-id pub-id-type="pmcid">PMC8265655</pub-id></mixed-citation></ref><ref id="ref411"><mixed-citation publication-type="journal" id="cit411"><name name-style="western"><surname>Rosario-Colon</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Eberle</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Adams</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Courville</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Xin</surname><given-names>H.</given-names></name><article-title>Candida cell-surface-specific monoclonal
antibodies protect mice
against <italic toggle="yes">Candida auris</italic> invasive infection</article-title>. <source>Inter. J. Mol. Sci.</source><year>2021</year>, <volume>22</volume>, <fpage>6162</fpage><pub-id pub-id-type="doi">10.3390/ijms22116162</pub-id>.<pub-id pub-id-type="pmcid">PMC8201314</pub-id><pub-id pub-id-type="pmid">34200478</pub-id></mixed-citation></ref><ref id="ref412"><mixed-citation publication-type="journal" id="cit412"><name name-style="western"><surname>Sherry</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Ramage</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kean</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Borman</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>E. M.</given-names></name>; <name name-style="western"><surname>Richardson</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Rautemaa-Richardson</surname><given-names>R.</given-names></name><article-title>Biofilm-forming
capability of highly virulent, multidrug-resistant <italic toggle="yes">Candida
auris</italic></article-title>. <source>Emerg. Infect. Dis.</source><year>2017</year>, <volume>23</volume>, <fpage>328</fpage>&#8211;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.3201/eid2302.161320</pub-id>.<pub-id pub-id-type="pmid">28098553</pub-id><pub-id pub-id-type="pmcid">PMC5324806</pub-id></mixed-citation></ref><ref id="ref413"><mixed-citation publication-type="journal" id="cit413"><name name-style="western"><surname>Spellberg</surname><given-names>B. J.</given-names></name>; <name name-style="western"><surname>Ibrahim</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Avanesian</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Myers</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Phan</surname><given-names>Q. T.</given-names></name>; <name name-style="western"><surname>Filler</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Yeaman</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>J. E.</given-names><suffix>Jr.</suffix></name><article-title>Efficacy of the anti-<italic toggle="yes">Candida</italic> rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis</article-title>. <source>J. Infect. Dis.</source><year>2006</year>, <volume>194</volume>, <fpage>256</fpage>&#8211;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1086/504691</pub-id>.<pub-id pub-id-type="pmid">16779733</pub-id></mixed-citation></ref><ref id="ref414"><mixed-citation publication-type="journal" id="cit414"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Uppuluri</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Mamouei</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Alqarihi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Elhassan</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>French</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lockhart</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Chiller</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>J. E.</given-names></name>; <name name-style="western"><surname>Ibrahim</surname><given-names>A. S.</given-names></name><article-title>The NDV-3A vaccine protects mice
from multidrug resistant <italic toggle="yes">Candida auris</italic> infection</article-title>. <source>PLoS Pathogens</source><year>2019</year>, <volume>15</volume>, <elocation-id>e1007460</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007460</pub-id>.<pub-id pub-id-type="pmid">31381597</pub-id><pub-id pub-id-type="pmcid">PMC6695204</pub-id></mixed-citation></ref><ref id="ref415"><mixed-citation publication-type="journal" id="cit415"><name name-style="western"><surname>Xin</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Mohiuddin</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Tran</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Adams</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Eberle</surname><given-names>K.</given-names></name><article-title>Experimental
mouse models of disseminated <italic toggle="yes">Candida auris</italic> infection</article-title>. <source>mSphere</source><year>2019</year>, <volume>4</volume>, <elocation-id>e00339-19</elocation-id><pub-id pub-id-type="doi">10.1128/mSphere.00339-19</pub-id>.<pub-id pub-id-type="pmid">31484737</pub-id><pub-id pub-id-type="pmcid">PMC6731527</pub-id></mixed-citation></ref><ref id="ref416"><mixed-citation publication-type="journal" id="cit416"><name name-style="western"><surname>Aschwanden</surname><given-names>C.</given-names></name><article-title>Five reasons why COVID herd immunity is probably impossible</article-title>. <source>Nature</source><year>2021</year>, <volume>591</volume>, <fpage>520</fpage>&#8211;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-021-00728-2</pub-id>.<pub-id pub-id-type="pmid">33737753</pub-id></mixed-citation></ref><ref id="ref417"><mixed-citation publication-type="journal" id="cit417"><name name-style="western"><surname>Trotter</surname><given-names>C. L.</given-names></name>; <name name-style="western"><surname>Maiden</surname><given-names>M. C.</given-names></name><article-title>Meningococcal vaccines and herd immunity:
lessons learned from serogroup C conjugate vaccination programs</article-title>. <source>Expert Rev. Vaccines</source><year>2009</year>, <volume>8</volume>, <fpage>851</fpage>&#8211;<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.48</pub-id>.<pub-id pub-id-type="pmid">19538112</pub-id><pub-id pub-id-type="pmcid">PMC3988355</pub-id></mixed-citation></ref><ref id="ref418"><mixed-citation publication-type="journal" id="cit418"><name name-style="western"><surname>G&#243;mez-Redondo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ard&#225;</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gimeno</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Jim&#233;nez-Barbero</surname><given-names>J.</given-names></name><article-title>Bacterial
polysaccharides: conformation, dynamics and molecular recognition
by antibodies</article-title>. <source>Drug Discovery Today Technol.</source><year>2020</year>, <volume>35-36</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.08.002</pub-id>.<pub-id pub-id-type="pmid">33388123</pub-id></mixed-citation></ref><ref id="ref419"><mixed-citation publication-type="journal" id="cit419"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Xiong</surname><given-names>D. C.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>S. C.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>Y. S.</given-names></name>; <name name-style="western"><surname>Ye</surname><given-names>X. S.</given-names></name><article-title>Total synthesis
of mycobacterial arabinogalactan containing 92 monosaccharide units</article-title>. <source>Nat. Commun.</source><year>2017</year>, <volume>8</volume>, <fpage>14851</fpage><pub-id pub-id-type="doi">10.1038/ncomms14851</pub-id>.<pub-id pub-id-type="pmid">28300074</pub-id><pub-id pub-id-type="pmcid">PMC5357306</pub-id></mixed-citation></ref><ref id="ref420"><mixed-citation publication-type="journal" id="cit420"><name name-style="western"><surname>Sletten</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Danglad-Flores</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Leichnitz</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Abragam Joseph</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><article-title>Expedited
synthesis of mannose-6-phosphate
containing oligosaccharides</article-title>. <source>Carbohydr. Res.</source><year>2022</year>, <volume>511</volume>, <fpage>108489</fpage><pub-id pub-id-type="doi">10.1016/j.carres.2021.108489</pub-id>.<pub-id pub-id-type="pmid">34922155</pub-id></mixed-citation></ref><ref id="ref421"><mixed-citation publication-type="journal" id="cit421"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Pan</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><article-title>The clinical use of Fondaparinux: A synthetic heparin
pentasaccharide</article-title>. <source>Prog. Mol. Biol. Transl. Sci.</source><year>2019</year>, <volume>163</volume>, <fpage>41</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/bs.pmbts.2019.02.004</pub-id>.<pub-id pub-id-type="pmid">31030756</pub-id></mixed-citation></ref><ref id="ref422"><mixed-citation publication-type="journal" id="cit422"><name name-style="western"><surname>Hanson</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>Crespo</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Abraham</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Moynihan</surname><given-names>K. D.</given-names></name>; <name name-style="western"><surname>Szeto</surname><given-names>G. L.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>S. H.</given-names></name>; <name name-style="western"><surname>Melo</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name><article-title>Nanoparticulate STING agonists are
potent lymph node-targeted
vaccine adjuvants</article-title>. <source>J. Clin. Invest.</source><year>2015</year>, <volume>125</volume>, <fpage>2532</fpage>&#8211;<lpage>2546</lpage>. <pub-id pub-id-type="doi">10.1172/JCI79915</pub-id>.<pub-id pub-id-type="pmid">25938786</pub-id><pub-id pub-id-type="pmcid">PMC4497758</pub-id></mixed-citation></ref><ref id="ref423"><mixed-citation publication-type="journal" id="cit423"><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Didierlaurent</surname><given-names>A. M.</given-names></name><article-title>Correlates
of adjuvanticity: a review on adjuvants in licensed vaccines</article-title>. <source>Semin. Immunol.</source><year>2018</year>, <volume>39</volume>, <fpage>14</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id>.<pub-id pub-id-type="pmid">29801750</pub-id></mixed-citation></ref><ref id="ref424"><mixed-citation publication-type="journal" id="cit424"><name name-style="western"><surname>Bonam</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Partidos</surname><given-names>C. D.</given-names></name>; <name name-style="western"><surname>Halmuthur</surname><given-names>S. K. M.</given-names></name>; <name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><article-title>An overview of novel adjuvants designed for improving
vaccine efficacy</article-title>. <source>Trends Pharmacol. Sci.</source><year>2017</year>, <volume>38</volume>, <fpage>771</fpage>&#8211;<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id>.<pub-id pub-id-type="pmid">28668223</pub-id></mixed-citation></ref><ref id="ref425"><mixed-citation publication-type="journal" id="cit425"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><article-title>Glycoconjugate vaccines: Principles
and mechanisms</article-title>. <source>Sci. Transl. Med.</source><year>2018</year>, <volume>10</volume>, <elocation-id>eaat4615</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aat4615</pub-id>.<pub-id pub-id-type="pmid">30158151</pub-id></mixed-citation></ref><ref id="ref426"><mixed-citation publication-type="journal" id="cit426"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Costantino</surname><given-names>P.</given-names></name><article-title>On the mechanisms
of conjugate vaccines</article-title>. <source>Proc. Natl. Acad. Sci.
U.S.A.</source><year>2019</year>, <volume>116</volume>, <fpage>14</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1819612116</pub-id>.<pub-id pub-id-type="pmid">30578318</pub-id><pub-id pub-id-type="pmcid">PMC6320500</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>